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ABSTRACT

PRECISION MEDICINE AND ITS ETHICAL AND SOCIAL IMPLICATIONS:
PUBLIC HEALTH AND GLOBAL PERSPECTIVES

By
Evangel Sarwar
May 2019

Dissertation supervised by Professor Henk ten Have
Ever since President Obama's launch of the Precision Medicine Initiative (PMI) in 2015,
precision medicine (PM) has been anticipated as the new paradigm for healthcare with the
capacity to “empower patients, researchers, and providers to work together toward the
development of individualized care,” through research, technologies, and policies (President
Obama, 2015). Precision Medicine (PM), in the form of genomics, offers unprecedented promise
of providing new tools for improving health and reducing the burden of diseases, not just for the
U.S. - but also globally. According to World Health Organization, genomics research and
precision medicine will play a major part in the prevention, diagnosis and management of many
difficult or impossible to control diseases. Genomics research is progressing at an extraordinary
speed and soon the application will be important for clinical application to benefit healthcare, in
the U.S. and globally. In order for PM to be implemented in the everyday primary care setting,
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many considerable ethical and social implications of PM for families, researchers and
policymakers need to be addressed, that will ensure the protection and fair treatment of patients
and participants. The medical impact of PM will be less than revolutionary if proper
implementation and translation processes are not in place, taking into consideration the social
and ethical implications, and addressing the challenges involving public trust and participation,
and adequately preparing the healthcare workforce to administer or give advice on the
applications of PM. Recent studies that compare trends in the genetic curricula in the US and
Canadian medical schools have identified that there is a need for health provider education and
competency rich in genomics and ethics. Despite the barriers, it is evident that the precision
medicine initiative is at the forefront of clinical practice and will impact the quality, safety, and
cost of healthcare.
The primary focus of this dissertation is to analyze the clinical significance and social and
ethical implications of PM in healthcare in order to critically explore how PM can be ethically
implemented in the time of genomics and personalized medicine.
The dissertation is elaborated in nine chapters, with Chapter One being the introduction.
Chapter two will give an overview of PM as the new paradigm of healthcare. Chapter three will
focus into genomics and pharmacogenomics and PM’s clinical significance. Chapter four will
look at the relevance of PM in infectious and non-communicable diseases, while Chapter five
will look at the relevance of PM in Public Health Genomics and Global Health Genomics.
Chapter Six will elaborately focus on the social and ethical implications of integrating Precision
Medicine into healthcare. Chapter Seven will expand into laying the ethical foundation for the
implementation of PM in healthcare organizations by looking at the organizational ethical issues
that may arise, and how healthcare organizations can prepare themselves to address these
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challenges. Chapter Eight will look at the competency of healthcare workforce in the era of PM.
Lastly, Chapter Nine will present the concluding thoughts.
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Chapter 1: Introduction
Background
Ever since President Obama's launch of the Precision Medicine Initiative (PMI) in 2015,
precision medicine (PM) has been anticipated as the new paradigm for healthcare with the
capacity to “empower patients, researchers, and providers to work together toward the
development of individualized care,” through research, technologies, and policies. 1 PM, in the
form of genomics, offers an unprecedented promise of providing new tools for improving health
and reducing the burden of diseases, not just for the U.S. - but also globally. The World Health
Organization (WHO), in its 2002 report, “Genomics and World Health: Report of the Advisory
Committee on Health Research”, stated that genomics research and precision medicine will play
a major part in the prevention, diagnosis, and management of many diseases which have been
difficult or impossible to control. According to the WHO (2002), genomics research is
progressing at a remarkable speed, and soon the application will be important for the clinical
application to benefit healthcare, in the U.S. and globally. The expectation is that PM will shift
medical practices from being “reactive” treatment, to being “proactive” healthcare management
that includes screening, early treatment, and prevention; and is expected to change the healthcare
delivery system and the therapeutics business models, including roles of patients and physicians.
The National Institutes of Health (NIH) has defined Precision Medicine as: “an emerging
approach for disease treatment and prevention that takes into account individual variability in
genes, environment, and lifestyle for each person.” According to the NIH, PM is anticipated to
replace the traditional "one-size-fits-all" approach - enabling physicians, and scientists “to
predict more accurately which treatment and prevention strategies for a particular disease will
work” effectively, and in which specific groups of people. 2
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Although the term “Precision Medicine” is new, the NIH states that the concept has been
used in healthcare for a while, in a relatively limited role, such as blood transfusion. As scholars
like Colleen M McBride point out, that the idea of PM has been dramatically improved by the
development of large-scale biologic databases (such as the human genome sequence), robust
methods for characterizing patients (such as “proteomics, metabolomics, genomics”), and
computational tools for analyzing large sets of data. McBride also adds that PM is being
considered as the emerging, cutting-edge healthcare delivery service of the future for the targeted
prevention and treatment of chronic, noncommunicable diseases such as cancer, cardiovascular
diseases (CVDs), diabetes, and other infectious diseases; and in the control of pandemics. 3 The
approach has advanced so rapidly that PM is anticipated to become part of the regular healthcare
services in the future. As scholars like Favalli et al. (2017) note, pharmacogenomics (PGx), a
new area in PM that studies the effects of genes on the response to drugs – is an integral part of
PM's approach to developing effective, safe medication and doses that will be tailored to the
variations in a person's genes . Wang et al. (2016) is optimistic that the deep understanding of
patient's genetic and genomic information will enable in disease prediction, leading to the
development of effective prevention, diagnosis, and treatment - empowering doctors to select the
most appropriate drug with the optimal dose for the individual, and with the least side effects
from the medication.
The Precision Medicine Initiative (PMI), as announced by President Obama seeks to
move the field of precision medicine more rapidly into clinical care. According to scholars like
Shah et al. (2016), the PMI is structured to fund efforts in cancer genomics with longer-term
goals of advancing PM to all areas of health and will be supported through the creation of a ‘1
million person cohort study’ across the United States . It has been anticipated by WHO (2002)
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that the PMI will provide an unprecedented opportunity for researchers and clinicians in
cardiovascular disease, and other conditions, to galvanize the collective resources and wisdom
and unite to establish and disseminate the knowledge required to translate discoveries to reduce
the global burden of such diseases . PM holds promise for improving many aspects of health and
healthcare– individual, community, public health, and global health priorities. The World Health
Organization reported that genomics research and PM would play a significant role in the
management of noncommunicable illnesses, such as chronic illnesses, as well as in the control of
infectious diseases and epidemics, which are among the top global public health burdens. Studies
have noted that genetic information about immune response could inform vaccine development
and distribution, and disease treatment strategies; and that ongoing research on vaccine use has
already provided more details about the critical role of genetics in vaccine safety and efficacy.
In order to facilitate the creative approaches of PM, the PMI will provide the base for the broad
research program; and also help in the testing process, and help build the evidence-base needed
to guide clinical practice.
However, a myriad of scholarly articles also notes that the PMI with its enormous
potential and promises raise significant ethical and social issues, many of which arise from the
need for technological infrastructures that are either in the early stages of development or have
not yet been developed. Data security have been pointed out as a critical issue that results from
health data on such a large number of people, and emphasis has been put on the need to find
ways to protect participants’ privacy and the confidentiality of their health information.
Participants will also need to be educated on the risks and benefits of participating in PM
research in order to build trust and increase participation, which is a critical component for the
PMI. Currently, there are fears regarding the potential for misuse of genetic information - giving
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rise to issues of confidentiality, discrimination, stigmatization, access, and equity. Scholars fear
that there will be a creation of a genetic underclass that may be denied medical insurance, due to
genetic testing and screening. Some of the fears also reflect past misuses of genetic science in the
interest of advancing a national or international eugenic agenda.
A rise of equity in the provision of health services to disadvantaged groups, in both
economically developed and developing countries have been cited as concerns by many studies.
Scholars like Aicardi et al. (2016), Prince (2015) and McClellan et al. (2013) all point out the
many harmful and beneficial consequences related to genetic information, which often discloses
information not only about the person who donated the data but also about the biologically
related (or even unrelated) others, resulting in issues of incidental findings (IFs) and reporting of
these, and the right to not know. Such findings create the need for an appropriate balance and
relationship between rights and duties. Studies have also cited particular challenges concerning
clinicians' ethical and professional responsibilities. Cost is also an issue that is anticipated with
PM since new technology and infrastructures will cost a hefty amount; and so will the drugs resulting in problems in access and reimbursement from private insurance companies - also
raising fears of exacerbating health disparities.
Understanding the ethical, legal, and social implications (ELSIs) is essential to provide
patients, families, and communities with competent, safe, adequate health care - and there has
been a lot of discussion and research in favor of ELSI scholarship and research. Genomic
research is advancing rapidly, and soon this approach is expected to be utilized in the benefiting
of globally. The World Health Organization (2002) has stated that profound inequities exist in
the health status and disease burden of populations in low, middle, and high-income countries –
where low-to-middle income countries account for 85% of the world’s population and 92% of
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the global burden of disease. Even though PM promises to address the global burden of health,
questions arise about the equitability of such an approach. Opponents argue that PM will only
increase the 10/90 gap. However, genome-related technologies are anticipated to contribute to
improving global health equity. The WHO (2002) states that it is imperative that developing
countries pick up in the race of genomics and work towards forming genomics research with a
more comprehensive, integrated strategy to address the determinants of ill health specific to their
needs .
Scholars like Hawkins and Doherty (2010) point out that addressing people's fears
through informed public discourse is essential not only for benefiting people but also in building
public trust to ensure public participation, which is the most critical component of PM . Scholars
like Andrew Faucet also points that healthcare provider, have a social and professional
responsibility to provide fairness and equity to patients, families, and communities. 4 According
to Roy C Ziegelstein (2015); genetics differ from medicine in that it involves families, rather
than only individuals. Healthy patients are curious about the future risk of developing or
transmitting a disorder. The patient's perceptions of risk and their attitude towards genetic testing
depend on factors such as cultural beliefs, ethnicity and personal experiences of disease in the
family. Accurate information for one family member usually relies on sharing of information
from other family members, and the lack of ownership in genetic information becomes ethically
problematic, which will be an added dilemma on primary providers. Education in ethics will be a
significant contributor to address such dilemmas. Moreover, scholars like Laurie Badzek et al.
emphasizes the need for healthcare professionals to bridge the gap between physician knowledge
and training, and interpretation of genetic test results through reformed education curriculum in
order to be ready for this technology.
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Recent studies that compare trends in the genetic
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curricula in the US and Canadian medical schools have identified that there is a need for health
provider education and competency rich in genomics and ethics. Despite the barriers, it is evident
that the precision medicine initiative is at the forefront of clinical practice and will impact the
quality, safety, and cost of health care. It is critical that the various ESLIs be taken into
consideration and addressed to implement PM into the healthcare setting in the future
successfully.
Outline of the dissertation
The dissertation will be elaborated in nine chapters – with Chapter 1 being the
introduction. Chapter 2 will give an overview of PM as the new paradigm of healthcare - starting
with the concept of PM and how PM came into the limelight with the Precision Medicine
Initiative. Advances in PM have already led to improvements in therapies in certain cancers, and
cystic fibrosis cited as a critical example by President Obama in his State of the Union Address
(2015), where targeted therapies based on genetic mutations can treat the underlying cause of the
disease. Genomic studies also hold promise for the identification of novel therapeutic targets that
could fuel the development of new pharmacological agents for prevention and treatment of
disease, through the involvement of public participation of about at least 1 million volunteers
from around the United States. PM is expected to allow not only individual diseases to be
correctly diagnosed, but also allow future conditions to be predicted in advance for each before
any symptoms from patterns of genomic variation. Although, knowledge of genomics continues
to expand rapidly, promising numerous opportunities for improving health; it will not be of any
importance without public understanding and acceptance. Against this backdrop, Chapter 2 will
highlight the importance of Biobanks and Big Data integration in the successful implementation
of PM, and the need for building public trust and public participation.
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Chapter 3 will focus on the clinical significance of PM in healthcare for individuals.
Prevention of premature deaths, reduction of related health care costs, preventing complications
and catastrophic events, and improving the detection, and treatment of non-communicable
diseases, will be the major goals of PM in clinical medicine. Pharmacogenomics (PGx) is a
significant area in PM, with the responsibility of maximizing the potential benefits and
minimizing the potential risks of medications, especially adverse drug reactions (ADRs). There
are plenty of genetic tests that can help people make informed decisions about prevention and
treatment of diseases. However, many social and ethical challenges also arise. Many of the social
and ethical challenges that have been identified appear due to lack of knowledge, fears, and
concerns about the application. Understanding public attitudes are part of the solution in
addressing these issues. Chapter 3 will focus into genomics and pharmacogenomics - its potential
in preventing, treatment, and management of diseases through genetic tests and screenings, and
prevention of adverse drug reactions, and other areas that PM has the potential to impact. It will
also discuss the importance of Family Health History (FHH) and Family History (FH) as a tool
in clinical settings in the era of PM. Chapter 3 will also identify and briefly talk about the social
and ethical challenges that need to be overcome in order to realize the full potential of PM in
healthcare.
Chapter 4 and Chapter 5 will expand this focus on clinical significance initiated in
Chapter 3 to look at the relevance of PM in infectious and non-communicable diseases (chronic
diseases and epidemics and pandemics); and relevance of PM in Public Health Genomics and
Global Health Genomics, while tying into the ethical and social issues anticipated to arise.
Chapter 4 will focus on PM's role in the management of Noncommunicable Diseases (NCDs)
such as cancer, diabetes and cardiovascular diseases (CVDs), and in the area of pandemics, while
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identifying challenges and ways to overcome them. Chapter 4 will also focus on the ethical, legal
and social implications (ELSIs) that may arise due to PM’s potential for tailored interventions for
specific groups of the populations for public health and clinical practice. Public health plays a
significant role in ensuring the success of genomic medicine, because of its focus on the
population that has the most vulnerable segments. Chapter 5 will look at health-related benefits
and harms between individuals and the broader community, including threats to individual
privacy and autonomy, and warranting just distribution of scarce resources. This Chapter will
also look at the relevance of PM and the benefits of this technology from a global perspective.
Since PM and genomics research is a new technology, it requires high capital investment, which
according to the WHO, creates the fear of its potential to the widening of disparity in global
spending ("10/90 gap") on health research between the developed and developing countries. To
make the promises of PM a reality, it will only be wise to anticipate and address the potential for
inequitable access to healthcare occurring from using genetic information, and ensuring that the
health of individuals in less privileged countries are also taken care of. Against this backdrop
Chapter 5 looks at the ethical issues that may arise due to the high expenditure in development
and integration of genomic and personalized medicine into healthcare, and address how this
technology can be distributed, and be effectively achieved by the developing countries, without
incurring a significant increase in the expenditure on their healthcare.
Critical challenges exist to precision medicine's implementation in healthcare, especially
in knowledge transfer of the genomic information from research into clinical care, and achieving
greater patient and clinician engagement and trust. To move the genomic agenda forward, there
needs to be a broad collaboration between health professionals, researchers and public health
practitioners, and a supportive-base of well-informed public, to address the complex issues of
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translation, utility and equity. Large numbers of samples and data need to be collected and
analyzed to investigate gene-gene, gene-disease and gene-environment interactions over time.
Only collaborative efforts in population studies can achieve such depth. It must also be
emphasized that public participation is also crucial in PM and this is driven by trust, a shared
belief in the common good and thoughtful engagement. Keeping these in mind PM must be
implemented in healthcare settings. Chapter 6 will elaborately focus on the ethical and social
implications; challenges and needs; the legal and equity issues; and public attitudes toward the
need for screening and other tools for PM to be implemented - while recommending the demands
for better regulatory standards, policy considerations and collaboration and education amongst
various vital entities.
Chapter 7 will expand into laying the ethical foundation for the implementation of PM in
healthcare organizations (HCOs). With all the recent promises of utilizing individual’s genetic
information to tailor medical treatment decisions to optimize patient care, PM also raises
questions about the upcoming changes in healthcare organizations, costs, and ethical obligations
of HCOs. Overcoming challenges in these areas will require straightforward strategies that can
provide clear solutions, and can drive systemic and cultural changes. With a clear understanding
of the set of challenges and the best strategies for overcoming those challenges, a roadmap for
healthcare systems to advance the precision medicine paradigm can be built. The purpose of
Chapter 7 is to look at the organizational ethical issues that may arise in the era of PM, and how
HCOs can prepare themselves to be ready to address these challenges while delivering healthcare
services that meet the organization’s mission equipped with the tools needed.
Chapter 8 looks at the competency of the healthcare workforce. PM is anticipated to
provide potential tailored interventions for particular individuals, populations or subpopulations,
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which raises ethical, legal and social implications (ELSIs). In order to address the ELSIs and
utilize this translation of genomic information into practice, healthcare providers will need to
have proper knowledge and training of genetic tests and how to interpret the results. Recent
studies that compare trends in the genetic curricula in the US and Canadian medical schools have
demonstrated inadequate incorporation of genomics material into the curriculum, showing the
need to adequately prepare the healthcare workforce to incorporate genomics into regular
practice in the era of PM. Chapter 8 looks at the current education and competency level of the
healthcare professionals and recommends the need for education and competency rich in
genomics and ethics for healthcare professionals in the era of PM. It proposes potential solutions
for educators to keep pace with this rapid advancement of PM while looking at existing
educational gaps and challenges.
Finally, Chapter 9 will have the concluding thoughts based on the various arguments,
insights and analyses made throughout the different chapters in the dissertation to offer the
summary of the various arguments made so far in order to foster a good understanding for the
topic that includes both the benefits of such a technology and also the concerns that might arise
with such advancements in technology in healthcare.
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Chapter 2: The Emerging Field of Precision Medicine – The New Paradigm for Healthcare
2.1. Introduction
The newly emerging field of ‘precision medicine' (PM) has been anticipated as the new
paradigm for healthcare.1 The Precision Medicine Initiative (PMI) launched by President Barack
Obama in 2015, aimed at ‘enabling PM as the new era of medicine that can bring patients,
researchers and providers together toward the development of individualized care through
research, technology, and policies.’2 Although PM is held at high esteem as the innovative
technology in healthcare – scholars like Armstrong et al. argue that implementing PM into
routine clinical setting will need to address considerable challenges that include addressing
ethical issues, and the need for public engagement, and participation in trust building through
informed public discourse. 3 This Chapter aims to look at PM as the new paradigm of healthcare,
and some of the essential challenges that need to be addressed to realize its potential; focusing on
the imminent need of public education in developing trust and partnership. The Chapter starts
with the concept of precision medicine (PM), and the Precision Medicine Initiative (PMI) created
to bring this concept to reality.
2.1.1. Concept of Precision Medicine (PM)
Precision medicine, defined as an evidence-based approach, uses innovative tools and
biological and data science to customize disease prevention, detection, and treatment; and
improve the effectiveness and quality of patient care. According to Fradkin et al., PM aims to
move away from the current "one-size-fits-all" treatment that is based for the average patient and
does not work for all - to tailor treatment toward the individual, based on the individual’s
variability in genes, environment, and lifestyle.4 The United States, along with countries
including Canada, the United Kingdom, and Estonia is working towards a precision medicine
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priority. Although research and clinical care considering genomic and other individual-level
differences are not new, this broad research program, as Shah et al. notes, creates the opportunity
to utilize technological advances in the development of new clinical approaches and also test
them.5 All of these groups of goals united into the PMI will lead to the paradigm shift that the US
government and the scientific community are envisioning for the future healthcare delivery. It
has been argued that achievement of the broader reaching goals of the PMI will likely have
significant implications across all medical disciplines.
The National Institutes of Health (NIH) also affirms that ‘Precision Medicine’ (PM) is an
emerging approach for disease treatment and prevention that will allow doctors and researchers
to predict more accurately the treatment and prevention strategies specifically for groups of
people. PM’s goal is to focus on more specific disease treatment and prevention strategies, taking
into consideration genetic variations, in contrast to the "one-size-fits-all" approach.6 It is evident
from the various studies that PM requires large-scale biological samples, and extensive
collaboration between multiple actors, to facilitate the collection and sharing of data.7 The
anticipation, according to Wang et al., is that PM will make more effective prevention, diagnosis,
and treatment, by developing a “deep understanding” of patients' genetic and genomic
information – making it easier for doctors to select sensitive drugs, optimal dose and time for
medication usage, and the least side effect.8
As scholars from Genetics Home Reference highlight, the idea of precision medicine has
always existed, however, the increasing cost of drug development led to the necessitation of
newer innovative healthcare models that would be faster and cheaper. The slow drug
development process, with the small amount of medications that actually worked for people,
demanded for innovative technology for the development of efficacious drugs. As the scholars
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argue, the discovery of genetic variants in the prevention, treatment and management of diseases
– including better targeted medication with least amount of side effects was indeed a very
appealing concept.9 Although the concept of PM is not new, the term ‘precision medicine’ as
highlighted by the scholars is new, and researchers hope this approach will preferably expand
into all areas of healthcare soon.10
Godman et al. noted that multiple definitions has been assigned to PM, including
‘personalized medicine’ (commonly used in the past), ‘genomic medicine’ and ‘stratified
medicine’ – essentially all of which include targeting of diagnostic or treatment approaches to
improve the future care of patients.11 The ‘precision medicine’ term has recently become
preferred over personalized medicine to avoid implying that novel treatments will be designed
for each person. Rather, David J. Duffy highlighted that ‘precision medicine’ would be an
approach focused on classifying individuals into subpopulations, with different susceptibility to
disease.12 Although people still use the two terms ‘personalized medicine' and ‘precision
medicine' interchangeably, there were always concerns that the word ‘personalized medicine'
could be misinterpreted to apply for individuals only (per National Research Council). The
National Research Council prefers the term ‘precision’ because of its focus on identifying
approaches that are effective for patients based on their “genetic, environmental, and lifestyle
factors.”13 Clayton Christensen from Harvard Business School coined the term ‘precision
medicine’ and used it in his book, The Innovator’s Prescription (published in 2009), to describe
how molecular diagnostics can allow physicians in precisely identifying the cause of a disease.
The US National Research Council’s report, "Toward precision medicine, developing a
framework for creating a new taxonomy of human disease," enabled the term to gain wider
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acceptance in 2011.14 The next section looks at the creation of the Precision Medicine Initiative
(PMI) and its goals.
2.1.2. Precision Medicine Initiative (PMI)
In 2015, President Obama launched the Precision Medicine Initiative (PMI) that proposed
to implement several health activities including health research with one million volunteers. The
two main components of the PMI are: a near-term focus and a longer-term focus. The near-term
focus aimed at cancer, which was the most obvious choice; and the later aimed at generating
knowledge to target the whole range of health and other conditions. As Francis S. Collins points
out that we have both the components within our reach today through advanced research in
molecular biology, genomics, and bioinformatics. This initiative also taps into other trends such
as social media and mobile devices that are used by Americans in their persistent desire to be
active partners in healthcare research, as noted by Collins. Collins adds that PMI also entails
pursuing greater knowledge for better understanding and assessment of disease risk, disease
mechanism, and prediction of therapy, with the goal of expanding PM into a myriad aspect of
health and healthcare.15
Per NIH, PMI’s significant components involve building a national research cohort of 1
million U.S. volunteers that “will reflect the broad diversity of the US population,” to provide the
medical and other health-related data. Fradkin et al. note that the PMI will pioneer a new model
of patient-powered research, with the promises to accelerate biomedical discoveries; and new
tools, knowledge, and therapies, for clinicians to select the best treatment for the individual
patient.16 They note that the NIH’s goal, by the end of 2016, was to enroll at a minimum 79,000
people; and by the end of 2019, the goal was to have at least 1 million people enrolled as
volunteers. To eliminate disparities, Fradkin et al. also added that the NIH is also working
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together with the Health Resources and Services Administration (HRSA) to begin collaboration
with Federally Qualified Health Centers, with the goal of identifying approaches that will bring
underserved populations into the Cohort Program - particularly those historically
underrepresented in biomedical research.17 As studies suggest, the PMI can leverage these
advances in genomics and the emerging technologies, while ensuring privacy, and equity, only
through collaborative public and private efforts, with the purpose of generating information for
the development of novel therapies and approaches to treat and prevent diseases only. 18, 19
Although healthcare providers and patients in general, endorse the concept of PM, the
practice of PM is currently not in routine use for disease management. President Obama’s
initiative will hopefully accelerate the pace of these efforts, test these concepts, produce the
necessary scientific evidence, and support implementation for PM in healthcare settings, across
different diseases.20 Patient privacy has been emphasized repeatedly, and with that in mind the
national cohort of volunteers will support the overall goals by initiating the foundation of a more
open and responsible data sharing, that also puts patient participation at the center of the
initiative.21 The initiative, as observed by Shah et al., will allow participants to be in control of
the utilization and sharing of the information in research, with participants having access to their
data for better decision-making about their health, which is contrary to other research cohorts. 22
The next section looks at how PM works.
2.2. How PM works?
Although the concept of PM is not new, scholars like Samantha A. Adams and Carolyn
Petersen note that the development of large-scale databases, the methods used to categorize or
stratify patients, and the tools used for analyzing the data have all lead to PM's enhanced
opportunities for its widespread use in practice.23 PM relies heavily on genomic sequencing,
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which is technically big data - built on information technologies and databases.24 Data in
genomics are “representations” of an individual’s DNA, as pointed by Frizzo-Baker et al.25
Biobanks - or biorepositories - are collections of biological specimens and associated health data
used for research purposes. Biobanks are valuable sources of data for PM, with the type and
amount of specimen varying with the object, and scope of the biobank.26 According to scholars
like Schwab et al. and Richard Tutton, the widespread use of biobanks in research - especially
population-based biobanks - has only blossomed in the past two decades. Population-based
biobanks were designed for analysis into genetic, environmental and lifestyle factors associated
with common, complex diseases or the genetic basis of drug response.27, 28 The next two sections
give a brief description of what biobanks are, such as the extent of their use, organization, and
quality.
2.2.1. Biobanks in PM
Human biospecimens contain genetic material that can be used to analyze gene variations
associated with human diseases and have become enormously valuable for medical researchers.
As pointed by Karen J. Maschke, researchers can develop new diagnostic tests and targeted
treatments for specific conditions, and investigate how genes interact with environmental factors
by analyzing genes, opening up ways to treatments that are tailored to a person's genetic makeup
– which is the approach used in PM.29 J.E. Olsen et al., states that biobanks are essentially,
repositories that house collections of human biological material that comes in many different
forms - depending on the type of stored samples, and the “medical-scientific” domain in which
they are collected.30 Eric M. Meslin & Ibrahim Garba also note that PM requires large scales of
research on genetics and “thousands of human studies,” to understand the influence of genetic
variation on human health and disease.31 Biobanks are an important step towards the
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improvement and development of PM and can provide critical research and infrastructure
support. Gail H. Javitt notes that the collection and analysis of data available on health and
disease - promise to enhance the quality and efficacy of healthcare, and to enhance the quality
and longevity of life. The access to biospecimens, provided by human biobanks, has increased
over the past decade both in the United States and internationally and, as noted by Javitt, is an
essential component in the progress of PM.32
Biobanks, bio-repositories or tissue banks - as they are called - have been acknowledged
as valuable tools in bio-molecular research, with the potential to providing improved techniques
for predicting individual susceptibility to particular illnesses, as well as providing more targeted
and innovative ways to treat many diseases. These repositories, according to Robin Bunton and
Lesley Jones, seek to integrate collections of biospecimens with corresponding population data,
such as genetic profiles, medical histories, and lifestyle information; and offer opportunities for
better understanding of common, complex diseases - such as heart disease and cancers.33
Moreover, Bunton and Jones state that the type of specimen and amount of clinical information
stored by biobanks depends on the purpose and scope of the biobank, and ultimately affect its
shape. They add that biobanks can range from collections of specimens from a large number of
individuals in different states of health to focused specimen banks that collect specific samples
and data from individuals with a particular disease or disorder.34
Scholars like Michaela Mayrhofer portray biobanks as an organized collection of
biological samples and associated data.35 Although biobanks have existed forever, they gained
prominence only recently when some countries and health providers initiated large populationbased studies to facilitate PM. The practices of collecting samples differ widely from institution
to institution, and the coordination between different biobanks also varies. Herbert Gottweis and
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Alan Petersen note that most of the biological specimens stored in biobanks occur as part of a
medical intervention; during which tissues or fluids are already being sampled for diagnostic or
treatment purposes - where patients agree to biobank these specimens as part of the surgical
consent process.36 In addition to samples obtained through routine medical procedures, Schwab
et al. add that biological specimens may also be obtained from individuals who consent either to
participate in a research study or to donate to a biobank. They also note that many samples are
gathered using procedures such as skin, swabs, oral swabs, that involve negligible physical risk.
Samples once collected are preserved in biobanks, and an electronic coding of the sample's
genome is stored (probably forever).37
Berthold Huppertz et al. note that specimens stored in biobanks require linking to
pertinent medical data to be of value in clinical research; and are most often stored in a way that
relates them directly or indirectly to identifiable personal health information - like diagnoses,
prognosis, and treatments.38 Amy Fletcher notes that advances in information technology have
enabled scientists and clinicians with a new and powerful set of research tools that directly link
tissue, fluid, microbiome, and genetic samples with large compilations of medical data. As
Fletcher points out, biobanks gain tangible social and economic value when data they contain
potentially translate into progress toward PM.39 To provide the basis for the ranges and
frequencies of expression used in the translation of the stored data sample most ‘omics' data
depend on trusted, secure access to these collections.40 Richard Tutton notes that biobanks seek
to gain legitimacy in the form of financial investment from the governmental and charitable
sectors, through the willingness of individuals to volunteer their biological samples, medical
records, and other personal data.41 Scholars like Bernice S. Elger and Arthur L.Caplan explain
how data is utilized in biobanks. They state that biobanks utilize various data management
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techniques for associating information about the donor and the donor's medical history or
“disassociating the sample” from information about the donor. Samples may be stored as
“anonymous, unlinked anonymized, linked anonymized, coded (de-identified), or identified
samples.” Anonymized samples are those that are “stripped of the information” that would allow
possible identification of donor. When samples are “delinked, the stripping is irreversible” –
Elger & Caplan point out that there is no way to relink the sample and/or information to the
donor.42
According to scholars like Edward S. Dove, biobanks are a critical emerging research
infrastructure, mainly because resources comprising biospecimens and data from many
participants are viewed as particularly promising drivers of PM.43 Huppertz et al. further
describes biobanks as belonging to three categories: 1) Population-based biobanks that obtain
biomarkers of susceptibility and population identity. 2) Disease-oriented biobanks that collect
biomarkers of exposure, used for epidemiological purposes by using a substantial number of
samples, following a healthy exposed cohort/case-control design. 3) General Biobanks, which
are also disease-oriented (e.g., tumor banks), usually associated to clinical data, and sometimes
to clinical trials, where it is essential that the amount of clinical data linked to the sample
determine the availability and biological value of the sample.44
Biobanks vary considerably in the data they store, the organization of information, and
access to information. According to Scott et al., DNA, RNA, tissues, tumors, are all example of
samples stored in biobanks.45 Biobanks also differ in their organization and can serve as part of a
value chain, moving samples from primary sources to researchers. Alternatively, storage
schemes depend on the types, combinations, and volumes of stored samples and data, and the
technical requirements for storage and access. Fabricio F. Costa moreover add that geography
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plays a role in the way samples are exchanged, and also the way the infrastructure is developed
for managing and maintaining the bank, and the recovery strategies in the event of disasters.
They also state that the organization and access of biobanks dictates the conditions of privacy
(such as descriptors of source individuals), procedures for anonymizing data, and the regulatory
environment.46
Publicly funded biobanks set up to promote the public interest, have expanded across the
globe in recent years. Research suggests that biobanks exist on every continent, and enable largescale genomic analyses, as well as the validation of findings through samples of large cohorts;
thereby, promoting translational science and PM. Biobanks also advance genomic research in
various other ways for the betterment of society. Researchers can begin to develop meaningful
answers only by linking data from multiple resources. Huppertz et al. add that although the costs
of whole-genome sequencing (WGS) are increasingly declining, it is critical to have reliable data
to foster public trust - and clinically reliable data will be the key to drive this field past research
to clinical utility successfully.47
Huppertz et al. recommend the collaboration between academic, nonprofit and managed
care researchers, stating that this will produce better progress in PM. Linking biological data to
electronic medical records (EMR) is the essential role that biobanks play in the transition of
precision medicine. However, biobanks face many challenges in identifying meaningful links
between the many factors. Pharmaceutical and diagnostics researchers should be involved in the
biomarker studies to develop better screening and diagnostic approaches to providing the data.
As Huppertz et al. point out that the data shared must be useful to clinicians and integrated into
the healthcare system for PM to work. However, Huppertz et al. also note that data sharing
complicates the obligations and expectations of all stakeholders, and therefore, ensuring that the
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data is reliable is crucial for biobank collaboration, especially for fostering public trust in
biobanks.48 The next section talks about big data and data integration.
2.2.2. Big Data and Data Integration
According to Frizzo-Barker et al., data mining is the process that discovers the patterns
and the meanings from the large datasets - that involves gathering different types of data from
users and consumers, with or (sometimes) without consents - and translates this information to
achieve different organizational and institutional goals.49 According to scholars like Marinka
Twilt, cancer research is one field where PM through pharmacogenomics (PGx) is expanding
rapidly. However, the scholar adds that other chronic diseases, such as diabetes and
neurodegenerative diseases are not further behind in their research initiatives.50
According to Stoeklé et al., the practice and development of PM require the four essential
elements connecting patients and doctors: “biobanks, databases, bioinformatics platforms, and
genomic platforms.” Medicine, mainly used in cancer treatment and interventions, require large
amounts of data, which are primarily electronic.51 The success of PM relies heavily on biobanks and recruitment of participants across all age, sex, and racial groups have become a major goal of
researchers, governments, private corporations, and advocacy groups.52 As highlighted by the
Precision Medicine Initiative (PMI) Working Group Report to the Advisory Committee to the
Director, biobanking is essentially the collection of biological specimens - such as (but not
limited to) DNA, RNA, plasma, and also blood specimens from participants - is essential to the
mission of the PMI.53 The Report emphasizes the need for a large volume of accurate data,
stating that it will be critical for the PMI’s cohort mission to have a large number of
participants.54
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The PMI Working Group Report also point out challenges that are related to insurers and
payers and the data that will be derived from the EHRs, stating that there will be a need to
address these issues given the anticipated large number of participants from different
organizations with EHR systems. The Report emphasizes in need for proper technology, data
security and organizational policies to address the anticipated challenges, which they suspect
may also increase given the number of organizations that will be involved in the data collection
and translation process.55 In order to address these challenges, the Report highlights the need for
the establishment of a central biorepository early in the formation of the PMI cohort. According
to the Report, the scope of the PMI biobank would cover all aspects, from specimen collection to
analysis, as well as translation and communication between the recruitment centers, and
approved vendors with the purpose of establishing “in-house high-throughput analysis
platforms.” 56 Moreover, the Report encourages establishing procedures that will guide in the
maintenance of the accuracy of the specimen coding and linking, utilizing Clinical Laboratory
Improvement Amendments (CLIA) standards. The Report also emphasizes the need for the PMI
biobank to maintain security at all times.57
Data sharing has been emphasized as the key element to realize the potential of PM.
However, opponents have voiced concerns over sharing of data due to issues of ownership,
proprietary knowledge, and commercialization.58 As Stevens Hallam notes, the issues were
mostly related to technical problems due to the lack of infrastructure capabilities to meet the
sizeable, growing volume of sequence data produced by genome projects.59 However, Hallam
adds that bringing data into a standard and consistent format for sharing, and collaboration
through data sharing of different kinds of information could mitigate these issues. 60, 61 Although
the EHR data have been argued as beneficial for clinical and genomic research associated with
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diseases, and drug response; the Report however, points out that the issues mentioned earlier
must be addressed in order for the EHR data to be useable.62
A fundamental truth that has been highlighted by the PMI Working Group Report is
about the issues of incompatible formats currently used by the EHR systems that use no specific
standard naming and coding conventions. The Report explains that this creates for additional
steps to normalize the data, and therefore data curation process is essential to maintain the
heterogeneity of the data quality. The Report recommends knowledge of local conventions and
coding to ensure the proper flow of data.63 The PMI Report further points out the technical and
policy challenges that exist in aggregating the narrative text present in clinical EHRs from
clinical observations, that has the potential to reveal participant identity inadvertently, and
computational methods that are not in place to ensure anonymity when applied to unstructured
data sources. Ongoing collaboration between healthcare provider organizations (HPOs), have
been highlighted in the Report, to ensure with data security, quality and address any questions
that may arise.64 Biorepositories and data sharing raise ethical challenges and concerns and
needs to be addressed. These issues will be discussed further later on in a different chapter.
The trend towards PM has resulted in an explosion in the amount of generated biomedical
datasets – in particular, ‘omics' data (e.g., from genomics, proteomics, microbiomics).65
According to Edward S. Dove, validation requires analyses of large numbers of familial cases
and controls, ideally from multiple populations; hence, international collaboration is a
requirement for progress of PM. Dove adds that ‘unduly’ restricting data sharing across national
borders or the matching of biospecimens with medical registries, and patient records limit the
possibility of validating biological findings in larger cohorts. The results are less powerful,
diminished medical breakthroughs, and lack of tangible improvements in healthcare.66 There are
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challenges with the collaboration of different biobanks. As scholars like F Martin-Sanchez & K.
Verspoor point out, success depends on the quality of specimens and data used to identify or
validate biomarkers, but a lack of quality control for samples and data is only distorting the
scientific data since flawed information will only take longer to sort. Because data linkage and
sharing is an integral part of integrating disparate data sources in order to enable biomedical
research and is pivotal to the advances in chronic diseases and infectious disease surveillance –
they add that it is critical to use standards in Big Data sharing in genomics.67 The next section
looks at the challenges and ethical and social issues that are associated with biobanks, and PM.
2.3. Challenges & Ethical and Social Considerations
The translation of genomics in big data technologies from research labs to the clinical
setting can increase the risk to individual privacy, while being a benefit to PM. Addressing social
and ethical considerations is crucial to adopt PM in regular clinical settings. As Chow-White et
al. point out that there is a need to better address issues such as risks of re-identification,
informational harms, and data security vulnerabilities in the clinical environment - to reconcile
the unpredictable pathway of research and practice in the networked information society.68
According to many scholars, the increased use of genome-wide association studies (GWAS), and
the increased ability to share data in PM leads to new issues of consent, feedback of results,
privacy, and the governance of research. The next section looks at the ethical and social issues
that are frequently raised in biobanking and genomics - such as, challenges in the areas of
biobanking and informed consent, privacy, and confidentiality, genetic discrimination and
equity.69
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2.3.1. Ethical and Social Considerations
Issues with informed consent - Biobanks contain both samples and data resulting in the
legal and ethical controversy that relates to privacy and informed consent.70 As Ma’n H. Zawati
point out, the expansive collection of samples in population biobanks that looks at sample data
collected on a large population scale, and over an extended period makes it challenging to inform
participants as to the use of their samples as resources for future research in health and
genomics.71 Moreover, scholars like Stoeklé et al., point out that although population biobanks
are limited regarding what information they can provide to research participants during the
consent process, broad consent can be detrimental, since informed consent means more than a
simple communication form between the different entities involved. With the increasing
numbers of retrospective cancer studies, they add there is a need to consider the kind of informed
consent, not just the contents, that should be provided at all academic medical centers with close
ties to care and research. After all, the informed consent is an essential form of communication
between patients, clinicians, researchers, and industry.72 William Wei Lim et al. noted that
although biospecimen research reported on consent and approval, they did not do it in a
meaningful way, even though they stress that non-meaningful ethics reporting does not imply
inadequate consent and approval processes.73 Yann et al. noticed that informed consent is
increasingly challenging because of the sheer volume of information. Given that PM requires a
significant amount of patient participation, giving patients more access to their data is both
empowering and leads to more informed choices and better quality of consent. From research, it
is evident that the consent information for PM is not possible to be given all at once, and has to
be an ongoing process, which provides more time for researchers to translate information, as well
as for patients to absorb the given information.74 One of the most pressing challenges found for
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clinical genomics revolves around the process of gathering informed consent. Frizzo-Baker et al.
point out that the Internet plays a significant role as a barrier to the development of PM due to
increasing individual privacy risk and creating challenges in the management of patient health
information. Despite these issues, most stakeholder discussions fail to address the role of the
Internet and information technologies with patients.75
Privacy and confidentiality – PM raises concern for potential consequences of privacy
breaches. Even though the PMI includes focusing on responsible data sharing and privacy
protection, there is little information on how to accomplish these goals.76 According to data from
research, participants voiced high levels of privacy concerns over the privacy of genetic
information that prevented them even from supporting or participating in genetic research.
Participants were concerned about the access to data (i.e., insurance companies), and its
protection.77 According to Holly et al., participants were concerned about privacy and its effect
on the individual when it was a matter of the common good.78 Scholars like Maya Sabatello and
Paul S. Appelbaum add that the issue of genomic privacy has generated considerable public
debate since genetic information is uniquely sensitive and personal, as it may reveal attributes of
individuals and family members that are beyond anyone’s control; and also because knowledge
of individuals’ genetic disposition to disorders may lead to stigma and discrimination.79
Branković et al. adds that the protection of data from patients with serious infections is of
particular importance due to the potential for discrimination which can result from current
interpretation as well as from future research in genomic technologies.80 Other issues according
to Sabatello and Applebaum are related to genomic data sharing by professionals, especially in
the context of new informational technologies - resulting in intense debates about the benefits of
optimized care versus the harms from risk of privacy breaches and misuses of genomic data.81
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The significance of data protection cannot be underestimated, especially in the handling of
samples taken from individuals who are afflicted with serious infections, since genome-based
information can lead to risks of stigmatization and discrimination.82 Even though scholars like
Frizzo-barker et al. note that anonymization and informed consent are both treated with equal
weight by the traditional bioethics model for privacy, it is however nearly impossible to outline
and attain informed consent with clinical genomics data for numerous unforeseen reasons..83
Genetic discrimination and equity- Yann et al. highlight that concerns related to
genetic discrimination in PM leading to genetically at-risk individuals being excluding from
critical socioeconomic goods and services have convinced policymakers of many countries to
adopt broad legislative solutions to prevent anticipated abuses. However, they also point out that
the actual extent and impact of genetic discrimination have never been established. The current
U.S. legislative framework, Genetic Information Nondiscrimination Act (GINA), enacted in
2008, was designed to prohibit insurers and employers from discriminating based on genetic
information. Yann et al. add that the Act includes prohibitions on denying coverage or charging
higher premiums to a healthy individual based solely on genetic predisposition to a condition and
similarly bars employers from using this information when making decisions about hiring, firing,
and promotions.84 Nicholas Rose also points out that identifying how a population may react to a
particular drug could also result in the denied access to treatment for an individual on the basis of
probability of poor response, or risk for adverse effects (identified for similar genetic variants of
that population), even if there were no other drugs available for the treatment. Probability is not a
certainty, and someone excluded from even the slim chance of benefit may well feel injustice.
On the other hand, Rose adds that the development of drugs whose efficacy is specific to
particular population groups would only provide incentives to pharmaceutical companies with
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lowering their costs in trials and investing in products with most valuable markets, but would not
ensure incentives to the medical needs of those who suffer from more prevalent diseases; thus,
creating a fear of a new kind of racial segmentation of medicine. Moreover, Rose highlights that
the promise of personalization via PGx may be more problematic than its advocates often
suggest.85
As scholars like Samantha A. Adams and Carolyn Petersen noted, with the establishment
of PM and the availability of diagnostic tools and treatments, equity is feared to be a significant
issue at both the individual and population levels.86 Scholars are afraid that if the numbers of
patients seeking precision based medicine increase with the right-to-try laws, equity may become
a more significant problem than it currently is. They point that such legislation allows patients to
request any compound included in Phase 1 testing directly from the manufacturer and will enable
patients with higher socioeconomic status (such as higher education, insurance or greater
personal wealth) be able to access these compounds more than patients with lower
socioeconomic status. Adams and Petersen add that another pressing concern is the degree to
which various groups of patients will benefit most from PM. Although PM is anticipated to
focus on common diseases such as diabetes, this can potentially widen the gap between patients
with prevalent diseases and other patients groups (such as rare diseases).87 Concerns about
patient autonomy in PM have also become prominent, which will be discussed later in this
chapter. The next section looks at issues of data harnessing, knowledge transfer and citizen trust.
2.3.2. Data Harnessing, Knowledge Transfer and Citizen Trust in Data Sharing
According to scholars like Ipek Demir and Madeleine J. Murtagh, the generation of large
volumes of data, in combination with the medical data associated with the sample – also known
as “big data”- opens new avenues in “personalized and stratified” medicine.88 However, at the

28

same time, this is also one of the major challenges of these technologies. Demir and Murtagh
added that the data analysis has not been able to follow the speed of technological achievements,
producing large data sets that cannot be analyzed properly, making it impossible to utilize the
important information generated by biomarker identification and stratification of diseases.
Biobanks provide a platform for knowledge creation, rather than themselves creating scientific
knowledge. No single biobank can provide a sufficiently large sample - data from several
biobanks must be shared. This need for data sharing per Demir and Murtagh further focuses on
biobanking science, on the specific challenges of using potentially disparate data sources. The
technical challenges of sharing data, with the stated goal of translating biobank science into
diagnostic and therapeutic interventions, are significant and well recognized. 89
Differences in how to collect and store bio information can create problems when it
comes to sharing data from across biobanks, as they incorporate different kinds and types of
data, depending on the priorities and the population base of that biobank.90 As scholars like
Herbert Gottweis, and Demir and Murtagh point out, these are thorny issues when it comes to
sharing, and is usually because two biobanks may use the same variable, but the usability of the
data depends on the way the variables were collected and recorded. They further add that in data
sharing - taxonomical and conceptual disparities, different styles of processing and grouping
samples and associated data, different categorization and recording techniques – raise
comparison, adjudication, as well as data sharing problems. The scholars point out that there is
also the added risk that many times, such differences go unrecognized and lead to the sharing of
incommensurable data - and hence flawed science. One way out of this issue might be to
prospectively standardize - develop and apply uniform rules and procedures that can govern data
collection, storage, and recording across all the biobanks. 91, 92
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Even though standardization of specific rules/procedures may be desirable, Jennifer R
Harris et al. suggest that it is not possible to impose identical rules and procedures across all
biobanks for numerous reasons. First, it would be difficult to impose uniform rules within a
given country, never mind globally. Second, biobanks differ in the biobank’s population sample
and/or its focus or scope. Third, even during the lifetime of one biobank, Standard of Operations
(SOPs) may change as new techniques of data collection come into use. Fourth, there is the
problem of imposing rules retrospectively on existing biobanks, long after the data were
originally collected.93 Demir and Murtagh also add that standardization can only be done
prospectively. They stress that harmonization of operational procedures and adopting best
practices in biobanking operational procedures is critical for the success of global biobanking.
They state that harmonization is critical for two main objectives. First, it increases the amount of
usable data and numbers of biospecimens to achieve the statistical power needed to detect effects
underlying the disease etiology. Second, translational science will rely on fundamental biological
data to (re)classify human disease based on causality and to identify relevant drug targets and
biomarkers.94 Yann et al. also comments that harmonization is not an easy task; it is time
consuming, resource intensive and requires very high levels of accuracy and consistency.95
Aronson & Rehm thinks highly of PM as a ‘patient empowerment tool,’ and recommends
PM as a patient-centered approach that could be advantageous in the clinical setting, and they
believe will act as a catalyst in the shifting of the nature of the physician-patient relationship.
However, they recommend more public engagement and new collaborating processes.96 As
suggested by the PMI Report, improved decision-making based on access to more up-to-date,
real-time knowledge/evaluation techniques, has the potential to healthcare costs by reducing
unnecessary or ineffective care. Open data-sharing resources due to partnering of academic
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medical centers with commercial activities, will be instrumental in reducing cost of genomic
research and limiting the scope of conflict-of-interest problems, setting precedence for data
sharing rather than keeping its propriety, ensuring that commercial relationships are based on
open principles.97
According to the PMI Report, it will be important for the PMI cohort to enable a
centralized and bidirectional, user friendly participant portal for information sharing. This would
empower participants to participate in an informed and voluntary and ongoing manner, and
would also provide PMI cohort with the volume of participants that it needs. The PMI Report
also recommends providing participants with adequate information, in a language that is easy to
understand.98 As Mirnezami et al. note, building partnership and trust are one of the goals of the
PMI cohort, which can be accomplished by allowing active discussions by healthcare
communities and the public about the ways to build shared responsibilities for health knowledge.
They think that this can be a good way to empower individuals, families, and communities to
make informed decisions, which are helpful in overcoming the challenges of lack of
communication, and lack of public trust.99 The PMI Report also highlights the importance of
successful participation engagement by viewing patients as central participants, with the power
to shape and develop the research with the right opportunities and access in the PM community,
instead of being perceived as subjects only.100 Moreover, the PMI Report also emphasizes
collaboration between organizations with the same goals to generate better knowledge about the
Cohort and its goals, stating that this will be essential in keeping participants informed and
motivated.101
The alignment of incentives for both individuals and organizations will guide the success
of building a PMI cohort data resource that will contribute to the greater community good of a
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national research resource.102 According to scholars like Francis S Collins and Harold Varmus, it
was identified that participants believed that education in genomics would enable the public to
better balance the anticipated benefits, limitations, and potential harms of genomic information.
They believe this would minimize the current fears or misperceptions about genomics, and also
lead to empowering individuals to be more informed and involved in their healthcare decisions.
They also noted that education was critical since it would create more trust in PM and increase
public participation, which is critical for PM.103 A. K Hawkins and K. O'Doherty also noted that
patient resources that are accessible to healthcare consumers will be critical for people to make
informed decision-making in the era of PM. These will provide the basic knowledge about
genetics and how the genetic tests work. However, according to studies it was noted that a
substantial portion of the population does not have this understanding. Therefore, it will be
important for both clinicians and patients to have access to required trusted online resources that
will provide easy to read/understand information about genetics, and their roles in diseases and
PGx to promote informed decision-making and support patient engagement in PM.104 Scholars
like Holly et al., further point out that governance mechanisms were also viewed necessary to
address the complex issues inherent in biobank research in many ways that include, “ensuring
accountability, providing oversight, enforcing rules and regulations, and ensuring public values,
opinions and viewpoints were taken into account.” Additionally, appropriate biobank governance
was also considered as a trustworthy framework to counter the shortcomings of the informed
consent process - particularly as it pertains to unknown, future research on stored
biospecimens.105 Educational campaigns, as well as informed consent documents related to
genetics research, as pointed out by Ma'n H. Zawati - should explicitly state what safeguards will
be in place to protect participant data, and also report the limitations of that protection. The
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informational elements, noted by the scholars, should be tailored to the local context, taking into
account data protection laws, as well as resident concerns.106 The next section looks at the
recommendations that focus on developing partnerships that unite the expertise of researchers
and clinicians with the goals and perspective of the participants to create a thriving PMI cohort.
2.4. Recommendations
Scholars like Ma'n H. Zawati notes that critical challenges, especially in knowledge
transfer of the genomic information into clinical care and research exist to PM’s broad
implementation in healthcare; which also affects achieving greater patient and clinician
engagement and trust. To move the genomic agenda forward, the scholars recommend that there
needs to be collaboration between enthusiastic health professionals, forward-thinking public
health practitioners, and a supportive and well-informed public, to address the complex issues of
equity, utility, and translation. Zawati further adds that large numbers of samples and data need
to be collected and analyzed to investigate “gene-gene, gene-disease and gene-environment”
interactions over time. However, in their opinion, this can be achieved in such breadth only
through collaborative efforts in population studies.107 Scholars like Erik Parens also views public
role as central in PM, which he states is driven by trust, shared belief in the common good and
thoughtful engagement. It is critical that these are taken into careful consideration in the
implementation of PM into healthcare settings.108 The next two sections look at addressing
concerns about patient autonomy and building trust, which are critical in implementing PM into
the healthcare setting.
2.4.1. Retaining Autonomy
The data generated for applications in PM raises concerns about patient autonomy and
the trust connecting all - patients, clinicians, researchers and industry in real time. Even though
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there are more research on PM, patients still remain less knowledgeable about PM and its
applications, and this creates a fundamental ethical challenge that needs to be addressed before
PM can be implemented. According to scholars like Jane Kaye et al., retaining autonomy is vital
in the physician-patient communication and the decision-making process in PM, and informed
consent and its conception are critical components in addressing the ethical issues related to
participant abuse in research ethics and PM. Kaye et al. note that PM raises issues of abuse in the
form of infringements of privacy and the misuse of information. They explain that the process of
obtaining informed consent was partly meant to ensure that individuals were not coerced into
decisions. They also add that information may have different meaning for different people,
thereby affecting individuals differently.109 Zawati adds that PM is complex since the precise
specifications of future use of data cannot be provided at the time of research initiation, and
therefore, creates greater concern of (maybe not) “adequately” informing patients. Furthermore,
traditional notion of informed consent focuses on the individual, which in genomics research,
presents pressing issues also for the family, community, and population groups in addition to the
individual.110
While traditional autonomy strives to provide direct benefit to the patient, human genetic
research aims at benefiting the future generations as well. As Zawati points out that although
individual autonomy's sole focus is on the participant, population studies destabilize the balance
created by the various stakeholders involved - with the ultimate goal of better health for the
population, which in turn, increases public trust in these endeavors.111 According to scholars like
Alessandro Blasimme and Effy Vayena, population biobanks are limited in what information
they can divulge. They highlight that with such large volumes of data, usually involving more
than 10,000 individual, it can be tiring or even impossible for these projects to re-consent
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individuals every time a researcher's request for access is received. Therefore, they add that the
nature of consent and its specificity are limiting in fields of innovative technology that generate
vast amounts of non-interpretable data.112
However, Blasimme and Vayena argue that PM not only promises to change our
understanding of a disease and the way health care is delivered to patients - but also controls how
research participants and patients are considered in its developmental process, and their
entitlement of information in the treatment decision-making. 113 They add that this initiates the
stage for bioethical debates and public discussion about novel issues such as rights and interests
of those who participate, and this leads to the trust building that is necessary for PM's cohort to
take shape. They further emphasize that participants should be offered meaningful ways to
become a part of the precision medicine community. 114 Sabatello and Appelbaum also agree that
participants should be offered options to become members of such a community and have access
to those freedoms. They suggest offering a detailed description of the cohort’s governance
structure and the opportunities that are associated with the cohort. They add that public
participation will also help balance relations of power and control between research participants
and scientific experts, and ultimately build public trust.115
2.4.2. Building Trust
According to Stoeklé et al., PM faces a crucial ethical challenge in maintaining and
improving the trust of patients, clinicians, researchers and industry in academic medical centers.
Indeed, the Presidential PMI rests on an appeal for citizens’ sharing of genetic, environmental,
and lifestyle data in exchange for partnership and engagement to further advance individual,
community, and population health.116 Research suggests that engaging participants in the design
and conduct of the PMI cohort can lead to increased public trust initiative.117 Kaufman et al.
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suggest the need for appropriate modern digital communication networks to maintain the trust
and to improve the organization and effectiveness of the system. They also add that there is an
inherent need to reconsider the form and content of informed consent (IC) documents at all
academic medical centers, and a dynamic and electronic informed consent (e-IC) need to be
introduced.118 Kaufman et al. point out that participation informs people about the initiative.
Information sharing will be critical for PMI, as it will not only foster trust but will create
willingness within the people to participate.119 As Stoeklé et al. noted from a study conducted by
NIH, participants were interested in "governance-related tasks," and they highlighted that it
would be beneficial to give participants the feeling they were "equal partners" in the initiative.
They also noted that participants trusted the NIH researchers with their data; however, they were
not comfortable sharing it with international entities. Therefore, they suggest addressing the
negative attitudes about sharing of data with participants and clarifying how sharing would
benefit all.120
The PMI Report highlights the importance of building and retaining trust through
collaboration amongst researchers and the communities for the success of the PMI. According to
the Report, studies has shown trust to be based on communication – leading researchers to
believe that open and safe communication, anywhere, at any time would allow participants to
trust the system and share their personal samples and data.121 Educational efforts and
comprehensive safeguards put in place for the protection of participant data have been viewed as
critical in building and maintaining trust. According to scholars these goals also form the basis
for recommendations regarding data access.122 According to Joseph D. McInerney, education
that prepares the public for a genetically based revolution in medicine will require two things:
the central message should be about the variations and individuality; and increased educational
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emphasis should be put on the nature of genes in species and population.123 Additionally,
Hawkins and O'Doherty add that education should also prepare the public for the transformation
of medicine based on genetic perceptions of diseases.124 They also add that deliberative
democracy can be used to enhance informed and widely representative views of the public
interests. They add that deliberative forums that allow bi-directional exchange of information can
be influential communication between policymakers and the public.125 Holly et al. also agree
that deliberative forums offer a possible solution of bringing together a diverse group of lay
citizens in the effective formulation of recommendations for policymakers. This can greatly add
to the issues of social and ethical implications of biobanks and create an opportunity for an
informed debate.126
Furthermore, Holly et al. highlight that literature reviews reveal that understanding the
public perception about genetics and genomics research, public concerns, and public attitudes
towards using genetic and genomic information in making health decisions is critical in the
planning and provision of genetic services, and policy and ethical decision-making. They add
that diverse community engagement methods such as Focus groups, surveys, and interviews can
be instrumental to engage community stakeholders in PM research initiatives.127 In the era of
PM, transparency and accountability will be vital to foster trust and participation in genetics
research; in turn, it will also help provide information to general practitioners who are faced with
increasing numbers of patients curious about their predisposition to illnesses. According to a
survey, a large number of respondents responded positively to the use of genetic information in
health-related decision-making, which is consistent with positive attitude toward the application
of genetic advances.128 Kaufmann et al. highlight that although the aim of the PMI, launched by
President Obama in 2015, was to speed up the implementation process of PM in all areas of
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healthcare; the speed has not picked up yet. Kaufman et al. point out that by providing consumerfriendly educational resources to the public can speed up the implementation process by helping
people understand PM’s approach in determining the genetic predispositions to diseases, and
identification of disease risks; and how effective treatment (through PGx) are generated. 129
Conclusion
Scholars have defined PM as a predictive, preventive, personalized, and participatory
healthcare service delivery model.130 The national cohort study of PMI aims “to foster open,
responsible data sharing, maintain participant privacy, and build on strong partnerships between
researchers and participants," as noted by André J Sheen. Through this initiative, participants
will have access to findings from the research, as well as personal research results. 131 The
medical impact of PM will be less than revolutionary if proper implementation and translation
processes are not in place, and that involves public trust and participation, through education.132
There are considerable challenges for families, researchers, and policymakers that need to be
addressed in order to ensure the protection and fair treatment of patients and participants if PM is
to be implemented in the primary care setting. In order for PM to be successful, addressing
people's fears through informed public discourse is essential. Scholars like Hawkins and
O'Doherty argue that public discourse that involves deliberative civic engagement to explore the
public values, concerns, and interests underlying recommendations about biobank governance to
achieve trust in biobanks through accountability, transparency, and control - is essential. 133
Genetic variation can have significant impact on patients’ response to different drugs, even
causing serious side effects and death.134 PGx gives the new definition to drug development, and
selection of the drugs to the patient based on their genetic make-up, greatly reducing ADRs.135
As scholars like Dua et al., and Beery & Smith highlight that the ultimate aim of PGx research
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will be to provide the knowledge of individual variation in genes controlling drug dose, and drug
response, to improve efficacy, to avoid toxicity, and treatment failures. 136, 137 The next Chapter
looks at PGx in response and toxicity to drugs
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Chapter 3: Clinical Significance of Precision Medicine – Genomics and Pharmacogenomics
(PGx)
3.1. Introduction
Despite the advances made by modern medicine, life spans are still lower in the U.S. than
comparable countries due to lack of access to care, unattainable cost containment for research,
and development, and clinical use - especially for new technologies such as precision medicine
(PM). The Agency for Health Care Research and Quality (AHRQ) made the observations that
unsafe and ineffective drugs cause avoidable deaths; adverse reactions (ADRs) resulting in costly
hospitalizations; and wastage resulting from discontinued medications. They also noted that the
efficacy of prescribed medicine was around 50% to 60% for most common ailments and only
20% for cancer therapies - with ADRs resulting in more than 770,000 injuries and deaths each
year, resulting in costs up to $5.6 million per hospital, depending on the size. According to
Vogenberg et al., a report published in 2009 by the National Academy of Sciences emphasized
the need to monitor and treat any malfunction according to the individual patient.1 Scholars like
He et al. are optimistic about the potential of PM, especially in improving the practice of
medicine and its outcome, by increasing accuracy and efficiency of drugs through the use of
Pharmacogenomics (PGx).2 Brian Godman et al. also asserts that PGx studies are anticipated to
tailor treatments based on the variation of individual's genetic variation, thereby effectively
enhancing drug effectiveness, and reducing toxicity, and resulting in the improved management
of conditions from prevention to treatment - depending on the availability of targeted therapies.3
However, Fradkin et al. adds that the lack of infrastructure and mechanisms for data collection,
storage, and sharing will create impediments in the implementation of PM.4 Scholars have also
pointed out that physicians would be critical players in the implementation process and eventual
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success of PGx, and must be taken into the implementation equation. This Chapter looks at PM
and the area of PGx, and its clinical significance; while looking at the essential challenges that
include ethical and social challenges that need to be identified and addressed in order to realize
its potential in the clinical realm fully.
3.1.1. Clinical Significance - Impact on Healthcare
According to Nicholas Rose, PM through the use of PGx is anticipated to potentially
enable tailored treatment on the basis of genomics of an individual’s disease-pharmacogenomics,
with greater accuracy and efficiency. Rose adds that it is expected to not only allow diseases to
be correctly diagnosed, but also predict the correct disease in advance prior to symptoms, and
also improve the efficiency of medication with the correct dosage, and prevent administration of
drugs, which will be ineffective or cause toxicity, and ADRs - all based on the patterns of genetic
variations.5 Although, PGx was initially focused at being, “personalized, predictive and
preventive medicine,” that has however, shifted to disease susceptibility.6 As noted by David J.
Duffy, advances in PM have already led to improvements in therapies in certain cancers and
cystic fibrosis, as cited by President Obama, where targeted therapies based on genetic mutations
now can treat the underlying cause of the disease. Duffy also adds that PGx holds the promise for
the identification of novel therapeutic targets that could “fuel the development of new
pharmacological agents” for the prevention and treatment of disease.7 Duffy insists that these
extremely ambitious goals of PM may bring numerous rewards such as reducing the everincreasing healthcare costs, and more importantly, improving the welfare of citizens and patient
outcomes.8
Cancer is a potential area of focus for PM.9 According to Raymond Bingham, BRCA
testing for breast cancer has a large financial and public health impact due to its high cost, and

41

the high volume of tests ordered, as well as the cancer detection and prevention measures
subsequently chosen by those tested. Breast and ovarian cancer remain among the most
significant causes of morbidity and mortality among U.S. women; and have a dramatic impact on
the quality of life for millions of patients, survivors, and their families. Bingham notes that
roughly 5 to 10 percent of breast or ovarian cancers in the U.S. have a genetic, or hereditary,
component. He highlights that the risk for hereditary breast and ovarian cancer (HBOC), based
on family history, can be of high concern for any woman if cancer occurred in her birth mother
or another female family member closely related by blood - such as a grandmother, aunt, or
sister; if the diagnosis was made in the affected person before age 50; or if it occurred in a male
family member.10 Bingham insists that the prevention and early detection of these cancers are
highly desirable and can save lives. He is very optimistic that the advances made through HGP
will make it possible to identify women with HBOC. According to Bingham, the highest lifetime
breast and ovarian cancer risk known for these women: 50–80 % for breast cancer and 11–65 %
for ovarian cancer; and these women are also more likely to develop cancers at younger ages
compared with the general population.11
Scholars like Elvira D'Andrea et al., note the options that are available for women with
HBOC. Some of these options include managing essential and difficult decisions that are
better/effective to start early in young adulthood, such as cancer screening, chemoprevention,
and/or preventive surgeries. It has been demonstrated from research that early detection of
BRCA1 and BRCA2 genes have resulted in effective cancer diagnosis and early detection, and
increased overall cancer-specific survival. They point out that an estimated up to 1 million
people in the U.S. carry a BRCA1 or BRCA2 gene (BRCA) mutation, and more than 100,000
people undergo BRCA testing annually, and moreover, BRCA testing is usually covered through
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private insurances, making it available, and accessible.12 Karen Lisa Smith and Claudine Isaacs
also note the clinical significance for genetic testing for common conditions (e.g., cancer) and
their use in PM for several reasons: 1) BRCA testing is clinically proven, being used for more
than 15 years; 2) there is evidence for its clinical utility, and 3) published guidelines are widely
available for its appropriate use. They assert that such testing allows for early detection, thereby,
often resulting in prevention, and treatment. However, Smith and Isaacs also note, despite the
advances in BRCA testing, personalized cancer medicine due to its young age still needs more
information regarding the management of BRCA mutation-associated breast cancer; and this
issue exists for other genetic tests which are being introduced into clinical care for a range of
other health conditions.13
PM is widely used in PGx to indicate the safety and efficacy of drugs for patients.
However, the ultimate goal of PM as Duffy points out is the prevention, and control of infectious
and chronic diseases, both nationally and globally. Duffy adds that PM approaches are being
developed to improve the outcome and quality of life of patients with such conditions, both at the
“disease-specific and the co-morbidity level.” 14 Scholars like Rose points that the genomic
information generated through genome sequencing technologies allows for the stratification of
the population into groups with different probabilities of responding, to particular types of
medication or developing an ADR. Rose is hopeful that this stratification will ensure efficacy,
compliance, the accuracy of dosage; and thereby minimize ADRs, which will eliminate waste.
Rose explains that the reality of PGx is misconstrued and is not about providing individually
tailored drugs, but to utilize the information generated in the stratification of population into
groups with different probabilities of responding to particular types of medications or developing
ADRs.15
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Scholars like Semiz et al. are optimistic about the benefits of PGx in the improved
treatment management of chronic diseases such as Type 2 diabetes mellitus (T2DM), and in the
effective prescribing of oral antidiabetic drugs (OAD). T2DM is a known worldwide epidemic.
Patients are afflicted with considerable health and economic burdens. Semiz et al. add that more
than one drug is often used to treat T2DM patients that include OAD, and drugs to treat diabetic
complications, such as “dyslipidemia and hypertension.”16 Per Semiz et al., significant
pharmacogenetic evidence has demonstrated several variants related to “drug-metabolizing
enzymes, drug transporters, drug target, and diabetes risk genes,” to be linked to inter-individual
differences in the OAD therapeutic and side effects. PGx identification of drug-genotype
interactions of the OAD treatment might have clinical implications soon resulting in the selection
of more specific personalized therapy in T2DM. They note that although benefits are anticipated
for patients with certain monogenic forms of diabetes, there is anticipation for individualized
treatment options in the more common polygenic forms of diabetes as well. However, Semiz et
al. add that epigenomic research will also be needed to address potential barriers to the
translation of pharmacogenetic findings, in order to expand the scope of PGx towards optimized
drug therapy.17
According to Robert N. Schuck et al., PGx is also essential in the labeling of drugs,
which provides clinicians with information about its safety and efficacy and aids in preventing
ADRs, which is critical in influencing regulatory decision-making and clinical uptake of the
resultant prescribing recommendations. These are incorporated into drug development programs
and included in indication statements during the initial approval of many drug products.18 The
scholars add that although many kinds of pharmacogenetic information have been included in
drug labeling, the most important change has been the approval of targeted drug therapies for
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genetic subsets, widely adopted in the oncology community. The advent of targeted therapies has
been “lauded as a major medical breakthrough;” however, they add that research activity is
increasing in other fields as well. 19 According to Johnson et al., clinical pharmacology is
inclined in uncovering and using the information that causes the “interpatient variability” in drug
response to benefit the patient. Although “pharmacogenetics” was coined in the 1950s, it was not
until recently (past decade), that it was extensively used in research for discovering drug
efficacy, toxicity and dosage based on the genetic variants. They also add that PGx research on
cardiovascular drugs, although young, holds much potential and has already led to understanding
of the metabolism and pharmacological mechanism of many commonly used cardiovascular
drugs such as Warfarin.20 The next section looks more thoroughly at genomics and PGx.
3.1.2. Genomics and Pharmacogenomics (PGx)
Genomics is the foundation for PM, which aims to individualize care by understanding
differences in genetics, lifestyle, and environment.21 Substantial information demonstrates that
individuals vary on a genetic basis in their response to drugs - and PGx is promising because of
its potential to direct drug prescribing to increase safety and effectiveness.22 According to
scholars like Andrzej Śliwczynski and Ewa Orlewska, a growing number of drugs are present
today whose efficacy is tied to the presence of one or more molecular alterations - especially
used in oncology, with FDA-approved drugs targeting mutated genes. They note that off-label
prescription of the drug targeting the alteration is possible whenever such actionable mutations
unexpectedly occur.23 They also add that PM promises to accelerate the ability to recognize
disease heterogeneity and create new distinctions using large numbers of measurements, to
create prediction models in chronic diseases on large populations of patients.24 Additionally,
scholars like Andrea Sboner and Olivier Elemento assert that PM strategies in chronic diseases,
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such as diabetes and CVDs show that the addition of big datasets to the course of individually
profiling diseases and patients will be the key to developing PM.25
According to Dickmann and Ware, PM aims: “to offer the right treatment to the right
person at the right dose, thus maximizing efficacy and minimizing toxicity for each individual
patient.” They note that ‘pharmacogenetics’ and ‘pharmacogenomics’ are broad terms that tend
to be used interchangeably, and there remains debate as to the most appropriate definition and
use of each term. However, the aim of this Chapter is not to differentiate between the two terms,
but rather highlight that the terms both refer to the ability of genetic-based testing, to give the
correct drug at the correct dose to the correct patient, thus maximizing efficacy, and minimizing
toxicity.26 Dickmann and Ware also add that the ultimate goal behind PGx approaches in drug
discovery and development is to treat the appropriate classified group of patients “to maximize
efficacy and minimize toxicity.” 27
As pointed by Zhi-Wei Zhou et al., PGx studies the effects of genetic factors on an
individual's response to pharmacotherapy, especially to the risk of ADRs – which are a
significant public health concern and cause considerable patient morbidity and mortality.28 Zhou
et al. add that in the past 60 years, PGx has been applied to identify the genetic determinants of a
drug’s effect to maximize drug efficacy, reduce and minimize the ADRs, and select responsive
patients.29 Godman et al. also note that adverse drug event can be greatly increased by individual
genetic variability, thereby reducing effectiveness of drugs and leading to poor quality care
increasing costs. The scholars suggest that recognizing the complexity of the various biological
systems involved in different diseases can help explain the high number of non-responders to
certain drugs; adding that this increased knowledge can also impact drug development policies.30
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Genetic tests have the ability to identify the patients who would potentially benefit from
the drug therapy of interest, as noted by scholars like Hiroyuki Morita and Issei Komuro. They
add that adding PGx data to the variables for pre-specification in the clinical studies will allow
more accurate comparisons of the responders and non-responders, and thus improve the quality
of clinical studies.31 Additionally, Godman et al. observed that an estimated 20% to 95% of the
variation in drug disposition is attributed to genomes, translating into differences in clinical
outcomes including benefit and side-effects – resulting to the need for different dosing regimens.
Even then they add that current treatment regimens still tend to use ‘general or average’ doses. 32
Godman et al. add that PGx, through the inclusion of the identification of host genetic factors
such as biomarkers, that influence drug absorption, metabolism, and action at the receptor level,
could reduce the trial size, as well as minimize the toxicity.33 They point out that the use of
biomarkers with existing drugs has improved patient management, and can additionally increase
the number of drugs that can be more rationally prescribed and dosed.34
Scholars like Antonio Aceti looks at the potential of PM in infectious diseases and other
noncommunicable diseases, and asserts that PM through PGx has great potential to revolutionize
the prevention, diagnosis, and treatment of infectious diseases, and other noncommunicable
diseases. Aceti highlights that antibiotic resistance has become a predominant challenge in the
therapeutic management of infectious diseases, mainly due to the improper prescription and use
of antimicrobials. The ability to determine the antimicrobial resistance of different pathogens
using whole genome sequencing holds great promise.35 Mary S Hayney notes, through the use of
comparative genomics (using bioinformatics and microarray technology), “virulence
determinants, antimicrobial drug targets, vaccine targets and new markers for diagnostics” can be
identified. Hayney adds that human genomics also assists in the informed disease management
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by adding to our understanding how individual genomic variation affects response to the
pathogen, and to vaccine or drug used to prevent or treat infections. Hayney is optimistic that this
new understanding of the genome of the pathogen and the human genome will likely yield
multiple targets for drug development.36
Robert N. Schuck points out that genomics and PGx play a vital role in predicting
response to therapy and vaccines, and ADRs. PGx testing strategies have been recognized as a
valuable tool by the FDA, resulting in FDA to proactively incorporating PGx information into
labeling of new and drugs already on the market. However, they add that despite the readily
translated examples in routine clinical care, utilization of this information is still limited.37
Hayney add that PGx approaches to drug therapy have the potential to improve patient outcomes
by allowing clinicians to preemptively adjust dosages or choose alternative agents based on the
expected response associated with a given genotype, potentially resulting in greater
effectiveness, or fewer adverse events, or both. They further add that much knowledge needs to
be acquired and many obstacles overcome before the information can be translated into proper
interventions.38 All in all, Hayney asserts that PM will offer multiple rapid diagnostic for
identifying susceptibility patterns to infectious diseases over time that will provide clinicians
with real-time, crucial clinical information that should greatly improve the prevention, treatment,
and management of diseases - saving lives, improving the quality of life of infected patients, and
reducing healthcare costs.39
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3.2. Role of PGx in Toxicity and ADRS
Substantial studies show the potential of PGx in avoiding toxicity from use of drugs in
patients, and greatly reducing ADRS. As noted by Aceti, serious ADRs classed as idiosyncratic
reactions (IDRs), not directly related to drug concentration but may be due to an unusual patient
phenotype, are a significant cause of death and serious illness in patients. Aceti also states that
IDRs are an important cause of drug attrition in the pharmaceutical industry, both during drug
development and after licensing.40 Daily asserts that PGx gives the new definition to drug
development, and selection of the drugs to the patient based on their genetic make-up, greatly
reducing ADRs.41 Moreover, J. Dua et al. insists that knowing the individual variation in genes
controlling drug response would allow clinicians to personalize medicine and select the
appropriate drug at the appropriate dose.42 Scholars like Theresa Alice Beery and Carolyn R.
Smith also argue that the ultimate aim of PGx research is to provide information for PM, by
providing accurate medicine with the appropriate dosage to the patient, to improve efficacy, to
avoid toxicity, and treatment failures. They add that PGx research has the potential to a better
understanding of “drug-drug response and drug-organism response.” 43 The next section looks at
PGx in response and toxicity to drugs.
3.2.1. Response and Toxicity to Drugs
Primary care is changing rapidly with the use of electronic medical records (EMRs),
which according to Dua et al., is redefining the way we approach disease management by
reducing risk and optimizing quality.44 With the advance of PM, a complete understanding of
DNA sequence variation is needed to modulate drug response.45 Although traditional non-genetic
factors, such as age, organ function, other medications, and disease status, can affect drug
response - there is substantial evidence, according to Sonny Dandonna, that shows genetic
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variations to play a causal role in the alteration of drug response and drug clearance - especially
in “drug absorption, disposition, metabolism, and excretion, and drug action in patients.” 46
According to the WHO, people differ in their response to medication due to differences in
genetic make-up that interferes in drug processing and metabolism, and results to a medicine's
effectiveness and possible side effects. Therefore, Zhou et al. emphasizes, a better understanding
of how the genetic variations work in drug response is necessary and can have important
implications in the efficacy of drugs in patients. They add that the PGx research aims to
investigate the association of inherited genetic variants with response to drug therapy, including
drug efficacy or adverse effects, utilizing this search throughout the entire genome.47
The Nuffield Council on Bioethics points out individuals varies significantly in their
response to drugs due to genetic variations. They add that most drugs are effective in only 25%–
60% of patients, making it a challenge to optimize a dosage regimen. According to a study it was
noted that various genetic factors contribute approximately 20% – 95% to determine the
interindividual variability in drug responses. PGx enables scientists to assess specific genetic
variants that may be responsible for an individual's particular drug response by identifying the
specific genetic loci involved.48 Today, on an average, 30-60% of drugs work effectively in
patients' illness. Chunmei Huang and Jose C. Florez argue that the application of PGx will bring
the success of drugs to 100%. They add that in many cases of chronic diseases, patients were/are
mistreated or misdiagnosed due to a lack of exact symptoms and medications. The scholars are
hopeful that PGx will help with chronic disease diagnosis and treatment, and increase patient
longevity.49
Shabbir Ahmed et al. also argue in favor of PGx stating that PGx has been able to achieve
great accomplishments in achieving PM, specifically in cost-effectiveness. They cite Single
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Nucleotide Polymerase (SNP) screenings as an example of PGx, which allows pharmaceutical
companies to exclude people who would not benefit/or be harmed from testing certain drugs in
clinical trials; thereby, facilitating smaller, less expensive and safer clinical trials.50 They add this
ability of excluding people who will not benefit, will increase both physician's confidence in
prescribing drugs, and also the patient's confidence in taking the drug. This will in turn, make it
cost-effective, safe and precise, and is estimated to eradicate the likelihood of any ADRs –
reducing more or less 100,000 deaths, and two million hospitalizations in the United States every
year.51 Ahmed et al. also add that PGx studies can be used at various stages of drug development,
and can be used for stratification of patients based on genotype - resulting in a better selection of
effective therapy and eliminating treatments from ADRS.52
Another primary goal of clinical PGx according to Dua et al. is to establish “phenotypegenotype associations” through genetic tests that reveal genetic predispositions to disease and
drug toxicity. They add that the practical purpose is to “identify patients who are drug responders
and patients who are prone to drug toxicity.” They also add that this is a very challenging task
due to the complexity of human genome and diseases, and only limited success has been
achieved in recent years.53 Per Dua et al., genotyping in the area of CVDs may be applied to
predict risk for drug toxicity, such as risk for myopathy with statins, with the possibility of its
application “on a broader scale to choose the best combination of drugs to treat complex
diseases, such as heart failure.” Currently, the scholars highlight that PGx data are being used to
guide treatment in the clinical setting.54
It is evident that PGx is increasingly influencing medicine and biomedical research in
many areas, including clinical medicine, drug development, drug regulation, pharmacology, and
toxicology.55 Dua et al. highlight that routine screening and prediction of drug response is
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currently the focus of ongoing PGx research for the rapid determination and validation of
individual genotype that would result in the prediction of drug response and avoidance of
toxicity.56 Currently, there is an increasing demand for the application of PGx to predict
unwanted ADRs associated with genetic variants in clinical practice. Scholars like Qiang Ma and
Anthony Y. H. Lu add that there are a growing number of genetic variations “in genes encoding
drug metabolizing enzymes (DMEs), drug transporters, and drug targets that have been
identified” – that show an association with ADRs with varying strengths of evidence. However,
they add that there are many challenges and hurdles along the way to fully understand, and
elucidate the contribution of genetic variations to ADRs, and to translate it into clinical
practice.57 The next section looks at ADRs.
3.2.2. Adverse Drug Reactions (ADRS) and Costs
According to Dr. Edgard, more than 2.4 million people suffer a serious adverse drug
reaction, and more than 100,000 die every year in the United States alone. Johnson and Cavallari
add that this is usually due to inappropriate drug or incorrect dosage or because of the person's
genetic make-up which metabolizes medication to rendering it as ineffective, or deadly with side
effects. The application of PGx allows for the best drug and dosage to be determined for the
patient. They also add that many of the FDA-approved drug labels mention available genetic
tests today; and FDA-approved genotyping kits can also be used to evaluate the metabolism of
multiple medications.58 Steven R Kayser adds that the tests are, however, still not affordable for
all - ranging from $400 to a couple of thousands, and aren't routinely covered by insurance.59 As
Qiang Ma and Anthony Y. H. Lu note, ADRs are a significant concern in both clinical practice
and the pharmaceutical industry that owes to substantial morbidity and mortality in patients. Data
from PharmGKB, a web-based pharmacogenomics resource, have identified at least 244
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pharmacogenes associated with ADRs of 176 clinically used drugs. Moreover, 28 genes with
potential pharmacogenomic biomarkers associated with ADRs have been listed by FDA. The
scholars assert that the availability and affordability of PGx testing tools is allowing PGx to be a
feasible tool for the prediction, reduction, and minimization of ADRS in selected populations.
0.32% out of 6.7% of the hospitalized patients in the U.S. experience from fatal ADRs, ranking
ADRs between the fourth and sixth leading causes of death.60
An estimation of the annual cost for ADRs is over $136 billion. As Zhou et al. point out,
multiple factors can cause ADRs, including drug co-administration, lifestyle, age, and diet.
However, increasing evidence shows that “inter-individual” genetic differences are a significant
contributing factor to ADRs. Zhou et al. note that genetic variations in drug-metabolizing
enzymes (DMEs), drug transporters, and drug targets substantially contribute to the alteration of
pharmacokinetics and pharmacodynamics. A lot of research has been done to understand these
differences in order to find an association between these variations and ADRs. As the scholars
point out, many genetic mutations that result in cancer have been found to have associations with
ADRs. The drugs that can cause increased ADRs in patients with genetic mutations, as
highlighted by the scholars, mainly include anticancer drugs, cardiovascular drugs and
antipsychotic drugs (for the central nervous system).61
According to Dr. Edgard, the FDA has listed at least 50 genes as clinical
pharmacogenomic biomarkers that are significantly associated with “altered drug response,
clearance, and/or risk” of ADRs of more than 145 drugs. While looking at chronic heart failure
(HF), it was identified that the individual patient responses to HF pharmacotherapies are highly
variable due to genetic variations. Even though pharmacogenomics has proven successful in
other therapeutic areas, Dr. Edgard suggests more research is needed to prove the success of
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pharmacogenomics on HF.62 Dr. Edgard also adds that HF pharmacogenetics associations may
be race-specific, dose-specific, sex-specific, and drug-specific.63 According to Zhou et al., it is
unethical to assign patients the ‘regular’ dose or even the medication if it is not even beneficial to
the patient.64
As noted by Zhou et al, and Jasmine A. Talameh and David E Lanfear, genetic variations
in drug transporters are important factors in determining ADRs and drug response, since they
lead to alteration in the activity and/or protein expression level causing altered drug response.
Talameh and Lanfear note that about 50% of drugs interact with membrane receptors; therefore
genetic variation will cause significant alterations in drug response.65 Talameh and Lanfear
further add that applications of Genome-Wide Association Studies (GWAS) have increased the
identification of genetic mutations associated with ADRs. Although this approach is still limited,
many common and rare genetic mutations associated with ADRs have been identified. Many
PGx tests have been approved so far which will minimize ADRs induced by genetic variations.
However, the scholars add that there is still need for more clinical trials to validate the genetic
variation-ADR association, and determine the cost-effectiveness and benefits of PGx in clinical
therapy.66
ADRs are common, associated with morbidity and mortality, and costly to healthcare
systems worldwide. Caudle et al. point out, even though genetic variations are factors in
predicting ADRs, there are other factors that can also affect drug responses such as the type of
drug, the patient, and the disease. The scholars assert that genomic testing can be potential in
diagnosing and monitoring those at risk in order to provide vital future improvements in the
benefit-risk ratio of drugs. As Caudle et al. note, this genomic information if integrated can
develop a comprehensive and integrated approach to better drug responses in patients in the era
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of PM.67 Zhou et al. argue that it is imperative to prevent ADRs today, not only to reduce
morbidity and mortality, but also to improve compliance with medications. They add that
discontinuation of effective treatment due to ADRs is also detrimental either in the short-term or
long-term. An example the scholars cite is cardiovascular medications – stating that withdrawal
can increase the risk of cardiovascular events and death. They further highlight that an estimated
20-30% of ADRs can be prevented by using PGx testing – which is a pretty significant benefit
associated with PGx.68
Even with the advancement of pharmacogenomics, patients still receive the same oldfashioned treatment, often leading to different drug responses and unexpected therapeutic
outcomes. Zhou et al. point out that pharmacogenomic-guided personalized therapy can assist in
maximizing drug efficacy, thereby, reducing the risk of ADRs according to the recommended
clinical dosing guidelines which are a promising therapeutic approach with great clinical
significance.69 They add that PGx brings with it a new set of promises as well as ethical
concerns. The possibility of improved drug safety and efficacy and cheaper, faster, and smaller
clinical trials would represent a big boon for the pharmaceutical industry and the public as a
whole. However, ethical, legal and social concerns that arise due to lack of knowledge, fears and
concerns about the application must also be addressed to facilitate the development of this new
technology while minimizing negative social consequences.70
3.3. Identifying and Addressing Challenges
Studies demonstrate that the rapid advances in PGx research will continue to lead to
improvements in the pharmacologic management of disease processes.71 As is, most of the PGx
drugs are already FDA-approved; therefore, adoption of PGx in the clinical setting is dependent
on the implementation of the appropriate technical infrastructure. Scholars like Karczewski et al.
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have pointed out, that PGx applications will likely be helpful to not only physicians in the
clinical setting; but can also provide better drug development tools to pharmaceutical companies,
and in the design of cheaper and faster trials.72 However, advancements in technology will also
present ethical and social concerns that will need to be addressed.73 It will be critical to identify
and address the anticipated challenges in order to usher in the era of personalized drug treatment
in PM. This section looks at the ethical and social concerns and other challenges that yet remain
in the implementation of the PGx from the bench to bedside.
3.3.1. Social and Ethical Concerns and Other Challenges
As Andrea Maluso demonstrates, the use of PGx testing has implications that are similar
to genetic testing, especially in regards to PGx surrounding privacy, and possible genetic
discrimination that could result in loss of insurance, denial of treatment, or employment. Maluso
notes that patient and physician attitudes are important factors that need to be considered in the
implementation of PGx into the clinical setting. Maluso points to findings from a survey that
demonstrated that 63%–75% of patients felt positively about the benefits of PGx tests in helping
them choose the most effective drug, the apt dosage, as well as the lowest side effects. However,
Maluso also points out that 69% of the patients feared test results could lead to discrimination
from employers, and 71% of physicians expressed similar concerns. It was observed from the
findings that both patients and physicians were concerned about health insurance
discrimination.74
Studies have highlighted that the application of PGx could lead to the stratification of
patients according to their response to medicine, or according to the diseases. However, there are
concerns that this stratification can create fear for discrimination and denial of treatment. Race as
a proxy, if used in the stratification purposes, can be problematic and lead to inaccurate results.
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As research suggests, denying treatment to a particular racial group by using race as a proxy for
genetic profiling would be problematic, since different people in a specific race may have
genetic variations, this could lead healthcare professionals to use race as a proxy in determining
and eventually denying treatment if the correct PGx test was not available.75 Moreover, it has
been feared that this type of stratification would result in serious social and ethical problems, if it
were used to deny treatment to already socially and medically disadvantaged population.76
Better monitoring of such stratification approaches would be wise in order to avoid future issues.
Moreover, studies have emphasized that psychosocial effects of PGx testing be taken into
consideration to avert ethical and social issues in the future due to them. Given the nature of PGx
tests, the tests may reveal the patient's susceptibility to illness for which there are no effective
treatments available – maybe because the medication available for that condition, for that person,
has been identified as ineffective or cause toxicity/side effects. Such information, instead of
being helpful, could be as distressing as the knowledge that one already has the disease. Other
issues may be of the knowledge of limited options available. Consent has been identified as
another serious ethical issue, since PGx may reveal (more) information to issues that are not the
topic of query for which no consent was asked. Therefore, consent regarding return of result may
be difficult, and also raise ethical issues.77
Scholars have highlighted that with increasing possibilities come increased demands and
rising costs. It is feared that with the advances in PM and its innovations allowing for more
personalized diagnosis and cures, it will lead to a highly stratified patient population. As Gronde
et al. point out the negatives of smaller population qualifying for better outcomes, which they say
means a lower volume of sales for pharmaceutical companies, resulting in increased drug pricing
to generate revenues. They add that although, this shift will allow for many untreatable diseases
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to be treatable, it will also make healthcare unaffordable - even in high-income countries.78
Olvey and Bootman assert that the high prices of drugs maybe equating to unaffordable
healthcare even in developed countries. Out-of-pocket costs, although not uncommon in the
U.S., are also feared as a possibility for (willing) patients if insurance companies will not cover
PGx testing, or cover for some, and not all – may make healthcare less affordable for some. The
scholars suggest that patients may be willing to pay out-of-pocket if they perceive the test to
inform clinicians about the appropriate therapies. However, Olvey and Bootman argue that if
insurance companies are willing to provide some coverage then PGx may be more widely
utilized. However, the scholars highlight that the degrees to which costs and other economic
factors will impact patient uptake of PGx tests remain uncertain. Moreover, they note that
increased costs may affect certain disadvantaged populations (without insurance or with less
coverage, or those who cannot afford the additional costs) more. 79
Studies have identified lack of education in genomics as a challenge that must be
overcome to implement PGx successfully. Scholars like Leslie J. Dickmann and Joseph A. Ware
note that physicians will play a critical role in implementing PGx in the clinical setting.
However, recent studies indicate that healthcare professionals do not feel adequately prepared for
this application. They highlight results from a survey on U.S. PCPs, cardiologists, and
psychiatrists that show only 12.6% of the respondents being extremely or very familiar with
PGx, and only 11% had any formal training in PGx, with only 37% either strongly or somewhat
agreed that they were self-reliant on their understanding on PGx. Scholars highlight that many
professional associations and academic institutions are working diligently to incorporate PGx
education and training in pharmacy and medical schools currently. They are hopeful that this
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implementation in the early phases of healthcare professionals’ career will increase their comfort
in utilizing PGx approach in their routine care process.80
Scholars have also related various data related to informatics and PGx into the EHR, to
guide drug selection and dosing. According to Hicks et al., clinical decision support (CDS) has
been identified as a critical tool for the implementation of PGx into routine patient care. They
cite that the large volume of evolving PGx knowledge presents challenges in integrating PGx
into clinical care.81 W. Francis Lam also state that the clinical implementation of PGx
biomarkers can raise social issues. Lam notes that there is a fear that patient’s socioeconomic
status (inability to pay for insurance/ or copayment) could prevent them from accessing the
potential benefits of PGx testing, and exacerbate the existing health disparities. Moreover, Lam
adds that the identification of a person as a nonresponders, or being at high risk for ADR, may
lead to incidents where PGx test can be used as a “gatekeeper” of accessibility to drug treatment.
And this might pose a problem, especially if there is no suitable alternative drug available, and
the patient is willing to take the chances. Lam also points out another potential concern, the
liability for the healthcare provider in the case if a PGx test is used to guide therapy, and a
different medication is prescribed which also affects the gene previously tested. Lam highlights
the need for some point-of-care mechanism that will make the clinician aware of the genetic test
results relevant to the prescribed drug, and guide in the treatment process. Lam also emphasizes
that the immediate implications with the availability of PGx should not be ignored for clinical,
ethical, and legal reasons.82
Although at least 10% of drug labels in the EU and USA contain information on genetic
factors determining drug response, studies have noted that very few genetic tests are currently
used in the clinical practice. Scholars like Ana Alfirevic and Munir Pirmohamed suggests that
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many reasons can be attributable to this slow implementation process of PGx. They highlight the
clear need for evidence that reflect the benefits of implementing PGx. Among other areas that
deserve priority, they highlight: lack of knowledge and training in using PGx testing, interpreting
results among healthcare providers; and the lack of computerized decision support with
appropriate information for clinicians.83
3.3.2. Recommendations
As highlighted by scholars, PGx will play a role as one of the first clinical applications of
PM, in drug dosage and preventing ADRs. Many challenges were identified in the previous
sections. However, infrastructure and regulatory hurdles remain to be discussed, especially as
scholars like Karczewski et al. and Toon van der Gronde et al. point out that developing ways to
continually update findings, delivering the knowledge to physicians, and integrating PGx into
medicine will be critical.84, 85 Well-designed infrastructure that allows the flow of validated
information from one end to the other to enable accurate use of the information in regulatory
submissions will be crucial in the era of PM.86 Patrice M Milos and Albert B Seymour explains
that the challenges lie in the ability to effectively mine the data sets with the clinical data, and
requires a comprehensive information technology solution. However, this will have to be
addressed to enable maximum return on investments in pharmacogenomics.87
Integration of PGx data, into the CDS in EHRs for clinician utilization will be critical.
However, once integrated this will be an essential tool to address the other implementation
challenges, such as the evolving PGx data, complexity of the tests and interpreting results. Hicks
et al. point out that curating PGx data with all relevant clinical recommendation will be an
essential role of the EHR with CDS, which will also distribute the information that is patientcentered at the point-of-care in clinical settings.88 Mary V. Relling and William E. Evans
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suggest that the cost and complexity of the computational approaches should also be identified,
and genetic variants that influence drug responses should be catalogued and prioritized for
addressing barriers of uptake of PGx testing. They also add that substantial level of expertise and
manual interpretation is still needed to apply PGx information in the clinic.89
Communication and collaboration between the various key players were also identified as
essential challenges that need to be addressed. The FDA regulates drugs and drugs labels in the
U.S. Karczewski et al. point out that it will be essential to develop a communication between
researchers and the FDA for the adoption of PGx information on drug labels; with evaluations
depending on the trial design, sample size, reproducibility, and effect size. As PGx research
continues and more data are generated, bioinformatics will play an integral role in the extracting
data and translating that into updated knowledge bases, such as PharmGKB, which will be
integrated into a centralized EMR system that will be accessible to all. They also add that a
curated and updated database with the FDA approved drug-gene interactions should be available
for the clinicians in order to implement PGx in the clinical setting.90
Another important recommendation made by studies was for all stakeholders, including
insurance companies, to be on board, and also beware of both the advantages and the
disadvantages of the applications of PGx to dispel myths and ethical issues. Moreover, genetic
testing facilities that meet the U.S. government's Clinical Laboratory Improvement Amendments
(CLIA) certification requirements need to be established to provide patients with adequate
genomic data for clinical use. The recent rise in drug prices is feared to create health disparities
and need to be addressed through policy frameworks. As Gronde at al., noted, “striking a balance
between rewarding investments in innovation, achieving reasonable drug pricing for
governments and securing equitable access to medicines will be the challenge.” 91 Moreover
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Gronde et al. state, access to medicines needs to be central to any policy intervention.
Transnational cooperation between various entities like the European Union, African Union,
World Bank or the WHO could create a collective negotiating power, by increasing their
bargaining power and bringing the drug prices down. Such cooperation would also lower
administrative costs, and also stimulate positive exchanging of trial data, and sharing of data, and
result in improved evaluation methods. Such a global framework for cooperation among drug
regulatory authorities would also increase the benefits even further by amplifying the WHO's
existing framework that helps in reducing drug prices by utilizing the essential medical list which
facilitates compulsory licensing.92
Better laws that address the concerns about the use or misuse of genetic information by
insurers and employers must be in place to protect individuals. As Vogenberg et al. note, GINA
signed into law in 2008 by President George W. Bush, explicitly prohibited employers and health
insurers from discriminating against individuals on the basis of their genetic risk factors.93
However, Gina has limitations, such as life insurance and long-term care insurance companies
are not prohibited from using genetic information, and GINA only protects patients who have a
genetic predisposition, but not with a diagnosed disease. Despite these concerns, scholars argue
that GINA enables people toward taking advantage of the predictive knowledge of genetic
research.94 However, to prevent discrimination due to stratification, it has been recommended
that those responsible for monitoring the access of different ethnic groups to treatments establish
procedures for assessing whether critical problems emerge from the development and
application of PGx.95
The public perceptions of PGx are important in part because resistance to PGx testing
could lead to patients not receiving the best care. Patients might not be given the most beneficial
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medicines if these are only prescribed with a genetic test which they refuse to take. Even more
serious is the possibility that a medicine may be administered without an associated PGx test and
result in a serious, predictable and avoidable ADR.96 Despite the benefits of PGx, D.C. Wertz
fears that PGx will likely be more beneficial to those who are more affluent, causing inequalities
between the developed and developing world. As with most expensive technologies, equality
will be a major issue for PGx, which will warrant for regulations that safeguards the benefits of
this revolution is accessible by all. 97 Public-private partnerships have been encouraged for
providing the funding efforts and the support needed to provide PGx research on the most
commonly used medicines to improve efficacy and safety.
Given the variation within racial groups, using genetic variants to categorize racial
groups have caused considerable debates about whether it will be meaningful in the field of
genetics. It has been observed that such categories are used in the development and marketing of
medicine in different countries. This can be concerning because such drugs are advertised
directly to consumers and there are serious risks if those medications are marketed using
misleading or even wrong information.98 It has been recommended that PGx researchers should
be aware that misunderstanding and prejudice may arise from racial stereotyping, and regulatory
bodies should be vigilant about claims of racial specificity in the marketing of PGx tests and
medicines.
Conclusion
As highlighted by Jesse J. Swen et al., PGx promises personalized medicine rather than
the established "one size fits all" approach to drugs and dosages, and will be one of the first
clinical applications of the PM. It has been expected that the reduction in trial and error as a
result of PGx would lead to efficacious drugs. Although, the recently commercially available
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PGx tests have been approved by FDA, their applications in patient care still remain limited.
This demonstrates that the implementation of PGx in clinical setting still faces significant
challenges.99 Scholars suggest that PGx will ultimately influence patient care by having an
impact on optimal target selection, and by increasing efficacy in clinical developments by
targeting patient populations based on genetically defined disease phenotypes - thereby
providing a clear benefit to physicians' to deliver better care.100 Johnson and Cavallari, and
Relling and William, both assert that there will be need for clear guidelines for translating
genomic knowledge into the decision-making process, but regardless of the barriers, we must
continue the research process of acquiring better understanding the genetic influences in drug
response and treatment processes.101, 102 Scholars also highlight the need for ethics in preventing
inequities and injustices from occurring in the name of so-called ethnic-therapies, or race specific
drugs; and enabling the advancement of a justified PM approach that will lead to the success of
health and well-being for us all.103
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Chapter 4: Relevance of PM in Infectious and Non-communicable Chronic Diseases and
Pandemics
4.1. Introduction
Research demonstrates that human genetic variants affect our risks for many of the major
non-communicable diseases (NCDs) - also known as common chronic diseases - such as
cardiovascular disease (CVD), diabetes, and cancer.1 Chronic diseases are concerning because
they cause serious personal and economic challenges in people. It is hopeful that precision
medicine can address these NCDs in the future and yield the most benefits for healthcare.2 So far,
scholars have highlighted PGx as the first type of PM approach that will be instrumental in
maximizing the potential benefits, and minimize potential risks of medications.3 Additionally,
PM is also expected to play a critical role in addressing infectious diseases, which remain a
challenge as of today - killing several millions of people each year due to the “emergence and
reemergence” of new and more virulent pathogens. 4 Genomics research is anticipated to be vital
in mitigating pandemic threats - such as Ebola outbreaks (most recent), severe acute respiratory
syndrome (SARS) and avian (H5N1), and pandemic H1N1 2009 influenza (commonly referred
to as ‘‘swine flu'') - to name a few.5 Moreover, scholars have highlighted the successful
application of genomic science in the design and development of vaccines, used in the successful
treatment for certain infectious diseases.6 PM’s major future goals, as discussed by scholars, will
include preventing premature deaths, reduction of healthcare cost, and better prevention and
management of infectious, non-communicable diseases and management of pandemics.7 Despite
all these advantages of incorporating PM into the clinical setting, it will be difficult to navigate
through the challenges and the ethical and social issues that are anticipated to arise for the
clinical practice, public health, as well as policy making in the era of PM.8, 9 The focus of this
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Chapter is to look at the importance of PM in infectious and non-communicable chronic
diseases, and pandemics - while identifying and addressing some of the anticipated challenges.
4.1.1. Precision Medicine in the Management of NCDs - CVD, Diabetes and Cancer
PM has the potential to be the emerging healthcare technology of the future.10 PGx
studies is expected to enhance the effectiveness and reduce toxicity of prescribed medicine based
on the knowledge of biomarkers in patient subgroups – in order to enrich the management of
diseases from prevention to treatment - depending on the availability of targeted therapies.11
Personalized treatment guided by PGx is one of the anticipated applications of ‘precisionpersonalized’ medicine that will be used in clinical practice.12 PGx holds promises of shifting the
way medications are prescribed, and is anticipated to reduce ADRs and toxicities.13 DNA-based
risk assessment has been recognized important in the determining of chronic diseases risk.
Different scholars like McBride, Godman et al., Favalli et al. and Beery and Smith et al., all
advocate for PM in the management of NCDs such as CVD, diabetes and cancer. It is not long
until PM will play an active role in healthcare. This section looks at PM, and its clinical
significance, particularly in the areas of CVD, Cancer, and Diabetes.
According to the WHO, NCDs have potential serious socioeconomic consequences.14
Each year, an estimated 9 million plus deaths are caused by NCDs throughout the world before
the age of 60 years, with associated negative impacts on productivity and development, creating
a significant burden on health systems, and on country economies (WHO, 2010).15 The WHO
also lists the leading causes of NCD deaths in 2008: CVD (17 million deaths, or 48% of NCD
deaths); cancers (7.6 million, or 21% of NCD deaths); and diabetes (1.3 million deaths).16 As
Miller et al. point out, developments in genomics, including low-cost next generation sequencing
(NGS) technologies; will hopefully usher in a more personalized approach to clinical care, with
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improved risk stratification and treatment selection.17 Beery and Smith note that there are clinical
genetic tests available for more than 1,500 diseases, with an additional 277 tests available for
participants in research studies.18 PGx has already been highlighted by scholars as an
instrumental application in the prediction of drug response and toxicity.19 Finally, de Denus et al.
highlight that PM promises the use of diagnostic testing to provide the best clinical decisions
based on a patient’s genetic profile, by analyzing the coding and structural variants in a patient’s
genome to provide information about the causes of existing conditions, future risks for disease,
and responsiveness to drug therapies.20
CVD: Favalli et al. note that coronary heart disease remains a leading cause of death and
disability worldwide. They point out that findings from decade-long genomics research in
Iceland suggest coronary heart disease is related to multiple genes. They further add that a
thorough understanding of the genetics of coronary heart disease would be helpful in
understanding the molecular mechanisms that would aid in therapeutic or preventive
interventions.21 Zaiou and Amri point out that cardiology has already taken the lead in applying
newer tools of PM, such as sophisticated phenotyping, combined with machine learning to find
patterns in diseases. Substantial evidence suggests that most of the burden of CVD is supposed to
have complex genetic and environmental origins.22 According to Morita and Komuro, many
successful stories show that Genome Wide Association Studies (GWAS) has been important in
the discovery of novel genetic biomarkers such as single nucleotide polymorphism (SNPs),
which have been effective in providing the knowledge of the likelihood of “disease onset,
progression prediction, and management.”23 Zaiou and Amri point out that these genetic
variations were also helpful in explaining observed “inter-individual” differences in
cardiovascular protection from different classes of used medications.24 To add to all these
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arguments, Wells et al. also agree that cardiac pharmacogenomics is a rapidly growing field that
offers the potential for improved treatment outcomes, as well as the prevention of adverse drug
reactions.25
Cancer: Cancer is predicted as an increasingly important cause of morbidity, and
mortality in the next few decades - in all regions of the world. The challenges of tackling cancer
are enormous, with the forecast that the estimated incidence of 12.7 million new cancer cases
reported in 2008, is expected to rise to 21.4 million by 2030. According to the WHO (2010), the
leading causes of cancer deaths in high-income countries “are lung cancer among men and breast
cancer among women.”26 The WHO states that cost-effective interventions are available across
the four broad approaches to cancer (breast, cervical, colorectal, skin and oral cancers)
prevention and control: through primary prevention (screenings), early detection, treatment, and
palliative care.27 Nora M. Gerhards and Sven Rottenberg noted that despite the substantial
advances in the treatment of various cancers, many patients still receive anti-cancer therapies that
are not beneficial in eradicating tumor cells, and instead inflict adverse side effects injurious to
the health of the patient. They added that a major goal of PGx is to identify predictive markers
for a personalized therapeutic strategy.28 PGx is steadily advancing in the area of cancer
genomics. Karczewski et al. add that the very nature of cancer is ‘‘personal,” since “each specific
cancer is caused by the unique sum of individual somatic mutations” (mutations that are not
inherited or passed and occur in the individual after birth). They add that currently, cancer drugs
are utilized in a “guess and test” manner and as a result, have many toxic side effects. 29
Karczewski et al. are optimistic that the ability to sequence cancer cells will enable researchers
with better knowledge of cancer cells and somatic mutations. This knowledge will greatly
empower physicians in the decision-making capacity and allow them to administer the best
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treatment for a particular individual, without wasting time on treatments that would fail.30 Berm
et al. note that it is important that the safest and most effective pharmacological treatment be
selected (to avoid severe toxicity), that is based on the molecular characteristics of both the
patient and the tumor. They add that providing the basis for the best-tailored treatment is not an
easy task since “multiple genes, as well as pathophysiological and environmental factors,” must
be taken into consideration. However, they add that PGx will be critical in establishing this
relationship with drug outcomes and biomarkers in order to provide the basis for the best-tailored
treatments – ultimately providing the optimized, cost-saving health outcomes by preventing
hospitalization due to ADRs associated with inappropriate, expensive drug treatments.31
Diabetes: Scholars like Elizabeta Topic, and Wang et al., pointed out that diabetes is a
worldwide epidemic with significant health and economic consequences - with 366 million
prevalent diabetes cases reported in 2011, and a projected 552 million cases expected by the year
2030 - becoming a leading public health challenge worldwide.32, 33 According to the WHO
(2010), diabetes is the seventh leading cause of death in the United States - two to three times the
health-care resources are required for those afflicted with this condition, accounting for up to an
increase of 15% of the national healthcare budget for diabetes care.34 According to Wang et al.,
an estimated ~285 million adults suffer from type 2 Diabetes Mellitus, and in the next 20 years
this number has been projected to rise to 438 million – and additionally, it is important to point
out that T2D etiology is known for having a considerable genetic component. According to twin
studies, the heritability of T2D ranges from 26% to 73%. The rapid development of genotyping
techniques has resulted in the identification of numerous T2D loci that has also been replicated
by GWAS among the world's major ethnic populations.35 Therefore, Herder and Roden are
optimistic that the identification of T2D-related genes could improve risk prediction, and lead to
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better prevention, and management of diabetes.36 Studies from the WHO have also identified that
the response to any antidiabetic medication may considerably vary between individuals due to
genetic variations.37 Therefore Zhou et al. is optimistic, advancement of genomics will help to
better understand the multifactorial etiology of type 2 diabetes mellitus (T2DM), as well as the
multiple subtypes of monogenic diabetes mellitus.38 A variety of PGx treatments already exists
for patients with T2D, in addition to dietary and physical activity.39 Läll et al. report that GWAS
have been highlighted as having high prospects in T2D risk assessment through the identification
of genetic risk score (GRS) - with the strongest association with T2D status in a populationbased cohort.40 Although, the current knowledge is not sufficient for the prediction of diabetes
risk or for decisions regarding specific prevention, or treatment measures using genomics –
Herden and Roden suggest that a more complete understanding of the genetic role in T2D, in
combination with lifestyle and environmental factors will be invaluable to the reassessment of
the clinical relevance of genotype data.41
4.1.2. Clinical Significance and Costs
Dandona and Roberts state that the availability of the GWAS in 2005 has substantially
enabled the identification of genetic variants related to drug risk, and drug metabolism, which
has been remarkable in identifying more than 1200 DNA common risk variants for more than
160 human diseases. The scholars are optimistic that PM will play a crucial role in avoiding
ADRs and allergies, which are responsible for more than 100,000 annual deaths reported in the
United States, with 2 million surviving after periods of hospitalization, costing over $4 billion in
the U.S. alone. The FDA claims ADRs as the fourth most common cause of death in the United
States. Dandona and Roberts furthermore, add that PGx in PM can be successful in prescribing
“the right drug, in the right dose, to the right person.” 42
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Bloss et al. also argue that PGx is the area of genomics that provides the clearest example
of the targeted utilization of genomics in order to provide individualized treatments, and
positively influence the clinical care. They cite the example of Warfarin, an anticoagulant
medication, most commonly prescribed worldwide for the prevention of stroke, and venous
thromboembolism. However, Warfarin metabolism can be affected by many factors, which
complicates its dosing. Bloss et al. add that there is evidence for the importance of genetic
variants in Warfarin metabolism which has led the FDA to update Warfarin's label to include a
statement acknowledging the importance of “genotyping during the early phase of dosing.” They
further add that as a result of this and PGx research efforts, there has been an increase in drug
safety and efficacy, to the extent that PGx today symbolizes genomics' role in disease treatment
and prevention of ADRs, and is a step forward in ushering in a new era of PM.43
According to Blaus et al., safety is a major concern for the use of PM by researchers,
drug developers, and regulatory agencies. They argue that amongst the many areas covered by
PM, the most exciting one is the ability to identify the likely responders through “genetic,
proteomic,” or other tests - so that only likely responders will be treated - reducing ADRs in
response to drugs, and increasing the potential benefits of the drug. Thereby, PM through PGx
has the potential to reduce the costs of treatment and at the same time, increase the efficiency of
drugs for individual patients.44 Blaus et al. also argue that “genomic or pathophysiological
markers” can aid in improving the efficiency of clinical trials, by identifying and enrolling only
the population in whom the number of events is expected to be higher, and with larger effect
size. Furthermore, they add that this will reduce the costs and the time needed to complete
clinical trials, as well as improve the effectiveness of the clinical trial.45
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Scholars like Claude Lenfant noted that CVDs remain the dominant cause of death
worldwide due to the limited clinical applications, due to limited knowledge of genetic risk and
mechanism of action of genetic factors of prevalent CVDs. However, they also note that PGx
research advances have widely opened the concept of PM in CVDs, and have become an active
field today, providing clinically valuable information regarding individualized, personalized drug
prescriptions, and contributing to the reversing of trends of expected CVDs.46 Fiona M Walters
points out that cancer is another potential area for PGx. According to recent work undertaken by
the European Commission funded Multicenter Collaborative Oncological Gene-environment
Study (COGS) on genetic variation and breast cancer risk - testing for genetic variants can be an
effective way to stratify the population. They argue that this will allow for earlier and more
frequent screenings of those with a higher genetic predisposition to breast cancer; while those
with lower risks can even opt out or be recommended to forgo the screening. Walters argue that
this could effectively minimize the harms of mammography, while still detecting most women
with breast cancer. Walters add that similar work is underway on CVDs, where risk scores
through genetic testing would identify people with higher risks before they develop the
“phenotypic markers of risk,” thus avoiding administration of statins to those who will not
benefit.47
Śliwczynski and Orlewska also looked at the role of PGx on diabetes. According to highdimensional EMR data, and genotype data from 11,210 individuals from Mount Sinai Medical
Center in New York, a tailored treatment plan of T2D using the characters of the diversity of the
patient population, looked more appealing than the one-size-fits-all approach.48 Śliwczynski and
Orlewska added that based on the findings, by using an accurate risk prediction tool and through
better risk targeting - higher efficiency of lifestyle interventions and limited occurrence of the
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side effects of metformin, for example, could be achieved. They argue that PM can be used to
determine the exact subtype sensitivity to therapies.49 They also assert that PM can be more
effective in a more proactive management of diseases and healthcare, that includes screening,
early treatment, and prevention, and could change the roles of both physicians and patients by
making them more involved in health care, and health research.50
Scholars like Gilchrist et al. look at PM’s role in infectious diseases, and argue that PM
has a potential role in the prediction, prevention, and management of infectious diseases,
epidemics and pandemics – nationally and globally. PM, through the utilization of whole
genome sequencing (WGS), can facilitate in the rapid and accurate identification of virulence
factors, aiding in the identification of the path of the disease transmission within a population,
and in providing information on the probable source. They add that the advance of inexpensive,
ultra-high throughput DNA sequencing tools, have transformed the microbial WGS from a costly
enterprise to a very accessible routine exercise in molecular biology.51 Gilchrist et al. note that
through phylogenetic analysis, “evaluation of the evolution of strains during an outbreak is
possible;” and it can be especially useful in comparing the “finished assembly and trace genetic
changes,” not only about the current epidemic - but also in the broader global context. Moreover,
Gilchrist et al. add that the advances in NGS have enabled the rapid WGS of the “causative
microbe” during an outbreak. They emphasize the need for first responders to be well-informed
about the capacity, as well as the limitations of WGS, so they know how “to collect appropriate
samples” that will be useful for WGS, in the prediction, prevention, and management of
infectious diseases, epidemics and pandemics - “to predict the course, or define the origin, of an
epidemic.” 52 The next sections look at PM in infectious diseases.

73

4.2. PM in Infectious Diseases
According to scholars like Geller at al., advances in the genetic sequencing technologies
are contributing greatly to the development of more personalized approaches of prevention and
treatment of infectious diseases. At the same time, these technologies are influencing future
policies and procedures for infectious disease management, since we are better able to
understand the interactions between human genomic and pathogen genomic factors, and their
roles in the different immunologic responses to vaccines, infections, and drug therapies.53 Gupta
et al. point out that discovering novel pathogens and elucidating the implications of genetic
variation among existing pathogens, is critical for rapidly mitigating pandemic threats, as
demonstrated recently with the severe acute respiratory syndrome (SARS), and avian (H5N1),
and pandemic H1N1 2009 influenza (commonly referred to as ‘‘swine flu’’).54 The next two
sections will look at the use of genomics in infectious diseases, clinical significance and costs.
4.2.1. Genomics in Infectious Diseases
It is evident from studies that genomic information creates more opportunity for more
personalized treatment, and prevention in clinical practice, and public health setting. According
to scholars like Sintchenko V. et al., bacterial genomics in pathogen genotyping has improved
our understanding of the different “molecular pathogenesis, host-pathogen interactions, and
antibiotic-resistance mechanisms.” Sintchenko et al. noted, bacterial genomics has also
facilitated the study of population structures, epidemics and outbreaks, and newly identified
pathogens - which resulted in numerous opportunities for clinical pathologists to contribute to
bacterial genomics - including the design of new diagnostic tests, therapeutic agents, and
vaccines. Sintchenko et al. also add that the sharing of data on pathogen profiles creates a greater
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understanding of the transmission patterns and processes, and is critical in the informed disease
management and surveillance.55
Sintchenko et al. emphasizes that the accurate classification of pathogens with epidemic
potential can optimize communicable disease control, and reduce associated costs. According to
studies, analyzing the dynamics of infections that have epidemic potential relies on the “accurate
demarcation and identification of individual strains or epidemic clones,” together with the
identification of specific virulence factors and other validated markers. Together, the scholars
add, this information can be consolidated into a pathogen profile. Sintchenko et al. also note that
the systematic collection and construction of pathogen profiles from a combination of genomic
or other markers in a manner that enables data to be integrated and shared - is essential for
successful surveillance and disease management. For example, genetic markers are used to
identify antibiotic-resistant strains of Mycobacterium tuberculosis. Similar monitoring is also
utilized for HIV or hepatitis C virus (HCV) infections.56
Sintchenko et al. further suggest that there is a need for a larger volume of data relevant
to microbial profiles to characterize the entire phenotype of a pathogen in an environmental or
experimental context. The scholars note that linking annotated profiles systematically with
clinical and research databases can lead to the identification of previously unrecognized genes.
They moreover, note that although public electronic bacterial typing databases exist, data sharing
is still difficult due to lack of conventional structures.57 Sintchenko et al. explains that microbial
typing are important since they can confirm or refute the epidemiological links that might trigger
public health investigations, and can also determine unrelated clusters to rule out further action.
However, they add that pathogen profiling goes beyond the investigation of outbreaks, and can
also be important in the monitoring of diseases; thereby, aiding in providing information for
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organic-specific infection control policies, and predicting clinical outcome. According to
Sintchenko et al., molecular profiling also facilitates the detection of chains and patterns of
infection transmission and aids in the construction of epidemic trees that can guide appropriate
control efforts.58 However, Sintchenko et al. also point out that microbial genotyping alone might
not always be the best classification method, since outbreaks are occasionally caused by several
different agents, rather than a single, virulent clone - for example, sewage contamination of
water or food could cause an outbreak of diarrhea.59
4.2.2. Impact of Genomics
As highlighted by scholars like Olsen et al., NGS platforms and bioinformatics tools are
opening a new Chapter in the history of infectious disease research and clinical pathology
laboratory practice. In the past, it used to cost a lot ($one million) and take a long time (a year) to
complete bacterial genome. Today, depending on the instrument, it is possible to sequence the
complete genome of a bacterial strain in one day for much less than $1000. Similarly, a single
instrument can generate 100 or more bacterial genome sequences in less than one week.
Assuming this trend continues, Olsen et al. are hopeful that the cost will go down to only $10
soon. These low-cost, high-throughput sequencing platforms are readily available today,
enabling the pursuit of new investigations and novel applications that were previously
inaccessible. Olsen et al. argue that sequencing technologies provide pathologists with the
opportunity to not only perform research on infectious diseases, but also develop laboratory tests
applicable for clinical settings, and improve patient care. 60
Olsen et al. also point out the recent achievements in the decreased cost and increased
DNA sequencing capacity in bacterial genomics, which have transformed our understanding of
virulence factors, host-pathogen interactions, and population genetics – paving the way for
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rational design of diagnostics, therapeutics, and vaccines that may significantly improve patient
care.61 They add that this new knowledge can be used to design more effective vaccines and
treatment regimens, and also aid in public health efforts to prevent vector-borne infectious
diseases through preventative efforts.62 Moreover, Olsen et al. state that population genomics
allows investigators to study origins and subsequent evolution, thereby leading to insights into
how they are disseminated today. 63
Tang et al. add that bioinformatics algorithms along with the new sequencing
technologies have given rise to the field of genomic epidemiology where WGS methods are
integrated with epidemiologic investigations to yield the knowledge into communicable disease
outbreaks. Tang et al. note that infectious diseases continue to be one of the leading causes of
death worldwide, given the ability of the pathogens to evolve and spread rapidly which results in
the emergence of novel human pathogens, more virulent forms of existing pathogens, and
antibiotic-resistant organisms. 64 They add that the knowledge of the entire genome allows for
better identification and characterization of the pathogen responsible for the outbreak; allowing
better risk estimation and thereby, not only allowing for the selection of the most appropriate
interventions, but also a better understanding of the origins and dynamics of the outbreak.65 The
advanced genotyping technology will be able to detect various outbreaks and factors involved in
the transmission process, and can be applied in the informing and guiding of infection control
and public health practices. 66
The prevention and containment of debilitating and often-lethal infectious diseases have
had an enormous impact on world health. Seib et al. argue that the arrival of different sequencing
and profiling tools in the genomics era has created a shift in the development of vaccines, and
also in the development of antibiotics. They add that infectious diseases, however, create an
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enormous burden on the global population – observed in the “classic pathogens, newly
discovered causes of diseases and the emergence and reemergence of infectious diseases.” In
addition to all that, Seib et al. note that antibiotic-resistant forms of microbes are a novel
challenge to address. According to the WHO, at least one such new pathogen can be expected to
appear every year. Therefore, Seib et al. suggest that it is essential that we be well equipped with
adequate and effective vaccines and other therapeutics to limit infectious diseases from
spreading. They also highlight that the traditional approaches for screening vaccines are timeconsuming and ineffective in controlling many of the emerging or reemerging infectious
diseases.67
Seib et al. have noted that vaccines can generate “self'” immune reactions potentially
leading to damage to the host tissue – this must, therefore, be taken into consideration when
designing new vaccines. They add that studies have suggested that vaccine or drug targets should
be screened for “homology or similarity” to human proteins, to identify “self'” immune reactions
using BLAST (Basic Local Alignment Search Tool) to query human genome database. They
argue that PGx can determine the correct vaccine/drug and the dosage utilizing the genetic
differences in the way individuals metabolize therapeutics.68 Although we are still not sure about
the efficacy and protection of genome-based vaccines and therapeutics against infectious
diseases due to lack of valid models to measure their efficacy, Seib et al. are optimistic that the
increased understanding of microbial pathogenesis should greatly aid in this respect. 69
According to Olsen et al. genome-wide investigations of larger strain collections, as
generated by WGS and NGS technologies are needed to expand the scope of outbreak
investigations and provide a genetic basis for designing diagnostic tests and antimicrobial
therapies. Olsen et al. add that WGS sequencing of outbreak strains is similar to evolutionary
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relationships inferred from genomic comparisons of geographically diverse strains, enabling the
precise map of the dissemination and clonal evolution.70 Antibiotic-resistant strains are a major
cause of concern among specialists in infectious disease worldwide. Olsen et al. add that NGS
techniques have recently been used to identify the genetic basis of new antibiotic-resistance
mechanisms; additionally, WGS is anticipated to become the standard tool in the diagnostic
laboratory. Olsen et al. are positive that NGS tools are capable of economically generating
tremendous amounts of bacterial genomics data, able to aid in the investigation, containment of
present and future foodborne outbreaks.71 The next section looks at outbreaks and pandemics.
4.3. PM in Pandemics
Studies show that infectious diseases play a significant role in negatively affecting the
public health and economic stability of the population worldwide. Infectious diseases have been
identified as the leading causes of death, disability, and for impeding the growth of human
progress for centuries. According to scholars like Nii-Trebi, the continued emergence of new,
unrecognized and even old infectious disease epidemics persistently threatens our health and
economic stability, with far reaching effect on the global population as well. An estimated 30
plus new infectious agents have emerged affecting humans over the past thirty-five years showing a correlation with socioeconomic, environmental, and ecological factors – presenting a
formidable challenge. Nii-Trebi further emphasizes the urgent need for constant awareness and
pursuance of effective strategies for controlling infectious diseases and disease emergence. NiiTrebi adds that studies demonstrate that microorganisms generally cause infectious diseases, and
their importance is derived “from the type and extent of damage their causative agents inflict on
organs and/or systems” upon entry into a host.72 Nii-Trebi further points out the enormous
impact of the HGP on genomics and health - that plays a greater role in the prediction and
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prevention of the next pandemic through their sequencing techniques. The next section looks at
the clinical impact of genomics in pandemics.
4.3.1. Clinical Impact of Genomics in Pandemics
According to Nii-Trebi, infectious diseases can affect a person's psychological,
emotional, and mental wellbeing, and can greatly “worsen the plight of people living with an
infectious disease.” A notable example is leprosy. Nii-Trebi adds that in some communities, this
particular infectious disease has been reported to bring shame to those affected, shunning and
maltreating the afflicted ones – to the point where some even lose their freedom and worth.
Infectious diseases are also known to cause loss of capacity to work, which in turn increases
poverty in adults; this may consequently affect children's education, cognitive development,
leading to various social vices - ultimately adding to the burden created by the disease, and
worsening poverty.73 Bhutta et al. also add that infectious diseases of poverty (IDoP) affect the
poorest population in the world disproportionately, contributing to a cycle of poverty due to
decreased productivity ensuing from long-term illness, disability, social stigma, and even death.
The scholars also note that an increase of 111,000 deaths globally was attributable to IDoP - for
instance, neglected tropical diseases (NTDs) and malaria that have been reported in 2010 by a
study from the Global Burden of Disease.74 They add that mortality from NTDs in 2010 was
reported to have risen to 152,000, with an estimated more than 90% of the total impact as a result
of death and disability caused by neglected diseases occurring in Sub-Saharan Africa. The
scholars point out that the socioeconomic and physical conditions of those living in poverty
create environments that facilitate the transmission of vectors and pathogens, consequently
leading to a long-term illness that further exacerbates poverty by diminishing productivity.
Unfortunately, Bhutta et al. add, NTDs have slipped into the “neglected” diseases and is not
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given the attention needed to address them. As of 2010, NTDs only received 0.6% of the total
international development assistance for health.75 However, much focus is on malaria.
Malaria is known as one of the leading causes of mortality.76 The WHO (2016) reported
an estimated 216 million cases of malaria in 91 countries, which is an increase of over 5 million
cases over 2015.77 Globally, over 200 million annual malaria infections result in up to 660,000
deaths, of which 77% occur in children under the age of five years. Preventive measures are
crucial; however, prevention of most malaria deaths is by the use of antimalarial drugs.
However, scholars like Winzeler and Manary note that the development of resistance to these
malarial drugs threatens to increase morbidity and mortality by malaria. Artemisinins is one of
the few drugs used to cure multidrug-resistant Plasmodium falciparum infections. Unfortunately,
the scholars highlight, clinical trials from Southeast Asia show that artemisinin-based treatments
are beginning to lose their effectiveness due to drug resistance, thus resulting in the dire need for
genetic determinants for this resistance. As Winzeler and Manary note, a recurrent problem with
chemotherapy is the emergence of the spread of multidrug-resistant P. falciparum parasites,
making P. falciparum malaria complicated to cure. It is feared that this reduction in the efficacy
of chemotherapy could result in malaria again becoming an incurable and fatal disease. 78 With
the developing to resistance to artemisinin the search for markers associated with resistance has
become more urgent, and more feasible.79 Winzeler and Manary point out that study of
artemisinin resistance is already influencing patient treatment, and interventions to eradicate
malaria from regions where resistance has been observed. Nonetheless, the scholars add, it would
be wise for the world health community to reduce reliance on this class of drugs.80
Per Meltzer et al., influenza A virus is another example, which is responsible for the
deaths of thousands of humans every year. Historically, influenza pandemics have occurred for
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centuries, and have occurred three times (1918, 1957, and 1968) in the 20th century alone.81
April 2009 marked the first influenza pandemic of the 21st century with the emergence of a new
H1N1 influenza A virus strain (pH1N1) in North America that rapidly disseminated around the
globe, responsible for more than 18,000 deaths worldwide. From the comprehensive
phylogenetic analysis, Sant’Anna et al. noted that influenza A virus can change genetically rather
fast, which enables them to evade recognition by the immune system and allow constant
circulation among human populations - allowing for greater transmissibility and pathogenicity,
and resulting in drug resistance. Sant’Anna et al. note that as of today, seven distinct pH1N1
influenza A virus lineages around the globe have been noted in the first months of the pandemic
period.82 Sant’Anna et al. argue that genome sequencing allows for the monitoring of these
evolutionary changes and provides fundamental information about the chronological and
geographical distribution of the strains; and that data aids in vaccine development. However,
studies concerning the molecular evolution of the strain of pH1N1 are reported to be scarce,
resulting in the lack of data available concerning the evolution of the established pH1N1 viruses
in the current post-pandemic period, which can compromise the local public-health vaccination
policies.83 Sant’Anna et al. point out that it is important for public health agencies (globally) to
monitor the circulating strains in order to ensure proper local prevention and control measures.84
The outbreak of pandemic (H1N1) in 2009 (swine-origin influenza A) infected >296,000 persons
worldwide, which resulted in 3,486 deaths. Chen and Shi add that much important information
that can help in promoting influenza diagnosis, drug-resistance monitoring, and vaccine
development was brought out by sequencing many of the new strains of pandemic (H1N1) 2009
virus. However, Chen and Shi argue that researchers need to analyze the adaptive mutation of the
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pandemic (H1N1) 2009 in order to evaluate the likelihood of viruses from other nonhuman
species to adapt to humans.85
According to Gire et al., the Ebola virus (EBOV; formerly Zaire ebolavirus) - one of five
ebolaviruses - is a lethal human pathogen that causes Ebola virus disease (EVD) with a 78% case
fatality rate. Previously EVD outbreaks were confined to remote regions of central Africa - the
largest had 318 cases and occurred in 1976. As the scholars highlight, the current outbreak in
2014 started in February 2014 in Guinea, West Africa – spread rapidly into Liberia in March,
Sierra Leone in May, and Nigeria in late July – and was the largest known EVD, that expanded
exponentially with a doubling period of 34.8 days. The scholars noted that 2240 cases and 1229
deaths had been documented in August 2014, resulting in a major (ongoing) public health crisis therefore, there is a need for accurate and timely information in order to better target such
outbreaks.86 Gire et al. also pointed out that epidemiological and genomic surveillance must be a
continuous process. It is anticipated that new genomic technologies will be vital in the
multidisciplinary international efforts to understand and contain such expanding epidemics and
others.87 The next section looks at some of the applications of genomics in pandemics.
4.3.2 Applications of Genomics in Pandemics
One of the major potential uses of genomics tools is in the rapid identification of newly
emerging viruses, as pointed out by Lei and Shi.88 There are many new genomic tools, such as
high-throughput sequencing, viral and host mRNA and microRNA expression profiling, and
microarray-based analysis of pathogen and host single nucleotide polymorphisms (to name a
few). Lei and Shi point out that these tools have the potential to help identify the leads for
therapeutic intervention, predict the new emergence of novel genotype/pathotypes with altered
virulence, and also aid in the development of effective vaccines.89 Tim Downing adds that high-
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throughput sequencing can decode measurable evolution of cell populations within patients
associated with system-wide changes in gene expression during treatments. Downing also points
that a multi-faceted approach can enhance assessment of antimicrobial resistance by assessing
the transference dynamics between hosts to draw up a scheme of deterring resistance before it
emerges by optimizing antimicrobial treatment protocols.90As of today, scholars have noted that
influenza is still considered a major public health concern in the U.S., despite the significant
advancement in vaccine and virus research – responsible for over 200,000 hospitalizations and
30,000–50,000 deaths during seasonal epidemics. 91 As such, rapid and accurate identification of
an influenza outbreak is essential for patient care and treatment. Vemula et al. suggest that NGSbased “unbiased sequencing” can be effectively applied to investigate molecular characteristics
of nosocomial influenza outbreak by using clinical specimens (such as nasopharyngeal swabs),
and NGS-based sequencing moreover, offers added benefits through sequencing speed and
throughput, and reduced costs. 92
As pointed by Dziejman et al., the panic caused by the rapid spread of the pandemic
H1N1 2009 influenza/swine flu around the Globe triggered the (urgent) curiosity of all including governments, and the public - about the nature of this flu, and also its containment.
Dziejman et al. argue that genomics is already playing a critical role in the surveillance and
control of emerging infectious control, including resistant pathogens. They add that substantial
data generated from genome sequences of individual isolates and strains of pathogens opens up
doors to the identification of molecular changes, which enable the tracking of their spread and
evolution through time, and also in the generation of vaccines, and drugs necessary to combat
these diseases. Historically, cholera, a severe diarrheal disease caused by a bacterium called
Vibrio cholera, was a public health nuisance and had caused several pandemics (about six
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between 1817 and 1923). Dziejman et al. add that by 1900, cholera was no longer an epidemic
and endemic disease; only to appear in 1961 as the “7th pandemic of cholera” that rapidly spread
throughout the Asian mainland and in Africa, replacing classical strains as the cause of endemic
cholera. The scholars highlight that although a significant amount of studies have focused on V.
cholerae pathogenicity and its pandemic potential, the genomic sequence of this bacterium was
only recently reported.93 Dziejman et al. argue that with the use of another powerful new tool,
microarray technology, the genetic similarity among strains of V.cholerae isolated from diverse
geographical locales and over decades of time was investigated.94 Therefore, they add that
genomics can identify genes that lead to bacterial adaptation and fitness in human hosts leading
to prolonged infections of human hosts. The scholars are optimistic that it will be possible to
delete these genes systematically or develop better vaccines that can combat these pathogens
soon.95
According to scholars like Haagmans et al. (2009), “high-throughput sequencing
genomics tools are providing unprecedented ways to analyze the diversity of the genomes of
emerging pathogens as well as the molecular basis of the host response to them.” They add that
such technologies allow us to identify emerging pathogens, and “analyze the diversity of their
genomes as well as the host responses.” Haagmans et al. point out that since “zoonotic pathogens
typically may cause variable clinical outcomes in human hosts that differ in age, nutritional
status, genetic background, and immunological condition” - deciphering the complex interactions
between evolving pathogens and their hosts is a great challenge.96 They add that a better
understanding of the “relationship between the genetic variation and antigenic properties” can
help predict the emergence of influenza virus (for example), and develop vaccines that are
effective. 97
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Per Robinson et al., outbreaks of infection can range from a few individuals to epidemics
across countries or continents, and can have devastating effects on people and their societies. The
scholars emphasize the need to investigate outbreaks, in order to terminate the cluster of diseases
and to prevent similar occurrences. They also add that the identification and characterization of
an outbreak strain can be useful in learning the mode of transmission, its source, and how to
control and prevent it.98 Robinson et al. add that in the past, traditional laboratory and
epidemiology was used to track and manage outbreaks. Thus, the laboratory could provide
evidence to confirm or dismiss a common microbial cause. Additionally, an increase in
laboratory reports of given pathogen could provide the first evidence that an outbreak is
underway.99 However, sequence-based approaches are becoming portable and therefore are used
more widely so that results can be easily compared between different labs around the world. The
scholars also add that sequence-based approaches make archiving of information in national or
international datasets easier, allowing isolates and outbreaks to be placed in the wider pathogen
population context. Despite these advantages, Robinson et al. point out that there remain
drawbacks in sequence-based typing - such as a lack of standardization, and lack of real-time
data exchange between laboratories, due to costs and complex workflows.100
Scholars like Esther R. Robinson et al. also argue that WGS has the potential to make an
impact in the bacterial infection outbreaks in hospitals and community settings.101 G.Vernet adds
that hospitals and communities with the improved understanding of genomics and virulence and
resistance can better serve populations in the containment of epidemics, by limiting the spread of
infectious agents and improving surveillance approaches.102 For WGS to be routinely used in
clinical practices, Vernet adds that several challenges must be addressed - such as the need for
improved speed, ease of use, accuracy and longer read lengths. Moreover, G.Vernet argues that
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pharmaceutical companies can also use genomics in developing better vaccines, tailored drugs.
Moreover, Vernet argues that reverse vaccinology is used in pharmaceutical companies in order
to verify the sterility of injectable drugs and vaccines.103 G.Vernet adds that genomics has now
found its place in all domains of activities in the field of infectious diseases, from basic to
translational research, through disease diagnosis and surveillance, molecular epidemiology for
outbreak investigation, and emerging infections monitoring. Nonetheless, Vernet adds that
improvements in the storing, translation and sharing of WGS data need to occur before
sequencing results can be trusted enough to guide decision-making. They add that the current
trend to instrument size reduction, portability, and cost and turnaround time reduction will
change the landscape in the coming years by allowing smaller and decentralized laboratories to
access NGS technology.104 Given the improvements in accuracy and cost of these sequencing
technologies, it will likely be able to overcome the financial and technical challenges soon;
however, anticipated ethical and social challenges need to be addressed. The next section looks
at the ethical and social challenges.
4.4. Ethical and Social Challenges
According to scholars like Sintchenko et al. and Geller et al., previous studies have
demonstrated that genomics in infectious, non-communicable diseases and pandemics can be
cost-effective, especially through highly integrated, comprehensive disease-control programs,
which include routine microbial genotyping. Yet, incorporating multiple data sources, and
integrating genomics in healthcare, and public health policies remain challenging due to ethical,
legal and social implications (ELSIs). 105 Genomics will play a huge role in the future in
everything that is associated with health, and it is critical to anticipate and address the possible
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challenges in the future.106 The next sections look at the challenges associated with the possible
ELSIs.
4.4.1. Identifying Challenges
Geller et al. highlight that out of the 57 million deaths that occurred globally in 2008,
63% were attributed to NCDs – which pose a public health challenge - comprising mainly of
CVDs (~48% of non-communicable diseases), cancers (~21%), and diabetes (~3.5%).107 They
add that infectious diseases are also responsible for a large proportion of morbidity and mortality
worldwide, which account for a significant component of disease burden. Infectious diseases
vary by mode of transmission, and by the type of pathogen, and virulence. PGx studies have
been identified in earlier sections as potential tools in the identification, prevention, and
management of NCDs, as well as infectious diseases if implemented properly into clinical
practice. However, Geller et al. point out that the procedures for control of infectious diseases in
clinical settings and public health vary, “depending on the severity and chronicity, infectivity and
virulence, modes and ease of transmission, and on the availability of treatments, vaccines, or
other means of prevention.” According to the scholars these are important determinants of the
ELSIs with genomic applications.108
Geller et al. point out that, studies on genomics and disease control and ELSIs show that
the ability to distinguish a human source of infection or a ‘super-spreader' is a serious issue,
where the identified people are at a higher genetic-risk for contracting or spreading a disease.
They add that this ability creates potential questions of blame or legal liability, stigmatization,
and risks to privacy. Given our lack of understanding of the predictive value of genotypic
information, a major ethical challenge that may result from the variability, is how such
information can be used to inform risk management policy. According to Geller et al., unique
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ethical challenges may stem from the intersection of genomics and infectious disease control –
ethical challenges that stem from the benefits of personalized medicine (which is to benefit
particular individuals), versus those of public health (to benefit and protect entire populations).109
Scholars like Branković et al. argue that biobanks are invaluable resources in genomic research.
However, much of the legal and ethical controversies are surrounding biobanks today due to the
dual role it plays in containing samples, as well as data.110 The scholars note that confidentiality
and privacy have been cited as an obstacle in the translation of biobank data into the clinical
setting. This obstacle arises from a necessary pairing of biobank information with “personal and
unrelated types” of health information. They add that issues mainly arise regarding the protection
of data obtained from samples of patients who are afflicted with serious infections – which gives
rise to fears of possible discrimination. Branković et al. state that discrimination can result from
current interpretations of data, from future research, and upcoming innovations in genomic
technologies. Addressing issues of data protection is equally important, especially in the
handling of samples taken from individuals who are afflicted with serious infections. Genomic
discoveries concerning such infections potentially create various forms of discrimination in the
context of future discovery. Branković et al. highlight that the risks of stigmatization and
discrimination arising from genome-based information (the disclosure of a patient's illness or
infection status is a potential infringement of patient rights) cannot be underestimated, and needs
to be addressed.111
Scholars like Geller et al. have noted that in the context of infectious disease
management, there is a conflict with public health priorities and individual rights and liberties such as “autonomous decision-making; freedom of choice and action; privacy; and the right to
know or not to know information about oneself.” When it comes to infectious disease
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management, public health programs may already target people or subgroups with particular risk
factors. However, the scholars also highlight that any possibility of ascertaining or reporting of
any unobservable genetic-related risk factors raises issues of protection of personal information,
privacy, and autonomy.112 Fragoulakis et al. observed that genomics is also feared to exacerbate
challenges related to allocation of scarce resources, especially in developing countries where the
resources are limited; and must be spent wisely to address social justice and the right for equal
access in healthcare services by all the citizens in economically viable terms.113 Folarin et al. add
that “sequencing data from infectious pathogens represent a unique opportunity for the
identification of new drug and vaccine targets, which potentially have value for disease
management and control.” However, the scholars add that these data are also responsible for
creating genomics knowledge gap between developing countries and the developed countries.114
It is known that public health priorities conflicts with individual rights and liberties,
however, Geller et al. add that when the benefits to individuals are weighed against the potential
harms to population, incorporating biomedical advances into clinical practice and public health
can be justified. In infectious diseases, genomic discoveries have the potential to benefit at-risk
and affected individuals and minimize harm to them by identifying more effective and
preventive interventions. Any intervention with the likelihood of an effective immune response
significantly outweighs the risk, and severity of ADRs would be ethically justified. Additionally,
Geller et al. add, cost-benefit analyses and overall predicted impact on morbidity and mortality
might also be a good indicator for the ethical justifiability of such preventive interventions. They
further add that immunization programs may be willing to screen for the genetic risk factors
following an immunization/vaccination event, if the genetic predisposition for ADRS can be
identified.115
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Geller et al. states there can be a conflict between the public health framework and the
legal and policy paradigm of genomics. Genomics places importance on privacy, which can
result in individual rights getting less priority over public health's priority over the benefit of
others. In the U.S. all the states have enacted genetic privacy legislation; however, the scholars
are conscious that the scope of protection varies from state to state, and may also conflict with
state public health laws, and remain unclear. Geller et al. also noted that there is, however, the
Model State Emergency Health Powers Act that: “enumerates the powers that will be granted to
state and local officials to protect public safety in the event of a public health emergency, and
includes provisions related to mandatory vaccination and quarantine.” They highlight that many
states have adopted some of the provisions of the model legislation.116 Geller et al. have also
noted that the U.S. federal Genetic Information Nondiscrimination Act of 2008 (GINA) forbids
discrimination from genetic information in any aspect of employment, including job placement.
However, Geller et al. observed that host genomic factors might have additional legal and policy
implications - such as increased liability faced by providers for vaccine-related injury in patients
with genetic predisposition to ADRs to vaccines. Alternatively, people with genetic
predispositions to ADRs may be exempt from mandatory vaccine laws affecting the herd
immunity.117 The next sections look at addressing the challenges identified so far throughout the
chapter.
4.4.2. Addressing Challenges
Olsen et al. argue that WGS has become the preferred method “to study bacterial
virulence, investigate outbreaks, and characterize new organisms.” They add that species
assignments of isolates that cannot be otherwise identified, and real-time molecular
epidemiology of nosocomial infections, are also opportunities to affect patient care. Furthermore,
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well-curated databases containing bacterial strain genotype–patient disease phenotype
information are being developed for clinical decision support. As more strains are sequenced,
and discoveries are made, Olsen et al. point that those relationships will need to be continuously
reevaluated. However they add, data analysis bottleneck exists and must be overcome before
bacterial genome sequencing can be fully embraced in a clinical laboratory setting, which
requires new regulatory guidelines and reimbursement models to be developed to support better
data harmonization and analysis, which will be needed in order for all the different data collected
to translate meaningfully.118
Geller et al. point out ELSIs that arise due to the genomic sequencing information still
lingers. They add that the proper use of genomic data about individuals in the context of public
health or policy decisions is still unclear, thereby, making it difficult to initiate the utility of
genomic information in the public health context. However, it is certain that individual
genotyping and the information derived from it will affect personal liberties, and therefore, there
need to be better discussions as to how the information can be safely utilized to protect, as well
as benefit the people. Geller et al. add that it is evident that genomic data about individuals (their
genomic ‘fingerprint’) might be necessary when decisions about prevention and treatment are
considered, such as, the type of vaccine that will be appropriate for the person, and the effective
dosage. They note that genomic data about individuals and groups might be beneficial in
planning, assessing and developing public health policies.119
Scholars like Nii-Trebi highlight the importance of addressing emerging and neglected
infectious disease outbreaks, which pose a serious public health threat - having social, political,
and economic effects. Previous outbreak events have shed much light on the importance of
emerging infectious diseases, and far-reaching advances have been made. However, pandemic
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preparedness even as of today remains a major global challenge. Nii-Trebi adds that infectious
disease-causing pathogens continue to demonstrate their capacity to emerge and spread rapidly
by any possible means across borders, exhibiting high pathogenic potential, being able to evolve
or mutate to resist drug attacks. The scholar emphasizes the need for greater international
cooperation, involving local, regional and global network for surveillance of outbreaks. Nii-Trebi
points out that much research collaboration has also been emphasized to enable sharing of data
between different entities to strengthen the capacity for identification of microbial agents, to
enhance vaccine developments, and other effective prevention strategies for infectious epidemics
and pandemics.120 As Okeke and Wain point out, knowledge and genomic information combined
can equate to be a global public good. However, several indicators as pointed by the scholars
show that scientists from developing countries are not using genomic information or the tools
that are available to analyze genomic information. 121
Scholars like Eisen and MacCallum point out that there is no evidence that genomic
research will be used to alleviate the burdens of infectious diseases in developing countries, even
though high-burden pathogens are targeted to be sequenced. They highlight that although there
are existing problems of emerging infectious diseases in developing countries, it is evident that
the researchers in developing countries have not been able to participate fully in genomics
research, due to the technological isolation and limited resources. They emphasize the need for
an international partnership that will benefit all. 122 To this, Bartholomew et al. also add that
much collaboration between local governments, and international agencies, scientists and
educational institutions will be needed to help build scientific capabilities in developing regions.
They add that educating the next generation of young investigators within the regions will also
be necessary to move the genomic effort in infectious diseases forward, which in turn will
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promote health security in developing countries. They argue that building the scientific capacity
in developing countries will also add considerably to building trust and to the intellectual reserve
needed to address the critical outbreaks of infectious diseases that act as a barrier to their overall
development process.123
It is clear that WGS is already transforming the practice of outbreak investigation.
Sintchenko et al., argues that “molecular typing facilitates the detection of chains and patterns of
infection transmission, and also the construction of epidemic trees.” 124 This capacity of
pathogen profiling is especially important as changes in contact patterns often underlie the reemergence of disease.125 Bartholomew et al. note that, even though strong emphasis has been put
on the successful translation and integration of laboratory diagnostics in the improvement of
public health and clinical outcomes in medicine, there is a lack of a wide range of computational
tools necessary to analyze these sequences in sufficient detail. Even though new, powerful, faster
and cheaper sequencing tools are available in the developed world, and a deeper understanding
of outbreaks can lead to better understanding of emerging infections, the scholars highlight that
is not the case for developing countries where most emerging infections arise. Thus, the scholars
recommend for effective, collaborative biosurveillance programs between regional and global
entities.126
As Eisen and MacCallum note that even though not all information about all infectious
diseases is helpful, it is essential to have open, real-time access to information about other
diseases, and other organisms that might impact spread or evolution. They add that opponents
worry about possible risks and drawbacks to open access. An example they cite is of
governments that avoid release of data (flu in Mexico) due to fear of discrimination, and fear of
misinformation being spread. However, they also add that proponents argue that open source of
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genomic resources can be extremely beneficial in addressing outbreaks, pandemics and
biosecurity issues.127
Conclusion
According to PR Newswire US (January 09, 2018), various advancements in genome
sequencing tools: “have paved the way for the development of several precision medicine
solutions.” Which they see as: “the most modernized trends in the healthcare industry that has
projected tremendous level of progress in the last few years” – with the aim of making PM
“more adaptable and focused towards genetic diseases” related to NCDs and infectious diseases
among others.128 Leif et al. argue in favor of PM, that although certain NCDs such as T2D which
are lifelong, incapacitating and affecting multiple organs cannot be prevented or cured and
accounts for a substantial amount in direct healthcare costs – can however, be aided with genetic
analysis (>95% of patients are diagnosed with T2D), and offered better-personalized
treatment.129 Karczewski et al. also argue that PGx has the potential to eliminate the the flawed
“one size fits all” paradigm for drug delivery, and deliver on the promise as an essential element
of physician decision support.130 Chaudhry et al. asserts that PGx can impact the development of
drugs, as early as the drug discovery process itself. They note that only 25–60% of patients
respond positively to drug therapies due to variability in phenotypic and environmental factors,
and up to 95% of these variations may be determined by genetic factors alone.131 Klaus
Lindpainter also agrees that PGx is anticipated to revolutionize the face of medicine,
“realistically,” by providing better ways to diagnose and treat illnesses - but it will be a gradual
development process, building on the refined understanding of the disease mechanism, and the
administration of preventative tactics.132 However, it has been highlighted by scholars like
Ripudaman K. Bains, that there is a need for a coordinated international response to tackle
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outbreaks in the future; and for economically developing regions to proactively take the lead to
collaborate research projects to help address regional as well as global problems.133
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Chapter 5: Relevance of PM in Public Health Genomics and Global Health Genomics
5.1. Introduction
Given the potential of PM in the development of more effective, personalized approaches
to the prevention and treatment of infectious and noncommunicable diseases (NCDs), PM will
have a significant impact not only on individual health, but public health, as well as global
health.1 According to Rabah et al., it is an understatement to just say that genomics is “a
powerful tool to understand the totality of the factors that contribute to health and disease” – it is
a powerful tool that has the capacity to stratify the underlying causes of health and disease; the
metabolism and absorption of drugs; the identification of those who will benefit from a drug and
who will not; thereby, improving the effects of treatment, disease management as well as disease
prevention of certain diseases.2 However, as Kenneth P. Tercyak et al. point out, this potential
for tailored interventions for particular individuals, populations or subpopulations, raises ethical,
legal and social implications (ELSIs) for public health and clinical practice.3 Muin J. Khoury also
point out that public health plays a major role in ensuring the success of genomic medicine;
because of its focus on the population that has the most vulnerable segment.4 Khoury adds that
public health will have the priority to act as the controller and impartial mediator in informing
policymakers, and other stakeholders about the types of technologies that will be beneficial for
the positive health of the population.5 Moreover, Khoury adds that related public health
responsibilities will be involving: directing patients to the appropriate providers, implementing
specific programs (such as newborn screening), and creating general public awareness about
genomics by implementing education and policy interventions.6 Many ethical and social
concerns are also related to PM and global health - such as the social and economic disparities
(10/90 gap) between developed and developing countries, is feared to increase in the era of PM.
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The scope of this Chapter is to look at the relevance of PM in public health genomics, and global
health genomics; look at the ethical and social issues that are anticipated to arise with PM, and
also recommend some approaches to address the concerns.
5.1.1. Role of Public Health in Genomic Medicine: Infectious and Chronic Diseases
Public health played a major role in increasing the life expectancy, through improved
sanitation and living conditions, and reductions in infectious diseases in the twentieth century. 7
Today, genomics (through PM) promises similar potential for improving the health of
individuals and populations.8 Public health genomics aims to integrate genome-based knowledge
responsibly and effectively into population health.9 According to Gostin and Memorial,
genomics offers an unprecedented promise of providing new tools for improving health and
reducing the burden of diseases – chronic as well as infectious.10 They add that physicians and
researchers have heralded genetic information in PM as the best way to maximize health care,
and treatment benefits in the future – genomic knowledge will be used to classify disease, select
a medication, provide a therapy, or initiate a preventive measure that is particularly suited to a
given patient.11 As Hernandez, Lyla M. ed., notes that this would change the meaning of the
Institute of Medicine's definition of public health, giving a deeper understanding to issues in
health care that most people do not benefit from due to genetic variants (effects of vaccines) making public health initiatives more efficient, as well as cost effective.12
Family history and genetic testing, and other genomic approaches such as
Pharmacogenomics (PGx), will play an important role in the personalization of prevention and
treatment of common, chronic diseases.13 Scholars like Geller et al. are optimistic about the role
that genomics will play in the management in high priority global public health concerns – such
as in the prevention and treatment of infectious diseases, and prevention and containment of

99

acute and chronic epidemics (influenza, tuberculosis, and HIV). 14 The scholars note that the
genetic variants play a role on the severity of the illnesses, and with the genetic knowledge about
immune response to these illnesses, they are confident that vaccines can be developed to better
treat and prevent these (and other) illnesses. They point out, that research on genomics has
already provided much information about the safety and efficacy of many of the vaccines. 15
Chronic diseases - such as diabetes, stroke, and cancer - all inflict the affected with many
inconveniences, as noted by Minkyo Song et al., causing a great loss at a national level as well as
at a personal level - directly translating into the longer duration of care needed, which equates to
higher medical costs, and poorer function of the individual.16 According to the scholars, this
means rising medical costs and health inequalities, with needs for improvements in medicine and
related fields – both nationally and globally. Thus, the rational solution would move from
‘treating the ill’ to ‘aiding the healthy to maintain their good health’- a goal of PM in public
health genomics – with the increased benefits in the burden of public health perspectives as
preventive measures are applied to a larger population.17 Elizabeth K. Bancroft adds that
knowledge of genetic basis of diseases is expected to be beneficial for delivering healthcare and
public health in several ways. First, the identification of individuals at higher risk of certain
diseases will enable screening based on needs – leading to both personal and economic benefits,
as screening enables earlier detection of disease such as various cancers; thus Bancroft notes,
decreasing morbidity and mortality.18 Second, Bancroft adds, the data allows the stratification of
people into different risk groups enabling better preventive strategies that can reduce the risk of
disease development in individuals within a population. Third, genetic knowledge informs
potential therapeutic targets and drug dosages in the treatment of disease.19 Bancroft further adds
that previous research has documented that different people react differently to drugs, and this
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presents serious clinical conditions - sometimes the drugs prescribed have no clinical benefit for
the person. Genetics, through PGx, has been noted by the scholar to have huge potential in
predicting the response to drug treatments, increasing efficacy and avoiding ADRs in public
health.20
Lindsey Mette et al. note that population-based analysis and implementation of PGx has
the potential to maximize therapeutic benefit and avoid ADRs; and can guide pharmaceutical
companies in developing more safe and effective drugs. Thereby Mette et al. adds, populationbased PGx can help governments (in resource poor settings, without multiple drug choices, or
with high burden of infectious diseases) efficiently use their funds, making healthcare more costeffective and safe.21 Scholars like Lindsey Mette et al., assert that integrating PGx into national
healthcare plans can be the mechanism to save lives through better medicine development and
better provision.22 As Stefania Boccia adds that genomic medicine has been hailed as the future
of healthcare, and public health genomics (PHG) is looked as more of a gatekeeper, making sure
that the genomic knowledge and technology is responsibly implemented into public policy and
health services for the benefit of population health. However, Boccia notes that the
implementation of genomic medicine in public health practice has been extremely slow. They
also emphasize the benefits of genome testing and screening, such as early detection of carriers
of diseases such as rare diseases (RD) and cancer, which they argue can lead to benefits such as
mortality reductions; and can be applied in public health as preventative interventions.23 Geller et
al. agrees that PHG can also offer better understanding in the human and pathogen genomic
factors to contribute to individual differences in immunological responses to vaccines, infections,
and drug therapies. Thereby contributing to future policies and procedures for infectious disease
management; and guiding of future vaccine development and treatment strategies, while taking
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into consideration the various ethical, legal and social implications (ELSIs) for public health and
clinical practice.24 The next section takes a closer look at the potential benefits and harms to
individuals and populations because of genomics.
5.1.2. Benefits and Harms to Individuals and Populations
Multiple possibilities have been presented for improving public health by incorporating
PGx into medicine – one of them being alleviating ADRs, and allowing for better drug
development – leading to reduced social and economic implications of ADRs. As Mette et al.
point out, incorporating PGx technologies in pharmaceutical development will have the potential
to identify patient responder groups; thereby, preventing ADRS, and improving health which
ultimately translates into cost-effective means of healthcare provision, and allowing increased
access to medicine.25 Mette et al. also points out that PGx has great potential to target the three
most frequently addressed infectious diseases that pose the largest burden globally - malaria,
tuberculosis, and HIV/AIDS. Mette et al. note that the existing treatments are often insufficient,
expensive, and difficult due to disease susceptibility, and drug metabolism in tuberculosis and
malaria in the infected population groups. However, the scholars note the success of PGx in
treating HIV globally.26
Scholars like Heidi L. Rehm highlight that genomics is also being used across the
lifespan of individual communities – from conception to elderly care, to provide personalized
and informed precise approaches for optimizing health and combating diseases, such as
screening for carrier status for Tay–Sachs disease within the Ashkenazi Jewish population.
Other disorders such as cystic fibrosis, shared across all communities, are leading to broad
recommendations for genetic screening. As such, Rehm adds that these tests are increasingly
being included during preconception counseling to determine the risk for future pregnancy in the
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United States.27 Rehm further comments, prenatal testing has been offered for more than 60
years on the basis of “heightened risk of a chromosomal abnormality,” suggested by ultrasound
findings or advanced maternal age, and in rarer cases – “for a known familial pathogenic variant
for a disorder previously identified in the family.” 28 Moreover, the scholar highlights statistics
from CDC that indicated a 6% reduction in infant mortality rate from congenital malformations
between 2005 and 2011 due to preconception and prenatal genetic testing.29
Opponents, however, are still unsure about the benefits of PM in public health. As
Hernandez, Lyla M. ed., note, even though genomic discoveries have been anticipated to
improve our understanding of infectious disease and inform new management strategies,
opponents fear there may be potential harms without adequate countermeasures. It is evident
from studies that ELSIs of PHG must be taken into consideration; especially before
implementing PHG into policies. Hernandez ed., add that a serious inquiry about social justice
should be made to ensure that the benefits and burdens of population-based genomics will be
distributed fairly throughout society.30 The incorporation of PM into clinical practice and public
health can only be ethically justified as long as the benefits to individuals and/or populations
outweigh the potential harms – and as long as there is equity in the distribution of benefits.
Among the important challenges that have been identified by Geller et al. that relate to balancing
benefits and harms between individuals and the population were: “minimizing threats to
individual liberties; promoting justice in the distribution of scarce resources; and treatment of
marginalized subgroups.” 31 Stefania Boccia highlight that because there is a lack of clarity in
the translation and utilization of genomics data in the improvement and better provision of
health, it is crucial that public health practitioners take a more active role and embrace the
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changes by welcoming the innovation, and the personalization of healthcare to ensure that it
works for the benefit of population health.32
Song et al. emphasizes that genomic medicine is anticipated to cause many psychological
effects on individuals, such as fear of serious suffering in the future, and discrimination, and
stigmatization. Many scholars have also emphasized fear of genetic discrimination by employers
and health insurance companies. Although GINA was established in 2008 in the U.S. to offer
protection to individuals, scholars have highlighted that it does not provide comprehensive
genetic privacy protections. Song et al. add that appropriate genetic counseling that requires
accurate and clinically useful information derived from well-designed, high-quality research is
also necessary since counseling helps weigh the benefits and harms.33 Discrimination and
stigmatization is often feared due to the ability for genomics to predict the risk of susceptibility
to, or transmission of certain infectious diseases, such as HIV. Geller et al. highlights that the
knowledge of genetic-predisposition to sexually transmitted disease may lead to stereotyping and
marginalization of the carrier; and can even result in the discrimination against entire subgroups
if, for example, there were correlations to any of the genetic variants.34
As stated by scholars like Christine Aicardi et al., genomics information is different from
other data since it discloses information not only about the individual but also about others, such
as family members.35 They express that the notion pertaining to rights to privacy, confidentiality
and self-determination entitle an individual to exercise control over the use and disclosure of
information concerning his self at every instance, but should be challenged from a broader
understanding of the nature of the data.36 Anya E.R. Prince notes that there should be a balance
between the harms as well as benefits in relationship to the rights and duties. Another area of
concern highlighted in studies is whether to report/disclose incidental findings (IF), given the
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widespread effects of genomic data. Even though there is a consensus that the researchers must
return clinically useful results to individual participants; Prince note that the boundaries of this
duty are not well defined. Some proponents support the idea of automatically disclosing the
information in the patients’ clinical records. However, there are negative sides to this. As pointed
by Prince, automatically disclosing findings will deny the participants to process the information
first, and may put them at risk to discrimination by employers and life insurance companies by
making this information readily accessible. Moreover, the scholar also emphasizes that the
information remains in the patient’s medical record permanently.37
Geller et al. point out that genomics and Public Health can result in conflicts due to the
prioritization of privacy in genomics on individuals, which are overridden in public health for the
benefits of the population. They add that an individual's genomic factors may have additional
legal and policy implications – such as screenings could influence decisions about access to
therapy in settings with limited resources, or restrict children - screened as being super-spreaders
- from going to school, placing a higher value on the harm that may be placed on others.38
Disparities in access to critical resources are another area of concern, which can be due to many
barriers such as socioeconomic, cultural, or environmental barriers. Public health agencies act as
the gatekeeper, making sure barriers are identified and addressed and whether the genetic tests
are reliable enough for the population in the clinical setting. As E. W. Clayton noted, public
health agencies has the role of developing strategies to educate both healthcare providers and
patients about genomic medicine - such as "the Secretary's Advisory Committee on Genetic
Testing and its successor, the Secretary's Advisory Committee on Genetics, Health, and
Society."39
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Although, as Geller et al., point out that it is highly unlikely that all the potential ethical
and social issues will be identified at once, anticipating and discussing about such considerations
will be helpful in guiding research questions and decisions about public funding, and
contributing to the ongoing effort in the development of policy recommendations for genomic
medicine, and its applications in public health and clinical practice in infectious disease, both
nationally and globally.40 The next section looks at personal and societal concerns about genetics
in public health, with a focus on the race controversy and race-based medicine.
5.2. Concerns about Genetics in Public Health - Race Related
As scholars like Rick Kittles note that genetic risk prediction is continued to be integrated
into medicine to provide new directions to build PM plans through improved diagnostics, and the
development of new drugs through PGx.41 Genomic research is largely population-specific, and
classification of data by racial and ethnic groups raises unique ethical challenges. Kittles,
moreover, noted that researchers and clinicians increasingly combine genetic information with a
variety of non-genetic information in clinical management of common conditions, which can be
problematic.42 Jaja et al. emphasizes in their study that random ascriptions (without much
thought) of racial categories in genomic research in the context of health disparities, could
become problematic and may have undesired and unintended effects, which may undermine the
successful clinical translation of genomic research.43 The next two sections look at the concerns
that are anticipated due to race-based medicine and genomic research.
5.2.1. The Race Controversy in Genomic Research
Opponents fear that genetic tests may increase health disparities, instead of improving
health outcomes, if participation across all communities is not ensured. As Kittles note,
currently, most diagnostic tests and information on risk assessment are specific to genetic
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information based on European ancestry. There is little information about risk assessment in
populations that have historically been underserved, or of color, in medicine.44 Therefore, Kittles
emphasizes that it is important that we continue to study diet, lifestyle, socioeconomic status and
other environmental exposures such as stress, discrimination, medical literacy, and so on,
independently of race to understand the gene-environment interaction that plays a role in
diseases. Kittles points out that geographic distribution of populations of the same race may also
vary, and this is an important area of much-needed focus.45 Although, increased knowledge of
race and ethnicity is expected to aid in the prediction of disease etiology and treatment response;
it is also feared to increase stereotyping and bias, preventing effective treatment for racial and
ethnic minority patients.46
According to studies by Kaphingst et al., significant differences by race/ethnicity in
responses to genomic information were observed. They reported that race/ethnicity of an
individual may be predictive to genomic risk, more than the genomic data; and noted that
race/ethnicity was associated with “interest in receiving a genomic assessment, discussing
genomic information with family members and with a doctor, and intentions to change health
habits in response to the genomic data.” 47 Nonetheless, Kaphingst et al. also noted that there is
not enough data that show how race/ethnicity might affect responses from underserved
populations regarding genomic information; since they observed that racial and ethnic minority
groups have been underrepresented in genetic research. Despite the limited data on racial and
ethnic minorities, Kaphingst et al. noted that Black women perceived fewer health benefits to
genetic testing than White women. Healthcare-related distrust has been shown to be higher
among Blacks than Whites. They also noted fewer positive and more negative attitudes were
attributed toward genetic testing amongst Blacks and Hispanics than Whites, indicating less use
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of genetic testing amongst individuals from racial and ethnic minority groups. They observed
lower awareness and lack of knowledge between minority racial and ethnic groups and Whites.
The scholars emphasize on further research to investigate the knowledge and interpretation of
genomic information amongst the underserved populations. 48
Much debate surrounds the conceptualization of race, and genetics - emphasizing “the
need for addressing ethical issues surrounding genetic technologies, genetic information, race,
and health inequities” - all of which are essential to improve the public's health as pointed by
Bonham and Knerr.49 They add that “race and ethnicity” are used extensively in identifying
genetic susceptibility to various illnesses, and cancer screening is a good example that may
benefit from this - leading to “early diagnosis.” In the fields of cancer research, treatment, and
prevention, many complexities have been faced in the use of racial and ethnic categories to
predict health-related outcomes, and medical decisions. While some clinicians agree that race
and ethnicity are beneficial, and useful predictors, Bonham and Knerr are concerned that this will
lead to the inappropriate utilization of race and ethnicity merely as a proxy, and will lead to
inaccurate decisions.50 They voice other concerns such as the influence of unconscious physician
stereotyping of patients, which can impact patient satisfaction and behaviors in clinical
encounters. Bonham and Knerr strongly urge that there is a need to understand the causes behind
racial and ethnic health disparities, and implementing interventions to address them is critical,
and will include unraveling the effects of “implicit and explicit bias.” They further point out that
this race related complexity has been illustrated in documentation of disparities in both risk
communication and treatment in the fields of cancer.51
Disparities in the management of cancer-related pain between racial and ethnic groups, as
well as in the utilization of surgery and radiation, have also been observed by scholars.
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Utilization of genomic technologies and information also has the potential to exacerbate health
disparities. Bonham and Knerr emphasizes that ethnicity and race not be used as phenotypes, but
rather as social categories and groupings that can correlate with genetic variation in the human
population, stating that, “viewing race as a phenotype can lead to barriers to effective patient
care.” 52 Genomic research currently highlights human variations and utilizes stratification of
population to stipulate susceptibility to diseases, drug response, and other health outcomes.
However, E.W. Clayton noted that certain racial groups were disproportionately affected by this
stratification of risk factors and diseases, and this concern is further aggravated by the fact that
health information is not private.53 Foster et al. adds that the development of a “broad crosscultural consensus,” on the “social relevance of purported associations between genetic and other
biomedical information and social identities,” can greatly reduce the risks of group
stigmatization and discrimination. Furthermore, Foster et al., suggests that bioethicists can help
researchers frame research findings that will draw attention to health disparities that exist
between groups, and help design protocols that will prevent others from defining groups from
“perceived biological differences.” 54 The next section looks more intently at race-based
medicine, and the issues anticipated with it.
5.2.2. Race-based Medicine, and Issues
From the very beginning of federal documentation of health disparities, racial and ethnic
disparities in health status have been observed.55 Williams et al. pointed out that national policies
have been implemented in phases to reduce and eliminate health disparities, and attain the
highest level of health equity among all population groups. Specific chronic conditions remain
prevalent across disadvantaged populations even though such policies are in place. Williams et
al. also identified a need to eliminate disparate care among multiple population groups, and
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increase the overall health equity through new knowledge of genomics.56 However, Gerard et al.
voiced their concerns that such advances in knowledge will only exacerbate the disparities that
exist today - especially if the information “is abused, misused or even incorrectly used” - and
that is a concern in PHG. The genomic advances face many challenges specifically in the
translation, interpretation and actual application of this new tool – finding optimal ways to
integrate the information into disease prevention and health promotion will be critical. 57
According to Dorothy E. Roberts, the success of race-based medicine and its utilization
depends on the approach to achieving racial equality and should be a medical, as well as,
political concern. Roberts also noted that there is still no consensus among African Americans
about the importance of race-based medicine; although there are opponents, as well as
proponents regarding this new technology. Roberts add that some African American scholars
have criticized race-based medicine as a scientifically flawed and commercially corrupted
misuse of biomedical research on health inequities. They argue that this will create dangerous
biological misunderstandings of race. While, Roberts add, proponents showed support by
arguing that racial therapeutics will be successful in redressing past discrimination, and fulfilling
longstanding demands for addressing the health needs of African Americans – such as the
Association of Black Cardiologists who co-sponsored the trial to test the efficacy of BiDil,
approved by the FDA in treating heart failure in African Americans. The National Medical
Association and some members of the Black Congressional Caucus also joined in support of
BiDil.58
Proponents of PHG argue that the application of race-based medicine will be effective in
the disease management strategies that consider that early identifiable risks will help tailor health
promotion, and disease prevention messages for segments of the population in ways never seen
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before. However, Gerard et al. points out that concerns arise due to the history of misuse of
public health services in the past - such as the unethical research study of Tuskegee syphilis
study. Therefore, Gerard et al. argues that past history of misuse issues a caution for public
health to proceed cautiously, with clearly articulated goals, and methods with public involvement
and accountability.59 Nils-Eric Sahlin and Göran Hermerén argues that genetics dictating which
patients would be less likely to benefit from personalized medicine would result in a lack of
fairness. Sahlin and Hermerén provide two interconnected principles defining distributive justice
in medicine that have been identified as relevant in addressing this issue: (a) health care
resources should be distributed according to need, and (b) no patient needs a treatment which
does not affect him or her.60 Public health ethics has always emphasized issues of justice, with a
concern that health benefits and burdens be distributed fairly across the population. According to
Jaja et al., the FDA’s approval of BiDil has heightened the need to address the relevance, societal
justifications, and implications of racial stratification in terms of existing health disparities in
genomic research. BiDil is hailed as the first ethnic drug, designed and marketed for the
treatment of heart failure in African American patients only. However, a critical concern raised
by scholars like Jaja et al., is whether differential responses to drug treatment between racial
groups are attributable primarily to genetic differences? 61 Advocates for race-based medicine,
such as BiDil, argue that racial disparities exist in illnesses and responses to treatment, and that
race matters biologically, and therefore, doctors and researchers cannot be colorblind. Jaja et al.,
however, argues that from history it has been noted that colorblindness is acceptable, even
preferable, with regard to social policies.62
Roberts also voices the fear that race-based medicine can affect the direction of State
efforts that are there to address health disparities and inequality, by diverting blame from
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inequitable social structural causes and access to healthcare, to genetic explanations. Rather than
addressing diseases, race-based medicine might play the devil’s advocate in shifting
government’s responsibility for addressing the causes to blaming genetic variations. Moreover,
much of the funding for developing racial pharmacogenomics is feared to cut into resources
available for social strategies as Roberts adds - characterizing a disease as a “genetic disorder,”
and placing the responsibility for ending health disparities on individual health decisions,
ultimately relieving the sense of societal obligation to fix systemic inequities.63 Marketing for
race-based medicine is also feared to promote the view that inequities resulting from neoliberal
policies are caused by natural differences between blacks and whites – ultimately placing the
burden on individuals for curing their unequal status, as pointed out by Roberts. Opponents of
race-based medicine argue that the genetic explanation of racial disparities provides a ready logic
for the staggering disenfranchisement of black citizens, as well as the perfect complement to
colorblind policies, giving the reason that racism can no longer be blamed for the cause of their
disempowered status.64 Furthermore, Jaja et al. states that given the United States’ history of
racial discrimination, diverse stakeholders are afraid that drugs like BiDil will oversimplify the
public understanding of genomic contributions to human health by reinforcing false notions of
racial profiles - ultimately weakening the scope for equity in healthcare.65
Genetic factors are advancing genomic research and reducing health disparities in many
common conditions. However, studies suggest that the specific genetic variability pertaining to
the specific clinical difference within the racial group is still not clear, and would require
extensive scientific research. Such knowledge would be useful in eliciting how race specific
variables can be beneficial in the context of genomics and health disparities. Alarmingly, studies
note that many people self-identify incorrectly. Therefore, racial self-identification cannot
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adequately substitute for genetic classification.66 Williams et al. point out that in order for PM to
be successful, medical guidelines and policies have to ensure the inclusion of all racial and ethnic
groups from diverse communities; otherwise, gaps in care between different groups may be
exacerbated, as in the case today. There are fears of discrimination, based on those who have,
and those who do not. Uncertainty about the costs of research and medical care could present
challenges as well, especially to those of lower socioeconomic status (SES). According to
Williams et al., it has been estimated that genomic sequencing can range from $1,000$100,000,000 depending on the desired information. Differences across racial or ethnic groups in
understanding the risks and beneﬁts of genomic medicine could result in disparities of care
related to use of, rather than access to, genomic medicine and personalized care. Federal agencies
recommend the collection of racial or ethnic background information to address racial or ethnic
disparities. Williams et al. emphasizes that it will be critical to understand the barriers and
address the disparities that exist due to racial differences, and it will be necessary to allow
analysis of patient, provider and system-level factors that play a role in creating the disparities.67
5.3. Future of Precision Medicine in Public Health
Even though PM has significantly influenced clinical practice over the last two decades,
and is now in a position to lead a change in public health practice, public health has yet to change
significantly in its response to the use of PM.68 R.L. Zimmern noted that PHG was established in
1977, and placed genome-based science at its core with its official definition set by experts in the
meeting in Bellagio in 2005 to be: “the responsible and effective translation of genome-based
knowledge and technologies for the benefit of population health.” So far the public health
approach has been to apply interventions to the population, framing the relationship between
intervention and outcome concerning the population as a whole – paying little attention to the
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individual’s genetic variation. Scholars like Zimmern argues that the concept of population in
public health should be moved implicitly from being an entity in itself to a set of individuals,
citing natural selection as working through individuals and not through populations – where they
argue that population is the “derived abstraction,” while the “fundamental biological unit through
which interventions work must be the individual.” 69
5.3.1. Current Priorities for Public Health and Economic Implications of Genomics
Current priorities in public health include early diagnosis of cancers and PGx that
addresses therapeutic interventions. Angela Brand et al., argues that genomics, through PGx is
essential in developing targeted drugs for different cancers, that can significantly improve
response to therapies. For example, Brand et al. states that Herceptin only works for 15 percent
of patients with breast cancer, “who overexpress a specific chemical receptor;” and Iressa, only
works for10 percent of patients with lung cancer, “with a mutation in a particular part of a
different receptor.” It is evident from studies that only patients with these specific molecular
features will respond to these drugs, others will not. This makes manufacturing of such drugs
less attractive to drug manufacturers versus manufacturing drugs that work on most patients.
However, Brand et al. argue that drugs that are effective for specific genetic characteristics
targeting lung cancer, may also work against other types of cancers with that characteristic.
Therefore, the scholars are optimistic that the genomic era can lead to personalized healthcare
and pharmacogenetics-enhanced drug development to prevent, or better manage diseases.70
Preterm birth (PTB), a major cause of death in children up to 5 years of age in the
developed world, is also a major healthcare challenge, in the developing countries. Early birth in
low-resource countries is the second greatest cause of death in young children - pneumonia being
first. According to Newnham et al., the potential impacts on individuals, families, and society of

114

PTB are considerable – children born too early will suffer from many life-long disabilities, such
as neurodevelopmental delay, hearing, and visual loss, cerebral palsy, and learning and
behavioral problems. Dedicated neonatal intensive care units are vital to minimize any potential
for life-long harm to such preterm infants, but costs considerably; however, the potential cost to
society throughout the lifespan of the individual is significantly more. Newham et al. is
optimistic that precision public health (PPH) is anticipated to offer opportunities previously
unavailable.71 Although PPH has arisen from the emerging field of PM, there is far more
potential to the concept of PM than just “drugs, genes, and disease,” argues Newnham et al. PM
approaches can identify population groups rather than just individuals, yielding greater
benefits.72 Therefore, PPH has the potential to benefit the right population at the right time.73
According to Newnham et al., a variety of population-based PTB prevention programs have
already been implemented in different communities, that target the needs specific to their
communities, aiming to overcome deficiencies that may be contributing to high rates of early
birth. In the U.S., several programs have been launched aiming to overcome health inequalities –
much of which has been resulted from the awareness of the very different rates of PTB among
the various racial groups. Newnham et al. provide data from 2014 that shows that the rates
ranged from 13.2% in non-Hispanic Black women to 9.4% in Hispanics, and 8.9% in nonHispanic Whites. Poor socioeconomic conditions and educational standards may be factors
playing a role in the high rates of PTB. The scholars argue that applying the principles of PPH
may enable progress that previously seemed unreachable.74
According to Burke et al., genetics can help to identify groups susceptible to developing a
particular health problem at the population level, such as the GWAS of the treatment response to
Carbamazepine, a medication which is used in the “management of epilepsy, trigeminal
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neuralgia, and bipolar disorder.” Background genetic risk information can inform investigations
of other risk factors, or of prevention approaches, and can improve the quality of health care.75
Belsky et al. states that PHG can serve as an institutional umbrella for these processes – that are
necessary to adopt the ‘product’ innovations in genomics “by quantifying not only the impact of
gene variations on the risk of the condition but also the effect of modifiable factors that interact
with gene variations.” 76 Genomic technologies can be beneficial in public health epidemiology
to inform the policy and priority setting by monitoring the health statuses of at-risk and
disadvantaged populations, as pointed out by Baynam et al. The scholars further add that this can
be critical in attaining health improvements for those living with rare diseases in underserved
populations - which are caused by destructive, but previously difficult to identify protein-coding
gene mutations - through early diagnosis and best care.77
Jaja et al. brings to our attention that PM is anticipated to be integrated into the healthcare
system soon, and public health research will need to take part in the controversial discourse as to
how to incorporate genomics into policies and practices that will benefit populations.78 Belsky et
al. states that genomics provides a bridge between medicine and community-based public health,
most importantly in the setting of clinical genetics. They point out that both genomics and public
health focus on populations, with the intention to understand the mystery behind the genetic
variations and the roles this variation play in dispositions to diseases, reactions to the
environment, and most importantly in healthcare – “responsiveness to medications.”
Additionally, Belsky et al. add that both genomics and public health recognize the importance of
cultural, societal, and ethnic contexts in healthcare as a part of population health.79
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5.3.2. The Place and Priority of Genetics in Primary Care
According to E. W. Ebomoyi & Josephine I. Ebomoyi, population screening for rare
diseases that can be prevented or mitigated with timely prevention would likely be an immediate
application of genomics in public health.80 New genetic discoveries could also identify sensitive
or critical periods in pathogenesis when intervention could be most effective, and also inform the
selection of intervention targets.81 Ridgely Fisk Green et al. states that pathogen genomics played
an important role in public health for decades and had been integrated into CDC’s activities
through the Advanced Molecular Detection Initiative, with the purpose of addressing
applications of pathogen genomics technologies. Green et al. adds that genomics is already an
important topic for Healthy People 2020 in their goals of providing “genetic services for
individuals at risk for Hereditary Breast and Ovarian Cancer (HBOC), and Lynch syndrome (or
familial colorectal cancer syndromes).” BRCA genetic counseling is a preventive service already
implemented in healthcare and covered by most insurers. Green et al. argue that the Office of
Public Health Genomics (OPHG) at the CDC was created in 1997 with the goal of working with
state health departments, and other partners to identify opportunities for genomics in the
improvement of population health, and provide support for genomics-related public health
activities.82
PPH has the potential to protect many people from various types of cancers, CVDs, and
diabetes. In 2008, the NIH indicated how cancer disease burden cost the USA nearly $210
billion; which included $74 billion in direct medical costs, $17.5 billion for lost productivity
from illness, and loss of productivity due to unnecessary and premature death equating to $118.4
billion.83 According to CDC, despite the decrease in cancer deaths, the U.S. is expected to see an
increase to nearly 2 million a year by 2020 due to newer cancer cases. As of today, cancer is a
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public health problem in the USA, with more than 1.5 million people being diagnosed, and more
than 500,000 dying from the disease. From research, it was noted that more than half of the
cancer deaths could be prevented through healthy choices, screening, and vaccinations.
Although, early screening tests can act as preventive measures for colon, cervical and breast
cancers, by identifying the disease when treatment works best; CDC states: “screening rates for
these cancers remain below national targets set by Healthy People 2020, the nation's agenda for
improving the health of all Americans.” Moreover, CDC states that vaccines can also lower
cancer risk - such as the human papillomavirus (HPV) vaccines (cervical cancer), and the
hepatitis B vaccine (liver cancer).84
Although data from 2006 showed that CVDs accounted for over 40% mortality in the
USA, killing about 95,000 yearly; researchers at the American Heart Association found that:
“Between 2000 and 2011, researchers found the national heart-related mortality rate declined at
an average of 3.7 percent per year, while stroke mortality declined at 4.5 percent per year.” They
credited this decline to advances in biomedical research and technologies. Even then they cited
stroke and heart failure to be the most expensive chronic conditions in the Medicare fee-forservice program in 2014.85 Projections by the American Heart Association show that nearly half
of the U.S. population will have some form of CVD by 2035.86 Tikki Pang asserts that genomic
medicine and screening technologies are anticipated to be vital in the reduction of strokes and
other chronic diseases. Amongst the many benefits that genomic medicine can offer, he adds
that the most important benefit is the early disease detection ability - when it is treatable and less
expensive; stratify patients into groups that enable the selections of optimal therapy; reduce
adverse drug reactions; improve the selection of new biochemical targets for drug discovery;
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reduce the time, cost, and failure rate of clinical trials for new therapies; shift the emphasis in
medicine from reaction to prevention and from disease to wellness.87
According to Leif et al., genomic medicine is also anticipated to play a crucial role in
reducing the prevalence of diabetes mellitus (commonly known as diabetes) - a lifelong,
incapacitating disease affecting multiple organs. They highlight that T2D presently cannot be
cured, neither can it be prevented, and is associated with devastating chronic complications that
impose an immense burden on the quality of life of patients. 88 Data indicates the increasing
prevalence rates of T2D in the adult U.S. population (estimated 6.3 with either diagnosed or
undiagnosed diabetes). Based on an individual's family history it is evident that genetics plays a
role in the risks of developing diabetes. 89 It was interesting to see Murff et al. note the
heritability of T2D diabetes: “approximately one in six patients who identified a relative as
having diabetes were almost three times as likely to have a plasma glucose determination when
compared with individuals without a family history.” 90 Treatment for T2D includes diet and
exercise, and drug treatment to control their glycemia. Unfortunately, scholars note that
treatment of T2D has not been very successful, many resulting in ADRs. Zhou et al. argues that
the advance of genomics has greatly increased our genetic understanding of the etiology of
diabetes, especially pharmacogenomics (PGx).91 They highlight that PGx seeks genetic
explanations as to why individuals differ in the reactions to drugs, concerning therapeutics as
well as adverse drug reactions (ADRs). 92 Zhou et al. also points out the role that PGx plays in
the investigation of antidiabetic drug response. 93
Baynem et al. reports on rare diseases, and the need for a national public health policy
framework. Findings from their studies suggest that sharing of knowledge and experiences
across different countries' rare disease networks and partnerships can help inform the
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development of a Strategic Framework for Rare Diseases (RD) like it did in Australia (Western
Australian Rare Diseases 2015–2018, RD Framework).94 The RD Framework has been able to
provide health briefings to the Australian government on the need for a National plan and has
guided in the precision diagnostic pathways and care into the Western Australian health system.
Findings from Baynam et al. suggest that the RD Framework can be used as a precision public
health framework for improving outcomes in rare disease populations, by informing public
health with the population needs, early and accurate diagnosis that can provide the appropriate
care. 95 According to Baynam et al., there is an estimated 5000–8000 rare diseases; combined
these affect up to 6–8% of the population. Additionally, they report that these amounts to “over
400 million people living with a rare disease,” making rare diseases a major global public health
issue - and “80% of these are genetic.” Although, RD first manifests in childhood and continue
across the lifespan and cannot be prevented or cured (yet), early diagnosis can result in early
intervention and can aim to improve management and ultimately reduce the associated human,
community and system cost.96
Scholars like Brand et al., and E. William Ebomoyi & Josephine I. Ebomoyi define the
role of public health in enhancing population health as: public health’s role being in managing
the distribution and utilization of genomic applications with the intention of benefiting
population health; and implementing the necessary evidence-based genomic applications to
improve and prevent diseases, excluding or limiting premature utilization or misuse/overuse; and
by serving as an unbiased convener of stakeholders.97, 98 E. W. Ebomoyi & Josephine I. Ebomoyi
also add that the Evaluation of Genomic Applications for Practice and Prevention (EGAPP)
launched by CDC in 2005, systematically reviews and updates the validity of genomic
applications, and makes recommendations for appropriate use, where prioritization is based on
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“the level of evidence, the burden of morbidity and mortality that can be prevented in the
population, and cost-effectiveness of interventions.” Moreover, E.W. Ebomoyi & Josephine I.
Ebomoyi add that public health plays a role in evaluating the health impact of public health
interventions using genomics tools, regardless of their current use of genomics. The National
Health and Nutrition Examination Survey (NHANES) is used as an example by E. W. Ebomoyi
& Josephine I. Ebomoyi, used at a national level to evaluate the health impact of interventions on
different segments of the population.99 Stratification of population based on genetic risk
prevention (high, low, moderate), can aid in the effective and efficient application of standard
public health interventions. 100 Genomics also has the potential to benefit the global population as
well - the next section looks at the potential for global health genomics, specifically for
developing countries.
5.4. Potential for Genomics for the Health of the Developing Countries
According to the WHO, fundamental social and economic disparities continue to exist
between developed and developing countries with communicable diseases constituting the
greatest component of the total disease burden across much of the developing countries.101
However, it has been noted in a Report by the Global Forum for Health Research that the
disease patterns have shifted towards multifactorial "lifestyle" diseases, such as cancer, heart
disease, and diabetes which were more prominent in developed countries before. 102 According to
a report by the World Health Organization, genomics research will play a major part “in the
prevention, diagnosis, and management of many diseases,” which have been difficult or
impossible to control.103 Since genomics research is a new technology, it requires high capital
investment. There is a fear that this could lead to wider disparity in global spending ("10/90
gap") on health research between developed and developing countries. Burket et al., emphasizes
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the need to address this disparity by stating that we can only move closer to realizing the goal of
precision medicine to improve the health of individuals by anticipating and addressing the
potential for inequitable access to health care occurring from using genetic information.104 The
next two sections look at the potential applications of genomics in global health.
5.4.1. Noncommunicable and Communicable Diseases
The WHO reported in 2008 that an estimated 36 million, or 63%, of the 57 million deaths
that occurred globally were due to NCDs, also known as chronic diseases – mainly CVDs (48%),
cancers (21%), and diabetes (3.5%) – 80% (29 million) of which occurred in low and middleincome countries (LMIC), and a higher proportion (48%) of the deaths in the LMICs were
premature (under the age of 70) compared to high-income countries (26%). As per the WHO's
report, these were treatable (rheumatic heart diseases and type 1 diabetes) through health
promotion, disease prevention, and comprehensive care. The WHO projected an increase in the
total annual number of deaths from NCDs to 55 million by 2030 if appropriate action is not
taken. 105, 106 As of date, the number of deaths has been staggering - 41 million people die each
year globally from NCDs, which is equivalent to 71% of all deaths globally (WHO, 2018).107 As
reported by the WHO, communicable diseases (also known as infectious diseases) place a
significant burden on all countries and regions, especially on those living in poverty and those
who are socially excluded or marginalized, and has been responsible for over four million deaths
worldwide each year. The WHO recommends implementing (already available) interventions for
prevention and control to greatly reduce this burden. 108 Nishi et al. states that advances in
genomics research have influenced epidemiology greatly – it can encompass all data on health
and diseases around the world, gaining new insights on causal associations; and has also aided in
the integration of molecular pathology and epidemiology, leading to the formation and
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development of molecular pathological epidemiology (MPE).109 Nishi et al. further promotes
MPE and social epidemiology by adding that these developments have been greatly beneficial to
global populations since it allows scientists to learn more about different molecular pathology
and pathogenesis of different disease areas, not just neoplastic diseases such as cancer. 110
It is not far when MPE increasingly be used in the diagnosis and classification of
virtually all diseases.111 Nishi et al. anticipated that MPE will enable the deciphering of the
different etiologies of diseases and address health disparities in a global scale, and will have the
potential to change the way in which global disease control can be addressed. The advancements
in molecular medicine, including diagnostics, imaging, and targeted therapeutics can have
immense benefits on individuals in global populations employing the interdisciplinary approach
of integrative MPE and social health science.112 Babatunde O. Adedokun et al. advocates for
genomics research, stating that genomics research can particularly be attractive for Sub-Saharan
African (SSA) countries, where new technologies and products from genomics research can help
alleviate the heavy burden of infectious and chronic non-communicable diseases (NCDs) – by
bringing about significant improvements in diagnosis, prevention, and treatment of several
disease conditions.113

Sarah Gibbon notes that efforts to align genomics with

epidemiology and infectious diseases in global population health are in progress.114 According to
the WHO, growing evidence suggests that better knowledge of the pathogen genomics will
provide insights to the spread of infectious diseases within populations, and anticipate the
emergence of epidemics and “new” or virulent forms of known infections, such as CreutzfeldtJakob disease, new strains of Influenza virus, Hantaviruses, and Human Sleeping Sickness.
Novel vector control approaches are also being considered for the prevention of communicable
disease such as malaria.115 Genomics is being applied to better understand variability in host
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response to infectious diseases depending on gene families, with considerable progress being
made in identifying a variety of gene families which are involved in modifying susceptibility to
malaria and other infections.116 Moreover, Singer et al. notes that genomic technologies are
anticipated to have the potential for the prevention, diagnosis, and treatment of HIV, malaria,
and tuberculosis; and can also be applied to understand the genetics of bacteria, plants, and
animals.117 Moreover, Singer et al. adds that genomics is expected to have direct economic
effects on the pharmaceutical market – with growth projection from US $2.2 billion in 1999 to
US $8.2 billion in 2004.118 Acharya et al. also argues in favor of genomic-related technologies,
stating that they are changing global perceptions by becoming simpler and cheaper, to the point
where older technologies in poorer nations can be easily replaced with newer ones. They add that
genomic-technologies has made it possible to develop simple and easy-to-use tests for
tuberculosis, hepatitis C, HIV, malaria, and other diseases.119 The polymerase chain reaction
(PCR) is a fast and accurate technology for making millions of copies of a specific sequence of
DNA. Besides being extremely sensitive, Singer et al. adds that PCR tests can provide results in
hours versus days, and can detect difficult or impossible to grow (in cultures) infectious
organisms, such as tuberculosis; or like HIV/AIDS which are dangerous to handle. Previously,
PCR tests were only available in the industrial world; however, Singer et al., notes that the recent
advances are beginning to bring this powerful tool within reach of the developing world.120
Singer et al. further emphasizes that molecular diagnostics present a robust “set of
methods” to address the health-related Millennium Development Goals: “Combat HIV/AIDS,
malaria and other diseases; Reduce child mortality and Improve maternal health.” They also
noted that “infectious and parasitic diseases” are responsible for 17 million of all deaths every
year. With HIV/AIDS, malaria and tuberculosis being the three major killers, Singer et al. adds,
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together claiming “at least 5 million lives a year.” They further add that “11 million children”
have been estimated to still die before reaching the age of five. Singer et al. states that: in order
to achieve this goal, improving public health for disease prevention will be important, but it will
also be important to make sure there are effective methods for diagnosis and treatment for these
diseases. They further add that developments of “rapid and accurate diagnosis, will not only
increase the chances of survival, but also avoid waste of resources on inappropriate treatments,
and help contain diseases.” 121 They also add that the antibody-based application is highly suited
to the developing world since: “Antibodies are molecules produced by the immune system in
response to infection,” which “can recognize and attack the proteins produced by the pathogens.”
Singer et al. notes “that antibodies are specific, that is they recognize and bind to specific types
of antigen,” making them “an excellent tool for the diagnosis of infectious disease.” They add
that recently: “simple and rapid antibody coated dipstick tests have been developed that have
increased the relevance of this technology for the developing world. Dipsticks can be used
anywhere, without the need for laboratory facilities, running water or electricity” which can be
scarce in developing countries.122
Singer et al. goes on to add that recombinant vaccines, another development of the
genomic research, can attain many of the Millennium Development Goals: “Reduce child
mortality; Improve maternal health, and Combat HIV/AIDS malaria and other diseases." They
add that the hepatitis B vaccine is an example: “which saves the lives of millions of people,
including children, every year, and many HIV vaccine candidates currently under investigation
are treated with recombinant vaccines.” Singer et al. adds to their argument that recombinant
vaccines are promising “to be safer, cheaper, and possibly easier to store and transport than
traditional vaccines.” The scholars add: “vaccines stimulate the body to produce a protective
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immune response, and thereby, reduce the likelihood of serious infections.” Singer et al.
moreover highlight that: “Advances in vaccine research are likely to have an impact not only on
communicable diseases but also on non-communicable ones such as cancer.”123 Singer et al
point out that pathogen genome sequencing can also contribute to the identification of: “the
genes that play a role in helping organisms develop drug resistance and point researchers in the
direction of treatments that can overcome the action of these genes.” Singer et al. add: “A serious
health concern worldwide is the emergence of pathogen resistance to previously effective
drugs.”124 The next section looks at the importance of pharmacogenomics and gene therapy.
5.4.2 Pharmacogenomics and Gene Therapy
According to Katherine Chadwell, the Agency for Healthcare Research and Quality
reported that 770,000 injuries or deaths are related to adverse drug events each year in the USA
alone - which costs between $1.56 and $5.6 billion annually. Although drug therapy can be
impacted by many variables, such as age, organ function, or drug-drug interactions, Chadwell
adds that it is estimated that pharmacogenomics dynamics could reduce this cost, since variations
in the molecular analysis has already shown that there is considerable individual variation in
response to drugs used to treat some of the more common diseases.125 Research suggests that the
burden of ADRs on patient care has been found to be high globally as well. According to Ushma
C Mehta, studies conducted in various regions of the world involving 419,000 patients,
approximately 6.7% of all hospitalizations were due to ADRs - where Mehta notes that more
than half of the ADRs were “preventable with improved prescribing, administration, monitoring
and adherence.” Mehta also observed that “patients with HIV/AIDS were found to have an
increased risk of ADRs” in developing countries. Mehta states: “Patients with HIV/AIDS were
found to have an increased risk of ADRs. This is probably due to the effect of the disease on the
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immune system (which is responsible for many idiosyncratic drug reactions) as well as the safety
profile of the complex drug regimens that patients with HIV/AIDS are often receiving.”126 The
WHO recognizes that genetic screenings are worthwhile in populations where there is a high
frequency of side-effects due to genetic susceptibility to drugs used to treat common
diseases.127Although the burden of poverty-related conditions and infections remain substantial
in the developing world, Burke et al. points out that the combination of increased affluence,
urbanization, and life expectancy has led to global growth in the incidence of complex diseases.
There is mounting evidence of diverging health outcomes within and between economically
developed countries and low and middle-income countries (LMICs).128
As noted in the Report of the Advisory Committee on Health Research, genomics always
looked promising in the cancer prevention and treatment, and as such will no doubt be integrated
into public health practice in the early identification of cancer. 129 Although, age is a common
factor for most of the oncogene mutations, studies from the WHO demonstrate that a much rarer
group is associated with a strong family history of cancer, resulting from mutations of a family
of genes called “tumor suppressor genes” which, evidence suggests, are inherited. 130 Tremblay
& Hamet argues that PGx and individualized drug therapy are "the building blocks of
personalized medicine." Additionally, they state that pharmacogenetics testing will help to
identify the differential responders, providing a basis for personalized drug treatment of a large
number of patients. 131 Per Donna Dickenson, sometimes overtreatment, or aggressive treatment
such as chemo that is part of the "one-size-fits-all" cause side effects leading to deaths. She
advocates for tailored medicine, stating that under such conditions, tailored medicine would not
only be more humane but also more effective. She further adds that it would be possible to
identify patients who are genetically programmed to respond more quickly to chemotherapy and
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to give them lighter dosage than to “kill or cure.” 132 Another important application would be
genomic testing for individual variations in drug metabolism, as pointed out by Andrew Blix,
“PM represents a major change in the way” health care will be delivered, and because cancer is
fundamentally a genetic disease, advances in genetics and genomics have profound implications
for oncology. Blix argues that PM offers the promise of treating diseases or predispositions
identified in the individual genome with specific, targeted pharmacogenomics medicines dosed
for the individual's unique metabolism; it can also be effective in determining fewer side effects
for patients.133
Genomics is also anticipated to play a role in disease identification and prevention of
chronic ill-health – known to contribute to death, increased disability, and health care costs,
which represents a substantial public health concern according to the WHO.134 Katherine
Chadwell makes an important observation where she states that although PM cannot reverse
health problems, it can offer the most effective treatment for a person's current chronic issues.
She adds that the key component for healthcare will be focusing on prevention and earlier
intervention with appropriate treatment, by addressing potential causes identified in a person's
genetic and genomic makeup.135 Genomics is already applied in diagnosing monogenic diseases
– the commonest being those involving human hemoglobin, the thalassemia and sickle cell
disease and its variants, conditions which have a particularly high frequency in developing
countries. As countries undergo the demographic transition, there is increasing evidence for the
transition in the pattern of diseases from malnutrition to other chronic illnesses, such as
cardiovascular disease, diabetes, and cancer, posing an increasingly severe health burden.136 Data
presented in the Report of the Advisory Committee on Health Research, demonstrate that NCDs
are accounted for the deaths of twice as many people in the developing countries than in the
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developed countries. T2D is an example, according to the WHO T2D is also a crucial risk factor
for CVDs, and appears to be reaching frequencies between 20% and 70%, doubling the global
number of 150 million affected people to 300 million by 2025.137
Gene therapy is primarily used as medicine to correct defective genes responsible for
genetic disorders, and as argued by Singh et al., gene therapy has the “potential to eliminate and
prevent hereditary diseases.” 138 Reports from the WHO also highlight the clinical impact gene
therapy will have on cancer therapy, especially in the targeting of abnormal functionalities of
oncogenes and drugs targeted to treat cancer and other common diseases.139 Scholars like Verma
and Somia also argue in favor of gene therapy, stating that gene therapy can be instrumental in
the eliminating and preventing diseases such as cystic fibrosis, which are hereditary diseases; and
is a possibility to cure heart disease, AIDS and cancer. However, they also point out that amongst
the disadvantages, gene therapies may not be effective due to immune responses which are shortlived. 140
A significant challenge in demonstrating the relevance of public health genomics in
LMICs, according to Burke et al. is to generate an evidence base that can confirm that a
genomics approach is at least as safe, effective, and cost-effective in these settings, as other more
traditional approaches, such as modifying environmental or social determinants.141 To add to
this, Sarah Davies points out that the majority of new drugs coming out today have been tested
on populations that cannot afford them, and the pharmaceutical industry is still able to maintain
support for its argument that patents are justified in such conditions. She highlights the
imbalance in the meetings that take place regarding pricing of medicines; where pharmaceutical
companies exert more influence collectively than developing countries. For instance, at the joint
WTO-WHO meeting and the WTO Doha meeting, more pharmaceutical representatives were
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present than representatives from developing countries.142 Aresha Manamperi adds to the list of
concerns by pointing out that despite the excitement about the potential promises of genomics on
the population health of developing countries, it is still not 100 percent clear how these advances
will affect the health of people living in the developing countries. She adds that although the
genomic revolution is anticipated to offer new opportunities for the prevention of chronic disease
from a public health perception; it is important to understand all the other factors involving
biological markers associated with people and their predisposition to these diseases and the
social and ethical implications in order to formulate public policies for genomic-based health
care.143
5.5. Challenges and Barriers to the Integration of Genetics into Routine Clinical Practice
Christopher Murray notes that the Institute for Health Metrics and Evaluation (IHME)
predicts that there will be a widening of health spending between the world's poorest and
wealthiest countries – with a projected 9% of GDP globally allocated to health spending by
2040, however, substantial variations will exist in the levels of health investment between the
low- and lower-middle-income countries, and high-income countries. According to Murray while
citing IHME, it is projected that: “High-income countries are expected to spend $9,019 per
person on health in 2040, compared to the projected $1,935 for upper-middle income countries,
$507 in lower-middle income countries, and $164 in low-income countries.” Murray notes that
the IHME also states, a high number (about 35) of “low- and lower-middle-income country
governments will likely not meet the international benchmark established by the Chatham House
of spending $86 per person to provide primary healthcare. Many countries in sub-Saharan Africa
are predicted to be the lowest spenders on health.” 144
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According to Murray, the IHME report also found gaps between donor funding and
disease burden in most regions, particularly concerning non-communicable diseases (NCDs).
Although NCDs are a mounting portion of disease burden in developing countries, and given the
expansion of funding related to NCDs from 2010 to 2011, Christopher Murray add that NCDs
were not even a focus of health development assistance for the developing countries.145 In order
to address this, there have been efforts put in place to help focus research efforts on diseases
representing the most onerous burden on the world’s health, that seek to improve the allocation
of research funds and facilitate collaboration between partners in both the public and private
sectors.146 It is imperative that developing countries pick up in the race of genomics and work
towards forming genomics research with a wider, integrated strategy to address the specific
determinants of ill health for their countries.147 Although PM is anticipated to inform medical
decision making through the use of genomics, there are fears that such use will not be equitable.
5.5.1. Justice and Resource Allocation
Scholars evaluated the effect of geographic ancestry on the interpretation of genomic data
and found that the extent bias toward European populations had an adverse effect on identifying
candidate variants in other populations. African populations have a disproportionate burden of
disease; as a result, the high genetic diversity provides a greater rationale for using genomics to
improve our understanding of the genetic basis for diseases - both communicable and noncommunicable - and to use the data to guide personalized medicine. Mulder et al. look at the
recent large-scale initiatives, such as the Human Heredity and Health in Africa (H3Africa)
initiative that has taken on the initiative to address some of the implementation of PM in Africa.
As Mulder et al. highlight, the H3Africa initiative is designed to make way for innovative
genetic and environmental research for diseases affecting the African people. This initiative is
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funded by the NIH and the Welcome Trust. Along with boosting research capacity at individual
institutions and three biorepositories for storing project biospecimens as a shared resource,
Mulder et al. add, the H3Africa hopes to focus on a diverse group of communicable and
noncommunicable diseases and the genetic and environmental factors associated with those.
Mulder et al. also note that the rise of premature death from non-communicable diseases is a
public health issue in Africa that has prompted six H3Africa research teams to join forces to
establish a combined African resource to enhance research in cardiovascular, as well as other
complex traits and diseases.148
Communicable diseases, such as trypanosomiasis, HIV, and surveillance of microbial
threats are also a focus of some of the H3Africa projects, among others. The surveillance project
led from Nigeria helped to develop skills and infrastructure for pathogen research in this region
and was instrumental in responding to the recent Ebola 2013–2016 outbreak which claimed
11,323 lives to date. The ill preparedness of the global community did exacerbate the situation.
However, the event also produced significant contribution from the African scientists within the
epidemic hit regions, and brought out the importance of strong international collaboration.
Mulder et al. advocates for the partnership between West African research expertise and
international partners, stating that such partnership has resulted in the formation of two key
organization: “the Viral Hemorrhagic Fever Consortium (vhfc.org) and the African Centre of
Excellence for Genomics of Infectious Disease (acegid.org),” which were, according to the
scholars: “These organizations were instrumental in quelling the outbreak by utilizing
polymerase chain reaction-based diagnostic tests to identify the first cases of Ebola in Sierra
Leone in May 2014 and Nigeria in July 2014.” Mulder et al. also advocates for investment in
infrastructure to support endemic public health challenges like Lassa virus, which they argue
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have demonstrated the potential of well-established collaboration between domestic and
international networks to respond to regional outbreaks that could not have been achieved in
isolation.149 Mulder et al. state that research in areas of: “Microbiomes also play an important
role in diseases” and have been focused within the H3Africa consortium, with the focus of
microbiome-specific diseases, such as pneumonia in children, and cervical cancer in women.
Mulder et al. add that the African Collaborative Center for Microbiome and Genomics Research
(ACCME), based in Nigeria, “is a multicenter study of host germ line, somatic, and human
papillomavirus (HPV) genomics and epigenomics….and the vaginal microenvironment and their
association with cervical cancer.”150
Pang Tikki and David Weatherall bring up an important point about the benefits of
improving global health and reality. Although there are apparent benefits of genomics to global
health, the reality is that the developed world made most of the advances in genomics, geared
towards their priorities, which raises many concerns that need to be addressed for
implementation of genomics into developing countries. Pang Tikki and David Weatherall point
out that the “issues of confidentiality, stigmatization, and misuse of genetic information are high
on the list of concerns.” They also voice the concern that there is a fear that genomics will create
a “genetic underclass” that may be denied health insurance. Moreover Pang and Weatherall voice
their concerns related to the health equity between the developed and developing nations due to
genomics.151 They highlight the findings from the WHO: 80% of investments in DNA patents in
genomics from 1980-93 were held in the United States. Only 13 (out of 1233) of the new drugs
marketed between 1975 and 1999 were explicitly approved for tropical diseases relevant to
developing countries. They strongly recommend that the quality and education in genetics and
genomics be increased at all levels of society, both nationally and globally. Otherwise, it will not
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be possible to have the informed debates about the issues at hand, and those who will be in
charge may be at risk for overselling the services a new, still ambiguous and rapidly expanding
research field. However, they do agree that there has been a globalization of diseases, and with
that in mind, medical schools, research funding bodies, industries, and governments of developed
countries, as well as developing countries must form a mutually beneficial and equitable research
partnership for the purposes of fighting global health inequity.152
Like other global public goods, global health and global health research suffer from
insufficient investment as underlined by the 10/90 gap, and as previously mentioned. The
problem is that, in allocating resources, decision makers take mostly national and local
considerations into account, and not a worldview of needs for health and health research. As a
result, opportunities to provide essential benefits for all are lost. Although the leading UN
agencies for health take a global view on health and health research, they cannot alone
sufficiently influence decisions at the national level to ensure the integration of a global
perspective. Scholars from the WHO argue that there needs to be a multitude of actors involved
in “world health research governance,” to study the problem and ensure that externalities are
gradually integrated into the decision-making process.153
5.5.2. Reclaiming Genomics for Common Good - Need for Justice Approach
As noted by a Report from the Global Forum for Health Research, 2000, the “10/90 gap”
is feared to be widened further since the current global research agenda is determined by
developed countries, and are focused on the needs of the developed countries. This will
undoubtedly result in products that are developed for the needs of the developed countries, and
will have a negative effect of the needs and health of the developing countries.154 There are fears,
as emphasized by scholars like Minkyo Song et al. that this gap will be exacerbated further by
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the genomics revolution.155 The WHO states that the paradigm of health is shifting from simply
“living a longer life” to “living a healthier and longer life.” However, people today suffer from
chronic diseases which create many inconveniences in everyday lives, some of which require
medical attention; and chronic diseases also cause a significant loss at a national level, as well as
at a personal level. This directly translates into the longer duration of care needed, meaning
higher medical costs and poorer function of the individual. Nationally, this means rising medical
costs and health inequalities, which is further pronounced with improvements in medicine and
related fields. Thus, the rational solution is to unravel the problem beforehand, at its causal
origin, by preventing diseases before the occurrence, which is one of the goals of genomics.156
Scholars like Kelly A. McClellan et al. highlight the anticipated benefits of genetics and
genomics in the health and medicine of developing countries, and the UNDP Human
Development Report (2001), advocates for building technological capacity for developing
countries.157 McClellan et al. further, advocates for PM’s tailoring abilities to genetic variations
of individuals, stating that it can give rise to many advantages such as optimizing patient care
through guided medical decisions. They also note that tailoring medical treatment decisions
using genomics also gives rise to many advantages for the society as well – such as integrating
the use of personal genetic information into healthcare delivery is “hoped to result in significant
cost savings by administering treatments only to those most likely to benefit,” resulting in costreduction and efficient healthcare delivery.158 The objective of healthcare is evolving from
simply ‘treating the ill’ to ‘aiding the healthy in maintaining their good health.’159 However, fears
regarding the potential for misuse of genetic information are high, giving rise to the concept of
‘genetic discrimination,’ based on genetic variation from the perceived normal human genotype.
Wylie Burke et al. highlight concerns of inequity due to the utilization of genetic information to
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inform the medical decision, stating that: “policies or practices surrounding the use of genetic
information in medical decision-making may have an unintended effect of denying individuals
access to healthcare on non-medical grounds.” Some of the fears are justified by reflecting on
past misuses of genetic science in the interest of advancing a national or international eugenic
agenda. Other issues related to the equity in the provision of health services to disadvantaged
groups in both economically developed and the developing countries also arise and require
elaborate discussions not only about access to essential medicines but also about global justice
and human rights.160
The terrain of genomics research and genetic medicine has only been recently aligned
with ‘Global health’ - even though the WHO has been consistently highlighting the relevance of
genetics to addressing human health since the 1950s. According to Gibbons et al., genetic
knowledge and technology is being used to address a wide range of healthcare challenges,
encompassing not only ‘rare’ diseases, but also growing rates of non-communicable chronic
diseases in low- and middle-income countries (LMICs), as well as infectious diseases. They state
that genetics is also being utilized in large transnational epidemiological studies to address
epidemics and pandemics such as “Malaria and Ebola virus.”161Scholars like Gibbons et al. have
highlighted the need to bridge the so-called ‘genomic health divide' through economic
investment in research, and expanding the provision of genomic services and technologies to the
‘global south’ by including a greater diversity to encompass ‘minority populations’ from ‘other
ethnic groups,’ and to ensure that “those most in need are not the last to receive the benefits of
genetic research.” Despite the global expansion and ethical repositioning of genetic medicine and
genomic technologies concerning social inclusion and justice, Gibbons et al. highlight that there is evidence of inequitability in stratified access and rights to health care resources.
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Moreover, they point out that finding from research in the Sub-Saharan African countries
demonstrated that research was only focused on infectious diseases (HIV, TB or malaria), while
ignoring NCDs such as cancer and CVD, even though a steady rise in the incidence of NCDs
was noticed, “with an even higher projected burden in the next 25 years.” It is evident that
greater efforts need to be directed toward research into diagnostic and treatment technologies for
conditions such as cancer and CVD in the developing nations as well.162
Even though genomics has significant characteristics as a global public “good,” these are
not fully developed in developing countries.163 Gostin and Memorial write that, although
knowledge is theoretically free to be disseminated, in practice, constraints, in the means of
considerable investment, are often put on its use.164 According to Tikki Pang, some of the
benefits of investing in genomics technologies are: strongly supported significant investment in
infrastructure for translational research on the grounds will build capacity; shape the organization
of health systems and services; result in more effective public health programs that is able to
incorporate accurate measures of genetic, environmental, and social determinants of health and
provide a powerful means of effectively evaluating new and existing public health interventions.
A key question, according to Pang, will be about ensuring equitable access to genomic tests,
vaccines, drugs and diagnostics procedures (that are needed for the diseases of the developing
world) to those who need it. Pang recommends “a strong international leadership” scientific
community, international organizations, governments, and industry is required through
promotion of innovative partnerships and cooperation strategies,” in order to overcome existing
barriers. Pang also recommends highlighting to the world leaders, about the potential of
genomics to generate “economic and health benefits for developing countries,” to initiate a
political motivation. Pang emphasizes that the application of the knowledge of genomics need to
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be delivered to the “diseases of the poorest people as well, and that we all have a responsibility
to help make these opportunities into realities.”165
5.6. Recommendations: Delivering Genomics for Improving Health
As singer et al. best highlights, that most genomic technologies are developed for the
applications of the developed countries, even though genomics has a potential to benefit both
developed and developing countries – this creates a fear of the formation of a “genomics divide”
between the two. They further add that if this inequity is left unchecked, this could lead to even
greater disparities in health, between the developed and developing countries. 166 Scholars like
Baynam et al. have also pointed out that an effective mechanism for addressing these challenges
can be through the development of policy frameworks by governments of both developed and
developing countries, working in a joint partnership to alleviate the inequalities and address the
challenges. Clearly defined policy frameworks, according to Baynam et al., can give directions
to help ensure that health systems can translate and optimize the application of the new
knowledge, and the rapidly advancing technologies, in a coordinated and strategic fashion- to
improve the patient journey and outcomes for all people living with not just any disease, but also
rare diseases.167 Sarah Davies is positive that soon genomics will be an integral part of the
healthcare delivery system.168 Burke et al. also agrees that individuals will be more likely
inclined to routinely have their full genome sequenced, shifting the burden of interpreting
genomic data from research to the clinical setting. They highlight the need for addressing the
many challenges that will need to be addressed by healthcare professionals and public health
professionals in the era of PM. 169 The next sections look at the areas of focus that will be
needed and ways to prepare for future challenges.
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5.6.1. Areas of Focus
Scholars like J Scott Roberts et al. briefly explains the various disciplines encompassed
in public health genomics, stating that it is an extended interdisciplinary enterprise that includes
many longstanding disciplines such as: “genetic epidemiology, biostatistics, health policy, and
health education, as well as state-funded programs focused on surveillance and prevention of
birth defects and heritable disorders.” Roberts et al. explains that amongst the many areas of
focus is the mandatory population-based, Newborn Screening (NBS), provided by every state in
the U.S. These tests are coordinated through each state's department of health, where a variety of
disorder types are screened, such as: “inborn errors of metabolism, endocrine disorders,
congenital heart disorders, cystic fibrosis and hearing loss” – disorders that Roberts et al.
emphasizes as serious lifelong conditions without cure. The benefit is to detect these in newborns
to prevent the progress of irreversible damages such as cognitive impairment or even death. Each
year 12,000 children with rare inherited disorders are identified by NBS, who are then connected
with life-saving interventions before irreversible health effects or death occurs.170
Gostin and Memorial talk about the next-generation sequencing (NGS) as being another
emerging genomic technology with the potential to help improve the quality of screenings for
current NBS conditions, by increasing the predictive values of NBS results. However, NGS
raises many programmatic and ethical issues for NBS programs - NGS could potentially uncover
additional, unanticipated information, such as incidental findings (IFs) associated with hereditary
cancer syndromes for infants. Moreover, Gostin and Memorial are concerned that some of the
information based on the results may not be immediately actionable for the child, and may harm
the child and the families with unnecessary burdens of fear, and anxiety. Therefore, the potential
harms on children and families should be examined before incorporating NGS into testing
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protocols.171 Additionally, both Gostin and Memorial and Roberts et al. add about the
implications of lifelong metabolic conditions such as “PKU and galactosemia” which require
special diets, and are expensive and sometimes lack coverage by third-party payers, leading to
issues such as forgoing treatment because of inability to pay for treatment. Although, some states
pay for the formulas and medical foods for such conditions; this service is increasingly becoming
difficult for the state to provide due to cuts in state public health budgets. Recommendations
have been made that these children receive appropriate and high-quality clinical care that
maximizes health outcomes through long-term follow-up surveillance. 172, 173
Mulder et al. reiterate their concern about the equity of health in developing countries.
Despite the growing incorporation of genomics into public health and clinical practice, they
observed that for most of the people living with a rare disease globally, too much remains
unchanged. More explicitly, there are still too many families for whom a diagnosis has yet to be
provided so that they can access evidence-driven best care, “a core pillar" of our health systems.
Due to a data deficiency, and consequently a knowledge gap, there is a “paucity of evidence,”
and public health data on the impact of rare diseases on the health system, and the actual impact
on the families living with the conditions and the wider community. For example, African data
are poorly represented in public repositories. In order for PM to become a reality in Africa, more
considerable reference, and control populations, and more appropriate data generation tools are
needed according to Mulder at al.174 Although many emerging technologies and approaches are
providing opportunities to address some of the deficits, Baynam et al. reemphasize that there still
remains a need for a shared global agenda, from governments and funding agencies, designed to
maximize the impact and benefits that may be derived from the limited funds available for rare
disease research.175
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The World Health Organization (WHO) is optimistic that genomics will play an
important role in the control of infectious diseases in the developing countries. With the large
datasets of drug resistance pathogens and regular surveillance capacity of genomics research, as
highlighted in the Report of the Advisory Committee on Health Research, genomics has been
expected to be an essential addition to public health measures in developing countries –
especially in the control of emerging antibiotic resistant strains of pathogens.176 Studies from the
WHO demonstrates that individual drug response has major implications in the control of
infectious diseases, as such, the WHO, in its report, is optimistic that the clinical application of
genomics will have positive effects in the health of the population globally. 177, 178 Moreover, the
report also emphasizes the need for health ministries in developing countries to develop formal
processes to test and evaluate potential genetic screening programs, to ensure the local needs and
cost-effectiveness of the programs.179 It has been advised by the WHO to integrate genomics
alongside other traditional and proven healthcare interventions in order to avoid any negative
effects.180
5.6.2. Legal and Policy Considerations, and Educating Professionals
Understanding the ethical, legal, and social issues in the translation of genomic
information into practice is essential to provide patients, families, and communities with
competent, safe, effective health care.181 Amidst the rapidly developing technology of genomics,
it has already been identified by many research studies that there is a need for health provider
education and competency.182 Healthcare professionals often look to professional codes of ethics
specific to their practice when seeking ethical guidance. They need to recognize that their actions
and those of others providing healthcare based on genomics are of significant concern, since a
single act may simultaneously benefit one person while harming another.183 According to the
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WHO: “ethically, legally, and socially responsible genomic research requires openness, not
privacy, as its organizing principle.” To be responsible and effective, the WHO adds that largescale genomic research should take place in the “view of the public and the law,” while adopting
openness in risk disclosure and informed consent; with elaborate dialogue and data-sharing
among researchers and participants; and thoughtful self-regulation.184
Although public health genomics has the potential to provide immense benefits to human
health - the benefits must be delivered within the framework of the law, and in a manner that
adheres to core ethical principles of human subject research.185 While GINA was established to
protect individuals from discrimination, it is not comprehensive and fails to formally forbid the
use of genetic information in “setting rates or determining coverage for life, disability, or longterm care insurance,” as noted by the WHO. Moreover, as the WHO notes that much of the
regulation of genomic research falls on medical practice or direct-to-consumer genomic services.
Additionally, individual states have their own approaches to regulate genomic services and
research that adds to the issue.186 Appropriate regulation will be the key to technological
advancement, as noted by Katherine Chadwell, who recommends the diligent and cooperative
partnership between the genomics community to make sure that an emerging regulatory
framework incorporates, “certain fundamental distinctions” where applicable.187
The WHO also emphasizes that education and competency are crucial to translating the
benefits of genomics to the patient, and for guarding against potential harms not just nationally,
but globally. The WHO adds that developing countries need to keep up with the education and
training in genomics in order to apply PM and reduce the 10/90 gap. As highlighted in the report
by the WHO, developing countries will need to forge international partnerships between
academic researchers and local universities in order for potential genomic advancements to
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evolve.188 Scholars like Ojha and Thertulien emphasizes the need for education at a societal and
healthcare professional level about genetic tests' scope, stating that “genetic and molecular
assessments” will soon become a routine component in healthcare. They stress that continuous
assessments of the screenings and disease identifications will be needed to ensure this
technology is beneficial to all.189
Challenges have been cited by Baynam et al. in the implementation of PM in the U.S.
that includes limited evidence for clinical use and lack of data from diverse populations.
Capturing structured “phenotype-disorder” knowledge was also highlighted as challenges that
need to be addressed since they are critical for maximizing the understanding of RD. Moreover,
Baynam et al. emphasize that “achieving this in the context of the real-time clinical data
acquisition” is essential to enable clinical and research breakthroughs in disease identification.190
Furthermore, the scholars add that the incomplete linking of detailed phenotypic terms to
genomic variants presents a limitation in providing clinical confidence around variant calls,
therefore, in order to address these limitations there is a need to adopt “standardized phenotypic
nomenclature, and disease classification terms and coding, to facilitate genotype-phenotype
reference databases and privacy-preserving data sharing.” 191
In order to address issues of lack of diverse populations, there is a need for the
development and implementation of guidelines to support decision making in clinical settings.
Mulder et al. has noted that the infrastructure developed by the H3Africa consortium has
contributed significantly to PM by providing the needed “phenotyped cohorts across different
ethnic groups, background reference population genetic data, and the development of the skills
and infrastructure to collect, store, harmonize, analyze, and interpret the data.” Mulder et al. adds
that the he H3Africa consortium infrastructure has not only improved our understanding of
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NCDs but has also prepared laboratories in Africa to fight against pathogen outbreaks. As noted
by the scholars, the Ebola outbreak in 2014 prompted African scientists to prepare themselves
with the equipment and the skills. However, implementation of PM in clinical settings in Africa
faces ethical challenges that relate to questions about resource allocation and equity. Making sure
that the introduction of PM is not taking away funding for other important healthcare programs
that affect the larger population will be critical. One definite recommendation from the scholars,
for research and care to contribute to reducing global health inequality effectively - is to make
sure that interventions are improving the fate of the worst off. More evidence-based cost-benefit
assessments to explore, whether and when the introduction of PM is desirable and ethical are
needed.192
There is a need for global benefit sharing and development of novel technologies such as
PM, as identified by the International Bioethics Committee of UNESCO, and this calls for
international collaborations between developed and developing countries, that ensure that both
are benefiting.193 As emphasized in the report by the WHO, the national governments of each of
the countries will need to consider the issues that are related to the interests of their people.
WHO has pointed out that most genomics and pharmaceutical companies have more expertise in
negotiating, and therefore, it has been recommended by the WHO for the governments of the
developing countries to acquire negotiating expertise.194 The WHO recommends that developed
countries initiate medical education that is also focused on the needs of the people of developing
countries. The WHO highlights the growing problem of the increasing commercial interests that
are driving the research agenda in the developing countries, which will need to be addressed.
According to the Genomics and World Health: Report of the Advisory Committee on Health
Research, it has been recommended that the WHO takes the lead in increasing awareness of the
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complex problems, and encourage the developed countries to take a more global view of medical
education and research activities.195
Conclusion
Genetics and genomics integrated into mainstream healthcare will contribute to a
significant change in practice, affecting the delivery of healthcare at all levels.196 As Conley et al.
note, genetic and genomic information is being integrated into the management of nearly all
common diseases. 197 Scholars like Gilbert S. Omen argues that public health genomics will have
the responsibility to ensure that the next generation of “human genomic research and commerce”
are practiced responsibly, addressing the substantial new issues.198 Genomics has contributed
greatly to the development of effective interventions that target the molecular basis of diseases,
as reiterated by Clayton.199 Hall et al. also notes that the successful utilization of this new
technology will depend not only upon the costs of genetic screening, and effectiveness on
reducing the morbidity and mortality rates of the conditions, but also our ability to prevent
misuse of the genomic information through effective public health policies. 200 According to the
main argument of the Genomics and World Health Report (2005), genomic technologies open up
many possibilities for the benefits of health of developing countries, and this technology should
not be considered as a luxury for a few, but should be considered a necessary tool for all. 201 A
crucial factor that sets up the vicious cycle of the 10/90 gap, as cited by D. Vidyasagar, is the
“paucity of research” in the developing countries. Investigators are attempting to quantify this
gap.202 In light of all these arguments, we can agree with the Global Forum for Health
Research’s Report that the only way to correct the 10/90 imbalance is to create capacity
development by establishing the core of trained people needed in developing countries to do
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cutting-edge research and play their part in the global research agenda, thus contributing to the
correction of the 10/90 imbalance.203
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Chapter 6: Social and Ethical Implications of Integrating Precision Medicine into
Healthcare
6.1. Introduction
Understanding the underlying concepts of human genetics and the interactive role of
genes, behavior, and the environment will be crucial to the appropriate collecting, and applying
of genetic information and technologies, in the improvement of disease diagnosis, and treatment
in the era of PM. 1 Juengst et al. point out that the completion of the HGP opened up possibilities
for PM as the “paradigm shift” in health care, leading to discussions of the pros and cons of this
technology. There are many benefits of PM. However, advances in PM also gave rise to ethical
and social implications that need to be addressed before PM's potential can be fully realized.
Proponents argue that PM is more “personalized,” “predictive,” “preventive,” and
“participatory” than the conventional medical routines.2 Plenty of genetic tests are already
available to help people make informed decisions about prevention and treatment of diseases.
However, research indicates that the public knowledge and attitudes need to be taken into
consideration if PM is to be utilized in clinical care.3 PGx, an area in PM, has the potential to
stratify either patients or diseases by using individual’s genetic variations to target prescribing
medicine, and preventing ADRs; which as Demissew Berihun Haile et al. point out, ranks as the
fourth and sixth leading causes of mortality in the US alone.4 Despite the many challenges, PGx
is believed to be an area of genomic medicine where PM could have an immediate impact soon.5
Given PM’s potential, the implementation process has been slow so far due to many ethical and
governance challenges. As Jusaku Minari et al. note, there are implications for the meaning of
validity of consent, due to the blurred boundaries that exist between research and care in the
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healthcare system, that also increases the potential for discrimination. These scholars also argue
that the increased sharing of personal information, which is the basis for PM, raises concerns
about privacy, commercialization, and public trust. 6 This Chapter looks at the social and ethical
implications of PM’s integration - taking into consideration the public knowledge and attitudes
about PM, and the potential it has on the healthcare system; identify and address various
challenges in the integration of PM into clinical practice, and also recommend some approaches
to address the concerns.
6.1.1. Integration: Looking at Ethical and Social Concerns, Challenges and Needs
As scholars like Simone Vernez and Sandra Soo-Jin Lee point out, PM has been
promised for decades to revolutionize the healthcare delivery system, by improving individual
health through the utilization of personalized risk information, drug metabolism, and thereby
predicting whether individuals are carriers for certain diseases and so on. They add that the very
foundation of PM promises to reshape the personalized health profiles of individuals, through
active public participation in order to achieve better health outcomes.7 Scholars like C.H. Song
also asserts that the reduced cost and high accuracy of results of these tests have already created
a pathway for sophisticated clinical testing and better identification of pathogenesis.8 However,
Henderson et al. are concerned about the various debates around the ELSIs surrounding
genomics and have impacted the implementation process of PM into the clinical settings. They
add that the benefits of PM must be weighed against these challenges posed by the technological,
financial, ethical and cultural limitations - and they are right about that. Among the most
frequently raised concerns cited by the scholars include those related to privacy, data protection,
insurance, genetic discrimination, and the management of unanticipated results whose clinical
significance is uncertain.9 Moreover, Song highlights the critical issues related “to data integrity,
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misuse of results and return of incidental findings, refusals of health insurance and job
discrimination because of familial risk,” that have been repeatedly identified as causes for
concern - for both practitioners and patients.10 Scholars like Rodolfo Valdez et al. have argued
that better legislation should be in place to protect consumers against any future discrimination
by insurance agencies and that critical ethical dilemmas and challenges associated with the
integration of PM need to be addressed in order to speed up the proper delivery of PM.11
According to the International Bioethics Committee (IBC), genomics raises issues
regarding respect for autonomy. A person’s genetic data is ideally considered as personal data,
and should be accessible only by the person the data belongs to. However, genetic data is
different in that it relates to the person, as well as other family members, and even the
community he/she belongs to – hence, respect for privacy becomes a concern in the era of PM.
Although information from a person’s genetic makeup is supposed to be beneficial in the
diagnosis and treatment of diseases, it can be harmful by causing uncertainty, and anxiety and
moral burden. Genetic tests can present psychosocial risks of distress, anxiety, and confusion; as
well as stigmatization and discrimination, particularly when only the risks can be identified,
without providing adequate treatment or prevention – this may also have a detrimental effect on
the quality of the decision-making process. People who share their genetic information may need
counseling regarding the results, and the reliability of the results, and with interpreting the
certainties and uncertainties.12 Additionally, as Sonia M. Suter point out, the individual might
also face discrimination in employment, insurance, and other venues. She adds that many fear
that any information regarding personal genetic makeup, regardless of how beneficial they may
be in identifying and predicting risks (even for some inherited cancers), may be viewed as
potentially harmful given the possible psychosocial risks.13 Moreover, IBC adds that autonomy
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in genetics is challenging because of the implications the genetic information holds for the
person being tested, as well as their relatives, and their communities - due to the shared nature of
the genetic information. This gives rise to issues of ‘right not to know’ and/or not to disclose
information, especially when there are situations where family members have to be informed
regarding preventable or treatable diseases. There still exists a lack of sufficient information
about the genetic makeup which makes it challenging to understand its significance
meaningfully. Opponents of PM also fear that good health may eventually be seen as a personal
choice and a result of responsible behavior; and this might have implications for justice as well.14
Juengst et al. talk about the virtues of PM, and they state that the most attractive virtue to
all is PM's promise to shift the focus of healthcare from disease treatment to disease prevention.
The prevention of diseases is meaningful to patient advocacy groups since this promise to spare
families and communities the suffering. Juengst et al. also state that for clinicians, healthcare
institutions and commercial service providers - prevention promises “better outcomes and the
extension of services to asymptomatic at-risk patients who seek to manage their health better.”
For health policy-makers and public health agencies, Juengst et al. add that prevention promises
lower healthcare costs and better population health measures.15 Prevention of disease, according
to Juengst et al., is a classic public health goal, one that measures “the reduction of morbidity and
mortality caused by the target disease within the screened population over time.” However, many
fear that the screening tests and interventions for prevention may initiate new ethical and social
dilemmas, especially related to eugenics (newborn screening for genetic diseases is an example),
even though such interventions are still in the realm of individual, rather than public health
interventions, and cannot be viewed as eugenics. Given America’s history of eugenics, the
scholars suggest that it would be wiser to be certain that PM has not failed to focus on issues of
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eugenics (even if they are but shadows). Therefore, Juengst et al. emphasizes the importance of
analyzing the logic and scope of prevention in PM.16
Incidental Findings (IFs) and the return of results have become challenges for researchers
in PM, as noted by Henderson et al. They state that it can be taxing to know exactly what
information and how much of it to disclose to participants since the results are often of uncertain
meaning or significance - and may lead to misunderstanding, confusion and even harm.17
Moreover, they add that the scope of biospecimens research has been credited for the challenges
with IFs in clinical research. The generation of large amount of data that pertains to the
identification of multiple mutations, potentially associated with complex disorders like cancers,
lead to the identification of IFs. The scholars argue that there is a critical need for appropriate
protocols for handling a high volume of IFs, and also being aware that research subjects may
have the expectations that information of potential clinical significance can be found.18 IFs are
challenging because they are difficult to interpret, and are becoming more significant due to the
increasing use of high-throughput sequencing in medical practice. Effective disclosure and
regulation policies for various clinical and research settings are important to not only respect
autonomy, but also to avoid harm, and encourage the sharing of possible benefits. Since the
science of genomics is still young for clinicians to understand the significance of much of the
results, the findings do not offer much clinical utility, and this may pose issues of whether to
disclose the findings. As a result, this also presents informed consent challenges, as well as
negative psychosocial consequences.19
Cost and affordability of PM is another ethical issue. Although, the cost of customized
treatment is anticipated to decrease substantially, and proper use of treatment is anticipated to
lead to considerable savings in healthcare due to fewer inappropriate or ineffective therapies.
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However, as pointed by IBC, cost is still relatively high as of today, and given the variability in
the levels of health insurance, it can be difficult to provide equitable healthcare even within a
country. As pointed out by IBC, it would certainly be unethical if a person could be treated but
could not afford the treatment. Given the lack of certainty of the information about gene
mutations and variants, cost-benefit analyses are needed to assess the clinical utility and validity
of the procedures as well are what diseases it pertains to. Moreover, IBC highlights that
regardless of the promises of PM, we must not forget our priorities to the development of
treatment of neglected diseases, such as rare diseases and tropical diseases that are faced by most
of the populations around the world, especially in developing countries.20 IBC also adds that PM
is also feared to create pathways to the ‘commercialization of medicine’ through the practice of
Direct-to-Consumer (DTC) genetic tests, which is feared, will change the doctor-patient
relationship, and also change the way healthcare is delivered. DTC holds the promise of
promoting the consumerism of individual health and incentivizing economic growth. As IBC
notes, DTC tests have acquired an economic value, under the guise of therapeutic research,
whereby they can provide individuals with information about their genetic makeup and provide
them information about their risks for certain illnesses. However, DTC is challenging because it
provides easy access to commercial genetic tests without the need for medical professionals,
unless individuals are uncertain about the results, and would wish to consult medical
professionals.21 As highlighted by Sutter, DTC tests cover a wide range of genetic variants,
associated with genetic illnesses. The issue related to DTC is the generation of more information
in the clinical context, than what has been inquired, leading to the generation of IFs.22 Moreover,
as highlighted by IBC, DTC tests represent a business sector that is not contained within borders
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and pose challenges that need to be approached at the international level. DTC is an example of
the globalization of healthcare services that make national regulations imperative.23
Data integrity has been identified as another significant challenge in PM – particularly
issues related to standardization of data; sharing of data, and proper analysis; and translation of
data. PM has prompted the development of new laboratory guidelines and standards around the
world, resulting in the publication of numerous partially overlapping guidelines, as McGowan et
al. notes, some extremely general, while others are focusing on specific diseases or specific steps
in the process.24 The proper translation of genotyping is critical in the era of PM.25 Analytic
failure of a single genotype may lead to a catastrophic result. Śliwczynski and Orlewska point
out the need for greater efforts to protect consumers against potential harms of “premature
translation of research findings.” 26 The challenge for PM is to develop a network, which links
different “layers” of information relevant to health and grounds it with individual patients who
share their data, as noted by Kennet Offit.27 Although, it is evident that there are a lot of benefits
of PGx testing, it has been observed that data integration, and effective communication of the
different databases have still been an issue for the clinical implementation of PGx, resulting in
the slow pace of clinical implementation of PGx testing as observed by Yuan et al. Barriers
include the inadequacy of professional clinical guidelines for PGx genotyping, phenotyping, and
reporting; and also the inability to transfer PGx testing results to the EMRs, which Yuan et al.
suggests should be linked to CDS tools “to aid clinicians' understanding, interpreting, and
utilizing PGx information.” Moreover, they note that there is a reluctance to use PGx testing
amongst many healthcare providers due to a lack of training that has to do “with correct
interpretation and reporting of PGx variants.” 28
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Marc S. Williams observed the need for significant investments in the areas of: 1.
Infrastructures - to produce, store, link, and share the data- which includes sequencing and
secure high- throughput technologies, as well as reliable and standardized electronic health
record systems. 2. Education – for the general public, clinicians and other stakeholders about PM
to inform, and raise awareness about the applications of PM, that will lead to the increased level
of participation in large-scale population sequencing, as well as disease-specific research, and
ensuring that PM research efforts are translated to the daily patient care.29 With the issues of data
integrity, comes the issues associated with EHRs, which are becoming a part of the routine care
in the hospital and clinic settings. Williams states that effective use of EHRs has been shown to:
“improve care outcomes, patient safety, and care coordination, with the potential for cost
savings.” Moreover, Williams note that fully functional EHRs are capable of collecting,
synthesizing, and translating data that represents knowledge important to the clinician in the
form of point-of-care, “just in time” education, and CDS, which are of great importance in
genomic medicine.30 Moreover, McGowan et al. adds that EHRs can help non-genetic
healthcare providers to stay well informed about the genomic advances with the tools mentioned
earlier, overcoming certain knowledge-based barriers.31
Education of clinicians and public, as well as appropriate tools for data collection in the
healthcare setting were also identified as barriers in the integration of PM in clinical settings.
Sboner and Elemento note that privacy and HIPAA compliance are important in a precision
medicine workflow, because genetic data are patient data, and can be linked to patient identity,
even if temporarily anonymized.32 They also add that informatics plays an important role in
nearly every aspect of a precision medicine program.33 However, Zhou et al. point out that
multiple reasons like sensitive testing methods, lack of PGx knowledge and skills in clinicians,
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all attribute to the limited application of PGx biomarkers in clinical practice.34 Caudle et al. point
out that, “a lack of knowledge of how to translate genetic test result into clinical action based on
currently available evidence,” was another reason why genetic data to guide medication use was
not utilized. They highlight the need for new educational models in medicine, with a greater
focus on information management, to provide healthcare providers with “the required
diagnostics, informatics, and decision support tools.” 35 Routine clinical care generates a
significant amount of data from patients using family history (FH).36 Although self-reported FH
may not be complete or accurate, it can still be useful in the risk assessment for patients with
documented clinical validity and utility.37 Sboner and Elemento argue that reporting is a key step
in a PM workflow; and also useful in the communication of results to patients and physicians.
The scholars emphasize that inconsistent reporting must be avoided at all costs.38 There is a need
for better FH tools and reporting. Family history has been identified by studies as a great
diagnostic tool, which can help guide decisions about genetic testing for the patient and at-risk
family members. Furthermore, it has been emphasized in studies that early identification of
increased risk can allow for necessary steps to be taken to reduce risks.39 The next section looks
at legal and equity issues that are anticipated in the era of PM.
6.1.2. Legal, Equity Issues
Genomic information can provide tailored screening and prevention strategies in
healthcare if it is used with FH and other environmental factors.40 As Sweet et al. add
implementation of PM requires diverse genomic data, to develop optimal methods for
information delivery.41 Sweet et al. brings to our attention about the issues of limited
knowledge/information with which participants consent to genetic tests. They argue that this
raises unique issues related to participant expectations, such as “overestimation of developing a
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disease, causing unnecessary worry, anxiety, risk, and expense.” 42 Fakruddin and Chowdhury
highlights the various concerns raised by PGx, such as possible social and economic harms, such
as discrimination, stigmatization, or marginalization of groups due to “being difficult or
expensive to treat.” The scholars voice their concerns that this can lead to the controversial issues
of equity and can make it difficult for the just distribution of therapies for all.43 As noted
previously, genome sequencing may reveal information about the health of participants as well
as their families, leading to issues of privacy and access to information.44 , 45 Manolio et al. argue
that the early identification of “responders and nonresponders” to treatment could result in
improved therapeutic effectiveness, and may result in avoidance of unnecessary exposure to
harm, and side effects. Manalio et al. note that despite the successful tailored prescription of
medications through PGx, there is a fear that exists about such drugs not being accessible, or will
result in inequity and discrimination, and fear that the treatment flagged as unsafe maybe the
only treatment option available, and therefore being denied by insurance companies. 46
Liu et al. emphasize that certain legal issues, such as knowledge of a person’s genetic
makeup, and the implications it may have, need to be discussed before PM can be implemented.
They further explain that knowledge of a person's genotypic information can be a serious
concern because it opens up the genotypic information about the person, the family, and even the
community of the person - resulting in the breach in privacy of the whole community, whose
consent has not been taken. This can also lead to the creation of a group susceptible to a
particular drug, having the possibility of having a particular disease in the future and so on.
There are pros and cons to this. It can prompt over worrying and taking extra unnecessary steps,
or it can lead to early lifestyle changes that will lead to prevention and treatment. However, the
prediction of no treatment or cure can be psychologically harmful. PGx is also feared to have the
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potential to the opening up of some constitutional issues like those of getting some special
incentives or of minority status.47
PM is still in its infancy as far as evidence for benefits goes. Based on a workshop
summary by Fakruddin and Chowdhury, an estimated 6% of eligible patients would benefit from
a well-evidenced genomic test that identifies a treatable condition, and they credited this to the
implementation of inconsistent clinical testing. 48 Other ethical issues related to available
evidence and the level of certainty to warrant clinical introduction were also highlighted by
Korngiebel et al. Relevant factors such as the scope of estimated benefits, existing alternative
treatments, potential harms and the overall quality of evidence were suggested to be taken into
consideration with full consideration of the views and preferences of all stakeholders by
Korngiebel et al.49 Furthermore, they added that implementing promising new tests in a timely
fashion may be beneficial if they are tied to the collection of data that reduce uncertainties about
tests outcomes over time.50 The potential to automatic updates to EMRs with patient clinical
utility validated provides exciting possibilities for implementations of research advances.
However, Korngiebel et al. were also concerned that such growing knowledge and understanding
might lead to issues such as “reporting of incidental findings (IFs), and whether to contact
patients” - leading to undue burden as well as “medico-legal risks.” 51 Collins and Varmus
noted that ensuring equal access to genomic technologies will also be important in reducing
disparities in chronic disease outcomes. They argued that rigorous evaluation of delivery
approaches that increase the likelihood that appropriate and affordable support services
accompany genomic technologies to individuals and/or systems would be critical to success.52
Colleen M. McBride questions the uniqueness of genomic information, stating that it is
debatable whether genomic information warrants special protections beyond those in place for
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standard medical information. He states that concerns and fears of genetic information vary by
country. He provides examples of the fears that exist in the U.S. and the U.K. regarding genetic
information, stating that in the United States of America, fear of discrimination by employers
and health insurers is the main concern; whereas, the use of genetic information by life insurers
is the major concern in the United Kingdom. McBride points out that in the U.S. many states
have their own legislation that protects people from genetic discrimination by employers and
health insurers. McBride further adds that in April 2008, the U.S. Congress passed the Genetic
Information Non-discrimination Act (GINA), which affords national protection of genetic
information, a step that will help lower the barriers between participation and clinical use of
genomic applications.53 Juengst et al. highlight issues related to regulation that provoke ethical
concerns. They emphasize that costs related to PM, if not attained, will limit the ambitious goals
of tailored therapy and other forms of healthcare services, thereby limiting access and bringing
social justice challenges to PM's priorities. They add limiting PM to patient-risk stratification
based on ethnic, racial and socioeconomic conditions, will only add to the existing social
issues.54 Andrew Smart et al. warn us that “pre-prescription genotyping” may lead to further
stigmatization and social discrimination by labeling people as “good responders” or
“nonresponders” or “difficult to treat.” Smart et al. emphasizes that this would further create
insurance/coverage issues and also add to psychological consequences.55
According to scholars like Smart et al., secondary information about diseases
risk/prognosis by PGx can also have broader social implications associated with genetic testing.
Although it has been argued that the ethical issues of PGx testing are distinct from those in
disease testing – it is difficult to maintain this distinction – leading to important implications for
the governance of PGx testing. Smart et al. note that resource allocation and priority setting
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made by financially pressured healthcare providers already raise issues of justice in PGx, and
based on this context - PGx has the potential to further widen inequality.56 As with all new
innovation, PGx products are expected to be significantly more expensive than conventional
products, which raise issues about the distribution of access to the better treatment they might
offer. It is evident that people with private healthcare will have access. On a global scale, this
means that healthcare systems in less affluent countries would not have access to PGx
products.57
Smart et al. point out that PGx intervention may need to address ethnic and racial
inequalities in drug development due to financial obstacles, since PGx interventions would lead
to the underrepresentation of some groups, resulting in the inhibition of discovery and
development of PGx intervention of such groups. Moreover, Pharmaceutical companies might be
financially less inclined to develop products for socially disadvantaged people, leading to the
socially marginalized ethnic minority groups having the worst access to PGx products.
Additionally, Smart et al. voice their concern of racism, and the practice of linking of PGx to
ethnic and racial groups, even for the most honorable ends, they point out should be recognized
to have associated social risks. The first of these risks, according to Smart et al. is “the danger of
reinforcing discredited crude biological notions of race.” The second is “the potential for the
whole population groups to suffer from stigmatization.” 58 Lastly, they state that “experience has
shown that research and clinical decisions based on ethnic or racial classification often lead to
poor or ineffective care.” All of these combined, according to Smart et al., pose a serious social
risk that may exacerbate the patterns of inequality already faced by some socially disadvantaged
groups.59 Smart et al. further argue that PGx has the potential to create new risks in drug
development through selection bias that may create inequalities between genetic sub-groups –
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resulting in the unequal distribution of drug response profiles and ultimately adversely affecting
the people of these groups in the event of inadvertent or inappropriate off-label prescribing.60
They add that the introduction of PGx may lead to treatment being inappropriately denied on the
basis of probabilistic data, and there is danger that access to services may depend on geography,
education or wealth, because the necessary service infrastructure may not be in place due to
initial costs. To ensure equal access to PGx services, it will be important to ensure
comprehensive and easily accessible PGx services in public healthcare systems.61
Smart et al. also recommend that governance frameworks that accounts for the novel
aspects of PGx should be established, with the aim to ensure control over the collection, storage
and use of personal genetic information to protect privacy and confidentiality and prevent
discrimination resulting from misuse of both primary and secondary information. They add that
there should be guidelines for health professional services, as well as the possibility of legal
sanctions where necessary. They add that it is critical to make sure measures are taken to ensure
that ethnic and racial groups are included in the process of testing and developing new drugs; and
that professional education and equality programs should be introduced to ensure that prescribing
practice is based on evidence and not prejudice. They suggest that such a framework of policy
recommendations involves new responsibilities for multiple stakeholders such as “industry,
government, research funders, health services, clinicians and patients;” and adopting such a
framework will help to ensure that the introduction of PGx is managed in a way that ensures
equitable sharing of benefits, and just clinical practice and research activities.62
6.2. Public Attitudes towards Genetic Tests
Findings from research show that the public attitudes toward genetic testing depend on
the positive or negative outcomes/benefits of the tests. However, it was also found that the level
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of knowledge and awareness, and concerns or fears about the uncertainty of the application
results and data access, also plays a role as to whether people would like to have genetic tests.
According to Vermuelen et al., family history (FH) was identified as a good genomic tool that
helped in the assessments of diseases. Although, participants in favor of using FH on themselves,
were reluctant about the implementation of the data generated by FH in clinical settings.63 In
order to implement PM into the clinical settings, there is a need to find out whether people will
be willing to use the various tests available through PM. This section looks at the public attitudes
towards genetic testing in the prevention and treatment of noncommunicable diseases, and how
FH can be used as a tool for assessing risks and benefits.
6.2.1. Attitudes towards Genetic Tests
As Natarajan and O'Donnell note, despite the rapid evolution of genomics, patients and
providers still have a “limited understanding” of human genetics. They highlight the need for
accurate representations and education regarding incremental risk and modifiable risk from
“genomic risk scores” for appropriate interpretation.64 Bailus Walker Jr., also notes that it is still
not clear how the environmental history affects the genetic makeup in manipulating a person's
health risk/disease susceptibility, and response to treatment. 65 According to findings from
Valdez et al., informed participants are more likely to choose genetic testing for the disease and
adapt to lifestyle changes to prevent it.66 Miller et al. made the observations that most
participants expected the genetic knowledge to be useful (and even considered the information as
important health information for other family members) and permitted action (they approved
relaying the relevant risk information to relatives as well) to avert harm.67 It will be important for
legal and policymakers to look into population-based testing for genetic markers for inherited
diseases, such as breast cancer while considering screening tests for all. Based on a survey by
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Shaw and Bassi that looked at the randomly selected people's attitude about personal and societal
issues of genetic testing and disease susceptibility; it was found that most respondents were
optimistic about the benefits of the testing, and their attitudes were related to their interests in
having control over the diseases (if it had a cure); and if the test was highly predictive. The
survey also found that respondents were not willing to grant access to results to anyone other
than doctors and family members, and were hesitant to allow the government, religious leaders,
and the courts any form of involvement in regulating genetic testing. According to Shaw and
Bassi, these findings have important implications for researchers struggling to find some solution
to issues related to population-based genetic testing for inherited diseases.68
Shaw and Bassi also noted that while genetic testing for disease susceptibility is already
offered to certain high-risk individuals (such as women with a family history of breast and
ovarian cancer) - there is considerable debate about whether to offer genetic testing to all
members of the public. They argue that there are tremendous benefits of population-based
genetic screening. The identification of people genetically susceptible to certain diseases, allow
for early detection, prevention, and early treatment programs targeted specifically for those
individuals. Also, such screenings greatly reduce the disease-related anxiety for those people
who do not have the genetic markers. However, Shaw and Bassi also point out that there are
numerous societal and personal costs of population-based screening programs that will need to
be taken into consideration, stating that wide-scale genetic testing will be very costly in financial
terms. Moreover, they add, people with genetic markers will face considerable personal distress,
and anxiety, and may face potential discrimination from insurance companies and employers.
Considerable discourse needs to happen around the ethical and legal issues, which will help with
the understanding of the public attitudes about these topics, especially lay opinions and attitudes
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concerning the complex issues surrounding genetic testing. It is crucial that researchers in this
area be knowledgeable about the cultural and social aspects which are likely to influence the
attitudes of people to genetic testing.69
Shaw and Bassi also suggest that people generally desire to have control over their
environment, and it is likely that respondents would be more likely to want genetic testing when
there is a chance that the information would give them some control over their future health.70
People wished to reduce uncertainty or ambiguity in their lives, and Shaw and Bassi noted that
many women were motivated to engage in genetic tests for susceptibility to breast cancer to
reduce uncertainty and to have control of the disease. From the same survey, they also observed
that respondents were also concerned that the tests were not “conducted by the wrong people.” 71
Shaw and Bassi note, these results support previous findings that lay attitudes about genetic
testing were complex, and attitudes were related to personal interests about the tests - positive
attitudes were associated to greater interest, while negative attitudes were associated with less
interest – as was knowledge of genetics.72 Previous research by Tambor et al. suggests that
demand for genetic testing for breast and ovarian cancer susceptibility were high, even among
those at relatively low risk of carrying a mutation.73 Women without a FH of breast and ovarian
cancer have also shown a high level of interest in testing.74 Tambor et al. also noted that attitudes
toward mammography were important predictors of interest in testing. Data from focus groups
conducted by Tambor et al. suggest that helping family members was a strong motivation for
genetic testing. Women who reported that having regular mammograms gave them a feeling of
control over their health were more likely to be interested in testing, than those who did not
believe that mammograms gave them a feeling of control. Tambor et al. also noted that the
possible knowledge acquired through genetic testing, and “the subsequent improvement in
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decision-making ability” might appeal to individuals who are motivated by a desire to maintain
control over their health.75
Furthermore, findings by Tambor et al. indicated that only 6% of the respondents
reported that their mother was diagnosed with some form of breast cancer, and of these, only
14% had been diagnosed before age 50. Fifty-one percent of respondents reported that they were
aware of the breast cancer gene. Sixty-nine percent said they were interested in being tested to
find out if they had a breast cancer gene. Twenty percent said that they would not be interested in
testing, and an additional 10% said they did not know. Data also found that women younger than
60 were three times more likely to be interested in the test; white women were over twice as
likely to be interested as African American, and other women. Additionally, women who
believed their family would benefit if they had a mammogram were twice as likely to be
interested, and women who believed that regular mammograms gave them a feeling of control
over their health, were almost three times as likely to be interested in genetic testing, as those
who did not agree that mammograms gave them a feeling of control. However, the scholars
emphasize the need for more research on the various psychosocial factors associated with the
interest in genetic testing that will allow for legal and ethical scholars to have a better
understanding in public sentiments, and better prepare them with the issues of privacy and
regulation concerning population-based genetic testing programs. 76
Vassey et al. observed that hundreds of genetic loci associated with an increased risk of
many complex conditions were uncovered due to advances in genetic technology.77 According to
a survey conducted by Vassey et al., of the 521 young adults, two-thirds reported some interest
in tests that could tell them about the risk for heart disease, T2D, and stroke. They also noted that
individuals “with a first-degree FH of at least one of the three conditions were more likely to
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report some interest than those without a family history.” 78 Vassey et al. also observed that
participants with greater risk for future CVD, and T2D may be receptive to genetic susceptibility
information to help motivate that change.79 Knowledge of genetic susceptibility may motivate
young adults with higher personal risk for noncommunicable diseases, such as diabetes, to
improve their diet and exercise. However, Vassey et al. are not convinced that genetic tests could
motivate behavior changes, and suggested coupling a few other strategies with genetic tests.80
Even though PGx testing is critical in PM in determining the right dosage, and the right selection
of drugs, Susanne B. Haga estimated that only one-fourth of outpatients were taking medications
with PGx information. Previous studies assessed that public attitude toward PGx testing was not
the same as disease susceptibility genetic testing. Most people were suspicious of the safety and
efficacy of race-based drugs, and preferred individualized genetic testing versus race-based
medications, even though they were concerned about cost, privacy, and discrimination - as noted
by Susanne B. Haga.81
Haga also observed that PGx test implementation, like other genetic testing, will be
influenced by patient attitudes and interests, and therefore, it is critical to ascertain the public's
interest and perceived barriers to this application.82 Scholars like Natarajan and O'Donnell also
noted that many consumers will forgo testing if a test's predictive value is low, or if there is not
much to reduce risks.83 It is a well-recognized fact that individuals respond differently to drug
therapy – some may benefit, while others may not. Variations within families and between
individuals regarding the processing of probabilistic risk information, and ability to act on it, still
exists. As Kenneth Offit highlights that there is a need to take psychosocial context seriously in
the translation of genetic risk information.84 Kenneth Offit states that there is worry that even one
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strong ADR resulting in harm to the individual can have profound psychological or even legal
consequences in the era of PM.85
While looking at public opinion towards genetic testing, Henneman et al., presented
results from surveys conducted from 2002-2010 that showed that public opinion towards genetic
testing had been a changing process. However, the percentage of people having heard of genetic
tests remained the same over the years, and cancer tests were reported as the common test and
remained the same as well. Respondent's beliefs differed, and depended on the age and education
as demonstrated by the results.86 Henneman et al. compared results between 2002 and 2010 and
found more interest in knowledge about genetic makeup and disease susceptibility between
respondents in 2010. They also found that 43% in 2002 vs. 64% in 2010 believed that the
knowledge would help them live longer, and that genetic tests should be promoted, although
there were still about 37% who believed otherwise. Additionally, a larger number of respondents
in 2010 anticipated increased use of genetics in the next 10-15 years. Overall, findings
demonstrate that people are aware of the genetics behind the common chronic disorders, such as
diabetes; however, it has also shown that the public had limited knowledge on how genetic risk
factors influenced the development of the disease.87 Braithwaite et al. found that higher
education and income were associated with a stronger interest in having a genetic test. It was
also noted that several psychosocial factors were linked to interest, especially increased the
perception of personal risk, the anticipation of a positive impact of genetic testing, increased
cancer-related worries, and high need for certainty.88 Braithwaite et al. also looked at the role of
uncertainty in genetic counseling from a clinician's perspective and noted that there was little
research done in this area. Braithwaite et al. pointed out that the attitude toward uncertainty was
“hypothesized to be positively related to the intention” to have a genetic test, with people who
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hold more positive attitudes toward certainty being more likely to intend to have the genetic
test.89
Braithwaite et al. also studied the intention to undergo genetic testing for hereditary
cancer and noted that 17% reported feeling unsure about having the test, with a further 11% not
intending to obtain genetic testing.90 Braithwaite et al. attributed this change in attitude to
healthcare systems, and other barriers such as, “financial barriers, transportation barriers,
emotional and social barriers.” The authors also noted a lack of association between perceived
risk and testing intentions in the respondents with a family history of colon/breast cancer. They
noted that “the participants with more negative attitudes toward uncertainty” would be more
likely to undergo the test while those seeking more certainty may be discouraged from having
the test once told about residual risk.91 As Henneman et al. pointed out, most diagnostic tests are
only available to those as identified as “having a priori high risk,” maybe due to positive FH.92
Henneman et al. also noted that advances in genetic testing actually increased public
expectations about the application, and therefore, genetic testing will not meet much public
opposition. They state that these are important implications for all stakeholders, including
policymakers. However, they emphasize the need for responsible dialogue with the public
regarding the possible social and ethical consequence, that has to do with inequity, and
promoting policies that will address these issues.93
According to the researchers at the Genomic Medicine Institute's Center for Personalized
Genetic Healthcare at the Cleveland Clinic, FH can be a great tool that can help in predicting an
individual's risk of developing certain diseases. Scholars like Alspach, and Yoon et al. advocate
for FH as a tool stating that family medical history depicts everything about the patient,
including the person, health issues, and familial influences such as genetics; and reflects essential
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risk factor information about various disorders including coronary heart disease, diabetes and
cancer - and reports risk factors with a high degree of accuracy. The information generated by
FH can guide risk-specific recommendations, including referral to a specialist for evaluation and
possible testing. 94,95 Many of the Risks for NCDs such as certain types of cancer, heart diseases,
and diabetes have both a familial and a lifestyle component. Besides, it was observed that
completing a Family Health History (FHH) assessment promoted intended communication with
family members about chronic disease risk. Familial risk is significant, with up to 52% of
colorectal cancer, 19% of breast cancer, 72% of coronary heart disease, and 30% of diabetes
diagnoses attributable to familial history.96 Educating people through the use of a FHH
assessment tool may be one way to promote health and motivate people to act to prevent chronic
disease.97 The next section looks more elaborately at FH as a tool, and people’s attitudes toward
FH.
6.2.2. Attitudes toward Family History as a Tool
Valdez et al. argue in favor of FH stating that FH is “a simple, yet powerful clinical tool
with multiple uses in the clinical setting.” They add that FH can be applicable in informing
decisions about screening, and early treatment for chronic conditions that can help with patient
education, and prevention of the conditions. Moreover, FH information can help clinicians build
a relationship with the patient, and understand the other factors that play a role in the disease
mechanism, such as behaviors and environment.98 Yoon et al. observed that Americans were not
good at collecting or documenting their FH, although from a survey it was found that 96%
thought knowledge of FH was important for their health. They also noted that physicians did not
fare better either in collecting FH from patients, and in interpreting, and using the information to
recommend interventions. Yoon et al. attributed this lack of documentation by physicians to
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attributes like lack of time, lack of compensation, and lack of training to collect and interpret the
information.99 As Godman et al. noted, the variable predictive yield of GWAS have
demonstrated the need for a thorough understanding of genetics related to diseases, and patient
populations, and not just the expression patterns of the gene expressions.100 Moreover, Khoury
and Mensah point the issues with healthcare providers, and eliciting FH in medical records where they noted that FH is still not completely documented, and optimally used in the clinical
practice. They emphasize the need for public and healthcare provider awareness regarding the
importance of FH as a risk conveyer for health and disease prevention. Khoury and Mensah
makes an important observation that FH can initiate the process of building a link between “the
one-size-fits-all” approach to prevention, and the “one-person-at-a-time” approach to genetics.101
Valdez et al. points out that FH can be a consistent and “independent risk factor” for
many common chronic diseases in many ways, such as: the combined effect of shared genes and
environment is captured in a single concept; it shows the change in data over lifetimes of people;
it is also an inexpensive and easy-to-use approach to identify genetic risk compared to genetic
testing.102 Another main objective of using FH for chronic diseases of “complex etiology”, as
identified by Valdez et al., is to assess health risks using a few simple assumptions, such as “the
number of the affected family members, their ages at diseases onset, and the presence of
conditions known to be inherited among them” – all of these impact the level of familial risk.
Although the scholars admit that combining these factors to determine risks can be challenging,
FH is still considered “a consistent risk factor” for common NCDs such CVD, some cancers, and
T2D, and the associations are typically reported as “odds ratios or relative risks.” 103 Therefore,
the scholars assert that FH can guide risk-specific recommendations for disease management and
prevention.104
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Moreover, it has been highlighted that FH information could be used to motivate people
at an increased risk to engage in healthier behaviors.105 As Valdez et al. point out that the main
objective of the risk stratification is to identify individuals with a high risk for a condition, who
may benefit from a referral to a specialist or testing. 106 Scholars like Alspach also argues in
favor of FH stating that the information can be useful for healthcare professionals in many
ways.107 Alspach highlights the importance for FHH that it is needed for "establishing, updating,
correcting, maintaining, accessing, and sharing this information among and between family
members, as well as with various health care professionals.” 108 Although, privacy and
confidentiality concerns overshadow the importance of familial risks in developing chronic
diseases, and slow the implementation process into clinical settings, Alspach adds that it is
important for healthcare professionals to keep in mind that the FH, as of today, is still the most
reliable and valid tool available to make patient assessments, and provide guidance to patients
safely.109
Alspach furthermore, reiterates the importance of “creating, updating, and sharing a
family health history” as being empowering to individuals, “by making them more proactive in
their personal health and lifestyle surveillance, allowing them to make more timely and informed
health-related decisions, improving their health outcomes, minimizing the development of
serious complications, and offering them peace of mind in place of anxiety or fear of the
unknown.” 110 Screening tests can help people with an existing FH detect the disease earlier,
when they are treatable, like cancer; and also can detect risk factors such as high cholesterol, and
high blood pressure, which are treatable and can reduce the chances of getting other NCDs.111
According to CDC, tendencies towards acquiring such NCDs “can cluster in families,” and FH
offers important information for identifying risk to diseases in a family, and “members of the
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family can take steps to get tested for those disorders, and take steps to lower their chances of
developing, and dying from those disorders.” 112 As scholars like Carroll et al. point out that a lot
of work will be needed to facilitate the adoption of FH into primary care setting, its integration
into the EMR with “automated clinical support algorithms.” Carrol et al. also highlight the need
for more research on the value of FH risk communication “as a motivator for appropriate
screening.” 113
Adequately documented FH is essential. Scholars like Alspach states that the current
standard utilizes the documentation of 3 generation of relatives by birth: “You, Your children
and your maternal and paternal aunts and uncles.” The information sought for inclusion primarily
relates to major medical disorders, diseases, and/or conditions associated with a hereditary or
familial component, and the person's age when the disorder was first diagnosed. Alspach makes
a good observation that other environmental and lifestyle factors may also affect inherited risks,
such as diet, addiction, even intermixing of different racial and ethnic backgrounds, and can be
beneficial if documented. Also, Alspach adds, for every family member who is deceased,
relevant data points that are important knowledge, “are age at the time of death, the cause(s) of
death, and, when known, the person's age at the onset of that cause.” 114
Damman et al. observed that FH appeared to be prominent in participants’ risk
perceptions and interpretations. They noted that actual examples in the family led to a clearer
picture of the diseases, compared with people who had no examples in the family.115 Another
observation that was made was participants liked the detailed query in FH, and participants
talked a lot about FH in their answers to interview questions about their risk interpretations,
which indicated that FH largely influenced their perceived susceptibility. They highlighted that a
previous study also revealed that a detailed familial risk questionnaire contributed to users' risk
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acceptance and motivation to adopt healthier lifestyles among people with a positive FH. They
also observed that putting more emphasis on the FH of diseases in risk communication may have
reverse effects for people without a FH of diseases, who do have other risk factors. Damman et
al. also add that previous studies have demonstrated that the absence of diseases in the family
can also lead to low perceptions of risk.116
Kimberly M. Kelly et al. also asserts that FH is essential for assessing the risk of disease
and diagnosing disease. They state that some individuals are at moderate to high risk of cancer
compared with the general population because of FH. Familial forms of cancer are thought to
account for approximately 10%–20% of all cancers; this does not include family members with
no personal history of cancer, who may also be at risk for familial cancers. Thus Kelly et al.,
highlight that these high-risk cancers affect a large number of people in the population and
require earlier initiation of screening, more frequent screening, and often, specific types of
screening. They highlight that the challenge is to determine who is at general population risk and
who is at moderate-high risk. Communication about FH information is critical to distinguishing
those at higher risk concerning the number of family members and quality of diagnosis. 117 In
addition to cancer and other NCD diagnosis, Parrott et al. note that studies have found that FH
played a positive role in diagnosing blood clots, which can be difficult to diagnose in women.
Studies were done on 20 women who experienced a first venous blood clot between the ages of
18 and 50 years, identifying causal attributions the women made for thrombosis after the event.
Results showed that women with awareness of FH of blood clots, had diagnosis sooner, thereby
promoting survival and efficiencies in health care. 118
Parrot et al. bring to our attention that millions of individuals in the United States manage
to live with venous thromboembolism (VTE) that has become an illness of uncertainty, affecting
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health status, and personal and social relationships.119As Parrot et al. note, despite the human toll
in deaths and morbidity - the United States, United Kingdom, Canada, the Netherlands, and
Australia, have restrictive policies constraining the use of costly tests to diagnose VTE. Other
actions associated with diagnosing VTE include FH screening for genetic contributors, but these
have not been part of the standard medical history collected by PCPs.120 Scholars like Parrot et
al. emphasize the awareness of FH to conditions such as venous blood clotting risks. They
highlight that FH information functions as a gatekeeper to diagnostic resources, which in turn
relates to policies aligned with genetic testing.121 Parrot et al. point out that results that show that
diagnosis of VTE is often a long and costly path through many systems of care warrants attention
from a healthcare cost efficiencies perspective. Efforts to increase awareness regarding the role
of FH and genetics in VTE may improve the survival rates linked to blood clotting events.
However, Parrot et al. also points out the concern that overemphasis on the role of FH and
genetics may lead to neglect of numerous environmental contributors, and events which may
have negative consequences. They also noted that individuals often prefer to conceal rather than
disclose personal or negative information about them. This tendency toward self-concealment
appears to persist in the realm of symptoms linked to VTE. Parrot et al. suggests that a society
that emphasizes self-reliance, together with the geographic distance between family members
and the growing number of families without biological connections may all positively contribute.
They highlight that these barriers to knowing FHH suggest that there will be situations in which
only genetic testing can provide insights relating to inherited risk for thrombosis. As Parrot et al.
state that this makes it more important to emphasize awareness in cases where it is possible.122
Research by Kelly et al. has elucidated many shortcomings in the collection and use of
FH information. To begin, Kelly at al. highlights a variety of factors which are associated with
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poorer accuracy of FH information, such as “more distant family relation; less distinct type of
cancer; unaffected status; lack of awareness of family history; inability to research family
history; inability to distinguish between benign and malignant disease; and lower disease
prevalence in the family, or fewer family members with the disease.” They point out that these
are important for risk-communication, and may be because of lower family connection, weaker
family bonding, or not understanding importance of accurate information when communicating
about FH of conditions such as cancer. Kelly et al. also add that the method of collection of FH
information may be problematic due to the physicians’ lack of training, and understanding the
risk levels of patients, and inability to communicate the results to other healthcare professionals,
“resulting in underestimates and overestimates of risk.” 123 The next section looks at potential
approaches that can address the social and ethical issues that may arise in the integration of PM
into healthcare such as regulatory standards, policy considerations, and tools; as well as the
importance of collaboration and education.
6.3. Recommendations
Precision medicine's application requires the accumulation of massive amounts of health
and biologic data. In 2015, President Obama launched the Precision Medicine Initiative (PMI),
with the commitment of developing not only technologies, but also the infrastructure of
harnessing and sharing data from a national cohort of one million volunteers. As Geoffrey S.
Ginsburg points out, PMI's main two components include a near-term focus on cancers, and a
long-term aim to generate knowledge applicable to the whole range of health and diseases.124 In
order to integrate PM into routine healthcare, Sperber et al. suggest the need for strategies that
facilitate the integration of genomic data within existing EHRs, and educate stakeholders about
the value of genomic services.125 Many challenges have been brought up by previous studies.
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However, three challenges seem to reiterate: 1. Increased priority of integrating genomics within
the health system electronic health record (EHR). 2. Increasing knowledge and beliefs about
genomic medicine within the clinicians. 3. Engaging patients in the projects.126 This section
looks at approaches that can be helpful in integrating PM into the regular clinical routine.
6.3.1. Regulatory Standards, Policy Considerations and Tools
Advances in health information technology have enabled the facilitation of data
collection, analysis, and sharing of information across institutions, scientific disciplines, and
geographic boundaries. According to Diamond et al., this has great potential to transform
healthcare in clinical settings, quality, and public safety. However, many issues observed in
previous studies included incomplete data (no 100% participation) and “dirty data” (incomplete,
inconsistent, or wrong data).127 According to Manolio et al., this is a common challenge that all
facilities face due to the poor collection of data from multiple sources, and analyzing of that data
in a central location without efficient data cleaning mechanisms, which results in errors that are
not fixable without the proper understanding of the source data.128 Unclear organizational
policies, inconsistent modes for integrating genomic information into the electronic health record
system, and concerns about the cost of testing for patients and institutions, are known barriers
that have been reported in previous studies. Other factors related to poor uptake as noted by
Manolio et al., include providers’ lack of understanding on how to interpret data, patients’ lack
of understanding about how the tests work and the effects of the results, that all lead to decision
makers to not consider genomics at all in healthcare delivery.129 Manolio et al. suggest that
implementation of genomics in medicine would also benefit from establishing common
infrastructure such as a catalog of various information, similar decision support tools, and
collaborative projects to pool resources and identify best practices.130
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The time lag in the gathering and post-processing is another challenge that affects data
integration - both gathering, and post-processing take time. Recommendations for addressing this
challenge include using a networked technical architecture; and a federated governance model
that will preserve the original data, and ensure data cleanliness, while protecting patient privacy.
As highlighted by the scholars, clearly delineated information policies, and technical standards
must be set “that will lay the foundation for an environment of trusted population health data
sharing” of data - otherwise, the sources experience repositories of data as black holes, with data
disappearing into the repository, never to return.131 Manolio et al. also states that challenges in
implementing point-of-care tools need to be recognized, with considerations on the evidence
needed for high priority healthcare targets with the best risk/benefit ratio and strongest evidence
needed to determine which variants are actionable, the patient/group, and the clinical situation.132
They add that generating clear evidence of benefit for genomic interventions will remain
challenging, and comprehensive strategies will need to be implemented to generate the necessary
data to evaluate the impact of potentially important variants on clinical outcomes. 133 Point-ofcare tools have great potential to advance PM in clinical settings. In order to realize this
potential, there needs to be collaboration between the technology division (such as Engineers)
and healthcare professionals to work on solutions to ensure the PM goals are achieved without
any compromises.134
According to research by Makowsky (2017), the importance of addressing adverse drug
events (ADE) was brought to attention, stating that ADEs account for a large proportion of
preventable emergency room visits and hospitalizations. Having a FH tool where patients can
also complete a validated screening for medication-related problems during primary care clinic
visits can be helpful in prioritizing patients for pharmacist consultation in medical practices, even
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though it may be challenging to implement into practice.135 Research by Walter et al. shows,
there remains limited documentation of the impacts of the serious (Idiosyncratic) “ADRs on
patients and the health system at a population level.” Walter et al. suggest that “the availability of
jurisdiction-wide hospital admissions data, combined with International Classification of
Diseases–10th revision (ICD10)-based approaches for identifying ADRs,” can increasingly be
possible to evaluate rare ADRs. While there are limitations with ICD-based methods, Walter et
al. point out that there is considerable scope for population-level data on ADRs to quantify their
burden, and identify areas in need of closer investigation.136 Moreover, Walter et al. highlight
that although the prevention of (Idiosyncratic) ADRs is demanding; ADRs can be reduced using
a combination of approaches. They add, using enhanced monitoring of patients who have a
history of ADR or who belong to a high-risk group, can help detect early signs that may lead to
the prevention of serious ADRs in patients. Technologies, such as computerized decision support
tools in monitoring both drug dosage and clinical warning signs can also play an important role.
ICD based approaches can contribute to the timely population-level epidemiological evidence by
providing the surveillance system for monitoring ADRs and associated drugs, thereby
minimizing the possibility of dangerous drugs remaining on the market. Emerging machine
learning methods can also help in the prediction of drugs’ potential to cause ADRs, by using
information on a drug’s molecular structure and by helping to identify high-risk drugs before
they reach the market.137
Extensive genomic and phenotypic characterizations also raised challenges related to data
sharing, informed consent, and the reporting of IFs with potential implications for clinical care.
Previous research studies also noted that most physicians and other healthcare professionals were
inadequately prepared for the genomic advances that might be relevant to their patients, and were
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not adequately prepared to use genetic tests in their practices.138 Challenges associated with the
potential misuses of genomic information that can cause unnecessary anxiety, discrimination,
increased medical costs or diverted resources also need to be recognized and avoided.139 Sperber
et al. highlight that clinicians need information about the genetic test, ideally in readilyaccessible formats that clarify the strength of the evidence supporting its use, potential harms,
and alternatives. They recommend that implementation strategies should also offer clinicians the
guidance to ensure that patients are making informed decisions (in a shared-decision approach)
based on the best evidence available, which includes recognition that the best evidence available
may have significant gaps.140
Due to the substantially reduced cost of sequencing of DNA, a wide variety of direct-toconsumer (DTC) genetic tests have been made available by commercial companies in the last
decade, with the involvement of healthcare professionals.141 As discussed by Allyse et al.,
proponents argue that DTC provides genetic information to consumers, which enhances the
autonomy of consumers, allowing them to be in charge of their healthcare management without
the intermediary of doctors and hospital appointments, and it is information that consumers have
a right to, and also protects their genetic data against insurers and employers. Opponents,
however, argue that providing genetic tests in “the absence of medical supervision and genetic
counseling,” raises concerns regarding potential misinterpretation of test results by consumers,
which may lead to unnecessary distress and/or inappropriate healthcare decision-making.142
Scholars have asserted that the information provided is often misleading or inadequate, reducing
informed consent, and not sufficiently sensitive to the potential influences of ethnic and racial
differences across human populations due to only relying on large data sets generated from
studies of specific populations in making their estimates.143 Kalokairinou et al. point out that the
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rapid advance of genotyping technologies, and their decreasing costs have made DTC tests
increasingly available to consumers, thereby, outpacing the development of effective regulation
of such commercial services.144 Hudson et al. voice the concern that the quality of DTC tests
may be low due to the “fragmented regulatory environment for genetic testing in general.” 145
Hudson et al. cite recommendations made by the American Society of Human Genetics
that can be effective:
1. DTC companies should promote transparency by providing relevant information about the
offered tests in an easy to understand manner, to permit providers and consumers to make
informed decisions. 2. Ensuring that providers are aware of the tests that DTC companies are
providing, as Hudson et al. point out that “some of these tests may lack analytic or clinical
validity.” 3. Ensuring the analytic and clinical validity of genetic tests offered by the DTC
companies, and ensuring that the promises made are true and not deceptive, and the relevant
agencies of the federal government should take appropriate and targeted regulatory action.146 In
the future, DTC companies may be wise to usher in new collaborations between patients,
consumers, medical providers, and regulators that maximize the benefits of genetic information
through the empowerment of patients and providers.147 More research and discussions among
different institutions that include legislative institutions to potentially identify different
legislative tools that may be useful in helping guide DTC genetic testing companies to act
responsibly.148
Among the many ethical issues that have been identified, issues of inequity are a big
concern. Gershon et al. point out that PM is likely to be expensive in the beginning, and “may
negatively impact equity and access to drugs.” The objective will be developing drugs that target
a specific population, on whom the drugs work best, and this targeting will need careful
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implementation to avoid race/ethnic-based stigma. Genetic profiling for drug response based on
an individual's race is problematic, since not all people from the same race will have the same
variations.149 The ethical concerns raised by pharmacogenomics also extend beyond the
individual and extends to family members, other relatives, and individual's ethnic group.150
Collins and Varmus bring out the issues of conflicts that may arise between families “over
testing for high-risk genomic markers,” due to implications of test results for people who have
not been tested, and because of stigma within families, and within society. Other concerns noted
were the possibility of discrimination and stigmatization, the loss of privacy and confidentiality,
and the appropriate boundaries for human intervention. Collins and Varmus states that GINA
(2008), prohibits the discrimination against individuals based on genetic information related to
health insurance and employment, and can serve as a legal precedent and template for penalties
on the illegitimate use of an individual's genetic information.151 The next section looks at the
importance of collaboration and education in PM.
6.3.2 Collaboration and Education
Collaboration between multiple actors is necessary in order to integrate PM in healthcare
settings.152 The PMI promises the collection and sharing of a large amount of data from one
million volunteers, which will allow improved access to data across multiple networks.
Integrating genomic information into EHRs in clinical setting allows improved access to data
across different networks.153 Manolio et al. are excited that PMI will allow for research advances
to provide better assessment of disease mechanism, risk, and optimal therapy into many aspects
of health and healthcare.154 Alcalde and Rothstein argue that PMI emphasizes engaged
participation and open, responsible data sharing, will allow participants in accessing information
about their health, as well as the research. They add that there will also be a need for advancing
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the regulatory frameworks nationally, by implementing a strong collaboration between the
researchers, government and other public and private entities.155 Sperber et al. state that
educational campaigns to increase knowledge of genomic medicine among all will be most
effective if linked to local observable efforts.156 PM can still be very individualized in public
health, if public involvement is initiated in the early implementation process that takes into
account the “social norms, culture, risk perception, and family factors among other personal
information.” Sperber et al., also add that engaging patients to facilitate within family
communication is also a very effective strategy; to not only obtain complete FH information, but
also for pursuing cascade testing. They further add that good strategies will include
knowledgeable providers, who are effective in interacting with their patients in two-way
communication, to elicit the contextual factors for a comprehensive consideration of options for
and impact of genomic approaches.157 Moreover, they add that policy implications can
encompass support to speed up linking data across systems and broader-based education of
physicians and the public, about the use of genomic information in personal health decisionmaking to make personal health decisions.158
Knowledge of PM, and its applications and limitations by the individual, are essential for
buy-in and utilization. Educating the public and healthcare providers is especially important in
order to make PM a success. Per Y.W. Francis Lam, recommendations to improve clinician
knowledge about the applications of PM include the availability of a variety of educational
materials for clinicians to learn about interventions and how to utilize them in practice.159 As
suggested by previous studies, new paradigms in medical education are required which will be
essential in enabling students to understand, accept and apply an integrative approach to health
care, in accordance with PM.160 Other suggestions by scholars like Korngiebel et al. to educate
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the public, include the implementation and use of the innovation by using mass media, to
communicate with large audiences - such as news articles on TV, the radio, and local
newspapers. They add that email press releases forwarded by senior leaders within health
systems and externally to the general public and local media and journals with a potential reader
are another strategy that can be employed to create public awareness, and gain trust - thereby
creating public participation. They further emphasize that community participatory approach,
such as focus panels with patients to obtain input to develop patient educational materials, and
PGx education tools and research study strategies will draw more participants.161 Given the
broad scope of PM and the need for a large amount of diverse data, Sperber et al. point out that
“it will be increasingly important for the European Medicines Agency and the FDA to
collaborate on the development and establishment of harmonized guidelines for genotyping and
biomarker testing, and their incorporation into future targeted treatments, to guide companies.”
This could include standardizing trial data documentation.162 Ginsburg emphasizes the
importance of education in the application of genomics and PGx of health professionals and the
public to move the implementation of genetics into healthcare setting. As of today, there are no
broad initiatives to disseminate genetics and genomics education among medical professionals,
trainees, and the public at large.163 Also, education and proper skills will ensure that individuals
and population groups are protected from psychosocial and financial harms.164 Ginsburg also
adds that the continued leadership and collaboration among schools of public health, state health
departments, and other public health partners will be instrumental in ensuring genomics is
effectively utilized in the prevention of chronic conditions, and ultimately promoting health of
the population.165
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Khoury and Mensah suggest that public-private collaborations will generate the resources
and expertise needed for an evidence-based genomic medicine that will benefit both. They add
that CDC and others are looking to develop a sustainable public-private collaboration to create
the evidence-base needed for genomics and identify the gaps for further research initiatives. 166
As Lam notes, predicting individual response to drug therapy has been a goal of PM in every
therapeutic area. Advances in PGx have raised the public expectation that access to personalized
drug therapy is around the corner. However, barriers and logistical challenges such as knowledge
gaps in healthcare professionals, and lack of proper tools, have been cited by Lam as the reason
why implementation of this technology is still far away. In order to overcome the spectrum of
challenges and for PM to succeed, Lam adds that an expanded educational scope that includes all
stakeholders within the PM innovation ecosystem will be instrumental, rather than merely
focusing on simply educating current and future health practitioners. Lam highlights that PM can
only be achieved with all stakeholders in the field, only with a broader vision of a “knowledge
ecosystem,” working together and occasionally accepting a paradigm change in the current
approaches to implementation.167
As Henderson et al. state, the scientific complexity of genomic research and the high
degree of public interest in PM has highlighted the need for increased scientific literacy through
public education. Despite the highlight of this need, the scholars argue that the uncertainties and
ambiguities existing within the genomic research, results as treatment distinction as perceived by
potential research subjects, thereby presents challenge to efforts aimed at improving public
understanding about genomic research.168 Many topics of concerns were highlighted by the ELSI
Congress of 2011 which includes: informed consent, disclosure, data-sharing, special groups,
privacy, and confidentiality.169 The topics that remained consistently reiterative as the major
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focus of ELSI investigations related to PM, as highlighted by Callier et al., include topics such as
consent, disclosure, data sharing, privacy, and confidentiality - for reasons already covered in
previous sections of this chapter. The scholars have highlighted the critical need for exploring
topics involving particular indigenous, ethnic, and racial groups. The need for more research that
explored the topics of social justice, such as fairness and equity in research, about disclosure,
group harm, use of race as a category in research, and genetic discrimination was also cited by
Callier et al. It is well known, for instance, that genomic studies have historically focused only
on research participants of European ancestry. Scholars like Callier et al. have noticed a sharp
decline in publications on important, yet unresolved questions related to how investigators define
race and ethnicity in precision genomic medicine (PGM) research - and few articles were
observed that focused on recruiting minority populations to PGM research. Since PGM research
seeks to understand the roles of diverse genetic variation and environment on health, the scholars
emphasize the need for revisiting these issues. The scholars also raised concerns about the
changing international context of PGM research – which remains underexplored in the ELSI
literature - given the increasingly global nature of ELSI research. 170
Due to the level of global collaboration required to understand genomic research
findings and benefits to diverse populations in the United States and elsewhere, multi-country
ELSI research collaborations should be encouraged and may increase given initiatives like those
funded by Human Heredity and Health in Africa (H3Africa), which funds African investigators
conducting PGM research and ELSI studies. Another related concern observed was the number
of low ELSI investigations that focused on justice, which is a key principle of foundational
research ethics. As more communities from around the globe participate in PGM research, it will
be essential to address these issues for the benefit of participants from international and native
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groups – especially participants who are interested in finding results. Similarly, ELSI guidance
specific to PGM research in cancer, heart disease, and other major public health priorities is
needed since these could positively impact participants’ PGM research experiences. 171 Timing
and progression of the research process and the desire to translate research into clinical care can
become an emerging ELSI issue, since private and public entities will need guidance on
disclosure and marketing policies as partial details about genetic risks emerge. As medical
interventions aim to become adaptable across the full spectrum of life (from birth to death) to a
variety of diseases (common and rare), disease states, and populations, the research will also
consider the effects of diverse variables – such as age, gender, and location – on health and
health outcomes. Along the way, a correct balance of broad and population-specific ELSI
guidelines will be essential in the future to further inform PGM studies.172
Scholars like Y.W. Francis Lam argues that even though people are receptive to genetic
tests and prescribing, there must be some educational efforts that will alleviate their concerns
regarding privacy and confidentiality during the process of pharmacogenomics testing
implementation. There should be ways to protect patients' privacy and promote the application in
clinical practice. Besides, national protection of genetic information afforded by the 2008
congressional passing of GINA should be emphasized to minimize discrimination concern.
Addressing these concerns could further facilitate the integration of genomic services to clinical
practice, as well as encouraging informed patients to participate in necessary research to advance
the approach.173
IBC brings to our attention the enormous inequalities that exist in the distribution of
wealth between the developed and developing countries, stating that these are acting as a barrier
to the sharing of scientific advances and its applications, which are fundamental human rights.
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Gaining scientific knowledge is a matter of justice, and is true for lower and middle income
countries (LMIC) which can contribute significantly to the scientific progress through equitable
participation in research. However, a lack of resources in LMICs is acting as barriers in the
implementation of genomic applications. Genomic knowledge has been defined as “heritage of
humanity” in the “Article 1 of the Universal Declaration on the Human Genome and Human
Rights (UDHGHR),” thereby making it a common good, which should be allowed open access
to. Although this leads to many issues of informed consent and confidentiality and data privacy
due to data sharing; it also appeals to the international community to confront the issues of right
to access to scientific knowledge, with the initiation of protection of intellectual property. 174
Moreover IBC add that with the reach of genetic research extending beyond national borders, it
is inevitable to address the ethical issues through international frameworks and standards for the
direction of such research. Moreover, IBC also add that the establishment of universal norms will
not be useful, given the differences in social and cultural sensitivities. It will however be
beneficial for international organizations to develop ethical framework in the form of
declarations, reports and guidelines. Such a framework will be especially important for countries
without any national or institutional instruments in place for genetic research.175 It has been
further stressed that sharing of benefits are established between countries - and developing
countries should receive support to build the capacity to undertake genomic research capacities
that will support research in health services. There is a need to foster scientific and cultural
cooperation between industrialized and developing countries in order to help developing
countries build the capacity to participate in generating and sharing scientific knowledge that is
appropriate to the needs of the developing countries, thereby addressing global health issues.176
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IBC highlights that the United Nations can be instrumental in making fundamental normative
decisions regarding the safety and efficacies of the tools.177
Due to the vast differences in health care systems, available resources, and diverse
population needs, there may be an increased need for genetic counselors who are specialists, and
genetic counselors who are generalists in parallel, in the era of PM. While genetic variation has a
role in common complex diseases, Wicklund et al. add, it “does not fully explain the etiology” of
the diseases. An individual's environment, as well as lifestyle, should be taken into consideration,
in order to be able to treat and prevent disease precisely.178 Because of the difficult nature of the
results of genetic analysis, Wicklund et al. suggest special training in ethics for people
communicating the cases of diseases with multifactorial traits or new variants with unknown
impact on the individual. They also recommend that Doctors should be knowledgeable about
genetics in diagnosis, therapy, and prevention of diseases, as well as the ethical implications of
the results. According to Wicklund et al., the amount of information that can be obtained from
the current testing options has highlighted the importance of understanding the client’s
perspective, values, culture, and beliefs so that genetic counselors can determine the most
relevant and critical information for each client – but most importantly they need to be able to
address the psychosocial implications of the tests and results for the patient and their families.179
Greater collaboration between physician and genetic counselors will also be needed, in addition
to the incorporation of education in ethics and genomics into the medical school curriculum.
With the advances of genomic technologies, calls were made to bridge the ‘genomic
health divide’ through economic investment in research, and expanding the provision of genomic
services and technologies to the ‘global south.' Calls were also made to widen the scope of
genomics to include a greater diversity, which will encompass minority populations from other
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ethnic groups, and ensure that those who are in most need of genomic research, are not the ones
to receive it the last. Calls were made to make sure that those in the developing parts are given
the ‘right’ to become participants in, and potential beneficiaries of genomic research. However,
there are ethical issues that are becoming apparent owing to genomic research and technologies issues in terms of social inclusion and justice, as well as inequitable stratified access, and lack of
rights to health care resources are some of the anticipated issues that are most likely to arise due
to the emerging technologies of genomics in the global scope. These issues demands for a critical
and engaged attention.180 According to IBC, benefits to health protection and health care
resulting from advancements in human genetics, should be a “fundamental right of every human
being, to enjoy the highest attainable standard of health,” this should include access to healthcare
and medicine. Moreover, scientific progress should alleviate - not deepen - inequalities within
and among countries, and should not “be used for discriminating against individuals or groups.”
181

Due to the rapid implementation of biobanks that are raising issues of data protection,

internationally implemented safeguards should be in place to protect participants, and foster trust
in research activities. It is important to implement an international public registry of DNA
mutations and variants. Given the costs of genomic infrastructures, it is unlikely that LMICs will
have much access to large scale genetic technologies. However, it is recommended that LMIC
governments begin developing genomic policies addressing the human and technical capacity
within the context of their national economic and sociocultural uniqueness. Research is needed to
identify the promising technologies and the barriers to their applications, in order to bring the
benefits of genomics into the health of developing countries. Developing countries need to
generate their expertise in addressing the scientific, ethical, legal, social, and policy aspects of
genomics. Leadership development programs are needed to create a constituency on genomics
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policy in developing countries, which will strengthen the capacity to participate in international
negotiations. Building scientific and policy capacity also involves forming productive and
mutually enhancing partnerships with centers of excellence, wherever these may be; while
existing centers should be identified and supported, and new centers should be established.182
Deepening and updating of ethical reflections need to be reflected in the existing
declarations, warranting revisions - this task can be performed by “UNESCO” with its wellestablished role as a global forum for global bioethics, and relying on the contribution of its
institutional and expert bodies. The World Health Organization (WHO) can act as a mediator and
neutral broker between states, which are responsible for respecting, protecting, and fulfilling the
human right to health, and the pharmaceutical sector, which can contribute relevant products and
services. However, the WHO’s role should not be primarily to incentivize the pharmaceutical
sector directly but to facilitate and complement its activities to achieve alignment with global
public health needs of the developing world. The WHO will provide a neutral platform and act as
an independent broker and conveyor on important and controversial issues. The WHO can also
function as a mediator when needs arise in developing countries. The WHO can also promote
public-private partnerships, including product development partnerships, and convening working
groups to provide expert advice to decision makers and resolve controversial issues through
collaborative discourses.183 So far, the World Health Organization’s main priority has been to
improve equitable access to medicines for people and patients living in the developing world. In
this regard, it has acted as a neutral broker to provide a platform for discussing important issues
such as the need to link innovation with access, to delink R&D costs from the pricing of
medicines, and to explore feasible and workable alternatives to the traditional IP regime as an
incentive mechanism.184 Because of the complex nature of genomics, the WHO needs to work
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more closely in the future with other international organizations (e.g., World Intellectual
Property Organization and World Trade Organization) and important stakeholders, including the
pharmaceutical industry. These efforts need to be pursued in parallel with the building and
strengthening of R&D capacity and self-sufficiency in the developing world.185 The WHO also
provides technical advice through specific programs in the relevant areas. This in-kind support
and the association with the WHO can give more visibility to such initiatives.186 According to
IBC, human genome must not be interpreted only “as raw material,” but must be considered as
“one of the premises of freedom” by all. It is crucial to acknowledge the opportunities that the
scientific advancement of genomics is likely to offer, as unique tools against diseases, that these
opportunities should not become the privilege of few. As the IBC emphasizes, human genomics
should be viewed as the heritage of humanity and entails sharing both of responsibilities and
benefits.187
Conclusion
As Olvey and Bootman rightly states, that the sequencing of the human genome was one
breakthrough in recent history that holds many potential benefits to modern medicine, in the
name of Precision Medicine. In addition to providing economic value, PM aims to utilize the
genomic knowledge for identifying of patients at risk for developing diseases, in order to
prevent, early diagnose, and in the drug development of more targeted therapies - to personalize
healthcare. 188 PGx is also anticipated to play a critical role in addressing ADRs and toxicities.
PM also promises improved care and prevention of chronic diseases in healthcare setting, both
nationally and globally.189 From studies, it is evident that there is increasing appreciation and
acceptance of PM within people, making it easier to implement PM.190 However, according to
scholars there are challenges that need to be addressed otherwise the data generated will be
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useless, raising ethical and social issues that need to be addressed.191 Personalized genomic
medicine (PGM), with its goals, is promoted as the ‘new paradigm of healthcare.’ The
interpretation and ranking of promises differently, which include individualized diagnosis and
risk prediction, more effective prevention and health promotion, and patient empowerment carries ethical and social implications for the realization of PGM as an approach to healthcare.192
Substantial work highlights the challenges that frame the external social barriers, but very little
information is present that depicts what PM might look like in practice, which creates much
confusion and unease. We should be mindful of the goals of PM as promised to the people,
because different interpretations of its goals can take genomic research and healthcare in
different directions, some of which we are fearful of, such as eugenics and exacerbation of
inequities and lack of justice.193 The fruits of this technology should be a common good, and
with that in mind, PGM should be considered as a social practice. Therefore, developing a
responsible transition plan for PGM will require careful empirical mapping and analysis of all
the issues anticipated.194
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Chapter 7: Laying an Ethical Foundation in Healthcare in the era of PM
7.1. Introduction
Integrating personal genetic information into healthcare delivery is hoped to tailor
medical treatment decisions to optimize patient care; and thereby resulting in significant cost
savings by administering treatments only to those most likely to benefit. All of these
expectations also raise questions about the upcoming changes in healthcare organizations
(HCOs), costs, and ethical obligations of HCOs. As scholars like Moeckel Pritchard et al. point
out, overcoming challenges in these areas will likely require strategies to be implemented that
are straightforward, provide clear solutions, and can drive systemic and cultural changes.1
Moreover, Fillerman, Gary L., eds., add that a roadmap to advance PM in healthcare systems can
be built with a clear understanding of the set of challenges, and the best strategies for
overcoming those challenges.2 The purpose of this Chapter is to look at the organizational ethical
issues that may arise in the era of precision medicine, and how HCOs in the United States can
prepare themselves in order to be ready to address these challenges, while delivering healthcare
services that meet the organization’s mission, equipped with the tools needed.
7.1.1. Looking at Healthcare Organizations – Healthcare as Services
According to Fillerman, Gary L., eds., HCOs are expected to provide healthcare to the
sick and vulnerable individuals, and this represents a profoundly moral practice. Healthcare
professionals are inherently considered as effective moral agents, rather than (only as) skilled
professionals mainly because of their professional code of ethics and their values – providing
treatment and care to all.3 Communities place a high degree of trust in their hospitals, because
they are a community asset, and they have a responsibility to be trustworthy, and accountable to
those they serve.4 The study of ethics assists administrators, clinicians, researchers, and
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policymakers address ethical questions and challenges.5 Over time, hospitals have been widely
established to address healthcare needs in particular communities.6 Healthcare boards have
important ethical responsibilities and duties.7 In order to look at the ethical duties and roles of
healthcare leadership, it is important to understand the nature and purpose of healthcare.
Healthcare is a necessary human service, not optional - people need healthcare services to
maintain health, fight disease, and live satisfying, productive, and happy human lives. As
scholars like G. Magill and P. Lawrence point out that healthcare is a special type of business,
where its ethical foundation is rooted in the commitment to provide care, and ethical practice is
evaluated by how well its actions align with that core commitment. However, most hospitals
were built to address the health needs of specific communities, not just individuals, to advance
community health and welfare. Therefore, Magill and Lawrence argue that the ethical
commitment of HCOs clearly extends to communities in which they are a part, may as well
extend beyond the local community served, due to today’s interconnectedness.8 Martien
Pijnenburg adds that HCOs, as institutes are also structured by the society, and have a moral
responsibility at the level between individuals and the state, and HCOs institutionalize this
responsibility through the practices of solidarity with individuals in need for healthcare.
Pijnenburg also adds that solidarity in HCOs is expressed through their caring activities – within
the context of HCOs, this caring is a joint practice, where institutional care is an organized,
multidisciplinary, and structured activity, and solidarity is inherent to this joint practice of care. 9
While explaining the roles of HCOs, Pijnenburg adds that HCOs have different roles –
caregiver, organizer of care, and a public agent. He further elaborates the primary existence for
HCOs as a caregiver is to give care – good care that requires competence in the technical and
moral sense of the word, as well as a sound balance between personal, professional, and

193

organizational values. Pijnenburg further adds that meeting these requirements ensures that the
HCOs are ethically practicing solidarity and providing the gateway to sources of solidarity. 10
HCOs also preserve solidarity by the way they organize their caring activities, notes Pijnenburg creating the proper conditions for responding to the needs and wishes of different stakeholders,
where organizations make use of a mix of different moral understandings – focused on rules and
scientific validation, as well as on efficacy and efficiency, and on human resources management.
The scholar further adds that balancing between these mixes of different moral understandings
can also lead to many problems, since every singular understanding tends to become most
important.11 Pijnenburg explains that HCOs are also called public agents since they operate on
behalf of and in favor of a community that wants to take responsibility for its ill members –
where HCOs bear the moral duty to act as the “corporate citizens.” In this role, he states that
HCOs take responsibility for those who are unable to access healthcare and advocacy on issues
that are in the interest of the public's health. The Catholic Health Association (CHA, 2008) of the
United States advocates for “a just and compassionate healthcare system.” According to CHA,
this is not labeled as solidarity; however, the combined efforts of the members to improve the
situation of vulnerable citizens, is how solidarity should be understood as. Through the public
advocacy of solidarity, HCOs can contribute to its preservation of solidarity.12
Robert T. Hall states that non-profit HCOs, in the United States, are offered tax
exemption because of their social obligation to provide “community benefits.” 13 According to
the WHO, the primary rationale for the not-for-profit organizations is both economic and
social.14 Fillerman, Gary L., eds., argues that the community benefit is an essential dimension of
the healthcare services; so is playing a part in the local and national advocacy for an equitable,
accessible, and effective healthcare system - which contributes to the good of the community.
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They add that HCOs are also communities of practice - bringing together physicians, nurses,
administrators and a variety of business professionals - providing services through a complex
community of care. Moreover, Fillerman, Gary L., eds., highlights that HCOs are organized
health systems, intended to benefit the population at large.15 Hospitals may be different in sizes,
but they are similar in purpose – provide some healthcare to those in need using specialized staff
and equipment – and this similarity is also why they have similar stakeholders.16 Per Fillerman,
Gary L., eds., a Stakeholder is any individual/or group who can affect or can be affected by the
organization's achievement of the organization's objectives, and includes – “patients, families,
healthcare financing organizations, buyers, community organizations, professional and nonprofessional staffs, and professional associations and unions that represent them, regulatory
organizations, accrediting organizations, trustees or the governing board, other administrators,
suppliers, other hospitals and clinics, and the community in which the hospital resides.”
Fillerman, Gary L., eds. add that each of these individuals or groups can affect or be affected (or
vice versa) by the achievement, of the hospital's objective, and by the decisions made on their
behalf. They add that hospitals are unique in their visions and prioritize different commitments.
Understanding a specific hospital or healthcare organization requires understanding its specific
purpose - and how it achieves that purpose. 17
With the advances in medicine and informatics technologies, hospital care remains the
single largest category of health spending as of today. Fillerman, Gary L., eds. elaborates that
data from 1960 to 2000 demonstrate that half of the improvement in survival among heart attack
patients was attributable to technological advances. The scholars points out, although these
advances yielded many benefits, they also added to the demand for medical services and costs of
providing care. In 2014, approximately 50% of the rise in healthcare expenses over the past
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several decades had been attributed to advances in technology.18 However, Vogenberg and
Santilli emphasize that technologic innovations in PM will have to keep up with the changes, and
successful innovations will require providing a meaningful return on clinical or economic
investments, or both – requiring new metrics to determine such value calculations.19 Pijnenburg
notes that it is evident that an HCO needs enough financial margins in order to fulfill its mission
to care. But he points out that although these are products created by markets such as medicines
and technology, the fear is that market principles like competition and maximizing profits can
become dominant and lead to the suppression of care according to medical needs and to equal
access. Pijnenburg highlights the tensions that exist between market and care, since they cannot
be considered as mutually exclusive. Additionally, Pijnenburg points out that efficient use of
means and time, evidence-based care, and the prudent management of human resources present
many constraints on the goods to be pursued by any HCO – although they are not equally
important and must be weighed. However, the most important consideration for any HCO is
caring for people. 20
The American society considers the provision of healthcare to all as a moral obligation,
and it expects healthcare to be safe, effective, patient-centered, timely, efficient and equitable.21
The demand for healthcare is being raised because of advances in medicine, such as genomics
and PM, the rising implications of chronic conditions and a population that is aging – and with
the increased demand comes rising expenditures that healthcare organizations have to manage
with tight budgets without compromising its quality.22 Fillerman, Gary L., eds. add that HCO
leaders have the ethical responsibilities to recognize and understand moral complexities, and
consequences to the decisions they make; and they have the responsibility to nurture and
maintain organizational culture. They add that HCO leaders must ensure that the system they
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oversee function productively, that they change alignment with their purposes and goals, and that
they have a framework in place that can identify, and address ethical or moral issues
effectively.23 Moreover, HCO as a community of care and employer has an ethical responsibility
to cultivate a work environment where patient-centered quality care is delivered; in which
community members are both stakeholders and beneficiaries; and where work is just, respectful,
and mission-driven. As observed by V.T. Grigorean et al., HCOs should have Organizational
Ethics (OE) – which refers to a set of principles, codes and beliefs and values - to guide and
regulate their actions.24 Grigorean et al. state, OE is in itself an aspect of the organizational
culture – that consists of moral life, the rules and standards to guide employee relationship
according to the needs of all those involved. They add that the ethics is a means to calibrate
moral issues in certain contexts and can be implemented and managed through ethical
committees, codes of ethics, specific policies and procedures, ethical audits, training programs in
ethics and so on.25 Grigorean et al. further argue that the ethics is rooted in the assumptions that
healthcare is a necessary human service and a social good; and healthcare organization leaders
and boards must understand and act in accordance with their special responsibilities as
caregivers, community members, and employers. As demonstrated by various studies, ethical
codes can be implemented at various stages, and can include codes for the whole institution, and
also for the various departments and clinics; for human resources and legal departments, as well
as for the employees; making clear the values important for the organization, which becomes the
priority for the organization as a whole. As studies have reflected, it is insufficient to develop
ethical codes which only ensure the ethical and legal practices formally. Most companies state
that those ethical codes are useful but not sufficient. It is important that leadership support and
sanctions for unethical behavior – otherwise the efficiency of such codes will be limited. 26
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Scholars like Aditya Simha and John B. Cullen point out that an organizational work
climate is also essential to look at and implement in HCOs – they define it as the shared
perceptions of procedures, policies, and practices, (both formal and informal) of the organization.
Simha and Cullen, moreover, add that there are many climates: ethical, innovation, creativity,
communication, diversity, justice and safety climates and so on. All these climates are known to
influence behaviors of organizational actors – an ethical work climate constitutes to the
perceptions of what constitutes as right behavior, and becomes a psychological mechanism
through which ethical issues are managed. HCOs should be mindful of the various scandals that
have taken place in the history of once-respected organizations such as AIG, Countrywide
Financial, Lehman Brothers, and Siemens AG, to name a few – where insider trading,
embezzlement, corporate fraud, and workplace bullying were all traced back to the influence of
ethical work climates, which were at the center of their ethical scandals – raising public fear and
mistrust for organizations. Simha and Cullen argue that an ethical climate influenced HCO
would be influenced by ethics in both decision making and behavioral responses to ethical
dilemmas, which would be reflected in various work outcomes.27 Given the many organizational
scandals mentioned earlier, the World Health Organization (WHO) states that it is important that
the HCOs be able to hold on to the community and public trust; and therefore are built on ethics
and leadership which abides by the ethics of the organization to uphold the moral foundations. It
is important that the role of leadership is clearly defined, and the role is both a practical good and
ethical priority.28 The next section looks at the ethical and legal duties of the leadership in HCOs.

198

7.1.2. Ethical and Legal Duties of Leadership
According to the WHO, a good health system contributes to good health and ensures
inequality does not exist or does not worsen - to all population that it serves. Filerman, Gary L.,
eds. writes in "Managerial Ethics in Healthcare: A New Perspective," that the health system has
the responsibility to try to reduce inequalities, preferentially by improving the health of the
worse-off, through interventions where possible. The objective of good health according to
Filerman, Gary L., eds. is “twofold: the best attainable average level – goodness – and the
smallest feasible differences among individuals and groups – fairness.” According to the
authors, “goodness” indicates that the system serves the people as expected, and “fairness,”
indicates that the system serves the people equally, without discrimination.29
As articulated by IOM, HCOs are expected to have these essential values of care:
1. Safe – avoiding injuries to patients from the care that is intended to help them.
2. Effective – Per Fillerman, Gary L., eds., this is providing evidence-based services to those
who will benefit, and not to those who will not benefit (overdose, or overuse).
3. Patient-centered – Care that respectful and responsive to individual patient preferences, needs,
and values, and ensuring that patient values guide all clinical decisions.
4. Timely – reducing waits, sometimes-harmful delays for both those who receive and those who
give care.
5. Efficient – avoiding waste, including waste of equipment, supplies, ideas, and energy.
6. Equitable – Care that is of the same quality, provided to all regardless of personal characters.30
As Fillerman, Gary L., eds. write, healthcare is perceived to have a moral core by most
Americans. The responsibility for framing this moral core and seeing that it is implemented in
the day-to-day business of any HCO is the responsibility of all hospital stakeholders, specifically
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those in the leadership positions.31 The governing board establishes the mission, values, and
vision of hospitals. According to Fillerman, Gary L., eds., the board also selects the Chief
Executive Officer (CEO), who selects the leadership team. Responsibilities of the board include
helping the CEO implement the mission, values, and vision developed by the governing board.32
All board members have ethical obligations to exercise their responsibilities in a way that
advances the mission of the organization, understand that they are not representatives of any
constituent groups, and that they are required to have good personal judgment in order to make
an independent judgment for the good of the organization's mission.33
Organizational leaders commit to contributing to the moral climate of the organization to the mission and their purpose.34 There is a requirement for greater attention to alternative
forms of care delivery and partnership, relationship with neighboring HCOs, variations in
healthcare financing, emerging community needs that must be taken into consideration as part of
the leadership responsibilities.35 Filerman, Gary L., eds. insist that members must assist
management in responding to the new world healthcare delivery and financing. Healthcare
boards are entrusted with ensuring the delivery of high-quality patient care, as they note.
Directors have a vast and essential responsibility to oversee every dimension of care delivery,
including protection of patient's rights, promoting a culture of safety, monitoring key quality
measures, ensuring sound structures for clinical research, and approving all forms of physician
relationships. The quality committee of the board reviews quality measures and safety, and
patient safety data. The committee also works with management to advance the adoption of best
practices, and systems of control and continuous improvement. Other responsibilities, as noted
by Filerman, Gary L., eds., include ensuring that services are provided in a way that reflects
patient wishes, and choices in a manner that genuinely improves health, and reduces the risk of
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adverse outcomes.36 According to the authors, the board also has a fiduciary responsibility to
guide and oversee all dimensions of workplace justice and human resources. It requires a review
of policies and performance concerning employee relations and satisfaction labor relations,
compensation and benefits, training and development, and evaluation methods.37 They have an
obligation not merely to conserve past and present promises, but to guide the organization
toward the future while maintaining a commitment to mission and core values. Organizational
integrity is animated by the past but always reaching toward the future.38
According to Treviño et al., OE can guide HCOs with a broad range of organizational
phenomena - from individuals' attitudes toward ethics initiatives, to the organization's
approaches to dealing with ethical concerns. They note that senior management perceptions play
a significant role in several key aspects, such as the perceived goals of efforts to foster ethics and
legal compliance in the organization; perceptions of the overall ethical environment within the
organization; and perceptions of employees' willingness to seek ethical advice within and to
report ethical problems to management.39 Moreover, Treviño et al. point out that the ethical
climate of the organization influences behaviors and attitudes of the employees – which consists
of employees' perceptions of the organization's support for ethical behavior via the reward
system, consistency between formal ethics policies and everyday practices and decision making,
and senior executives' concern for and support of ethical conduct. They highlight that
perceptions of the reward system's support for ethics are particularly important; especially the
belief that ethical employees are the ones who get ahead and that unethical conduct is
disciplined. Treviño et al. note that recent changes in the Federal Sentencing Guidelines for
Organizations give renewed attention to the importance of organizational ethics and ethics
culture, and senior leadership - especially senior managers, are perceived to play an important
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role. It has therefore become important to understand senior managers' perceptions of
organizational ethics and how those perceptions compare with those of lower level employees, in
order to implement better organizational ethics climate.40
Scholars like Treviño et al. have further noted that the intensity of contact that individuals
have with an organization increases their tendency to define their own identity regarding their
relationship to the organization. Senior managers have been noted by the scholars to typically
experience a unique degree of intense involvement with their organizations, and play a key role
in building the organization's reputation, serving as agents representing the interests of multiple
organizational constituents - as opposed to lower level employees, who according to the scholars
are less likely to identify with the organization and are more likely to identify with their
workgroup, department, or unit. It was also noted by Treviño et al. that these different identities
with different roles, led to differences between how senior managers and lower level employees
perceived issues.41 Gary R. Weaver emphasize that managers must pay attention to moral
identity and moral agency – and avoid even the smallest of amoral behavior since it can create a
vicious cycle, leading to the normalization of amoral behavior in organizations. Weaver also
highlight that the provisions of opportunities for virtuous action in organizations are equally
important, providing the resources necessary for moral agency. He adds that organization-level
initiatives are not isolated from institutional phenomena. Therefore, weaver emphasizes that
policymakers need to pay attention to how larger, macro-cultural forces advance or inhibit the
development of moral identity in organizations. As moral agents, managers are responsible for
choosing and changing the organizational situations in which moral identity either thrives or
dies.42
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According to studies by Treviño et al., recent changes to the Federal Sentencing
Guidelines for Organizations mandate that organizations “promote an organizational culture that
encourages ethical conduct and a commitment to compliance with the law.” However, Treviño et
al. also note that some issues can result from senior managers believing that the ethical
environment is already quite positive, since this may result in them not doing as much as they are
supposed to do in order to uphold executive ethical leadership. Observers have noted in studies
that, as is, most executives already devote little of their resources to organizational ethics. As
pointed out by Treviño et al., such neglect of ethics can lead to additional problems, such as
worker cynicism, or reduced willingness to report ethical problems, particularly if lower-level
employees perceive that ethical problems do exist, while senior managers do not. Treviño et al.
state that more effort is needed by senior managers to find ways to seek out the perceptions of
lower level employees (in the hierarchy) in order to better understand issues. The scholars also
suggest that the efforts undertaken by organizations (surveys, as an example) may not be
sufficient, and need to create better opportunities for lower level employees to interact directly
and regularly with senior managers about ethics issues so that executives can gather high-quality
information, perceptions can become more aligned and executives can communicate their
commitment to ethics on a regular basis.43 They further suggest that initiatives can include more
interactive ethics training at different hierarchical levels, better communication across
organizational boundaries, and more research to investigate tactics to align senior manager and
lower level employees’ perceptions of ethics. 44
As Sidney Dekker point out, the charitable and public interest activities of a not-for-profit
healthcare organization constitute a substantial part of the organization’s corporate social
responsibility, and because of their tax exemption status, the Internal Revenue Services (IRS)
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and state tax agencies hold them responsible for maintaining a level of public interest activities
high enough to justify their tax relief. It is therefore important for such organizations to maintain
its public trust and character by abiding by its mission and social responsibilities. Dekker states
that healthcare is laced with complexities due to the continuing developments in the organization
and delivery of care. However, Dekker argues that new technology and new drugs, as well as
new procedures and new management, all allow practitioners to be more successful at what they
do; but he also adds that these same things can also create “new pressure points, new gaps, and
new failure modes.” 45 One example of such new technology that is anticipated to have the
potential to improve healthcare outcomes profoundly is precision medicine (PM). However,
Aronson and Rehm note that the results of the advances will require time to implement even
though “genetics is already being used to direct clinical decision-making, and its contribution is
likely to increase.” They add that fundamental changes will be needed in the infrastructure and
mechanism by which data is collected, stored and shared in healthcare settings to speed up the
advances. This will create a continuously learning healthcare system with seamless cycling
between clinical care and research. There are also ethical and social implications that need to be
taken into consideration in order to prevent future issues and move the transition of the
implementation process smoothly. Moreover, Aronson and Rehm add that patients must be
educated about the benefits and risks of sharing their information.46 The next section looks at PM
- the economics, and the impact it will have on healthcare systems.
7.2. Precision Medicine in Healthcare
As Kathryn A. Phillips et al. point out, the term “personalized medicine” has had many
name changes: from being known as “stratified medicine,” “pharmacogenomics,” to the recently
termed “precision medicine.” Regardless of the different terms, it is clear that Personalized
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Medicine/Precision Medicine is anticipated to result in higher quality, lower-cost healthcare
because of its targeted therapies to patients, which are more effective and safe.47 Muir Gray et al.
adds that clinicians now have access to an increasing array of tests with a better understanding of
the patient's genetic makeup, that allows them to determine which genetic variant exist in their
patients. Gray notes that despite the many benefits of PM, opponents fear about the ethical
implications anticipated with PM, especially how it will relate to equity, and roles of healthcare
payers, clinicians, and patients in the optimization of the potential of PM without reducing
equity.48 This section looks at the economics, and the anticipated impact PM will have on
healthcare systems.
7.2.1. The Economics of PM
Today, technology in healthcare has progressed into a learning healthcare system, in
which data from prior clinical experience provides an ever-expanding resource to guide
continuous improvements in health care.49 As such, PM through genomics has great potential to
bend the cost curve - genetic testing is anticipated to be cost-effective and even cost-saving,
although it has been noted in many studies that its ability to do so will depend on many factors the cost-saving promises have yet to be realized.50 Phillips et al. state that decisions about how to
assess the value of these technologies, which technologies will be adopted, and who will pay for
them will have to be made soon– in all the areas that economics can address. PM is also of
interest because of the increased emphasis on patient-centered care that takes into account patient
variability, including genetic differences.51 So far, a lot of promises have been made for PM’s
sake, but this Chapter will look at the hypes, as well as the myths.
Aspinall and Hamermesh state that PM is anticipated to dramatically lower the overall
cost of healthcare, mostly by providing early identification and initiation of treatments which are
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supposed to be optimal for the patient. Today, healthcare faces a big problem of giving drugs to
patients that do not benefit from them. According to the scholars, it has been demonstrated from
studies that most drugs prescribed are effective in fewer than 60% of the treated, costing the
healthcare system billions of unnecessary dollars. They use the example of Herceptin test to
detect for overabundance of HER2 protein in breast cancer patients, and costs about $400.
Aspinall and Hamermesh assert that identifying which patients should, and which patients should
not be treated with Herceptin - can save tens of thousands of dollars per person. They add that in
the case of HER2-positive patients, it can prevent cancer from metastasizing; and in the case of
HER2-negative patients, it saves money and resources by not prescribing a drug that will not
help them. 52
According to Derrick S. Haslem et al., PM as a cost-saving approach has been debated
for a long time. Although recent findings suggest that precision oncology represents an important
translational medicine paradigm, associated clinical outcomes are still maturing. 53,54 They state
that the advances in genomic technologies have made the genomic analyses of human
malignancies technologically and financially feasible for use in the clinic. Moreover, Haslem et
al. point that the clinical outcomes of information (such as, survival and cost-effectiveness) to
guide targeted treatment in patients with cancer remain unreported and challenging.55 Although it
is anticipated that the targeted cancer therapies will ultimately result in improved clinical
outcomes, the scholars note that there is still no information that demonstrates the impact of
implementing sophisticated technologies such as NGS on the cost of cancer care, versus standard
care.56 They attribute this lack of information to the limited availability of data (clinical
outcomes) and limitation on data sharing that are making such cost associated measures so
difficult.57 They emphasize that it will be critical to measure the cost associated with precision
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cancer medicine for its sustainability, in an era of increasing healthcare cost and limited
resources. 58
Molecular diagnostic (MDx) testing is an area in PM, as highlighted by scholars like
Akhmetov and Bubnov, has become a cutting-edge technology of present-day clinical practice widely used in numerous areas including oncology, cardiology and many other areas. They add
that advances in diagnostic testing is changing the way healthcare will be delivered, expanding
diagnostic testing into more portable, easy-to-use, cost-effective, and less time-consuming
platforms. Akhmetov and Bubnov also point out that in a report by AEI Brooking Joint Center
for Regulatory Studies, it was projected that testing for variants that guided “the initial dosing of
warfarin could provide USD 1.1 billion in annual savings to the US healthcare system and could
prevent 17,000 strokes with 85,000 bleeding events.” Moreover, MDx tests aiding in guiding
physicians' decisions on treatment, is leading to overall cost savings for healthcare centers. MDx
is also noted by Akhmetov and Bubnov to “improve adherence, compliance, and willingness to
undergo treatment or prevention through a better prognosis of disease occurrence and prediction
of the response to treatment.” 59
Akhmetov and Bubnov also add that MDx testing is also being used in pharmaceutical
companies, as it facilitates the discovery of biomarker-based therapies targeting the cause of
diseases instead of symptoms. These biomarker-based diagnostics, as the scholars note, if used in
clinical trials can boost the chances of regulatory approval, and enhance prescription. Akhmetov
and Bubnov also states that MDx is said to be critical in determining individual risk for disease
development, leading to the prescription of efficacious therapies. MDx is further thought to be
critical in appraising the response to therapeutic interventions during the overall treatment,
preparing viable disease management strategies, and so on. Akhmetov and Bubnov add that new
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generation MDx can add “downstream value” by their evolving characteristics such as higher
accuracy, higher throughput, shorter testing time, simplicity, portability, cost-effectiveness, and
so on.60 However, Gronde et al. are critical about the rising global health care expenditures and
drug prices. They state that people are doubtful that innovations will lower the drug prices. Even
with the promises of PM and targeted drug therapies to curb costs, the scholars argue that it is
expected that the drug pricing and funding crisis will deepen and reach a critical level for even
the wealthiest countries.61
Duffy and Crown criticizes the present “trial and error” or “one size fits all” approach to
the cancer treatment, as inefficient and resulting adverse effects and toxicity. They argue that PM
has the potential to increase efficacy and decrease toxicity.62 As Aspinall and Hamermesh state
that advances in PM have enabled drug companies to develop tools that can distinguish the
subtypes of what was once considered as “a single disease,” as well as chemical agents that
target each of these subtypes. They also add that what used to be known as deadly cancers, are
now managed as chronic conditions, by treating them early. Examples include leukemia and
lymphoma, which were the only types of blood cancer that could be identified, today 38 types of
leukemia and 51 types of lymphoma are known to us.63 Proponents of PM argue that
personalized approaches will increase the probability of positive response, being given only to
those who will benefit and reducing toxicity and side effects on others, will also ultimately lead
to overall cost savings.64
Aspinall and Hamermesh state that many tests are available today to spot many of the
genetic differences, allowing drug dosages to be customized. For some cancers, diagnostic tests
can help doctors assess the aggressiveness of the tumor and, determine on the type of treatment,
such as surgery or less invasive treatment.65 Drug therapy based on individuals' genetic makeups
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is also suggested to result in a clinically significant reduction in adverse outcomes, saving
billions of dollars in avoidable costs.66 Although there are assumptions that Lynch syndrome and
gene expression profiling for breast cancer can be cost-effective - these assumptions are not
enough - and are not helping speed up the implementation of PM into the health systems.
Scholars like Rebecca S. Eisenberg observe that new technologies like PM may cause much
uncertainty about how best to use them and whether they should be modified, even after they
enter clinical practice.67 G.S. Zaric notes that although PM has promised a reduction in cost,
there is still a need for more formal analysis of the cost implications of companion diagnostics.
According to findings, the United Healthcare reportedly spent $US500 million on genetic tests
in 2010. However, Zaric notes that payers remain skeptical that the costs of diagnostic tests will
be offset by more selective use and fewer side effects, and sarcasm still looms about whether
increasing the use of PM will reduce costs. Zaric emphasizes the need for the evaluation of cost
impact of companion diagnostic test implementations.68
Oncology remains the largest segment for FDA-defined marketed theranostic drugs
(integrating diagnostic testing to determine the presence of a molecular target for which a
specific drug is intended) that are on the market and has not been known to have lowered cost of
drugs by stratification.69 Greater than 40% of all marketed products are Oncology drugs – such
as Herceptin® and Gleevec®, labeled as “niche busters” - drugs targeted to smaller patient
populations but commanding premium prices, allowing them to achieve annual sales >$1
billion.70 As noted by scholars like Amit Agarwal et al., the major driver of growth for
companion diagnostic deals is the potential economic benefits for drug developers early in drug
development, to select patients for clinical trials, and reducing costs and shorten the time to
approval for drug developers.71 Ultimately, the scholars argue that this only shows that PM will
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lead to a more restricted market that drives prices of drugs up, and not down, by population
stratification.72
Jane Null Kogan states that “although spending on genetic tests currently accounts for
only 10% of health insurers' total laboratory costs,” it is expected that the increased utilization
will drive these costs upward at an annual rate of 15% to 20% - with a projected cost for genetic
testing “to reach $15 to $25 billion by 2021,” an increase from $5 billion in 2010. Jane Null
Kogan also adds that genetically targeted therapies pose an even greater cost risk for payers,
since targeted therapies are classified as specialty medications with the promise of benefits not
available from conventional drugs, with no substitutes - they are considerably higher priced.73
Jane Null Kogan adds that spending on specialty medications is growing each year and is
expected to account for 235 billion, which is half of the total annual pharmacy spending by
2018.74 Despite the slow adoption of PM into healthcare, Thomas Reinke notes that many health
systems are implementing PM. Reinke notes that Geisinger Health System and Kaiser
Permanente are two examples of integrated health systems that are building comprehensive,
costly genomics programs, with the goals to develop innovations in care, expand population
health initiatives and respond to health reforms that emphasize value-driven accountable care.75
According to Clay Christiansen, PM will be disruptive in its ability to drive down health
care costs without compromising quality or outcomes, and while PM is held at high esteem for
revolutionizing healthcare delivery, significant challenges stand in the way of its wholly
disruptive potential.76 Despite the conceptual potential of PM, scholars argue that PM may
increase costs without increasing benefits.77 Akhmetov and Bubnov note that more evidence is
required to prove the value of PM. However, they add that PM focuses on accuracy and
feasibility, and cannot be considered as solid evidence.78 There are currently no concrete, unified
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databases of economic evaluations of PM, making it difficult to assess the value of PM across
studies and interventions.79 The next section looks at the impact PM is anticipated to have on
healthcare systems if implemented.
7.2.2. Impact on the Healthcare System
Brothers and Rothstein states that advance in technology have caused PM to expand in
scope as well as complexity, and they anticipate the trend to continue in the years to come. With
all the expansions of scope and complexity in PM, the scholars emphasize that it will be
necessary to consider broader issues, such as the implications of the significantly increased
amount of health information associated with PM (privacy, discrimination, physician-patient
relationships and liability); and concerns about the potential of PM to aggravate disparities in
healthcare (the input-output problem, cost, and access to healthcare and access to information
technologies).80 According to Phillip Fasano, data shows that about 1.5 million preventable drug
errors occur in the United States each year killing 100,000, and doctors can reduce this by 55
percent by adopting EHRs and electronic prescription. Fasano adds that integration of such
technologies into health systems can result in a more affordable healthcare by all. Fasano
highlights that cost savings for PM can be hard to calculate, since prevention and preventive care
cannot be patented like blockbuster drugs or design for high-tech MRI machine.81 Although the
US and other countries are investing in multibillion-dollar projects to implement effective EHRs,
according to Mirnezami et al., it is unclear how effective this system will be in terms of
performing genetic tests, since EHRs have been reported by physicians in a survey, as poor
system for online test ordering, and not optimal CDS tool.82 Additionally, EHRs raises increased
privacy risk since EHRs are typically comprehensive, and contain records over an extended
period, with the ability to instantaneously distribute the information to multiple parties.
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As highlighted by Brothers and Rothstein, protection of informational health privacy is of
utmost importance; inappropriate disclosure of sensitive information may cause individuals to
suffer from embarrassment, stigma, discrimination and other harms to their dignity. They also
add that improper disclosure of sensitive information may result in receiving poor quality of
healthcare because of stigmatization or discrimination by providers (such as withholding specific
information). Moreover, the scholars add that public health harms are feared due to loss of
privacy, thereby resulting in individuals to decline treatment for infectious diseases, mental
illnesses, substance abuse or other sensitive conditions.83 Kimberly Shoenbill et al. point that
ethical issue surrounding genetic data adds to the risks. Potential benefits are outweighed by data
that are not clinically and analytically valid; and inaccurate data will have negative consequences
in guiding care, and will likely be harmful. Shoenbill et al. highlight that health information
technology (HIT) professionals will have more responsibility in ensuring data protection; by
making sure that effective data security and governance are put in place. 84
Fasano states that “big data” – large databases and care registries – are the big thing that
people are talking about today – that allow for the amass and analyzing of massive amounts of
data searching for breakthroughs in the treatment, prevention or prediction of illness.85 He adds
that advances in technology have provided many benefits, such as benefits after disasters - the
aftermath of Hurricane Katrina led to the panicking of medical staff over effects of the hurricane
on access of patient records.86 According to estimates from economists of RAND Corporation,
the potential for health benefits for using technology in healthcare for the entire nation was
staggering.87 They estimated a 2.2 fewer million drug errors, preventable medical errors slashed
significantly, saving lives and money by 4.5 billion to be precise. Fasano adds that the
computerized monitoring system could find millions of people 65 and up who did not receive
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important vaccinations such as influenza and pneumonia saving 20-38000 lives, and also alerting
those who have not received screening for colon and breast cancer, can help by detecting cancer
earlier so that it can be in treatable stages.88 However, big data can only be successful if it can
ensure security and privacy of personal data.89 Per Abouelmehdi et al., big data analytics “carries
many benefits, promises and presents great potential for transforming healthcare, yet it raises
manifold barriers and challenges.” They point out that new information systems and approaches
are needed to prevent breaches of sensitive information and other types of security incidents to
make effective use of the big healthcare data.90
Mirnezami et al. note that the physician-patient relationship will also be affected by PM especially on time-pressured clinical encounters, and on eliciting FH. The scholars point out that
there may be possibilities that PCPs will make trade-offs, such as spending less time on some
patient complaints, in order to spend more time on others. They add that this might lead to an
unsatisfactory physician-patient relationship, as well as the possibility that certain signs of
conditions may be overlooked until they become more serious. They add that healthcare
professionals will also need better training in order to be prepared for PM. International-Level
attention would probably be beneficial both nationally, as well as globally.91 Lack of counseling
services, as well as patients having to assume larger roles in their own health management may
be another issue faced by patients.92 The development of PM will almost certainly increase
personal injury litigation in the United States. It is feared that greater complexity of
systems/technologies will lead to increased risks for errors by providers, and this will cause more
harm to the patient and create the potential for liabilities for the providers. It has been well
documented that many physicians lack formal training and experience in the fast-moving field of
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precision medicine, thereby, raising concerns regarding their ability to meet a changing and more
demanding standard of care.93
Scholars voice their concerns regarding the advances in technologies which have led to
the commercialization and easy access to tools, such as Direct-to-Customer (DTC) genetic tests,
that can exploit people's lack of awareness. Patients' will need to adapt to key changes that
include monitoring and managing their own health in the era of PM. Mirnezami et al. voice their
concern that such detailed, open-access molecular information raises critical ethical questions
regarding data handling and privacy, and therefore, strict regulation will be needed in providing
the security. They argue that unless implementation processes to safeguard against the marketing
and distribution of bogus products are put in place, PM and other scientific approaches will have
no clinical effectiveness, and will create mistrust, and also affect the patient-doctor relationship.
Therefore, PM will warrant for unprecedented collaboration among all healthcare stakeholders. 94
Stratification of patients in PM raises critical ethical issues. According to Jason N.
Batten, dividing patients into smaller subgroups for targeted interventions allows scientists, to
differentiate between the genetic variations responsible for the disease, and allow them to
develop treatments that are effective for those particular groups of patients.95 However, this also
causes concerns for stigmatization, discrimination, as well as labeling of people in a socially
undesirable category or as “untreatable” – which becomes sensitive information. Batten adds that
clinicians also face ethical challenges in deciding whether to generate and disclose certain
prognostic estimates.96 Per Jason N. Batten, obtaining the data in PM is also ethically
challenging, since at times the data is collected at great cost- even harm - to patients, raising
questions about benefits versus harms in the implementation of a stratified approach to patient
care. Notions of informed consent also poses challenges in PM, since there are many
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unanticipated uses of the data collected that gives rise to unanticipated results.97 The possibility
of losing the person amidst the data is also a critical issue.98
As of today, PM has not been able to deliver on its promises of providing better-targeted
treatment with lower costs. Neither has it been able to provide the targeted treatments to causes
of illness that are hard to treat – such as rare diseases. Tabor and Goldenberg write that more
than 25 million Americans suffer from over 7,000 rare conditions, with an incidence of 1 in
200,000 or less. However, PM has only focused on approaches to studying more common
complex conditions such as heart disease, diabetes, and high blood pressure. Unless PM starts
addressing these conditions, PM will fall short of the promise it made to targeted treatment to
rare diseases, and will lose public trust.99 Tabor and Goldenberg have noted that access to
therapeutic innovations, still remain inaccessible, and raises ethical issues. They cite the example
of Nusinersen for the treatment of spinal muscular atrophy (SMA) - a rare recessive
neuromuscular condition cited as the most common cause of death in infants in the United States.
They state that the cost of Nusinersen ($370,000 per year for life, after $750,000 in the first
year), and the way it is administered (intrathecally), raises issues of how beneficial this “miracle
drug” is, when patients cannot afford it even though it is lifesaving. Tabor and Goldenberg state
that Nusinersen for SMA is just one of the recent examples of innovative targeted and precise
therapies based on a genetic diagnosis that have had implications for patients beyond
effectiveness. However, this demonstrates how high-cost and high-risk interventions are only
available to those with power, money, and access, and will likely exacerbate existing health
disparities and potentially exacerbate the burdens of specific diseases or disease risks.100
Given the history of minority groups' experience in unequal and unethical treatment in
research in the US, there exists a certain degree of mistrust of the medical and scientific
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community, which resulted in a low enrollment rate of African Americans and other minority
groups in many research studies. Furthermore, concerns of minority groups in the US include
unjust distribution of new resources, and the potential for genetic enhancements are anticipated
actually to exacerbate these disparities. Hildebrandt and Marron state that with the advances of
precision medicine technologies such as CRISPR/Cas9, such concerns must be taken care of
during the enrollment phase of new trials of CRISPR/Cas9 to warrant the adequate
representation of minority patients; and ensure that these historically mistreated groups are
provided with the adequate protection as well.101 Hildebrandt and Marron note that minorities
have been underrepresented in research; and if there is not adequate range of clinical variants it
will not be feasible to tailor therapies that are specific for the minority population; and
consequently, underrepresented minorities will miss out on potential gene therapy benefits.102 It
is also feared that gene therapies, once commercially available will exacerbate the gap between
the wealthy and the poor. Per Hildebrandt and Marron, some of this inequity in access is
hypothesized to be a result of conscious or subconscious racism and differential treatment in
medicine as well.103
It has been hoped that PM will contribute to the elimination of health disparities.
Unfortunately, many critics have argued that PM can exacerbate health disparities instead of
alleviating disparities. Brothers and Rothstein observe that the collection of medical data and
access to health services, and information technologies in healthcare will likely escalate the
disparities that already exist. They argue that much work that focuses on disparities within
communities, as well as fair access to healthcare globally will be needed.104 Opponents of PM
argue that work to explain race-based health disparities have inadvertently bolstered the mistaken
belief that racial groupings can simply be used to generalize the biological realities. They argue
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that highlighting genetics as an important route to addressing health disparities may only obscure
the importance of social, cultural and economic factors in perpetuating disparities.105 The next
section will look at the controversial issues that are anticipated to arise in healthcare, the
implications of transformation and the institutional solutions that can address the issues.
7.3. Controversial Issues and Healthcare
The advancement of medical progress raises issues of costs and inequities due to
technological innovations. Advancement in research in PM leads to the creation of extensive new
knowledge, and more future knowledge - making enhanced health a moral obligation. Craig E.
Johnson states that “healthcare organizations must be led and managed with integrity and
consistent adherence to organizational values, and professional, and ethical standards” - in order
to identify and address ethical challenges that can stem from various areas, and affect multiple
stakeholders. According to Craig E. Johnson, organizations run into trouble when they fail to
identify, and communicate their core values, or fail to live up to them. 106 There needs to be an
organizational culture in place that not only provides high quality, value-driven healthcare but
also promotes the ethical behavior and practices of individuals throughout the organization,
allowing the organization to act as a moral agent.107 This section looks at the implications of the
transformation of HCOs - in the form of issues, as HCOs prepares to integrate precision
medicine - and the possible institutional solutions. 108
7.3.1. Implications of Transformation – Moral Expectations
Scholars like Gallagher and Goodstein observe, the changing structure of healthcare
delivery from community institutions to modern technological corporations that offer the
residents of a community a collection of diagnostic and therapeutic interventions, has led to the
emergence of organizational ethics issues.109 They further note, in order to sustain this transition
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while maintaining the quality of services, and keeping up with the costs, HCOs are struggling to
assess and manage their duties to an ever-expanding array of stakeholders which include health
care professionals, subscribers, and the community.110 With the recent advances in genomic
sequencing and PM, Hazin et al. point out that there needs to be a lot of technological
innovations incorporated – such as the EHR system. The EHR is anticipated to be critical in
optimally using genomic information for the diagnosis, treatment, and prevention of disease that
will allow the potential of genomic medicine to improve patient care outcomes, and lower
healthcare costs.111 However, they also note that existing EHR systems are yet to be ready and
will need remodeling to include genomic clinical decision support tools, to provide point-of-care
tools to physicians to practice genomic medicine. By ensuring health interventions are tailored
to individual's genetic makeup, the scholars are optimistic that PM will be able to reduce health
disparities in the U.S. 112
According to Hazin et al. EHR integrated with decision support tools will be critical to
enable PCPs to use genomic medicine at the point-of-care. However, they also note that
integrating EHR geared towards PM also has ethical implications – on patient autonomy,
confidentiality, privacy, and the obligations of the physician. The scholars emphasize that the
genomic data must be protected and needs security measures that protect the information that is
stored within the HCO, but also the information that is exchanged among institutions, and with
patients.113 They highly recommend that there is a fair balance between the need to improve
healthcare and the need to reduce potential harm before genomics can be implemented into
healthcare settings.114 Dale Fischer et al. have observed that HCOs has been focusing attention
on the moral issues associated with the anticipated transformation required in the future
implementation of PM in healthcare. They highlight community benefits should be construed as
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a fundamental mission of the HCOs. The development of new therapies, technology, and societal
expectations will open up the opportunity for more individuals to participate as information
becomes more freely available, and inequality will be less acceptable. HCOs must recognize that
the modern consumers will take control of their data and wellbeing and in the decision-making
of treatment plans in the era of PM, shifting the way healthcare is delivered today. Thus, ethics
and legislation will increasingly be a part of the healthcare delivery process. 115 As pointed by
Mary J. McDonough, the traditions of Catholic social teachings will continue to be critical of the
market system for its failure of injustice, as the distribution of healthcare remain a critical issue
with continued rising costs exacerbating equity issues.116
Rivers and Glover note that quality of healthcare, in healthcare, is defined as the
avoidance of death or increases in favorable outcomes. 117 Satisfaction with healthcare is closely
related to concepts of healthcare quality.118 According to Rivers and Glover, the organizational
mission is what defines what the organization can do about the quality and costs; and also sets
the basic values and principles to guide how services will be delivered. 119 In the transformation
process, the HCOs mission and goals will be critical since it will provide a general direction
regarding the quality of health and costs that also reflects the overall organizational internal
environment. 120 Advancement of PM will lead to the powerful forces of change within the
American healthcare system. As Baily et al. note, the transformation of healthcare management
and delivery taking place through healthcare Quality Improvement (QI) raises ethical issues
since QI attempts to improve the quality of care for patients may not be equal or equitable.121 QI
in healthcare takes many forms, and while QI uses a wide variety of methods, they all involve
deliberate actions to improve care, guided by data reflecting the effects. 122
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According to Abouelmehdi et al., improved technology has had an impact already in
HCOs. The advanced adoption of automation, for example, has led to improved patient care
workflow and reduced costs in healthcare settings. However, the scholars note that it has also
raised concerns for increased probability of security and privacy breaches in healthcare data.
According to the CynergisTek’s Redspin, 2016, 7th Annual Breach Report: Protected Health
Information (PHI), hacking attacks on healthcare providers had increased 320% in 2016, and
81% of records breached in 2016 resulted from hacking attacks alone. Additionally, ransomware
- a type of malware that encrypts data and holds it hostage until a ransom demand is met - was
“identified as the most prominent threat to hospitals.” Abouelmehdi et al. state that findings from
this Report point to the pressing need for healthcare settings to take stronger, comprehensive
approach to protect their information assets, and fight cyber-attacks that are a threat to
healthcare.123
According to Hollister and Bonham, EHRs are critical in PM research programs, since
they contain all the essential data collected through patient’s visits. Considerable challenges arise
due to inaccuracies in data recorded and inconsistencies across different EHRs, which limit the
usefulness and applicability of PM research.124 The scholars also point out that PM research
initiatives can also inadvertently cause harm unless they carefully consider the recording of data
without variation throughout the EHR systems.125 As the scholars point out that the inadvertent
inclusion or exclusion of data can limit the quality of the data, raising issues in PM research.
However, they also add that processes are put in place to make sure the data are carefully
collected from PM studies. 126 Hollister and Bonham point out that potential harm of exclusion or
inclusion can cause over representation or underrepresentation of populations, which can lead to
misleading/inaccurate conclusion of research studies.127 The scholars recommend that
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researchers should be mindful of the data and use it in such a way so as not widen the existing
injustices in healthcare. 128
Advances in automation technology and tools used in healthcare have raised many
concerns. Abouelmehdi et al. lists the privacy and security concerns in big data as the most
highlighted concern for HCOs. They state that healthcare organizations collect, store, maintain
and share vast amounts of data in order to deliver the optimum care it promises its users - data
that are sensitive information about personally identifiable healthcare information, that are
entrusted by patients and must be protected by the HCO. Abouelmehdi et al. point out, while
there are policies and governance in place that establish authorization required to ensure that
patients' personal information is being collected, shared and utilized in the right ways - security
for protecting these data had been identified as being insufficient. They argue that HCOs are still
not adequately equipped with the necessary technical support to maintain the security of data,
and remain one of the most vulnerable targets of cyber-attacks to publicly disclosed data
breaches. 129 Abouelmehdi et al. also noted that attackers used data mining methods and
approaches to violate patient information, and therefore, HCOs should implement strong
healthcare data security solutions that will protect important assets, and also satisfy healthcare
compliance mandates. 130
Abouelmehdi et al. argue that security in big data should focus on three matters: data
security, access control, and information security. The scholars recommend that healthcare
organizations implement security measures and approaches to protect their big data, along with
the associated hardware and software, and clinical and administrative information from internal
and external risks.131 Abouelmehdi et al. have also noted several successful initiatives
recommended by President Obama’s Counselor, John Podesta: 1. A policy should be
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implemented to focus more on the actual uses of big data and less on its collection and analysis.
2. Policy concerning privacy protection should address the purpose. 3. Research on privacy
protection needed, that can keep up with changes, and create appropriate balance among
economic opportunities, national priorities, and privacy. 4. More education and training
concerning privacy protection offered. 5. Privacy protections should be extended to non- US
citizens since privacy is a worldwide concern.132 Creation of policies and mechanisms that
address threats and attacks in each step of big data life cycle was also recommended.133
In order for HCOs to address the critical issues of invasion of patient privacy due to
emergent threats and targeted attacks, Abouelmehdi et al. recommend that HCOs must ensure
that privacy of patient is secured and protected at every level of the processing model – ensure
that personal information is kept private even in the events of changes in applications and/or
privacy regulations. Because health-related data informatics varies by organizations and
countries, there should be laws to protect data privacy that extends worldwide.134 They point out
data protection regulations (De-identification, and Identity based anonymization) and laws in
most of the countries along with salient features are, however, the same. 135 Big data security and
privacy continue to be considered as huge obstacles for researchers in this field.136 As a word of
caution, the scholars add that even as costs for NGS diminish and confidence increases,
population screening to detect disease susceptibility raises serious ethical concerns:
overtreatment because of false positives; disparities in access to confirmatory follow-up,
counseling, and insurance reimbursement; privacy and discrimination. They suggest that
necessary public health education and intervention are put in place to educate people about the
risks and benefits of utilizing PM and in turn, improve an underperforming U.S. healthcare
system. 137
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7.3.2. Institutional Solution – Maintaining Ethical Mission
According to Magill and Lawrence, there is an urgent need for OE to help nurture
virtuous organizations, rich in stewardship and integrity. They argue that this will help with the
ethical decision making and standards of conduct of all throughout the organization, which will
be beneficial in regaining the lost trust, and also regain confidence with a renewed commitment
to ethics.138 Lee and Mongan also add that in order to be defined as a well-organized healthcare,
there needs to be a clear idea of what the greater organization means for hospitals, doctors, and
patients themselves.139 As Cornetta and Brown suggest that in order to communicate the goals
and basis of this technology, it will be important to understand the underlying psychosocial and
ethical challenges that may arise from this technology. They also suggest a societal dialogue
between various community members from different fields, which will not only be educational,
but also identify ethical and moral concerns and barriers.140
According to Magill and Lawrence, a slow erosion in HCOs results from loss of trust in
areas of access, cost, and quality. 141 Therefore, ethics will play a critical role in HCOs in
providing practical strategies that will guide healthcare leaders toward a better alignment
between institutions and communities –strategies that will emphasize stewardship and integrity,
as HCOs try to enhance patient care and improve healthcare services – that is embodied in its
mission, vision, governance, and leadership. Magill and Lawrence further add that an
organizational ethics strategy should be targeted toward compliance programs that focus on legal
and regulatory requirements - seeking to foster a virtuous organization whose ethical principles
inspire appropriate decision-making and moral behavior among all its personnel.142 From
research, it is evident that ethical companies actually have a higher probability of being
profitable, and that is because of the trust that is developed through the ethics - making ethical
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choices also result in lower stress for manager and employees since making decisions that
conflict with personal integrity or beliefs can be highly stressful and unnerving. Overall, as
Natcha Dolson highlight, ethical conduct builds trust among the team and business relationships
which will ultimately validate and promote good business practices which will lead to success.143
Gallagher and Goodstein view the preservation of institutional integrity as a central focus
for organizational ethics. They highlight the need to align organizational decisions and actions
with the organizational mission statement and core values.144 Moreover they add that successful
organizations demonstrate strategies that reflect core ideology mission and values that motivate
progress and change.145 Elizabeth D. Scott also mentions the need for strong leadership to rebuild
community’s trust through processes that enhance the quality of care. Scott emphasizes
organizational values as the driving force behind higher productivity, job satisfaction and
organizational as well as individual outcomes.146 Values as Scott explains is everything
(purposes) that is important for the organization’s survival and flourishing, and becomes
embedded in routines as part of the organization culture. Scott highlights that HCOs have many
purposes, but the most important purpose should be to provide good and just healthcare.147
Magill and Lawrence views organizational ethics as fundamental for guiding leaders
across the industry by encouraging a sense of stewardship and decision-making that fosters
shared standards of ethical conduct. They highlight that there is a core concern with fulfilling
critical responsibilities and ensuring that choices made on behalf of institutions are responsive to
the market, financial, and legal realities.148 The American society, according to Fillerman, Gary
L. eds., considers the provision of healthcare to all as a moral obligation, and it expects
healthcare to be safe, effective, patient-centered, timely, efficient and equitable.149 They further
add that HCO leaders have the ethical responsibilities to recognize and understand moral
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complexities and consequences to the decisions they make, and they have the responsibility to
nurture and maintain organizational culture. The authors emphasizes that ethical leadership can
make a significant impact - leaders need to ensure that the system they oversee function
productively, that they change alignment with their purposes and goals, and that they have a
framework in place that can identify, and address ethical or moral issues effectively. 150 Jahn M.
Buell writes that a framework that addresses ethical concerns in HCOs helps with making sure
that the organization’s intentions – its vision, mission, values, strategy, and goals are represented
in the daily works of the organization’s leadership and other staff. Buell states that all aspects of
performance are reflected by how well the organization has embodied its ethical principles into
action. Buell points out that it only takes a series of small, unnoticed acts to erode the ethical
behavior that can lead to disastrous consequences for both the organization and as well as the
staff. 151 Buell further recommends that organizations should harness ethical wisdom, which is
collection of knowledge, experience and good sense to make good ethical decisions, and
organizational leaders should take the necessary steps to ensure that an ethical culture is put in
place.152
As Williams highlight, active engagement of institutional leaders from different areas is a
critical attribute of the successful implementation of change in healthcare systems.153 According
to Castlen et al., the transformation in healthcare delivery using genomics and PM warrants a
great deal of change in conceptualizing patient/client management, which requires technology
that will expedite interpretation of test results in a useful manner for clinicians. EHRs will have
to be changed in order to accommodate the assessment of FH and other patient-reported
symptoms that will be crucial in the care delivery. Castlen et al. further emphasizes the
importance of dissemination and implementation of genomics information in the utilization of
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clinicians to deliver care, stating that implementation process must include staff and organization
in delivering the intervention, financial, and political implications as well as the extent to which
systems are driven to improve population health. However, they note a tension between
physicians and administrators that they stress must be resolved to achieve the most ethical
outcomes for patients. They suggest increasing physician leadership in hospitals to promote good
understanding and reduce the power struggle that exist between physicians and administrators.154
Scholars like Fassano emphasizes that money is still an issue in the implementation of
PM into healthcare setting – stating that this is mainly due to the lack of proper infrastructure,
and standardized process of data collection and interpretation, which creates an obstacle in
ensuring that the shared data is accurate, up-to-date, accessible and secure.155 He adds that
accurate data is vital for fewer medication errors, coordinated care, and customized treatments.
156

In order to change the healthcare culture to become technologically savvy in the era of PM, a

comprehensive culture change is necessary for technology values to be realized.157 Moreover,
Fassano stresses that it will also be essential to convince doctors that PM is worth their time and
money, and by giving them a system that is easy to use.158 He adds that ensuring that patient
information remains private and secure will be critical, and privacy and security conversations
are building a culture of shared responsibilities between payers, providers, and patients.159
Fasano highlights the role of funding in ushering in innovations, and that there will be a critical
need to connect financing systems that use IT to enable the flow of payment, create innovative
ways for providers to be paid based on performance and achievement of goals - making sure that
the payment and outcomes are aligned.160 Dolson further highlights the importance of HCO’s
need to fully understand ethics; and the organizations’ meeting the requirements of social
responsibility, integrating it into the organization's culture in such a way that it is at the forefront
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of all interactions and decisions. Dolson goes on to add that organizations do not need to decide
between being successful or ethical, but instead become successful by being ethical. 161
7.4. Building an Ethical Foundation
Fillerman, Gary L., eds., note that our societal expectations of organizations have
expanded so much that we now demand organizations, even for profits, to behave responsibly.162
This view is agreed by Sturmberg and Lanham, who adds that healthcare organizations are
expected to operate ethically, and in order to build an ethical healthcare organization, it is
important to understand the complex system of healthcare delivery - quality of care, financial
viability, and intervention success rates, these are all emergent properties of healthcare delivery
systems.163 We know that hospitals define themselves through their mission, and other
documents, such as their codes of ethics.164 The overriding mission, per Craig E. Johnson, is to
provide the best, most affordable healthcare ethically, with compassion, and empathy for its
patients. 165 Magill and Lawrence suggest that healthcare organizations need to embrace an
organizational ethics strategy that recognizes the significance of fostering a virtuous organization
to inspire the ethical conduct of its personnel. This section looks at simple guidelines that can
help build an ethical organization. 166
7.4.1. Challenges and Principles for Integrating PM
Agarwal et al. state that technology has advanced faster than peoples' understanding of
how it should be used. When medical technologies are expensive, and budgets are tight, it is
difficult to decide whether to spend dollars on more sophisticated, and costly technologies that
help only a selected few, or invest in the less costly preventive medicine, and health promotion
that have the potential to help many. Agarwal et al. goes on and add that although health IT
(HIT) has tremendous potential to improve the quality and reduce costs in healthcare, significant
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challenges will need to be overcome in order to realize the full potential of HIT.167 It is crucial
for HCO leaders to examine the ethical components of the many decisions, and choices
encountered in order to develop a more comprehensive response or approach.168 HCOs have to
maintain their quality of care, and remain faithful to their mission, while reducing their
spending.169 Moeckel et al. note that research and innovation in PM are growing rapidly.
However, its adoption into clinical practice has not kept pace with its advancement. In order for
healthcare to transition into precision medicine, Moeckel et al. state that stakeholders will need
to make a progression of strategies to create a momentum. Moreover, Moeckel et al. note that
evidence indicates that in most cases PM is not even discussed at the point-of-care, and
according to a recent public survey, only four out of ten consumers are aware of precision
medicine, and only 11% of patients say their doctor has discussed, or recommended precision
medicine treatment options to them. 170
Moeckel et al. also state that practices and standards associated with the field of PM were
cited as the lag in clinical adoption of PM. While there are many programs, such as the
Personalized Medicine Coalition's (PMC) Healthcare Working Group (HWG), that has
facilitated a dialogue about how to incorporate genomic information into healthcare practice,
Moeckel et al. note that recent surveys showed that most healthcare organizations are not ready
to implement PM. PMC's HWG has identified common challenges involved in developing
precision medicine programs and the most promising strategies for addressing them.171
According to Moeckel et al., the following principles were recommended in order to integrate
PM into healthcare practice: 1. Development and application of effective healthcare delivery
infrastructure and data management systems so that it can be used to guide clinical decisions. 2.
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Establishment and implementation of best practices for healthcare delivery approaches,
processes and program operations that ensure access to PM.172
Moeckel et al. write that overcoming challenges in integrating PM will require near-term
strategies as well as long-term strategies. They suggests making progress in addressing
challenges that are easier first, thereby clearing the path to address more difficult challenges
later. They state that this will foster behavioral adaptation to PM as well. 173 Magill and
Lawrence emphasize the integration of stewardship and integrity with the decision-making
processes, and ethical behavior for organizational ethics in healthcare. They point out that for
HCOs to address ethical challenges, the decision-making process must emphasize the
identification of a specific problem; and resolution of the problem in an ethical manner.
Moreover, Magill and Lawrence recommend that HCOs develop and adopt a standard of conduct
that will enhance performance improvement throughout the organization, which will also be
integrated with the guidelines for stewardship and integrity that fosters the ethical decisionmaking processes. 174
Scholars like Grigorean et al. argue that in order to make the applications of
organizational ethics work, it is essential to set policies and procedures that include: (1) Ways of
solving ethical dilemmas; (2) The framework for developing ethics – oriented trainings; (3)
Ways of repaying ethical behaviors; (4) Consequences of violating ethical principles; (5) Ways
to solve employee complaints; (6) The implementation of a hotline used to report anonymously
suspicious unethical activities; (7) Activities to promote hospital organizational ethics contribute
to the creation of an ethical climate.175 Moreover, Grigorean et al. add that it is evident that the
HCOs will have to identify and address ethical issues related to the changes considering the
advances in medical technology. They further highlight the need to establish ethics committees
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in healthcare organizations, as an integrative component of hospital operations, authorized to
solve ethical issues wherever these might occur.176
Ethics committees within HCOs are noted by Grigorean et al., to be beneficial not only in
influencing the quality of care but also in aiding with the transformation, and addressing any
issues that may arise in the process. The scholars add that ethics committees in the US have
grown significantly from 1% in 1983 to 60% in 1989, and this percentage stepped over 90% in
1998. In 1992, the Commission on Accreditation of Healthcare Organizations (CAHO) of the
United States of America demanded from institutions to implement specific mechanisms
dedicated to ethical issues. Scholars highlight two main functions of the ethical committee:
- Acts in order to be compatible with the official regulations of the state and connected agencies;
- Offers a consultancy environment for ethically complicated situations which may occur either
during patient treatment or medical research. 177 The scholars further goes on the explain that the
aim of the ethical committees all over the nation is to elaborate clinical healthcare policies is
higher than estimated, as they have an important role in debating and solving medical and
clinical policies and cases. They add that many of the EC policies refer to important aspects of
medical policies, which apply not only to institutions but also to taxpayers, patients, and society.
The scholars assert that ECs play an important part in the medical system and are an essential
feature of hospital efforts to control complex ethical problems.178
As Sahini et al. point out that previously the adoption and management of healthcare IT
was left on the organization's chief information officer and other technical personnel, which in
their opinion were not successful. They cite that Boston Medical Center, Geisinger Health
System in Pennsylvania, Intermountain, Mayo Clinic, and New York University (NYU) Langone
Health, are all examples of organizations that had successful healthcare IT implementation by
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allowing all members to work in the implementation process. The scholars further add that senior
leaders and clinicians are essential constituents in the successful implementation; and
organizations should make pledges to improve quality that are more than words and are
visible.179 Sahini et al. suggests that senior leaders should not only encourage the development of
the necessary data infrastructure but also help establish a vision for how the collected data will
be used to improve productivity.180 The scholars point out that HIT systems also offer HCOs the
use of predictive analytics to guide future decision making in clinical operations. Predictive
models in precision medicine, according to the scholars, will be used to correlate particular
genetic mutations with specific forms of treatment.181 They also highlight the need for
specialized teams of clinical personnel to give meaning to the insights from the analyses to
delivering improved care.182
Castlen et al. argue that HCOs are continuously faced with the daunting task to reduce
costs and maximize efficiency. Administrators try to identify factors that can reduce spending
without adversely affecting patient care – which the scholars observed leads to physicians feeling
their role as caregivers being curtailed, and often leads to attempts to obstruct or resist changes.
They argue that physicians, administrators, and society at large desire just and excellent care for
patients, therefore, implementation of new procedures and policies and well-developed
guidelines will be needed to helpfully standardize the procedures, without impacting the doctorpatient decision-making process.183 According to scholars like White et al., there will also be a
critical need for the integration between informatics and interprofessional practice and
interprofessional education (IPE/IPP) that will be needed in the implementation process of
PM.184 In their opinion, the biggest challenge in developing solutions will be fostering
collaboration between the actors, processes and the context.185
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7.4.2. Building the Infrastructure to Support PM
Lee and Mongam note, for PM to work effectively, all the components of the US
healthcare system need to move from a fragmented system into a system that collaborates to
work together.186 There are a lot of complexities and costs associated with the operation of our
healthcare delivery system. In the era of PM, where genetics information will be crucial for
clinical decision-making, foundational changes in the infrastructure and mechanism for the
collection, management and sharing of the data will be necessary. As scholars like Samuel J.
Aronson and Heidi L. Rehm add, even though understanding of the genetic makeup is critical in
PM for providing care, clinicians will have the support of tests and tools that will match genetic
determinants to the patients. They also add that, simply matching variants will not be sufficient;
clinicians will need to determine the implications associated with the clinical indications, and
cross checked with other data to determine the best treatment plan for the patient. 187 A policy
must be put in place in order to avoid convoluted procedures and undesirable consequences on
individuals and institutes.188
An optimized infrastructure designed to support the precision medicine ecosystem
efficiently will manage and integrate the flow of material, knowledge, and data needed to
generate, validate, store, refine and apply clinical interpretations. EHRs and associated systems
will enable clinicians to apply results, both when they are received and as the patient’s condition
and knowledge of the variants evolve. At present, much of this infrastructure is at a very early
stage of development. However, the infrastructural foundation for precision medicine is
beginning to emerge.189 EHRs should serve as the clinician’s gateway to all of the patient’s
information, including any genetic data. Information should be organized and displayed in a way
that integrates with the clinician’s workflow and facilitates diagnostic and treatment decisions.
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Creating these interfaces often involves establishing electronic connections that span multiple
organizations and integrate systems from competing vendors. At this stage, only a few interfaces
exist due to costs associated with creating them. 190 Clinical knowledge-sharing infrastructure
and case repositories, especially when combined with EHR-derived content, can provide
clinicians and clinical laboratories not only with unprecedented access to clinical data, but also
make this information accessible to researchers. Improved infrastructure to capture both test
results and patient outcomes should enable the measurement of such benefits. 191
Moeckel et al. point out that effective strategies are needed in order to manage the large
volumes of information associated with PM. They add that strategies that combine efforts to
understand the different perspective of stakeholders and structured collaborations among
healthcare organizations can be a good starting point.192 Although health systems are challenged
with managing performance, the scholars observed that most organizations do not have a clear
understanding of how to address them.193 They highlight that HCOs must recognize the need for
increased use of data and analytics to improve strategic decision making in the era of PM. They
noted that 90 percent of CFOs and other senior finance executives in a survey in 2018 stated a
need for improved analytics and reporting for strategic decision making. 96 percent of the senior
finance executives, in the same survey, also acknowledged that cost transformation would be
significant for their organization. According to Seargeant and Spence: “leveraging data and
analytics to know where to focus cost efforts was the most commonly cited impediment to
achieving cost-reduction goals” - thereby “identifying and managing cost-reduction initiatives”
have been identified as “the most important performance management activity.” 194
Seargeant and Spence further note the importance of having cost benchmarking processes
in HCOs. The scholars state that benchmark-rich databases and analytic tools are essential in the
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successful operation of a HCO, since these tools can help assess strategic performance that will
drive the required transformation of care, quality, costs, and patient experience. They further
highlight that benchmark-based reports and scorecards can help leadership observe: “patterns of
performance that impact utilization, cost, quality, outcomes, and patient experience based on
factors such as diagnosis, comorbidities, treatment type, department, and physician.” They add
that other areas can also be targeted for improvement, and best practices can be developed from
areas of outstanding performance.195 Seargent and Spence noted from a survey that about: “18
percent did not perform any cost benchmarking.” However, they recommend all HCOs should
benchmark quality and cost performance to understand their competitive position. They also
recommended the redesigning of HCO’s financial planning process to identify appropriate
strategies that will move forward their organizations’ missions and other objectives. Seargent
and Spence suggest a “continuous measurement of performance” to ensure that the strategies
meet the expectations.196
Seargent and Spence further notes that the current healthcare environment addresses
multiple challenges related to changing payment and delivery models. There is a need for robust
performance management in order for organizational transformation. Per Seargent and Spence,
“finance leaders have a pivotal role to play” in the reduction of risks and centers on building
organizational agility in order to prepare the organization for changes. They also add that:
“Agility is enhanced through high-quality enterprise performance management processes and
tools that enable finance professionals to develop scenarios, set targets, track and communicate
progress towards goals.” 197 Additionally, Seargent and Spence specify the need for significant
new talent with expertise in areas that can keep up with the organizational agility and valuebased care delivery, as well as data analytics and technology to transform costs.198
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Research has demonstrated that there is a clear need for a dominant organizational culture
and ethical leadership in the era of precision medicine, especially in the adoption of the
technology.199 Manion et al. views ethical leadership as an essential component in organizations,
because leaders who strive for ethical conduct motivate followers to pursue ethical ways, and
also involves strategic planning process so that policies, decision-making processes,
consultation, accountability, ethical standards are put in place for guidance.200 They also add that
ethical leadership includes communication, collaboration, quality, succession planning, and
tenure.201 Lepore et al. note that organizational culture will be a crucial factor in understanding
the ability of any organization to perform and compete.202 Davies et al. explain that cultural
transformation must employ strategies that are highly selective, aims for a balance between
continuity and renewal, and identifies those cultural aspects to keep and reinforce, and those that
need to be reworked. 203 They point out that the organizational culture cannot be tackled in
isolation from such issues as the organizational structure, financial arrangements, lines of control
and accountability, strategy formulation, or human resource management initiatives.204 Davies et
al. emphasizes that the organizational culture must have a bearing on the clinical performance
and healthcare quality, and identify interventions and management strategies that can be
predictive of cultural attributable impacts in performance improvements.205
Scholars like Berkman et al. and Mackert et al., state that HCOs must take into account
the importance of literacy of the technology and tools used in the era of PM, and that health
literacy is tied to the acceptance of the technologies and tools, and is an essential factor in patient
health outcomes and results in health care costs. 206, 207 Hennemann et al. add that HCOs need to
understand that employees, staff and other stakeholders need to have adequate familiarity with
the meaning of language surrounding new technologies. They note that common disadvantages
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reported for such technologies in healthcare by providers are lack of guidance through a
therapeutic relationship, limitation of communication, and control or concerns about data
security. 208 Moreover, they add that healthcare professional attitudes towards the technology
were also identified as indicators whether the tool would be used or not. 209 Thy pointed out that
different healthcare professionals such as nurses and physicians also have roles as educators and
patient advocates and will need to be properly educated and trained in genomics and informatics
tools employed in PM to be able to understand the genomic language used in the practice
innovation.210 With the completion of the HGP, healthcare professionals face the challenges of
enormous change in practice, and may not be adequately prepared to address the challenges.
Given the psycho-social, and familial implications of genetic tests and screenings in PM,
scholars like Ishveen and Kelly argue that healthcare professionals will need education in
genomics and also ethics for the proper delivery of care in PM.211 Williams et al. also add that
the implementation process will not be optimal unless the participants as well as the institutional
leaders are aware of the PM approach and the benefits and the harms associated with the tests
involved.212
Conclusion
In healthcare, there are a lot of ethical issues that are dealt with every day, which must be
addressed in a well-reasoned way.213 Conflicts might arise among the mission, vision and patient
right statements due to many reasons, and may have ethical ramifications if the ethical standards
are undermined.214 Protecting patient information will be at the core of an ethical healthcare
organization. However, a well-organized healthcare system will ensure that the staff is well
educated about the needs of the organization, and ensure that both clinical and nonclinical staffs
are knowledgeable and involved in ethics and ethical decision-making without fear of reprisals
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for contrary opinion.215 As Sahini et al. writes that there will be constant challenges to revamp
the organization with new technologies in the era of PM. However, the top executives, the board
of trustees, physicians, and nurses will all have to work together to support these drive to
improve care.216
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Chapter 8: Education and Competency Rich in Genomics and Ethics is a Necessity for
Healthcare Professionals in the Era of PM
8.1. Introduction
Advances in genomics are anticipated to contribute to the development of more effective,
personalized approaches to the prevention and treatment of infectious diseases.1 Such potential
tailored interventions for particular individuals, populations or subpopulations, raises ethical,
legal and social implications (ELSIs) that requires good understanding of genomics as well as
ethical principles in order to address issues and utilize this translation of genomic information
into practice to provide patients, families, and communities with competent, safe, effective
healthcare.2 Recent studies that compare trends in the genetic curricula in the U.S. and Canadian
medical schools have demonstrated inadequate incorporation of genomics material into the
curriculum; as a result, the health care workforce is not adequately prepared to incorporate
genomics into regular practice in the era of PM. From studies, it has been identified that there is
a need for health provider education and competency rich in genomics and ethics. The purpose of
this Chapter is to look at existing educational standards and outline the specific needs and
challenges associated with advances of genomics and PM. This Chapter also proposes potential
approaches for educators to keep pace with this rapid advancement.
8.1.1 Era of PM - Knowledge of Genomics and Healthcare Professionals
Precision medicine (PM) uses various genomic, biomarker and drug metabolism
information to guide care for an individual patient in a precise manner.3 It encompasses various
diagnostic tools that measure drug metabolism, genetic risk for disease development, and tumor
type/markers that can guide better oncology treatments.4 As scholars like Terri A. Manolio et al.
and Adam C. Berger have pointed out in their respective studies, that the knowledge of this
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information and utilizing of this information has not kept pace in clinical practice; thereby
resulting in a substantial delay in the translation of genetic research findings into patient care
within the healthcare system.5, 6 In an era of PM, it is important to make sure our healthcare
workforce is adequately prepared to serve its population. This section looks at the knowledge
and confidence levels of healthcare professionals in genomics and PM, especially those who will
be in the first phase of interaction to initiate the process.
Despite the promises of PM, it faces several challenges, one of which has to do with the
human factor, and the lack of preparedness of the workforce.7 As Scholars like Dhar et al. point,
with the advances of genetic testing and genomic technology, it is now possible to have high
throughput sequencing of human genomes fast and at a low cost. Allowing it to be used to target
therapeutics, determine better prognosis by utilizing probabilistic risk assessment for many
conditions. It is not far away that practicing physicians will be utilizing these technologies and
making decisions based on the results generated for their patients in their practice.8 However,
training and education of genomics and genomic technologies used in PM have not kept pace
with the growing use of the application in clinical practice. Lack of provider awareness and
knowledge of genomic medicine has been reported by Plunkett-Rondeau et al. as a barrier to the
implementation of PM. A survey utilized in their study on primary care physicians (PCPs),
reported PCPs “lack knowledge of genetics relevant for daily practice, lack oversight of genetic
testing, and feel inadequate to deliver genetic services.”9 Paneque et al. also emphasized the need
for education around genetics and genomics - particularly, when and how to use genetic/genomic
testing – that this education extends across “continuing medical education programs, residency
and medical school levels, and all healthcare professions.” They also indicated that medical
students approaching graduation may not have appropriate mastery of critical genetics concepts,
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and that current physicians do not feel adequately trained in genetics and genomics, and few
PCPs are “comfortable ordering genomic tests or explaining test results to patients.”10
As the tools used in medicine is changing, so is the practice – making it difficult for
healthcare professionals to keep pace with the changes. As pointed out by Dhar et al., many
patients approach their primary care physicians (PCPs) for more information about the various
direct-to-consumer (DTC) genetic tests, and some even go to their PCP just to seek help in
“interpreting their test results.” However, Dhar et al. noted that PCPs felt they lacked the
knowledge or training to answer questions about DTC tests. Based on their study in 2012 on
2,402 primary care and internal medicine providers in North Carolina, of whom 382 responded,
only 38.7% were aware of DTC tests and of those, only 15 % felt prepared to answer questions
about DTC results. Dhar et al. suggest that this lack of knowledge may perhaps be due to the
misconception that genetic tests are only of concern to specific specialties, “such as pediatrics
and prenatal obstetrics.” Regardless, Dhar et al. feel, PCPs need to be equipped with the
knowledge to critically assess and explain genetic test results to their patients, and need to know
when to refer patients for specialty care in medical genetics, and counseling.11
As Plunkett-Rondeau et al. pointed out that a large percentage of U.S. medical schools in
the past did not even offer a course in human genetics - in 1981, only 28% and in 1988, about
18% offered a course. However, Plunkett-Rondeau et al. also noted that studies from 2005
demonstrated that the numbers have vastly changed with the genetics education being
incorporated into the curriculum with the majority of medical genetics (about 77%) being taught
in the first year; with 47% incorporating aspects of medical genetics training into the third and
fourth years of study. Plunkett-Rondeau et al. also added that education in genetics has not kept
up with the various advances such as DNA sequencing, DTC personal genome testing, and the
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use of exome sequencing. And they report that, in order to help medical genetics education to
evolve with the changing scientific and educational landscapes the Association of Professors in
Human and Medical Genetics (APHMG) updated its medical school core curriculum in genetics,
using “the Accreditation Council for Graduate Medical Education competency domains,” as a
framework of principles that can be incorporated into a wide variety of curricular formats.12
According to studies, at least 10% of patients seen in primary care had conditions with
genetic influence. However, due to PCP's lack of knowledge of genomics and genetics, patients
at risk of genetic disease may not be recognized, while those who seek advice may not be
referred, or managed appropriately. As Paneque et al. pointed out that serious consequence can
result from undetected genetic risks, such as increased morbidity, mortality, family burden, and
healthcare costs. With the advancement and availability of genomic technologies in clinic as well
as individual DTC genomic tests, educators need to ensure appropriate coverage of genetics and
genomics topics in training future healthcare providers. 13, 14 Lack of PCP’s knowledge in
ordering genomic tests has been an indicator in lack of PCP’s confidence in ordering genomic
tests for patients. The next section looks at the confidence level of the workforce.
8.1.2. Confidence Level of the Work Force?
In the age of genomics, PCPs will be increasingly involved in preventive care and
management of relevant surveillance processes, creating pathways to deal with patient requests
regarding genetic tests. Primary care can be provided by a range of health professionals and is
defined by the World Health Organization (WHO) as healthcare: “that is directly accessible by
patients as the first point of contact, as well as being comprehensive and ongoing. It involves
prevention, and pre-symptomatic detection of disease, as well as early diagnosis, all of which are
relevant to patients at risk of genetic disease.” According to studies by Paneque et al., it was
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identified that PCPs had three main responsibilities in relation to genetics: “being able to identify
patients at risk of a condition; contributing to medical management; and appropriate
communication of genetic information to patients.” However, they voice their concern that
genetics education is only very slowly starting to become a common part of medical curricula,
and research demonstrates that PCPs are not ready for precision medicine in the clinical setting.15
According to scholars like Allison A. Vorderstrasse et al., personalized and precision
medicine will require the appropriate interpretation and clinical “use of novel and personalized
information” by healthcare professionals; and providing the adequate support for patient
decision-making while being attentive to family may raise ethical implications in the approach to
care.16 They add that given the amount and types of data that will be collected in EHRs with PM
strategies, healthcare professionals will need to look at ways to optimize the use of personal
patient data of multiple types in patient care.17 Suther and Goodson identified key areas that
PCPs lacked confidence in: lack of genetic knowledge, lack of interpreting family history, lack
of referral guidelines.18 With the recent cost reduction and availability of DTC genetic test kits
that enable people to receive a list of genetic illnesses and whole-genome testing for markers
thought to be predictive of traits and disorders and chronic illnesses - dilemmas arise when
consumers face ambiguous or alarming results needing expert interpretation from their PCPs.19
Per Keyan Salari, data suggests that the American public will turn to their PCPs when
faced with a dilemma. Salari adds that according to a study on 1000 individuals in the U.S., 72%
indicated they were ready to go to their PCPs with questions. However, evidence indicated that
although some physicians are equipped to interpret such reports, the majority of physicians lack
training to deal with these issues, and that patients were likely to be disappointed and
misinformed. Salari furthermore adds that another study showed that 64% of patients with
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genetic conditions received no genetics education materials from the healthcare provider, even
though that was the most important part in the management of their condition. Salari also noted
that educational materials mailed by genetic testing companies to practicing physicians, as
indicated in a study, proved ineffective, since over half of the physicians answered basic
questions related to genetic testing incorrectly. This is an indicator that more fundamental
training is required to enhance physician's knowledge about basic genetic testing, and their
ability to provide the counseling needed. And as Salari noted that it was indeed reported, 68% of
physicians in the study acknowledged an increased desire to learn more about genetic testing.
Moreover, physicians spend little or no time to elicit detailed or any patient family history, which
according to several studies was credited to hinder the effective utilization of genetic testing and
counseling. Salari asserts that these studies together suggest that many physicians need the
fundamental education and training in order to be adequately trained to appropriately order
simple single-gene tests or to interpret simple results, and also communicate the results to the
patients who requested the tests. Salari emphasizes that in order to utilize genomics in medicine,
physicians must be able to effectively use, evaluate and interpret the results.20
According to research, the majority of underutilization of genetic services by PCPs was
due to lack of adequate genetics information and knowledge.21 According to Jeanette J.
McCarthy, recent reports indicate that medical students approaching graduation may not have
appropriate mastery of critical genetics concepts, and that current physicians do not feel
adequately trained in genetics and genomics, and that few PCPs are comfortable ordering
genomic tests or explaining test results to patients. In fact, lack of provider awareness and
knowledge of genomic medicine has been reported as a barrier to PM’s implementation.22
According to the Centers for Disease Control and Prevention (CDC), genomics plays a role in
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“nine of the ten leading causes of death.” Katherine Johansen Taber points out that heart disease
and cancer are at the top of this list. She adds that although many physicians understand the
importance of correctly collected and interpreted family history in the revelation of risk for these
diseases, some do not realize that genomic applications beyond the family history are
recommended, and usually assist in the diagnosis and treatment of many disease areas. Currently,
Taber adds, there are more than 26,000 genetic tests that are available for over 5400 conditions,
many of which are for rare diseases. However, PCPs either lack the knowledge, or are not
adequately trained to utilize these tests.23
Studies have also reported that PCPs have been inconsistent with the use of FH. Suther
and Goodson add that insufficient time and lack of confidence have acted as barriers in the
proper elicitation and utilization of FH in the clinical settings, leading to the failure of
appropriate referrals. Accurate FH is important in the proper diagnosis and determination of risks
of genetic diseases. It has been identified that PCPs have difficulty with genetic referral
decisions unless the risk is either very low or very high. Moreover, Suther and Goodson add that
assessing and counseling about genetic risks requires knowing which choices are available, and
PCPs lacked information about genetic services and options available to patients.24According to
scholars like Guttmacher et al., “genomics-based knowledge and tools promise the ability to
approach each patient as the biological individual he or she is, thereby radically changing our
paradigms and improving efficacy.”25 Paneque et al. add that by raising PCPs' confidence
through education that includes genetics, they would be able to apply this into practice,
implement personalized genetic risk assessment for patients, and potentially increase
receptiveness to additional genetics education and training. Nonetheless Paneque et al. point out
that it has been identified by research that the self-confidence of PCPs in their ability to provide
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genetic healthcare are generally low. According to data, although primary care pediatricians in
the U.S. reported that they frequently managed children with genetic conditions - they did not
feel competent with the issues either. Paneque et al. also add that many had ordered genetic tests
and referred patients to a genetic specialist mainly because of parental queries, and because they
wanted to obtain information to better manage the conditions they were unsure of.26 As Paneque
et al. highlight, if PCPs stay “genetically uneducated and incompetent” related to the use of
genomic information in general practice, individual genetic medical care is likely to be
unhelpful, and may possibly be even harmful.27
8.2. Education of Healthcare Professionals
Elizabeth A. Nelson and Amy L. McGuire state that even though good medicine has
always been personalized, where physicians use their medical expertise based on applying
known data on lifestyle and health of individual patients; patients today are mostly interested in
the concept of "personalized"- that is based on individualized genetic and epigenetic profiles,
without the population-based benchmarks and generic side effects. Given the unprecedented
technological advances, especially with the completion of the HGP, it is only a matter of time
when genomics will be integrated into the regular clinical practice. Nonetheless, according to
Nelson and McGuire, studies suggest that most physicians are not adequately prepared for this
technology, and lack the knowledge to interpret even the simplest of genetic tests, and as a result
underutilize/or not utilize the resources. In order to prepare physicians for this new technology,
studies suggest courses in genetics be integrated throughout the entire medical school
curriculum.28 In anticipation of the impact genomics will have on the future of healthcare, all
actors need to be educated and trained in genomics. Collaboration between different actors from
across different specialties - their work integrated towards the delivery of safe and effective
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treatment - is critical.29 This section looks at the existing education curriculum, the gaps, and the
importance of ethics education in preparing healthcare professionals in genomics and precision
medicine.
8.2.1. Looking at the Existing Education Curriculum
As Hyland et al. note, because of the completion of HGP and the development of genomicbased technologies, many of the disciplines previously viewed as rare are no longer viewed as
that. However, a comprehensive understanding of the principles of genetics and genomics, from
basic science to clinical application will indeed be critical to preparing physicians with the skills
necessary to make informed decisions.30 PGx is a major constituent in PM, where the genetic
variations of human individuals can guide the selection of drugs in order to maximize useful
effects, and to minimize harmful side effects.31 C. Carlberg adds that the application of PM is
anticipated to allow earlier detection, and more effective treatment of diseases. The basics of
pharmacogenomics are included in most pharmacology curricula for students in medicine,
pharmacology, and other health sciences. However, Carlsberg adds that the current medical
students need to be trained to understand and use this information appropriately and responsibly.
They add that this adaptation of biomedical education will enable future health workers with the
knowledge, skills, and attitudes required to practice PM. In spite of the importance of genomics,
studies show the majority of medical schools have yet to incorporate genetic or genomic courses
into their curricula.32
Taber notes that the perception of clinical value of genetic tests and genomic technologies
also plays a critical role in the uptake of PM in the aftermath of the lack of a prepared workforce.
Since the new genomic technologies are supposed to empower physicians with the best possible
treatments for the individual patients, physicians need to see evidence and demonstrations that
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using these new tools will indeed improve the care and health of their patients, and indeed is
worth the time.33 PGx is a good example. As Grace M. Kuo et al. add, although PGx has the
potential to provide safe and effective drug management to provide personalized care “using the
right drug at the right dose to the right patient,” there are also uncertainties about its application
in clinical practice by providers, because of which PCPs do not take the time to train themselves
in using PGx – thus PGx remains underutilized.34 Moreover, as Katherine Johansen Taber
highlight findings from a survey of PCPs who did not order PGx testing - more than half
responded, that was because they were not sure what tests to order. She adds that it is not that the
lack of genomics knowledge equates to poor provider care, it only implies that the adequate
knowledge and training would have empowered them to deliver the best possible treatment. This
shows that the gap in genetics knowledge results in the inability to order and interpret genetic
testing, and referral to specialists and counseling.35
As McCarthy highlight, although genetics contents have increased in the undergraduate
curriculum, studies show that current educational approaches do not prepare students to practice
in a healthcare environment. A literature review identified a lack of knowledge and confidence in
addressing issues related to genetics in the clinical setting as impeding the progress of primary
care services. As McCarthy point out, it was found that fewer than 25% healthcare professionals
felt prepared or competent to order genetic tests even though they recognize the clinical
importance of genetic tests.36 Similar gaps in genetics knowledge among ‘‘internists and primary
care physicians,” and among both medical students and practicing physicians were also
identified in published studies.37 Moreover, Guttmacher et al. also noted that deficiencies in
genetics knowledge among medical personnel were not limited to students and practitioners, but
was also identified among senior medical officers in major health plans in the United States,
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which they say, will likely act as an impediment to the integration and reimbursement of genetics
services.38
According to Dr. Michael F. Murray, Director of Clinical Genomics at the Genomic
Medicine Institute of Geisinger Health System in Danville, Pennsylvania - there is no
standardized approach in the United States to genomic education for physicians. Even as of
today, most healthcare professionals, feel inadequately prepared for any large-scale application
of genomic medicine. It is true that medical schools have increased the amount of genomics they
incorporate into the curriculum, and more recent graduates have a more extensive educational
exposure to genomics. However, he adds that the educational programs vary widely for residents
and fellows in graduate medical education (GME) training, and are not consistent, and the level
of genomics education also differ among clinical specialties. Dr. Murray also add that generally,
providers are usually quick at grasping the working knowledge of laboratory test with use, but
with genomics and genetics most physicians do not order testing for patients - and surveys show
that a significant percentage of physicians admitted to not having adequate understanding of the
testing menu, or the specific indications for the tests. Without the inclusion of genomic medicine
in medical education, physicians will not be able to meet their patient’s demands.39
Carlberg adds that medical schools can supplement their curricula with learning
objectives that contain deeper understanding in the concepts of genetics and genomics (and
PGx), and training for their practical applications, such as translating the family genetic history
of a patient into choosing the most appropriate out of more than 2200 available genetic tests. He
adds that the students should learn how to interpret the statistical significance of such test results
in the context of the individual patient’s medical profile, select the best-suited drug, and to
calculate the adequate dose, respectively.40 As highlighted by Plunkett-Rondeau et al., data
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suggests that even though medical schools are integrating genetics and genomics into their
curriculum it is not occurring uniformly across all institutions, and because genetics typically
does not have a heavy weight on pre-clerkship hours, most institutions only have a small fraction
of genetics in the integrated examinations. As a result, they add that some graduates of medical
schools may be able to pass and move forward without meeting basic competencies in medical
genetics, and this is one of the reasons why most health care providers do not feel competent
utilizing genomics in their everyday practice.41
8.2.2. Ethics Education and its Applications in Medicine – Identifying Gaps
Precision medicine brings with it many ethical issues pertaining to individual as well as
familial issues. Physicians need to consider the ethical principles of autonomy, non-maleficence,
beneficence, and justice in the decision making process. With the dramatic effects of risk
predicting, genetic counselors will play a big role in the era of personalized medicine. As J. Ryan
et al. point out the philosophical underpinnings of genetic counseling practice are founded on
care-based and feminist ethics according to the National Society of Genetic Counselors Code of
Ethics. They add that counselors recognize the importance of the individual patient, or client
factors in providing care, and counseling; as well as the importance of broader-based contextual
relationships and factors that influence a person's needs, decision making and approach, keeping
in mind the genetic information and its impact on relatives. Ryan et al. also add that genetic
counselors understand the familial implications of genetic tests, and therefore consider both the
personal and familial aspects of such information. When appropriate and necessary, genetic
counselors encourage family members to be present during counseling appointments.42
In looking at the different areas of ethics, autonomy is a core concept embodied in the
code of Ethics by the National Society of Genetic Counselors. Autonomy relates to respecting
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individual's right and information that enables patients to make informed decisions. In genetic
counseling, it has a broader, relational approach as it takes into consideration familial values and
other relationships, while also recognizing the social and historical context. The principle of
avoiding harms - non-maleficence - relates to ensuring actions or services do not harm the
individual client. As J. Ryan et al. note, in personalized medicine, there are several potential
harms - the harm associated with the possibility of lacking adequate information may result in
the inability to make a fully informed choice regarding counseling. This can result in decreased
autonomy and potential emotional and psychological consequences. Ryan et al. also add that
these potential harms may be mitigated by the implementation of a “carefully considered service
model, grounded in the principles of care-based or feminist ethics.” Other harms cited are
consequences of psychiatric genetic counseling, that relate to increased fatalism or stigma that
could be associated with attributing illness to genetics.43
Moreover, Ryan et al. add that for genetic counselors the principle of beneficence need to
promote positive outcomes as well - through alleviating guilt by modifying clients’
understanding of cause of illness. Carefully implemented genetic counseling services, embody
beneficence by respecting and accommodating an individual's right to accurate information.
Attributing an illness to either genetics or the environment can have serious negative
consequences such as experiencing self-blame. 44 They add that overestimating and
underestimating risks can be problematic; this is where genetic counselors play a role in helping
clients make more fully informed decisions. The principle of justice in personalized medicine
relates to making genetic counseling services available equally to all, and making allocation of
resources within a health care system to all in a fair and just way.45
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There were gaps identified in the education of healthcare providers in genomics.
Although extensive genomic curricula have been developed for PhD students, nurses, and
pharmacists, a gap in genomic education in medical school curricula has been identified and
acknowledged that extends into many training areas.46 Scholars like Laudadio et al., have noted
the eight subject areas which were initially identified that can be used to address the gaps: “basic
genetics and genomic principles; ethical, legal, and social issues; sample acquisition; quality
assurance and validation; regulatory and compliance; testing and interpretation; reporting; and
patient management”.47 However, with the field of genomics evolving, one challenge will be in
keeping the educational material, as well as the educators of this curriculum up-to-date. They add
that the curriculum should be considered dynamic and should be reevaluated as needs change.
The genetics education that physicians-in-training typically receives in medical school and
graduate medical education is ill-suited for practicing PM. Laudadio et al. add that medical
schools should include in their curricula more basic science concepts in genetics and genomics,
as well as, practical training for the applications. Surprisingly, a recent study reported that only
11% of U.S. and Canadian medical schools had practical training as part of their curricula. 48
According to the NIH, medical education should include the principles of genetic
variation, and how to conduct and analyze genome-wide studies of complex diseases in the
human population. A set of core competencies in genetics were also identified by the National
Coalition for Health Professional Education in Genetics that all health professionals should
possess. Both these organizations offer valuable strategies that will serve as a strong starting
place for medical school, and graduate medical education reform.49 However, along with
fundamental training needs it has been identified that medical schools need to identify and
implement the most effective education models that will enable trainees with the required
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knowledge. According to a novel hands-on genomics course developed by Stanford University in
2010, it was demonstrated that medical students should also have the option to undergo personal
genome testing (PGT) as part of the course curriculum. Results from research on this training
demonstrated that students improved their understanding of genomics, and concepts of clinical
genomic testing. Salari et al. state that in order to realize the potential of genetics and genomics
in healthcare it is evident that medical trainees be provided with the proper educational
foundation that is continued throughout clinical training; and should include ethics education in
order to address the ethical, legal and psychosocial issues.50 Cornetta and Gunther also add that
medical curricula that actively combine holistic care (such as psychological, and spiritual) and
precision medicine will help create more empathic physicians, who will not only know when to
order genetic tests, but also know when their patients' need to be referred to counselors for
guidance and support. This combined approach will be ideal for the era of PM which will require
knowledge of PM and delivery of personalized care.51
8.3. Delivering Personalized Medicine on a Regular Basis
Advances in genetic knowledge and technologies are moving genetic issues into the basic
healthcare of every patient, accompanied by numerous ethical and professional challenges. As
noted by Matthew A. Bower et al., PCPs will be utilizing genetic services in providing and
referring patients to appropriate genetic tests and other services. Genetic counselors will likely be
called upon to educate PCPs about recognizing and resolving ethical dilemmas when patients
have genetic concerns. As the demand for genetic testing grows and expands into primary care,
Bower et al. add that it is highly likely that genetic counselors will run into more complex cases,
and they will need more training and readily available resources to address the ethical issues
inherent in these complex cases.52 Facilitating and supporting patient's informed decision making
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in PM involves understanding and delivering results specific to disease risk - which will be a
major challenge of genomic medicine in the clinical setting.53 The healthcare professional needs
to be prepared with advances of genomics as they arise on a constant basis. 54 Genetic counseling
with the unique skills and roles will also be an important part in the healthcare delivery because
of the ethical and professional challenges related to application of genetic testing and treatment. 55
The next section looks at genetic counseling and its role in delivering genomics in healthcare.
8.3.1. Comparing Genetic Counseling, and Delivering Genomics in Healthcare
As Heather Skirton et al. note The National Society of Genetic Counselors has defined
genetic counseling as a “process in aiding people to comprehend and adapt to the medical,
psychological and familial implications of genetic contribution to diseases.”56 Genetic
counseling is effective in enhancing healthcare systems and in coordinating genetics knowledge
in public health policies. Recent findings also conclude genetic counseling as an important tool
for the implementation of genetic disorders prevention strategies.57 Genetic counselors have
become an integral part of medical teams in many hospitals and clinics throughout the world due
to the ethical dilemmas associated with the provision of the services. Didactic preparation in
ethical reasoning and applied experience influences the ways in which genetic counselors
address challenging ethical dilemmas.58 Being responsive to client emotion, and enabling
cognitive processing, are both necessary to enable clients to process information and enable them
to use it effectively in decision making.59
According to Ormond, there are debates about what “genomic counseling” will include
and who will practice it in the era of full genomic medicine approach – the incorporation of
genomic medicine will create differences in the scope and approach of genetic counseling. 60
Amongst the many challenges, one crucial challenge for counselors will be discussing which
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incidental findings (if any) should be determined and returned to patients. It is important to
remember that patients will most likely not be familiar with the wide range of conditions, making
it more challenging to make informed decisions in this area.61 Ormond adds that genetic
counselor roles have expanded vastly from the original prenatal and pediatric genetic counselor
roles to specialty areas such as oncology, cardiology, neurology, as well as working as experts
with the non-geneticist specialist physician.62 As Bereshneh et al. point out that diagnosis in
medical genetics is vital because at least 10% of sperm and 25% of mature oocytes have
chromosome abnormality and about 20% of all known pregnancies end in spontaneous abortion.
Moreover they add, about 2-3% of infants have congenital malformations where genetic factors
are evident in more than half of them; and 5-10% of common cancers are genetically based.
They also add that there are over 21,000 diseases and single-gene traits registered up to now in
OMIM (Online Mendelian Inheritance in Man); and over 500 metabolic disorders with genetic
origin have been reported as of today. Diagnosis of medical genetics is becoming critical in the
early diagnosis of such inherited diseases.63
Counseling persons or families with genetic concerns frequently pose challenges to the
involved professionals who have to deal with often complex ethical situations. According to
Brigitte Gschmeidler & Magdalena Flatscher-Thoeni, a focus group study identified 16
ethical/professional domains encountered by genetic counselors in the United States: “informed
consent, withholding information, facing uncertainty, resource allocation, value conflicts,
directiveness/non-directiveness, determining the primary patient, professional identity issues,
emotional responses, diversity issues, confidentiality, attaining/maintaining proficiency,
professional misconduct, discrimination, colleague error, and documentation.” 64 As noted by
Alliman et al., although general healthcare goals may be similar across countries, practitioners’
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decisions regarding patient care may vary due to differences in their cultural, religious, spiritual,
and ethical values. The scholars add, as clinical genetic services evolve worldwide, genetic
counselors are playing an integral role in helping patients receive the necessary information to
make appropriate decisions.65
Alliman et al. also highlighted the areas of challenges and stated that, Informed Consent
issues raised ethical dilemmas concerning the patient’s ability to make voluntary decisions since
not all the information can be provided in some cases. They also noted that counselors also
questioned their own ability to present relevant material to those patients in an understandable
fashion. Issues involving consent in presymptomatic testing were also critical issues.66 Facing
Uncertainty was another domain that consisted ambiguity due to insufficient information about
the clinical utility of a genetic test result, interpretation regarding severity and unclear patient
care standards.67 Withholding Information raised question about whether to reveal unanticipated
information. This domain also includes situations in which a patient declines a genetic test result
that provides clinically valuable information. Diversity presented challenges to patient care
arising from differences in cultural, socioeconomic, religious, and/ or spiritual beliefs between
the patient and the counselor. Alliman et al. also pointed that in the area of Professional Identity
Issue, there were challenges regarding the professional role and the ambiguity that can result
from feeling “caught in the middle”, and a lack of appreciation for the unique skill set that
counselors bring to the clinical practice was often voiced in surveys.68
Directiveness/nondirectiveness involved situations in which genetic counselors questioned the
extent to which they should guide the patient in decision-making.69
According to Veach et al., Informed Consent will continue to be problematic as more
genetic tests and technologies enter the marketplace, and as companies begin to more
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aggressively market their products. According to a study on the scope of ethical and professional
issues that genetic counselors, physicians, and nurses faced, Informed Consent was the most
prevalent issue for all three professional groups - since it took on some unique aspects with
respect to genetic information. Informed Consent is usually equated with the information
provided, usually with regards to invasive procedures, in the present context it has to do with
information provision, which is complex with genetics and makes information provision a
critical issue. Moreover, Veach et al. noted that sometimes this information can have negative
emotional impact that the professional can do nothing about (such as no cure/treatment); and the
interpretation of genetic test results is not always black and white.70 Informed consent also raised
issues due to the fact genetic information was not always enough information and patients did
not always have the ability to understand the implications of the information.71 Bower et al. also
added that this was particularly challenging when it involved cases of presymptomatic testing
and genetic testing of minors. Results from a survey of 177 cases of APC (adenomatous
polyposis coli) gene testing indicated that only 16.9% of cases had obtained written informed
consent. Today, they added, brochures are provided by many companies and clinics to promote
and describe genetic testing. However, Bower et al. noted that only 10% of the examined
pamphlets from 125 organizations discussed the risks and benefits of genetic testing; very few
discussed the rights of patients or the intended use of the test; and only one pamphlet mentioned
insurance discrimination; and none mentioned the need for written informed consent prior to
testing. This clearly demonstrates the issues of patients not being fully informed about the
genetic tests prior to making decisions.72
According to Groepper et al., genetic counselors’ roles are expanding rapidly beyond the
clinical context due to the advancement of complex genetics and genetic testing, and as a result a
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growing percentage of genetic counselors are working in laboratory settings as well.73 According
to Alliman et al., the extensive role of genetic testing in clinical setting will need a reevaluation
of the direction for counselors. Currently, the National Human Genome Research Institute
recommends informing the individual about the purpose and medical implications of the test,
before any genetic test is performed/ordered. The most prevalent strategies recommended were
“Further discussion with patient, Consult with professional, and Referral to a professional.”74 As
Cornetta and Brown point out that not all genetic tests will require counseling of patients, neither
will it be practical. There will be a need for best practices for counseling and for creating
appropriate curriculum, and that can be accomplished by gathering input from PCPs.75
8.3.2. Existing Gaps between Genetic Counseling and Genomics in Future
In the era of PM there will be a critical need for appropriately educated genetic
counselors. Alarmingly, as Hazin et al. point out, there are only 3,026 board-certified genetic
counselors in the United States, with little effort to expand genetic counseling programs. This
lack of counselors will hinder the application of genomic testing in clinical practice.76 As
Michael L. Begleiter point out, only handful countries provide formal courses in genetic
counseling, while others leave genetic counseling in the hands of medical practitioners or
medical geneticists. Genetic counselors are uniquely trained to provide support, explanations and
guidance to individuals or families who have been diagnosed with a genetic disorder. The
completion of the HGP has resulted in the identification and amplification of testing for a variety
of genetic conditions, as a result of which there is a need for appropriately trained genetics
professionals to deliver this information to families, and to assist them in adjusting to the
implications of their diagnosis.77 Scott McGrath and Dario Ghersi point out that although there
are trained specialists to help interpret genetic test results, their number in the U.S. and globally
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is low compared to the future needs in the era of PM. 3,021 genetic counselors were employed in
the U.S. in 2015, with an additional 135 practicing outside of the U.S. The American Board of
Medical Genetics and Genomics (ABMGG) lists only 1,286 certified clinical geneticist in the
world as of July 2014. McGrath and Ghersi also point out that only 1,194 of the 1,286 clinical
geneticists work in the U.S, which is equivalent to 0.18% of the total physicians in the U.S.78
Michael L. Begleiter also points out that genetics services worldwide are provided to
families through a team approach, consisting of clinical geneticists, nurses, genetic counselors
and other medical professionals, who are supported by cytogeneticists, biochemical geneticists
and molecular geneticists, who provide laboratory expertise that aids the diagnosis and
management of individuals with genetic conditions. Begleiter highlight, although genetic
counselors identify risks of genetic conditions for patients and families, they are also important
partners in the decision making process for patients and families. Counselors need to be trained
to appreciate the entirety of humanness taking into consideration the social, ethical and legal
issues.79 According to Elisabeth Pain, some of the essential skills identified as necessary for
genetic counselors are: “Communication skills, Critical thinking skills, Interpersonal counseling
and psychosocial assessment skills, Professional ethics and values.” As Elisabeth Pain notes, a
career in genetic counseling requires a thorough understanding of genetics, extensive medical
experience, and excellent communication and counseling skills.80 As Roy C. Ziegelstein notes,
genetics differs from other areas of medicine in that it so often involves families, rather than only
individuals. While providing accurate information to family members is important, Ziegelstein
adds that it can also be ethically challenging in terms of ownership of medical information, and
privacy issues, for counselors. He emphasizes that in order to deliver personalized medicine it
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has to be remembered to connect the ‘omics’ and see each patient and each person, as an
individual at the same time.81
Family history has been identified as the key to determining the mode of inheritance and
that is why it is recommended that basic health information be appropriately recorded across
three generations. The healthcare professional must be clear about why the genetic test is needed
or requested, and must make sure that the patient is involved in the decision-making process with
full knowledge of the implications of such requests/tests.82 According to Tarja-Brita Robins
Wahlin, counselors need to report findings about specific genes that seem to contribute to
specific disorders, and be able to explain about the clinical significance of the reports. For
starters, healthcare providers must be knowledgeable about the differences between abnormal
genotype and phenotype, and must have the basic wisdom about genotypic tests, and the
implications associated with it. Wahlin further adds that Predictive testing programs are complex
and raises challenges since it gives the applicants a choice to know or not to know their carrier
status, some of these choices can have emotional toll, and potential candidates need to decide
what they want to do - to know or not to know? 83
There are also challenges associated with incidental findings (IFs), with respect to the
design of electronic health record (EHR) systems for reporting IFs, since there are currently no
standardized protocols for handling and disclosing IFs in a manner that is consistent with the
aims of routine patient care.84 As Hazin et al. point out that patient privacy will be a critical
consideration in the adoption of EHRs. Although there is the Health Insurance Portability and
Accountability Act (HIPAA) and the Genetic Information Nondiscrimination Act (GINA) that are
supposedly put in place to protect patients, neither prohibit genetic discrimination. As a result
there are fears that lead to the controversial practice of opting out of documenting sensitive
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information into medical records.85 As Hazin et al. highlights that predictive testing is associated
with rising risks of suicide, putting emphasis on counselors to address the emotional, ethical
issues that arise with this application. It is the counselors’ uttermost duty to help the applicants to
make informed decisions based on their individual circumstances, ethical, and religious values.86
Currently, genetic counselors provide a majority of formal genetic counseling services in
this country. However, with the advances of genomics, physicians and nurses in primary care
will practice the majority of individualized, genetically based preventive medicine. Scholars
argue that this will prompt dramatic changes in the patient–primary care provider. With the
frequent utilization of genomics, there will be advances of more complex cases, as a result,
primary care providers will have to make determinations about appropriate referrals and be able
to prepare patients accordingly. As noted by Veach et al., that there will likely be a number of
ethical and professional dilemmas; and most likely not enough information will be available for
guidance and support. Since a great deal of genetic screening and counseling will move into the
realm of primary care, more research into the anticipated dilemmas are critical for the future of
PM, especially it is important to look into primary care providers’ perceptions of the anticipated
ethical issues.87 The next section looks at the educational needs and challenges, and looks into
recommendations.
8.4. Educational Needs and Challenges
As previously highlighted by scholars, there is a shortage of adequately trained
workforce, and documented low confidence levels within primary care physicians on the topic of
genomics. Failing to address these needs could slow or even prevent precision medicine from
becoming successfully integrated into healthcare.88 The current exposure received by healthcare
professionals across different specialties has been deemed inadequate and inconsistent. As
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highlighted by scholars like Lauddaio et al., the availability and declining costs of single-gene
tests are making the applications of genomics clinically useful for diagnosing and classifying
disease, determining disease risk, generating prognostic information, and predicting response to
therapy - as a result, healthcare professionals need to be able to utilize these applications.89 It has
become of utmost importance to address the educational needs and challenges that span didactic,
laboratory, and experiential teaching environments for professional, postgraduate, and continuing
pharmacy education (CPE).90 The next section looks at the educational approaches and strategies
that can be undertaken in order to address these challenges and needs.
8.4.1. Educational Approaches and Strategies
According to Walt et al., there is a need for better literacy in genomics in order for
physicians, and other healthcare providers to utilize the potential of genomics into clinical
practice. However, incorporating the essential education and training into medical education is a
complex process, and requires adequate discussion and planning within the community
academics.91 Previous research recognized that short-term educational initiatives alone were not
likely to cause significant changes in areas of genetic risk, assessment of risk and appropriate
management of patients in patient care. As Paneque et al. note that better objectives may be
aiming at changes in genetic awareness and the ability to locate relevant information instead of
only aiming at changes in knowledge. 92 As observed by Walt et al., a study at Tufts University
School of Medicine to examine ways to improve genomic education, noted that medical curricula
needed to include “technology, genome-wide association studies, ethics, statistics, and data
quality.” 93 Moreover, practitioners who were not genetic specialists also identified risk
assessment as an important topic; and scholars also identified other strategies to provide practical
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change - such as use of support/resources/tools at a policy level, and provision of clinical
decision aids.94
According to Laudadio et al., in order to identify better educational initiatives, a
comparison was done on the different healthcare related schools (such as pharmacy and
pathology) curricula in order to come up with better strategies to incorporate knowledge and
skills that will enhance the future healthcare professionals’ ability to incorporate genomics into
their clinical practices. It has been suggested that professionals with adequate knowledge in
molecular genetics and genomics will be able to fulfill the role of the expert.95 Kuo et al. state,
even though pharmacy professionals are assumed to take the leadership role in precision
medicine initiative, it was observed that they also lack confidence in pharmacogenomics, and are
not confident to apply this information into practice yet. According to a survey on 377
pharmacists working in community pharmacies, more than 70% indicated a score below 50% for
level of confidence in pharmacogenomics topics. Another study on 303 pharmacists reported that
85% of pharmacists agreed that pharmacists should be knowledgeable about pharmacogenomics.
However, 63% felt they were not confident in applying the results of pharmacogenomics tests to
the selection, dosing or monitoring of drug therapies. Kuo et al. note that even though
pharmacogenetics/genomics didactic teaching is increasing in schools of medicine, evidencebased educational materials about pharmacogenomics have been reported as not readily available
to healthcare professionals or the public.96 Educational campaigns toward bridging this gap
between pharmacogenomics, and practices of medicine, and pharmacy amidst clinicians is
needed. 97 Another growing emphasis, as pointed out by Weitzel et al., is on the need for
strategies to advance PM and clinical use of PGx data. However, challenges remain in the
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implementation and incorporation of genomic data into the EHR, ethical concerns, and
challenges in the areas of reimbursement and practitioner education.98
Many similar strategies and guidelines to assist educators in overcoming these challenges
are emerging.99 The National Coalition for Health Professional Education (NCHPEG) in the
United States have developed guidelines for genetics education, and defined core competencies
in genetics for health-care providers. According to Wylie Burke and Jon Emery, various
strategies to promote genetics education have been used, which include problem-based medical
school curricula, continuing medical education for practicing physicians and innovative
approaches for delivering genetics information to practitioners. They point out that three U.S.
federal agencies also funded a program to develop medical faculty skills in genetics - Genetics
for Primary Care (GPC). The GPC project utilizes dialogue between experts in genetics and
primary care to develop goals for genetics education for PCPs. These include a case-based
curriculum, and educational interventions, in the form of workshops, lectures and interactive
case discussions, by genetics/primary-care teams in 20 participating institutions. As Burke and
Emery note, the GPC curriculum emphasizes the clinical problems commonly seen in primary
care practice and uses an evidence-based approach, which incorporates information about rare
genetic diseases and basic genetics concepts in this context.100 As highlighted by Weitzel et al.,
the National Coalition for Health Professional Education in Genetics updated the guidelines in
2012 for competencies in genomics. Pharmacists, Pathologists, Nurses as well as PCPs should be
able to order, interpret and report test results; and for Pharmacists it is essential that they have the
knowledge to guide optimal drug selection and dosing based on those results.101
Because nurses are usually at the forefront of providing care, according to the members
of the National Nursing Organizations in the U.S, Williams et al. emphasize that there is an
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urgent need for genomic content across basic and continuing nursing education programs that
will allow students to apply this knowledge in the clinical setting with people across the lifespan
throughout the spectrum of health and illness; and provide resources to prepare faculty. Training
the workforce with the adequate genomic knowledge has been highlighted as critical in order to
close the gap.102 However, all health care providers, not just nurses, should be trained in
genomics - otherwise, nurses will bear the heavy burden of delivering and consoling patients. 103
However, Burke and Emery state that genetic information can be a double-edged sword – it has
the potential to provide important clinical benefits but is not always clinically useful, and can
sometimes cause harm – which is why healthcare providers need to be prepared in genomics.
Given the variety of healthcare settings in which primary care occurs, Burke and Emery add
there is a need for collaborative approaches between the various providers. PCPs, and all
frontline healthcare providers, and geneticists and genetic counselors should be encouraged to
continue a range of educational experiments, and an ongoing discussion of the lessons that are
learned from them.104
Scholars like Weitzel et al. suggests that gaps be addressed by implementing course
curriculum that offers pharmacogenomics or genomics-based primer courses during the first year
so that students will get the foundation of basic genetics knowledge that will be built upon and
integrated into second- and third-year courses in the curriculum. They have also emphasized that
practice-based patient care applications be included, so that patients can feel better prepared to
apply the knowledge and skills to patient care decisions in the third year and beyond of
experiential training.105 As explained by Scott McGrath and Dario Ghersi, PM offers the
potential to integrate big data analytics into healthcare, which offers great advantages, such as
R&D acceleration, expanded genomic analysis, and public health insights. However, they add
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that the adoption of the EHR will be a major component of PM, and will not be obstacle-free to
attain due to a lack of experts with the skillset to incorporate, and utilize this technology, in
addition to the under preparedness of the healthcare workforce. However, they add that the
promise of PM is a desirable goal, and will have a positive impact on human health at large if
implemented properly.106 According to the American Association of Medical Colleges (AAMC),
strategies should aim to provide tools for life-long learning. Genetics should not be viewed as a
specialized field that is needed by a small set of specialists – but rather as a field, that has an
overarching influence in health and disease of all in the future. Additionally, AAMC states that
because it is still unclear as to how soon PM will take effect, and in what manner it will be
integrated into the medical practice, creates a special educational challenge. The AAMC adds
that it is difficult to motivate students to learn things on the promise that they will be important
in the future, and it is also difficult to find current case examples and role models. However,
three domains were identified by AAMC for the integration of genetics into medical practice prevention, diagnosis, and treatment. Three-time horizons were also identified – during clinical
rotations, start of residency, and beginning of practice.107
As Korf et al. note, due to the volume, sensitivity and complexity of genomic information
(related to privacy, and handling of IFs, and testing of children, for example), it will likely
exceed the capacity of physicians to review the information on such a brief clinical encounter,
and surpass the clinician’s expertise in genetics, that genetic tests (even PGx testing) may very
well be deflected to trained professionals in medical genetics. 108 Other concepts recommended
in the education are application of models for evaluating genetic tests and consideration of ELSIs
of genomic testing.109 According to Williams et al., numerous barriers identified in the
framework developed for genomics education include limited curricular time, access to
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education opportunities, and resources within the educational institution to sustain inclusion of
genomic content into the primary care curricula (medicine, nursing, pharmacy and so on).
Additionally, limited genomic knowledge by faculty was also highlighted in studies.110
Weitzel et al. recommends collaboration among other colleges and schools and shared
teaching resources. They have also identified patient-centered, team-based approach to
experiential education as key to the education process. According to Weitzel et al., the NIH is
another valuable resource that works closely with health professionals to support sharing of
resources through the Genetics/Genomics Competency Center (G2C2) and the Global Genetics
and Genomics Community (G3C). G2C2 is a peer-reviewed resource that puts together existing
educational resources and aligns them with professional educational competencies; G3C
provides use-case scenarios for genetics and genomics.111 Moreover, Weitzel et al. note that
patient-centered, team-based approach to experiential education has been identified as key to
providing students with the needed training. They add that, practice-based experiences are
critical in the clinical practices, especially with training on how to use the EHR resources, and
problem-solving and communication skills. The also add that complementary education roles of
medical geneticists and genetic counselors should be emphasized.112 The next section looks at
quality improvements and competencies.
8.4.2. Quality Improvement and Developing Competencies
Surveys of both primary care and specialist physicians reveal unease, and even unwillingness
to use genomic data. The increasing use of genomics in caring for cancer patients and for some
pediatric patients will likely extend to other areas of healthcare. According to Korf et al., studies
reported that the age of nearly half of the practicing U.S. clinicians are more than 50. Which,
according to the scholars, means their medical school and residency training occurred before the
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advances in genomic medicine – which is why they are less confident or hesitant in using
genomics. As Korf et al point out, given the rate and evolving nature of genomics data, current
trainees are also faced with the challenges of keeping pace with the progress, which makes their
education out of date by the time they start to practice. With the increasing utilization of these
tools, it is critical that these challenges are overcome in order to implement PM into healthcare
setting. Misuse of genomics due to a lack of training can also result in harm to patient based on
inaccurate or unnecessary tests.113
In order to improve quality in the era of PM it is important that healthcare professionals
at the frontline of patient care be prepared to utilize this technology, especially in the use of EHR
technology. Hazin et al. add that appropriately designed EHR systems will be needed to
optimally utilize the genomic information. They also add that, given the sensitivity of the
genomic information, inclusion of this data into the EHR is anticipated to raise ethical, social and
legal issues. 114 Frontline healthcare professionals will need to know how to collect FH, obtain
informed consent for genetic testing, and administer gene-based therapies. They also have the
role of: advocating for, educating, counseling and supporting patients and families making
genomic-based health care decisions. D. Lea adds that frontline health professionals will also
need to have a good understanding of the ethical and social issues associated with these
decisions, and how to address them appropriately.115 Understanding the appropriate way to
deliver information and getting consent in the decision-making and consent process for the
patient and family will be critical for healthcare professionals. Lea also adds that there are a lot
of procedures associated with the utilization of PM that may need results to be shared with
family members who may be affected. Multiple ethical issues may arise with each patient that
has to be resolved, that may include privacy and confidentiality of genomic data, and fear of
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discrimination.116 GINA, as D. Lea states, is designed to prohibit improper use of genetic
information in insurance and employment decisions.117
According to Korf et al. the Genomic Medicine Competencies Working Group was tasked
with the development of a framework for competencies in genomic medicine for physicians in
various fields. The Working Group formulated a set of competencies, given the different medical
disciplines of physicians can be utilized as a starter for developing competencies geared to their
areas of practice.118 Moreover, Korf et al. add that The National Human Genome Research
Institute and the Inter-Society Coordinating Committee for Physician Education in Genomics
(ISCC) took up the initiative to develop best practices that they call “entrustable professional
activities” (EPAs), which have embedded competencies designed to guide residency training and
postgraduate medical education - eight in total: "Patient care, Knowledge for practice, Practicebased learning and improvement, Interpersonal and communication skills, Professionalism,
Systems-based practice, Inter-professional collaboration, Personal and professional
development.” 119
The five EPAs as elaborated by Korf et al. are listed below:
1. Family History: Healthcare professionals need to be able to elicit, document, and act on
relevant family history pertinent to the patient’s clinical status, includes conducting patient
interviews, use of standard pedigree symbols, recognizing patterns of Mendelian inheritance and
calculating simple and complex risks, and providing information to patients and family as
appropriate. Make appropriate referrals based on results of family history (Korf et al., 2014).
2. Genomic Testing: Healthcare professionals must be able to order, interpret, and communicate
the results of appropriate genomic tests, and be able to provide referral to appropriate specialist
for genomic testing of a condition outside the physician's scope of practice. Korf et al. add that
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the professional must be competent to use genomic testing to guide patient management of the
benefits, risks, and alternatives, be able to address issues of incidental findings, and also direct
patients to relevant clinical trials if applicable (Korf et al., 2014). 120
3. Patient Treatment Based on Genomic Results: Use genomic information to make treatment
decisions for patients and family such as clinical conditions and drug responses. Make relevant
information readily available to other healthcare professionals following proper protocols. Be
knowledgeable about databases available and relevant resources such as ongoing clinical trials,
pharmacogenomics, and patient-oriented Internet resources from reliable organizations (Korf et
al., 2014).
4. Somatic Genomics: utilized to guide the diagnosis and management of cancers/conditions
related to somatic genetic changes. Korf et al. also added, be able to explain the benefits and
limitations, including implications regarding treatment of the condition and clarification of
prognosis, guide choice of therapy and adjust drug dosage in patients with cancer.121 Ensure that
specialists and laboratory involved in a patient's care are communicating with one another and
with the patient; Stay up to date on progress, especially related to new cancer treatments, or other
tissue-based disorders (Korf et al., 2014).
5. Microbial Genomic Information: use genetic testing to guide treatment in infectious diseases
using the knowledge of microbes in human health and diseases. Korf et al. highlights, be able to
order, interpret and explain results to patients and families especially if there is "a risk for
contagion,” and take the appropriate containment steps. The scholars also add, keep an open
communication with appropriate healthcare professionals and specialists in order to make certain
that appropriate tests are ordered.122
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Without the proper education, training and incorporation of the technology, it will not be
possible to realize the anticipated potential benefits of precision medicine. As Mazmanian et al.
note, it will be essential to provide the continuing education to physicians to improve the care
provided to patients. This education includes instruction designed to help physicians acquire and
apply scientific knowledge, demonstrate skill, and perform effectively as caregivers.123 However,
there is no single standardized model apparent for evaluating the effects of individual Continuing
Medical Education (CME) activities, and no single standardized model appears to exist for
evaluating clinical outcomes in healthcare.124 Clinical outcomes of care may include healthrelated quality of life (HRQL), and Mazmanian et al. suggested multiple exposures to
information in variety of educational activities in the clinical setting can be necessary to affect
outcomes and performances.125 Frequency exposure was also looked at and it was found that
multiple exposures to content to meet instructional objectives intended to improved clinical
outcomes. Although CME interventions have always been linked to improved clinical outcomes,
and many studies have applied quality improvement (QI) efforts, Mazmanian et al. recommend
additional studies to decide whether the methods are clinically beneficial.126 According to
Katherine Johansen Taber, the two educational programs that stood out were The City of Hope
Comprehensive Cancer Center 14-month CME program, and El Camino Hospital in Mountain
View, CA 10-module course. These programs incorporated basic genomics skills and knowledge,
such as collecting FH, learning to utilize genetic tests, learning to interpret validity of the result;
and also employed distance pedagogical learning, comprehensive face-to-face training and other
continuing professional development training.127
Proponents of PM argue that educational barriers/lack of preparedness by healthcare
workforce is not a barrier that cannot be overcome, as long as there is a strategy put in place to
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prepare them.128 It has been suggested by Olle ten Cate and Fedde Scheele that deficiencies can
be easily overcome by teaching concepts with clinical relevance. Competency-based training
frameworks, although not new in medical education, have only recently been introduced into
postgraduate training on a nationwide scale, and their impact has been unprecedented. This shift
may be justified, but many scholars involved in medical training, worry that the competencybased movement will create new obstacles for sound training: focusing on competency rather
than expertise. Nonetheless, Cate and Scheele point out that competency framework for
postgraduate training are usually read as logical sets of general qualities that every medical
specialist should acquire, and have been reviewed by many individuals and committees for their
relevance and comprehensiveness.129 Scholars also recommend using EPAs, as the central focus
of curriculum building, in combination with general competencies – arguing this combination
will do justice to both educational theory and clinical teaching practice.130
Conclusion
It is evident that opportunities for genetic testing, and other applications of genetic
technology, such as PGx and gene-based therapies, are opening up to more utilization of
applications of PM, having important implications on primary care practice. If PM is to be
incorporated into clinical settings, PCPs and all healthcare providers at the frontline will need to
be adequately prepared in a rapidly evolving field. The challenges highlighted in this Chapter
points to the urgent need for educating PCPs and other healthcare professionals about genetics,
and the various ethical principles in delivering results.131 However, the best approaches to
educating healthcare providers in a way that produces meaningful changes in clinical practice are
not clear - especially given the competing coursework, and training needs that exist in today’s
increasingly complex healthcare settings. Incorporating ethics education into the curriculum has
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also been emphasized in order to provide healthcare professionals with the background to
navigate through the ethical, legal and social issues associated with the genomics testing and
delivering of results. It is evident from research that the most effective education process
involves the systematic collaboration between different specialties, and continuous training, and
education that starts from early on.132
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Chapter 9: Concluding Thoughts

9.1. Thoughts on the Potential of PM as the New Paradigm for Healthcare
Scholars like J.D. Prince emphasizes that PM has been anticipated as the new paradigm
for healthcare delivery, because of its potential ability to lower the cost of healthcare by shifting
from the “one-size-fits-all” approach (thought as wasteful, and inefficient) to a more
“personalized” or “individualized” care that is aligned with the genetic variants of the person, the
environment and lifestyle. PM is anticipated to improve and speed up diagnostics and treatment
of diseases, by offering more targeted therapeutic care – nationally, as well as globally.1 The
inception of PM started from the launch of the Precision Medicine Initiative (PMI) by the Obama
Administration in 2015, an ambitious project that aimed at developing individualized treatment
and prevention strategies for diseases such as cancer and other chronic, infectious and rare
diseases. As Spencer H. Nam and Clayton M. Christensen point out, PM would be ideal for
diseases such as cancer since some of the best-in-class drugs are reported to be ineffective in
twenty to thirty percent of all cases, and a five-year survival rate for most metastasized cases
are less than ten percent – therefore, cancer could significantly benefit from the personalized
treatment and prevention offered by PM.. 2
Helen K. Brittain explains that almost all medical specialties are virtually impacted by
genetic diseases, and the enhanced understanding of the role of genetic variants, in combination
with rapid advancements in sequencing technologies through PM is already transforming the
speed of diagnosis and providing increased opportunity for tailored management of diseases. 3
The PMI push from the US federal government has led PM to become an important concept
for health researchers, practitioners, as well as biomedical organizations. However, PM has a
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lot to prove, and has a long way to go in order to be successfully integrated, and smoothly
adopted into the healthcare system.
9.1.1. What We Know About PM So Far?
Sharon F. Terry points that PM aims to move away from the current treatment based on
the average patient – which is successful for some, but not all. The Precision Medicine Initiative
(PMI) launched by President Barack Obama in his State of the Union address before both
chambers in 2015, aimed at enabling PM as the new era of medicine, that has the capacity “to
empower patients, researchers, and providers to work together toward the development of
individualized care through research, technology, and policies.” President Obama also called
for increased investment in US infrastructure and research, and the 2016 budget submitted to
Congress, asked for $213M to fund the PMI. 4
According to Francis S Collins, director of the NIH, and Harold Varmus, director of
the National Cancer Institute, the PMI would have two main components: a near term focus
on cancer and a longer term focus on the application of PM to healthcare in general.
Moreover, Michael McCarthy adds that an allocated budget of $130M was also dedicated for the
creation of a “national research cohort” of a million or more volunteers - whose genetic,
medical, and lifestyle data would be collected for research purposes, with the promise that
these participants would be able to help design this program. 5 The anticipation is that PM will
make more effective prevention, diagnosis and treatment, by developing a deep understanding of
patients' genetic and genomic information – making it easier for doctors to select the most
efficient drugs, optimal dose for medication usage and the least side effect. 6
9.1.2 Highlighting PM’s Impact
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Cancer is a potential area of focus for PM. Garrido et al. states that PM has already
become a reality in oncology. They argue that PM’s implementation is not only an ethical
mandate and obligation of policy, efficacy in the treatment of patients and prevention of diseases,
but because it has proven in certain cases that it fosters the ability to select the patients who will
likely better respond to the treatment, not putting them through the torments of suffering from
lack of benefits, toxicity or effects of adverse reactions.7 Additionally, Jill Kolesar & M. Lynn
Crismon agrees that PM is anticipated to have an impact on the therapeutic innovation in the
future, with targeted therapies as the major drivers of oncology therapeutic innovation. They add
that recent forecast predicts that immune checkpoint inhibitors and targeted therapies will
constitute more than 95% of the lung cancer market by 2024. Patients getting the precise drug
will be critical, given the high cost of targeted therapies; these drugs are exclusively confined to
the treatment of specific subset of patients.8 In favor of PM, Solomon M. Adams et al. add that
cardiac pharmacogenomics is another rapidly growing field that offers the potential for improved
treatment outcomes, as well as prevention of adverse drug reactions. PM is also employed in
diabetic research – although the current knowledge is not sufficient for the prediction of diabetes
risk, or for decisions regarding specific prevention or treatment measures using genomics. 9
Public health genomics has evolved to responsibly integrate advancements in genomics
and according to Caron M. Molster et al., is anticipated to contribute to individual differences in
immunological responses to vaccines, infections and drug therapies in populations.10 To top off
all these advances in PM, the WHO's Human Genomics in Global Health Initiative has been
created “to provide information and raise awareness within the health sector, governments and
the wider public on the health challenges and opportunities” presented by genomics.11
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9.2. Implementing a New Technology Is Not Simple
As J. Larry Jameson & Dan L. Longo point out, PM has raised many high expectations
– to improve care and speed up the development of new targeted treatment – and these
expectations have only begun to be realized. With every new technology, there are daunting
challenges. Jameson & Longo add that as PM develops, the most daunting challenge for
providers will be to manage the complexity associated with implementing the sequencing
algorithms, especially at a time when most providers feel inadequately prepared in the area of
genetics. Additionally they add that much work remains to be done in order to prove whether this
approach will actually improve care, and reduce costs to healthcare - since in many areas the
implementation of PM will undoubtedly increase costs.12
J. Larry Jameson & Dan L. Longo also states that bioinformatics technology will be
increasingly applied to interpret results and apply interventions in PM. The opportunities are
tremendous for PM to improve health and health outcomes, but the challenges for the PCPs, on
the frontlines of patient care will also be tremendous.13 Opponents fear that the personalization
approach of PM may lead to the de-personalization of the patient-centered care it promises to
deliver - therefore, it is important to make sure that does not happen.14 Kathrin M. Cresswell et
al. states that integrating the needed technology and developing regulations and guidelines in
order to ensure that the massive amount of data is protected and secure will be the greatest
challenge in implementing this new technology.15 Also, making sure that the ethical, legal and
social issues are identified and addressed will be critical in order to ensure PM’s potential.
9.2.1 Barriers to Overcome
From studies it was noted that one important challenge is managing the interests of the
various stakeholders: patient, physician, health system, payer, and the industry. This is because
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everyone has a different interest. Although patient and physicians may have the same interest in
understanding and treatment of the diseases; physicians will also have the challenge of finding
the best treatment plan, with the least cost to the patient, and payers and also meet the industry
interests – related to cost of new diagnostics and profitable therapies. As Haslem et al. point out,
PM as a cost-saving approach has been debated for a long time. However, they add that from
studies it was found that precision medicine approach may be a feasible option in patients with
refractory cancer. 16, 17 Nonetheless, they also state that the impact of PM compared with
standard therapies on survival and the effect of implementing sophisticated diagnostic
technologies such as Next Generation Sequencing (NGS) on the costs of cancer care still remain
unknown.18
Scholars have argued that cost analysis of the effectiveness versus implementation will be
critical for the sustainability of novel therapies. However, Haslem et al. point out that due to
limited availability of data and limitations on data sharing, the cost associated with implementing
novel medical treatment approaches has always been difficult to measure.19 Similarly, the cost
associated with precision cancer medicine remains a primary question for both payers and
providers alike. They agree that given the increasing health care costs, and limited resources,
measuring the value of treatment will be critical to sustainability.20 Alexander P. Cole et al. also
add that comparing the cost to survival benefits of the different care settings with anticancer
agents has been difficult. With the ongoing debate regarding the costs of cancer therapies,
investments in simple systems‐based changes to improve cancer care delivery can be an
important and likely cost‐effective strategy which can be used to improve the survival of cancer
patients.21
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Another critical challenge is organizing the wealth of growing information in the era of
PM as pointed out by scholars like Arsia Amir-Aslani &V. Mangematin; and J. Larry Jameson &
Dan L. Longo. The enormous amount of information, which continues to grow, has created a
situation where handling the existing information, making use of it, and absorbing the
information from a wide range of areas - has become an extremely daunting task. With the
increased complexity in diseases PCPs will need to utilize bioinformatics tools with clinical
navigation and specialized referral pathways. 22,23
9.2.2. Need for Addressing the Ethical and Social Implications
The fast sequencing of data is generating vast amounts of genetic variants - some of
unknown clinical applications - raising issues of disclosing (or not) information to patients and
family members, who may be directly or indirectly affected. According to Marilyn J. Hammer,
although technological advances are allowing for faster and more accurate data leading to more
precise medicine - false positives, false negatives, and conflicting results by varying analytic
approaches make determination of disease risk less precise. To address these issues, she adds
that protocols for standardization are being implemented along with centralized resources that
can verify findings using “pooled information for accurate determination” of clinically relevant
genetic variants. 24
Moreover, Hammer adds that the generation of vast amount of genetic variants raises
issues of incidental findings (IFs), and return of results (issues of what to disclose and what not
to disclose by physicians) – leading to moral and ethical dilemmas of physicians involved.
However, Hammer adds that there are no clear guidelines as to how to answer these questions
yet, and decisions are often made on the specific case.25 With the promise of integrating new
genetic technologies into clinical settings come promises as well as technical and clinical
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challenges, which are similar to but qualitatively different from those that are usually dealt with
in traditional medical genetics. Ormond and Cho add that it will be important to implement core
ethical principles to address the ethical and social issues associated with PM, particularly as new
technology is integrated into clinical practice, and issues of potential stigma and impact on
perceptions of disability arise.26
According to NIH, genetic discrimination, emotional consequences, risk of behavior
changes, and confidentiality of test results are possible risks associated with genetic testing.27
Wolf et al. point out, although both ethics and law (HIPAA and GINA) protect the privacy and
confidentiality of health information about patients and research participants, mapping the
pathways by which this information may currently reach relatives, as well as the reasons that this
information may not be shared, helps illuminate the core question: whether relatives should be
granted broader access.28 Despite GINA, legal fear persists because GINA does not provide
protection against discrimination in life, disability, or long-term care insurance.29
In order to reduce the existing gaps in health in developing countries, developing
countries need to keep up in the race, and start putting more effort in the building of capacity
(research, technical skills and infrastructure). This is a pressing requirement for countries
wishing to develop their own pathogen genome projects directed at the communicable diseases
which are particularly common in their populations.30 According to the WHO, there is a crucial
need for all Member States to improve awareness and understanding of genetics, and the medical
potential of genomics in particular, through educational programs at all level to communicate
these concepts effectively. The WHO could play a major role in providing technical assistance to
Member States to aid them in establishing centers for clinical genetics, and genetic research
programs targeted to their particular health problems - through supporting regional meetings, the
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establishment of collaborative training programs between developed and developing countries,
and the development of local networking.31
9.3. Implementing PM into Healthcare
Per Carrie Anna McGinn et al., implementing the information technology is the most
critical challenge in the implementation of PM in healthcare. She adds that the EHR is an
important data repository for HCOs, as it contains sensitive information, and can be purposeful
in addressing many of the healthcare system challenges – such as better quality of care - and
benefits of its implementation are expected for patients (such as relevant, timely and up-to-date
information), healthcare professionals, organizations and the general public (citizen
empowerment and participation in decision making).32 McGinn et al. add that the most
frequently mentioned issue in the implementation of EHRs were issues related to the technical
aspects, such as technical limitations related to software or hardware and other system problems
– that were always considered as a barrier. Overall ease of use was also perceived as a barrier,
and was closely associated with the design and technical issues – more user-friendly, and easy to
use tools were desired. 33 According to McGinn et al., “Interoperability, Privacy and security,
Cost, Productivity, Familiarity and ability with EHR, Motivation to use EHR, Patient and health
professional interaction, Lack of time and workload,” were also cited as perceived barriers to the
implementation and use of EHRs in HCOs.34
According to scholars like Payne et al., it would be more convenient to utilize genetic
tests and genetically targeted therapies if payers opted to cover them. Therefore, collaboration
among payers, scientists, and clinicians is essential for accelerating uptake and value creation –
since collaboration with payers would create a unique opportunity to more rapidly develop the
information required for evidence-based decision making.35 Jane Null Kogan adds that a well-
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designed real-world observational basis in collaboration with payers could also strengthen the
evidence base for PM, which does not exist today and as a result slowing the implementation
process. 36
9.3.1. Ethical Foundation Is the Cornerstone
HCOs are expected to provide healthcare to the sick and vulnerable individuals, and this
represents a profoundly moral practice. The American society considers provision of healthcare
to all as a moral obligation, and it expects healthcare to be safe, effective, patient-centered,
timely, efficient and equitable.37 As Garrido et al. note, to enable the management and sharing of
the vast amount of data generated by the new sequencing tools, there will be need for improved
and secure information technology systems. More professional roles in the field of
bioinformatics and other research areas will be needed to facilitate the transformation of PM.
Substantial investment and multidisciplinary approaches will be needed to evaluate the
implementation of PM into healthcare. 38
PM’s greatest promise was, and still is, PM’s assumed beneficial economic impact,
especially through cost effective targeted treatments. Per Brett Doble, PM has not been able to
prove its promise in this area as of today - prices for such therapies have been quoted as high as
US $150,000 per patient per year, and if used as part of combination therapy or in sequence as
much as US $300,000 for the treatment of one patient. Identifying areas where PM will accrue
meaningful benefits at an affordable cost is a challenging endeavor. We can agree with Doable
that the application of economic evaluation to assess the value of PM and consideration of its
opportunity cost will be an essential first step.39
As pointed out by Jacques S. Beckmann, and Daniel Lew, healthcare is laced with
complexities due to the continuing developments in the organization and delivery of care. HCO
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leaders should be more focused in creating an ethical organization that will provide the care.
Although profit is also important, Beckmann and Lew add that it should not be the only
important goal. The goal should be focused on providing quality and ethical care. They add that
ethics and legislation will increasingly influence the processes that facilitate healthcare delivery.
The traditions of catholic social teachings continue to be critical of the market system for its
failure in justice, as distribution of healthcare remain a critical issue with continued rising costs
exacerbating equity issues. Beckmann and Lew add that in the era of PM, citizens will have an
increased role in managing their own health – warranting for the availability of adequate
resources to promote the people’s awareness of the approach and its benefits to their health. They
add that this will also create the trust needed, and incentivize them to participate in this medical
revolution. 40
9.3.2. Making Sure the Workforce is Ready
Genomics is the cornerstone of the cutting-edge PM programs – genomic sequencing in
PM is largely used as a screening tool.41 However, Jessica Santos argues that sequencing
genomes of healthy people will raise many concerns, such as the potential harm associate with
the probabilistic results, which can be uncertain as well as ambiguous. She adds that Direct-ToConsumer (DTC) testing companies have resulted from the commercialization of data generated
by sequencing technologies, and findings show that the application of these tools is controversial
because a person could carry about 54 so-called lethal genetic mutations, that do not seem to
harm their health. She states that this can cause dilemmas in physicians, since they do not know
what to tell healthy people with these variants. Research shows that >98% of DTC participants
buy these tests because of curiosity and personal interest in knowing about their health.42
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Research also shows that primary health teams in particular are likely to face increased demands
for genetic information about genetic disorders from their patients because of DTC.
Scholars like Sandy M. Thomas reports that from research it was identified that medical
education gives a low priority to genetics, and will need to include more education in genetics,
genomics, bioinformatics and ethics in the era of PM. A range of strategies and initiatives have
been made to correct this issue. However, given the fast advancement of genetics technologies
and their application in healthcare, there is an urgent need to provide the basic fundamental
training in genetics to all healthcare professionals including nurses. 43,44 Thomas also adds that
more genetic counselors will be needed in the era of PM. Although the current ethical standards
employed in genetic counseling is widely accepted, counselors have to remember they have
defined responsibilities that ensure that patients know that counseling is voluntarily undertaken
and that it provides accurate information.45 Although, previously much of the demand had been
driven by reproductive issues, Thomas explains that predisposition for common diseases are
likely to play an expanding role today. Strategies to deal with the increased demand for
information and advice about rare disorders and predisposition to common diseases at the
primary care level will require the integration of different healthcare professionals into local
teams. Genetic counselors, specialist nurses and practice nurses will be needed to support the
genetic practitioners.46
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